US20070049618A1 - Isoindole-imide compounds and compositions comprising and methods of using the same - Google Patents

Isoindole-imide compounds and compositions comprising and methods of using the same Download PDF

Info

Publication number
US20070049618A1
US20070049618A1 US11/513,563 US51356306A US2007049618A1 US 20070049618 A1 US20070049618 A1 US 20070049618A1 US 51356306 A US51356306 A US 51356306A US 2007049618 A1 US2007049618 A1 US 2007049618A1
Authority
US
United States
Prior art keywords
dioxo
dihydro
isoindol
ylmethyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/513,563
Inventor
George Muller
Roger Chen
Hon-Wah Man
Alexander Ruchelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to US11/513,563 priority Critical patent/US20070049618A1/en
Assigned to CELGENE CORPORATION reassignment CELGENE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, ROGER S., MAN, HON W., MULLER, GEORGE W., RUCHELMAN, ALEXANDER L.
Publication of US20070049618A1 publication Critical patent/US20070049618A1/en
Priority to US13/030,075 priority patent/US8481568B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • This invention relates to isoindole-imide compounds.
  • Pharmaceutical compositions comprising the compounds and methods for treating, preventing and managing various disorders are also disclosed.
  • angiogenesis a process known as angiogenesis.
  • cytokines include acidic and basic fibroblastic growth factor (a,b-FGF), angiogenin, vascular endothelial growth factor (VEGF), and TNF- ⁇ .
  • a,b-FGF acidic and basic fibroblastic growth factor
  • VEGF vascular endothelial growth factor
  • TNF- ⁇ tumor cell
  • tumor cells can release angiogenic peptides through the production of proteases and the subsequent breakdown of the extracellular matrix where some cytokines are stored (e.g., b-FGF).
  • Angiogenesis can also be induced indirectly through the recruitment of inflammatory cells (particularly macrophages) and their subsequent release of angiogenic cytokines (e.g., TNF- ⁇ , bFGF).
  • angiogenesis A variety of other diseases and disorders are also associated with, or characterized by, undesired angiogenesis.
  • enhanced or unregulated angiogenesis has been implicated in a number of diseases and medical conditions including, but not limited to, ocular neovascular diseases, choroidal neovascular diseases, retina neovascular diseases, rubeosis (neovascularization of the angle), viral diseases, genetic diseases, inflammatory diseases, allergic diseases, and autoimmune diseases.
  • diseases and conditions include, but are not limited to: diabetic retinopathy; retinopathy of prematurity; corneal graft rejection; neovascular glaucoma; retrolental fibroplasia; and proliferative vitreoretinopathy.
  • neoplastic tissue may not completely remove neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue. Radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent. Although hormonal therapy can be effective, it is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of cancer cells. Biological therapies and immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.
  • chemotherapeutic agents available for treatment of cancer.
  • a majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division.
  • chemotherapeutic agents Despite availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks. Stockdale, Medicine , vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10, 1998. Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous side effects including severe nausea, bone marrow depression, and immunosuppression. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even if those agents act by different mechanism from those of the drugs used in the specific treatment. This phenomenon is referred to as pleiotropic drug or multidrug resistance. Because of the drug resistance, many cancers prove or become refractory to standard chemotherapeutic treatment protocols.
  • This invention also encompasses methods of treating and managing various diseases or disorders.
  • the methods comprise administering to a patient in need of such treatment or management a therapeutically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the invention also encompasses methods of preventing various diseases and disorders, which comprise administering to a patient in need of such prevention a prophylactically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, or prodrug thereof.
  • compositions also encompasses pharmaceutical compositions, single unit dosage forms, dosing regimens and kits which comprise a compound of this invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
  • this invention encompasses isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof.
  • this invention encompasses methods of treating, managing, and preventing various diseases and disorders, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof. Examples of diseases and disorders are described herein.
  • a compound of this invention is administered in combination with another drug (“second active agent”) or treatment.
  • Second active agents include small molecules and large molecules (e.g., proteins and antibodies), examples of which are provided herein, as well as stem cells.
  • Methods, or therapies, that can be used in combination with the administration of compounds of this invention include, but are not limited to, surgery, blood transfusions, immunotherapy, biological therapy, radiation therapy, and other non-drug based therapies presently used to treat, prevent or manage various disorders described herein.
  • compositions e.g., single unit dosage forms
  • Particular pharmaceutical compositions comprise a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and optionally a second active agent.
  • this invention encompasses compounds of formula (I): and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein: X is O or S; R 1 is H or methyl; R 2 is: (C 2 -C 6 )alkyl, excluding cycloalkyl; (C 4 -C 6 )cycloalkyl; (C 1 -C 4 )alkoxy;
  • X is O. In another embodiment, X is S. In another embodiment, R 2 is phenyl, optionally substituted with one or more halogen.
  • R 2 is NHR 4 .
  • R 4 is (C 6 -C 10 )aryl or 5 to 10 membered heteroaryl, both optionally substituted with one or more of (C 1 -C 4 )alkoxy, halogen, and methyl.
  • the aryl or heteroaryl is phenyl, pyridyl, or naphthyl.
  • Examples of compounds of formula (I) include, but are not limited to, those listed in Table 1, below: TABLE 1 Compounds of Formula I No. Structure Name 1 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo2,3-dihydro-1H- isoindol-4-ylmethyl]-2- phenyl-acetamide 2 1-Cyclohexyl-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 3 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- benzamide 4 Furan-2-carboxylic acid[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-d
  • this invention encompasses compounds of formula and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
  • R 2 is phenyl, optionally substituted with one or more of (C 1 -C 4 )alkoxy or —O—CH 2 —O—. In another embodiment, R 2 is phenyl substituted with one or more (C 1 -C 4 )alkoxy, substituted with N(CH 3 ) 2 . In another embodiment, R 2 is (C 3 -C 6 )alkyl, optionally substituted with one or more of (C 1 -C 4 )alkoxy.
  • Examples of compounds of formula (II) include, but are not limited to, those listed in Table 2, below: TABLE 2 Compounds of Formula II No. Structure Name 40 2-(2,6-Dioxopiperidin-3-yl)-4- phenylaminoisoindole-1,3- dione 41 2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- methylenedioxyphenylamino) isoindole-1,3-dione 42 2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- dimethoxyphenylamino) isoindole-1,3-dione 43 2-(3-Methyl-2,6- dioxopiperidin-3-yl)-4- pentylaminoisoindole-1,3- dione 44 4-(Cyclopropylmethylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1
  • this invention encompasses compounds of formula and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
  • R 2 is —NH(CH 3 ) or —N(CH 3 ) 2 . In another embodiment, R 2 is (C 3 -C 6 )cycloalkyl.
  • Examples of compounds of formula (III) include, but are not limited to, those listed in Table 3, below: TABLE 3 Compounds of Formula III No. Structure Name 79 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide 80 [2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]acetic acid methyl ester 81 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide 82 N-Cyclopropyl-2-[2-(2,6- dioxopiperidin-3-yl)-1,3-diox
  • this invention encompasses compounds of formula (IV): or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof: and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein R 1 is H or methyl; and R 2 is 5 to 6 membered heteroaryl; with the proviso that if R 2 is furan or thiophene, then R 1 is methyl; and with the proviso that if R 2 is pyridine, then the pyridine is not connected to the core at the 3 position.
  • R 2 is not pyridine.
  • Examples of compounds of formula IV include, but are not limited to, those listed in Table 4, below: TABLE 4 Compounds of Formula IV No. Structure Name 85 2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-2-yl- methyl)amino]isoindole-1,3-dione hydrochloride 86 2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-4-yl- methyl)amino]isoindole-1,3-dione hydrochloride 87 [(Furan-2-ylmethyl)amino]-2- (3-methyl-2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
  • this invention encompasses compounds of formula (V): and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof: wherein: R 1 is H or methyl; and R 2 is: H; methyl; ethyl;
  • R 2 is phenyl, optionally substituted with one or more of methyl, halogen, (C 1 -C 4 )alkoxy, cyano, and —O—CH 2 —O—.
  • R 2 is naphthyl.
  • R 2 is not pyridine.
  • Examples of compounds of formula (V) include, but are not limited to, those listed in Table 5, below: TABLE 5 Compounds of Formula V No. Structure Name 88 1-Ethyl-3-[2-(3-methyl- 2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 89 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(3-methoxy- phenyl)-urea 90 1-(3-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 91 1-(3-Cy
  • this invention encompasses compounds of formula (VI): and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein: R 1 is H or methyl; and R 2 is: N(CH 3 ) 2 ;
  • R 2 is phenyl, substituted with one or more of methyl, (C 1 -C 4 )alkoxy, and halogen.
  • R 2 is pyrazine, pyrimidine, quinoxaline, or isoquinoline, optionally substituted with one or more of (C 1 -C 4 )alkyl and halogen.
  • R 2 is 5 membered heteroaryl, substituted with one of more (C 1 -C 4 )alkyl.
  • Examples of compounds of formula (VI) include, but are not limited to, those listed in Table 6, below: TABLE 6 Compounds of Formula VI No. Structure Name 105 3-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-1,1-dimethyl- urea 106 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-methoxy- benzamide 107 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-methyl- benzamide 108 3,4-Dichloro-N-[2-(2,6- dioxopiperidin
  • This invention also encompasses the compounds of the following formula, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof.
  • TABLE 7 180 cyclopropanecarboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- amide 181 2-amino-N-[2-(3-methyl-2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl]-acetamide 182 3- ⁇ 4-[(Benzofuran-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl ⁇ - piperidine-2,6-dione 183 3- ⁇ 4-[(4,5-Dimethyl-furan-2- y
  • this invention encompasses a stereomerically pure (R) isomer and a stereomerically pure (S) isomer of the compounds listed above.
  • this invention encompasses a stereomerically pure (R) isomer and a stereomerically pure (S) isomer of 2-amino-N-[2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide, and a racemic mixture thereof.
  • the term “pharmaceutically acceptable salt” refers to salts prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids.
  • suitable non-toxic acids include inorganic and organic acids such as, but not limited to, acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, gluconic, glutamic, glucorenic, galacturonic, glycidic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, propionic, phosphoric, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, p-toluenesulfonic and
  • solvate means a compound of the present invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound.
  • prodrugs include, but are not limited to, compounds that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • Other examples of prodrugs include compounds that comprise —NO, —NO 2 , —ONO, or —ONO 2 moieties.
  • biohydrolyzable carbamate As used herein, and unless otherwise specified, the terms “biohydrolyzable carbamate,” “biohydrolyzable carbonate,” “biohydrolyzable ureide” and “biohydrolyzable phosphate” mean a carbamate, carbonate, ureide and phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound.
  • stereoisomer encompasses all enantiomerically/stereomerically pure and enantiomerically/stereomerically enriched compounds of this invention.
  • a typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.
  • the term “enantiomerically pure” means a stereomerically pure composition of a compound having one chiral center.
  • enantiomerically enriched means a stereomerically enriched composition of a compound having one chiral center.
  • alkyl refers to a saturated straight chain or branched hydrocarbon having number of carbon atoms as specified herein.
  • Representative saturated straight chain alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like.
  • aryl means a carbocyclic aromatic ring containing from 6 to 14 ring atoms.
  • the ring atoms of a carbocyclic aryl group are all carbon atoms.
  • Aryl ring structures include compounds having one or more ring structures such as mono-, bi-, or tricyclic compounds as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl and the like.
  • the aryl group is a monocyclic ring or bicyclic ring.
  • Representative aryl groups include phenyl, anthracenyl, fluorenyl, indenyl, azulenyl, phenanthrenyl and naphthyl.
  • heteroaryls include, but are not limited to, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl, thiophenyl, thiazolyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, isoquinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl, quinoxalinyl, acridinyl, pyr
  • heterocycle means a monocyclic or polycyclic ring comprising carbon and hydrogen atoms, optionally having 1 or 2 multiple bonds, and the ring atoms contain at least one heteroatom, specifically 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.
  • Heterocycle ring structures include, but are not limited to compounds having one or more ring structures such as mono-, bi-, or tri-cyclic compounds. Specific heterocycles are monocyclic or bicyclic.
  • heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl and tetrahydrothiopyranyl.
  • a heterocyclic ring can be unsubstituted or substituted.
  • diseases or disorders include, but are not limited to, cancer, disorders associated with angiogenesis, pain including Complex Regional Pain Syndrome (“CRPS”), Macular Degeneration (“MD”) and related syndromes, skin diseases, pulmonary disorders, asbestos-related disorders, parasitic diseases, immunodeficiency disorders, CNS disorders, CNS injury, atherosclerosis and related disorders, dysfunctional sleep and related disorders, hemoglobinopathy and related disorders (e.g., anemia), TNF ⁇ related disorders, and other various diseases and disorders.
  • CRPS Complex Regional Pain Syndrome
  • MD Macular Degeneration
  • diseases or disorders include, but are not limited to, cancer, disorders associated with angiogenesis, pain including Complex Regional Pain Syndrome (“CRPS”), Macular Degeneration (“MD”) and related syndromes, skin diseases, pulmonary disorders, asbestos-related disorders, parasitic diseases, immunodeficiency disorders, CNS disorders, CNS injury, atherosclerosis and related disorders, dysfunctional sleep and related disorders, hemoglobinopathy and related disorders (e.g., anemia), TNF ⁇ related disorders, and other various diseases and disorders.
  • cancers include, but are not limited to, advanced malignancy, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastase, glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, recurrent malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C & D colorectal cancer, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karotype acute myeloblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T-Cell lymphoma, cutaneous B-Cell lymphoma, diffuse large B-C
  • this invention encompasses methods of treating, preventing or managing various forms of leukemias such as chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia and acute myeloblastic leukemia, including leukemias that are relapsed, refractory or resistant, as disclosed in U.S. publication no. 2006/0030594, published Feb. 9, 2006, which is incorporated in its entirety by reference.
  • leukemias such as chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia and acute myeloblastic leukemia, including leukemias that are relapsed, refractory or resistant, as disclosed in U.S. publication no. 2006/0030594, published Feb. 9, 2006, which is incorporated in its entirety by reference.
  • leukemia refers malignant neoplasms of the blood-forming tissues.
  • the leukemia includes, but is not limited to, chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia and acute myeloblastic leukemia.
  • the leukemia can be relapsed, refractory or resistant to conventional therapy.
  • relapsed refers to a situation where patients who have had a remission of leukemia after therapy have a return of leukemia cells in the marrow and a decrease in normal blood cells.
  • refractory or resistant refers to a circumstance where patients, even after intensive treatment, have residual leukemia cells in their marrow.
  • this invention encompasses methods of treating, preventing or managing various types of lymphomas, including Non-Hodgkin's lymphoma (NHL).
  • NHL Non-Hodgkin's lymphoma
  • the term “lymphoma” refers a heterogenous group of neoplasms arising in the reticuloendothelial and lymphatic systems.
  • “NHL” refers to malignant monoclonal proliferation of lymphoid cells in sites of the immune system, including lymph nodes, bone marrow, spleen, liver and gastrointestinal tract.
  • diseases and disorders associated with, or characterized by, undesired angiogenesis include, but are not limited to, endometriosis, Crohn's disease, heart failure, advanced heart failure, renal impairment, endotoxemia, toxic shock syndrome, osteoarthritis, retrovirus replication, wasting, meningitis, silica-induced fibrosis, asbestos-induced fibrosis, veterinary disorder, malignancy-associated hypercalcemia, stroke, circulatory shock, periodontitis, gingivitis, macrocytic anemia, refractory anemia, and 5q-deletion syndrome.
  • neuropathic pain examples include, but are not limited to, CRPS type I, CRPS type II, reflex sympathetic dystrophy (RSD), reflex neurovascular dystrophy, reflex dystrophy, sympathetically maintained pain syndrome, causalgia, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, trigeminal neuralgia, post herpetic neuralgia, cancer related pain, phantom limb pain, fibromyalgia, chronic fatigue syndrome, spinal cord injury pain, central post-stroke pain, radiculopathy, diabetic neuropathy, post-stroke pain, luetic neuropathy, and other painful neuropathic conditions such as those induced by drugs such as vincristine and velcade.
  • RSD reflex sympathetic dystrophy
  • reflex neurovascular dystrophy reflex dystrophy
  • reflex dystrophy sympathetically maintained pain syndrome
  • causalgia Sudeck atrophy of bone
  • algoneurodystrophy shoulder hand syndrome
  • post-traumatic dystrophy trigeminal neural
  • CRPS complex regional pain syndrome
  • CRPS and related syndromes mean a chronic pain disorder characterized by one or more of the following: pain, whether spontaneous or evoked, including allodynia (painful response to a stimulus that is not usually painful) and hyperalgesia (exaggerated response to a stimulus that is usually only mildly painful); pain that is disproportionate to the inciting event (e.g., years of severe pain after an ankle sprain); regional pain that is not limited to a single peripheral nerve distribution; and autonomic dysregulation (e.g., edema, alteration in blood flow and hyperhidrosis) associated with trophic skin changes (hair and nail growth abnormalities and cutaneous ulceration).
  • allodynia painful response to a stimulus that is not usually painful
  • hyperalgesia exaggerated response to a stimulus that is usually only mildly painful
  • pain that is disproportionate to the inciting event e.g., years of severe pain after an ankle sprain
  • regional pain that is not limited
  • MD and related syndromes include, but are not limited to, those described in U.S. patent publication no. 2004/0091455, published May 13, 2004, which is incorporated herein by reference. Specific examples include, but are not limited to, atrophic (dry) MD, exudative (wet) MD, age-related maculopathy (ARM), choroidal neovascularisation (CNVM), retinal pigment epithelium detachment (PED), and atrophy of retinal pigment epithelium (RPE).
  • keratosis refers to any lesion on the epidermis marked by the presence of circumscribed overgrowths of the horny layer, including but not limited to actinic keratosis, seborrheic keratosis, keratoacanthoma, keratosis follicularis (Darier disease), inverted follicular keratosis, palmoplantar keratoderma (PPK, keratosis palmaris et plantaris), keratosis pilaris, and stucco keratosis.
  • Keratosis is characterized by one or more of the following symptoms: rough appearing, scaly, erythematous papules, plaques, spicules or nodules on exposed surfaces (e.g., face, hands, ears, neck, legs and thorax), excrescences of keratin referred to as cutaneous horns, hyperkeratosis, telangiectasias, elastosis, pigmented lentigines, acanthosis, parakeratosis, dyskeratoses, papillomatosis, hyperpigmentation of the basal cells, cellular atypia, mitotic figures, abnormal cell-cell adhesion, dense inflammatory infiltrates and small prevalence of squamous cell carcinomas.
  • Examples of skin diseases or disorders characterized with overgrowths of the epidermis include, but are not limited to, any conditions, diseases or disorders marked by the presence of overgrowths of the epidermis, including but not limited to, infections associated with papilloma virus, arsenical keratoses, sign of Leser-Trélat, warty dyskeratoma (WD), trichostasis spinulosa (TS), erythrokeratodermia variabilis (EKV), ichthyosis fetalis (harlequin ichthyosis), knuckle pads, cutaneous melanoacanthoma, porokeratosis, squamous cell carcinoma, confluent and reticulated papillomatosis (CRP), acrochordons, cutaneous horn, cowden disease (multiple hamartoma syndrome), dermatosis papulosa nigra (DPN), epidermal nevus syndrome (ENS
  • pulmonary disorders include, but are not limited to, those described in U.S. provisional application No. 60/565,172, filed Apr. 23, 2004, which is incorporated herein by reference. Specific examples include pulmonary hypertension and related disorders. Examples of pulmonary hypertension and related disorders include, but are not limited to: primary pulmonary hypertension (PPH); secondary pulmonary hypertension (SPH); familial PPH; sporadic PPH; precapillary pulmonary hypertension; pulmonary arterial hypertension (PAH); pulmonary artery hypertension; idiopathic pulmonary hypertension; thrombotic pulmonary arteriopathy (TPA); plexogenic pulmonary arteriopathy; functional classes I to IV pulmonary hypertension; and pulmonary hypertension associated with, related to, or secondary to, left ventricular dysfunction, mitral valvular disease, constrictive pericarditis, aortic stenosis, cardiomyopathy, mediastinal fibrosis, anomalous pulmonary venous drainage, pulmonary venoocclusive disease, collagen vasular
  • asbestos-related disorders include, but not limited to, those described in U.S. publication no. 2005/0100529, published May 12, 2005, which is incorporated herein by reference. Specific examples include, but are not limited to, mesothelioma, asbestosis, malignant pleural effusion, benign exudative efflusion, pleural plaques, pleural calcification, diffuse pleural thickening, rounded atelectasis, fibrotic masses, and lung cancer.
  • parasitic diseases include, but are not limited to, those described in U.S. provisional application No. 60/626,975, filed Nov. 12, 2004, which is incorporated herein by reference.
  • Parasitic diseases include diseases and disorders caused by human intracellular parasites such as, but not limited to, P. falcifarium, P. ovale, P. vivax, P. malariae, L. donovari, L. infantum, L. aethiopica, L. major, L. tropica, L. mexicana, L. braziliensis, T. Gondii, B. microti, B. divergens, B. coli, C. parvum, C. cayetanensis, E. histolytica, I.
  • Specific examples include, but are not limited to, malaria, babesiosis, trypanosomiasis, leishmaniasis, toxoplasmosis, meningoencephalitis, keratitis, amebiasis, giardiasis, cryptosporidiosis, isosporiasis, cyclosporiasis, microsporidiosis, ascariasis, trichuriasis, ancylostomiasis, strongyloidiasis, toxocariasis, trichinosis, lymphatic filariasis, onchocerciasis, filariasis, schistosomiasis, and dermatitis caused by animal schistosomes.
  • immunodeficiency disorders include, but are not limited to, those described in U.S. provisional application No. 60/631,870, filed Dec. 1, 2004.
  • Specific examples include, but not limited to, adenosine deaminase deficiency, antibody deficiency with normal or elevated Igs, ataxia-tenlangiectasia, bare lymphocyte syndrome, common variable immunodeficiency, Ig deficiency with hyper-IgM, Ig heavy chain deletions, IgA deficiency, immunodeficiency with thymoma, reticular dysgenesis, Nezelof syndrome, selective IgG subclass deficiency, transient hypogammaglobulinemia of infancy, Wistcott-Aldrich syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency.
  • CNS disorders include, but are not limited to, those described in U.S. provisional application No. 60/533,862, filed Dec. 30, 2003, and the co-pending U.S. application Ser. No. 11/022,075, filed Dec. 23, 2004, both of which are incorporated herein by reference.
  • Specific examples include, but are not limited to, include, but are not limited to, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Parkinson Disease, Huntington's Disease, Multiple Sclerosis other neuroimmunological disorders such as Tourette Syndrome, delerium, or disturbances in consciousness that occur over a short period of time, and amnestic disorder, or discreet memory impairments that occur in the absence of other central nervous system impairments.
  • CNS injury/damage and related syndromes include, but are not limited to, those described in U.S. provisional application No. 60/630,599, filed Nov. 23, 2004, which is incorporated herein by reference.
  • CNS injury/damage and related syndromes include, but are not limited to, primary brain injury, secondary brain injury, traumatic brain injury, focal brain injury, diffuse axonal injury, head injury, concussion, post-concussion syndrome, cerebral contusion and laceration, subdural hematoma, epidermal hematoma, post-traumatic epilepsy, chronic vegetative state, complete SCI, incomplete SCI, acute SCI, subacute SCI, chronic SCI, central cord syndrome, Brown-Sequard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, neurogenic shock, spinal shock, altered level of consciousness, headache, nausea, emesis, memory loss, dizziness, diplopia, blurred vision, emotional lability, sleep
  • Other disease or disorders include, but not limited to, viral, genetic, allergic, and autoimmune diseases.
  • Specific examples include, but not limited to, HIV, hepatitis, adult respiratory distress syndrome, bone resorption diseases, chronic pulmonary inflammatory diseases, dermatitis, cystic fibrosis, septic shock, sepsis, endotoxic shock, hemodynamic shock, sepsis syndrome, post ischemic reperfusion injury, meningitis, psoriasis, fibrotic disease, cachexia, graft versus host disease, graft rejection, auto-immune disease, rheumatoid spondylitis, Crohn's disease, ulcerative colitis, inflammatory-bowel disease, multiple sclerosis, systemic lupus erythrematosus, ENL in leprosy, radiation damage, cancer, asthma, or hyperoxic alveolar injury.
  • Atherosclerosis and related conditions include, but are not limited to, those disclosed in U.S. publication no. 2002/0054899, published May 9, 2002, which is incorporated herein by reference. Specific examples include, but are not limited to, all forms of conditions involving atherosclerosis, including restenosis after vascular intervention such as angioplasty, stenting, atherectomy and grafting.
  • vascular intervention includes diseases of the cardiovascular and renal system, such as, but not limited to, renal angioplasty, percutaneous coronary intervention (PCI), percutaneous transluminal coronary angioplasty (PTCA), carotid percutaneous transluminal angioplasty (PTA), coronary by-pass grafting, angioplasty with stent implantation, peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries, and surgical intervention using impregnated artificial grafts.
  • PCI percutaneous coronary intervention
  • PTCA percutaneous transluminal coronary angioplasty
  • PTA carotid percutaneous transluminal angioplasty
  • coronary by-pass grafting angioplasty with stent implantation
  • peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries and surgical intervention using impregnated artificial grafts.
  • the following chart provides a listing of the major systemic arteries that may be in need of treatment, all of which are contemplated by the invention: Artery Body Area Axillary Shoulder and axilla Brachial Upper arm Brachiocephalic Head, neck, and arm Celiac Divides into left gastric, splenic, and hepatic arteries Common carotid Neck Common iliac Divides into external and internal iliac arteries Coronary Heart Deep femoral Thigh Digital Fingers Dorsalis pedis Foot External carotid Neck and external head regions External iliac Femoral artery Femoral Thigh Gastric Stomach Hepatic Liver, gallbladder, pancreas, and duodenum Inferior mesenteric Descending colon, rectum, and pelvic wall Internal carotid Neck and internal head regions Internal iliac Rectum, urinary bladder, external genitalia, buttocks muscles, uterus and vagina Left gastric Esophagus and stomach Middle sacral Sacrum Ovarian
  • dysfunctional sleep and related syndromes include, but are not limited to, those disclosed in U.S. provisional application No. 60/559,261, filed Apr. 1, 2004, and U.S. application Ser. No. 11/093,848, filed Mar. 30, 2005, both of which are incorporated herein by reference.
  • Specific examples include, but are not limited to, snoring, sleep apnea, insomnia, narcolepsy, restless leg syndrome, sleep terrors, sleep walking sleep eating, and dysfunctional sleep associated with chronic neurological or inflammatory conditions.
  • Chronic neurological or inflammatory conditions include, but are not limited to, Complex Regional Pain Syndrome, chronic low back pain, musculoskeletal pain, arthritis, radiculopathy, pain associated with cancer, fibromyalgia, chronic fatigue syndrome, visceral pain, bladder pain, chronic pancreatitis, neuropathies (diabetic, post-herpetic, traumatic or inflammatory), and neurodegenerative disorders such as Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's Disease, bradykinesia; muscle rigidity; parkinsonian tremor; parkinsonian gait; motion freezing; depression; defective long-term memory, Rubinstein-Taybi syndrome (RTS); dementia; postural instability; hypokinetic disorders; synuclein disorders; multiple system atrophies; striatonigral degeneration; olivopontocerebellar atrophy; Shy-Drager syndrome; motor neuron disease with parkinsonian features; Lewy body dementia; Tau pathology disorders
  • hemoglobinopathy and related disorders include, but are not limited to, those described in U.S. application Ser. No. 11/004,736, filed Dec. 2, 2004, which is incorporated herein by reference. Specific examples include, but are not limited to, hemoglobinopathy, sickle cell anemia, and any other disorders related to the differentiation of CD34+ cells.
  • TNF ⁇ related disorders include, but are not limited to, those described in WO 98/03502 and WO 98/54170, both of which are incorporated herein in their entireties by reference.
  • Specific examples include, but are not limited to: endotoxemia or toxic shock syndrome; cachexia; adult respiratory distress syndrome; bone resorption diseases such as arthritis; hypercalcemia; Graft versus Host Reaction; cerebral malaria; inflammation; tumor growth; chronic pulmonary inflammatory diseases; reperfusion injury; myocardial infarction; stroke; circulatory shock; rheumatoid arthritis; Crohn's disease; HIV infection and AIDS; NF ⁇ B related disorders such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions, septic shock, septis, endotoxic shock, graft versus host disease, wasting, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythromatosis
  • the use of compounds of this invention in various immunological applications in particular, as vaccine adjuvants, particularly anticancer vaccine adjuvants, as disclosed in U.S. Provisional Application No. 60/712,823, filed Sep. 1, 2005, which is incorporated herein in its entirety by reference, is also encompassed.
  • This aspect of the invention also relates to the uses of compounds of this invention in combination with vaccines to treat or prevent cancer or infectious diseases, and other various uses of immunomodulatory compounds such as reduction or desensitization of allergic reactions.
  • Doses of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof vary depending on factors such as: specific indication to be treated, prevented, or managed; age and condition of a patient; and amount of second active agent used, if any.
  • a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof may be used in an amount of from about 0.1 mg to about 500 mg per day, and can be adjusted in a conventional fashion (e.g., the same amount administered each day of the treatment, prevention or management period), in cycles (e.g., one week on, one week off), or in an amount that increases or decreases over the course of treatment, prevention, or management.
  • the dose can be from about 1 mg to about 300 mg, from about 0.1 mg to about 150 mg, from about 1 mg to about 200 mg, from about 10 mg to about 100 mg, from about 0.1 mg to about 50 mg, from about 1 mg to about 50 mg, from about 10 mg to about 50 mg, from about 20 mg to about 30 mg, or from about 1 mg to about 20 mg.
  • a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, can be combined with other pharmacologically active compounds (“second active agents”) in methods and compositions of the invention. It is believed that certain combinations may work synergistically in the treatment of particular types diseases or disorders, and conditions and symptoms associated with such diseases or disorders.
  • second active agents pharmacologically active compounds
  • a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof can also work to alleviate adverse effects associated with certain second active agents, and vice versa.
  • Second active ingredients or agents can be used in the methods and compositions of the invention.
  • Second active agents can be large molecules (e.g., proteins) or small molecules (e.g., synthetic inorganic, organometallic, or organic molecules).
  • active agents include, but are not limited to, hematopoietic growth factors, cytokines, and monoclonal and polyclonal antibodies.
  • specific examples of the active agents are anti-CD40 monoclonal antibodies (such as, for example, SGN-40); histone deacetlyase inhibitors (such as, for example, SAHA and LAQ 824); heat-shock protein-90 inhibitors (such as, for example, 17-AAG); insulin-like growth factor-1 receptor kinase inhibitors; vascular endothelial growth factor receptor kinase inhibitors (such as, for example, PTK787); insulin growth factor receptor inhibitors; lysophosphatidic acid acyltransrerase inhibitors; IkB kinase inhibitors; p38MAPK inhibitors; EGFR inhibitors (such as, for example, gefitinib and erlotinib HCL); HER-2 antibodies (such as, for example, trastuzumab (Herceptin®) and per
  • Specific second active compounds that can be combined with compounds of this invention vary depending on the specific indication to be treated, prevented or managed.
  • second agents include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; argin
  • Specific second active agents include, but are not limited to, 2-methoxyestradiol, telomestatin, inducers of apoptosis in multiple myeloma cells (such as, for example, TRAIL), bortezomib, statins, semaxanib, cyclosporin, etanercept, doxycycline, bortezomib, oblimersen (Genasense®), remicade, docetaxel, celecoxib, melphalan, dexamethasone (Decadron®), steroids, gemcitabine, cisplatinum, temozolomide, etoposide, cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, tamoxifen, topotecan, methotrexate, Arisa®, taxol, taxotere, fluorouracil, leucovorin, irinotecan,
  • Specific examples include, but are not limited to, salicylic acid acetate (Aspirin®), celecoxib (Celebrex®), Enbrel®, ketamine, gabapentin (Neurontin®), phenyloin (Dilantin®), carbamazepine (Tegretol®), oxcarbazepine (Trileptal®), valproic acid (Depakene®), morphine sulfate, hydromorphone, prednisone, griseofulvin, penthonium, alendronate, dyphenhydramide, guanethidine, ketorolac (Acular®), thyrocalcitonin, dimethylsulfoxide (DMSO), clonidine (Catapress®), bretylium, ketanserin, reserpine, droperidol, atropine, phentolamine, bupivacaine, lidocaine, acetaminophen, nortrip
  • second active agents that may be used for the treatment, prevention and/or management of MD and related syndromes include, but are not limited to, a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound, or a combination thereof.
  • Specific examples include, but are not limited to, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 ⁇ , pentoxifylline, tin etiopurpurin, motexafin lutetium, 9-fluoro-11,21-dihydroxy-16,17-1-methylethylidinebis(oxy)pregna-1,4-diene-3,20-dione, latanoprost (see U.S. Pat. No. 6,225,348), tetracycline and its derivatives, rifamycin and its derivatives, macrolides, metronidazole (U.S. Pat. Nos.
  • second active agents that may be used for the treatment, prevention and/or management of skin diseases include, but are not limited to, keratolytics, retinoids, ⁇ -hydroxy acids, antibiotics, collagen, botulinum toxin, interferon, and immunomodulatory agents.
  • Specific examples include, but are not limited to, 5-fluorouracil, masoprocol, trichloroacetic acid, salicylic acid, lactic acid, ammonium lactate, urea, tretinoin, isotretinoin, antibiotics, collagen, botulinum toxin, interferon, corticosteroid, transretinoic acid and collagens such as human placental collagen, animal placental collagen, Dermalogen, AlloDerm, Fascia, Cymetra, Autologen, Zyderm, Zyplast, Resoplast, and Isolagen.
  • second active agents that may be used for the treatment, prevention and/or management of pulmonary hepertension and related disorders include, but are not limited to, anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, vasodilators, prostacyclin analogues, endothelin antagonists, phosphodiesterase inhibitors (e.g., PDE V inhibitors), endopeptidase inhibitors, lipid lowering agents, thromboxane inhibitors, and other therapeutics known to reduce pulmonary artery pressure.
  • anticoagulants e.g., diuretics, cardiac glycosides, calcium channel blockers, vasodilators, prostacyclin analogues, endothelin antagonists, phosphodiesterase inhibitors (e.g., PDE V inhibitors), endopeptidase inhibitors, lipid lowering agents, thromboxane inhibitors, and other therapeutics known to reduce pulmonary artery pressure.
  • warfarin (Coumadin), a diuretic, a cardiac glycoside, digoxin-oxygen, diltiazem, nifedipine, a vasodilator such as prostacyclin (e.g., prostaglandin I2 (PGI2), epoprostenol (EPO, Floran®), treprostinil (Remodulin®), nitric oxide (NO), bosentan (Tracleer®), amlodipine, epoprostenol (Floran®), treprostinil (Remodulin®), prostacyclin, tadalafil (Cialis®), simvastatin (Zocor®), omapatrilat (Vanlev®), irbesartan (Avapro®), pravastatin (Pravachol®), digoxin, L-arginine, iloprost, betaprost, and sildena
  • prostacyclin e.
  • second active agents that may be used for the treatment, prevention and/or management of asbestos-related disorders include, but are not limited to, anthracycline, platinum, alkylating agent, oblimersen (Genasense®), cisplatinum, cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, tamoxifen, topotecan, methotrexate, taxotere, irinotecan, capecitabine, cisplatin, thiotepa, fludarabine, carboplatin, liposomal daunorubicin, cytarabine, doxetaxol, pacilitaxel, vinblastine, IL-2, GM-CSF, dacarbazine, vinorelbine, zoledronic acid, palmitronate, biaxin, busulphan, prednisone, bisphosphonate, arsenic trioxide, vincristine,
  • second active agents that may be used for the treatment, prevention and/or management of parasitic diseases include, but are not limited to, chloroquine, quinine, quinidine, pyrimethamine, sulfadiazine, doxycycline, clindamycin, mefloquine, halofantrine, primaquine, hydroxychloroquine, proguanil, atovaquone, azithromycin, suramin, pentamidine, melarsoprol, nifurtimox, benznidazole, amphotericin B, pentavalent antimony compounds (e.g., sodium stiboglucuronate), interfereon gamma, itraconazole, a combination of dead promastigotes and BCG, leucovorin, corticosteroids, sulfonamide, spiramycin, IgG (serology), trimethoprim, and sulfamethoxazole.
  • chloroquine qui
  • second active agents that may be used for the treatment, prevention and/or management of immunodeficiency disorders include, but are not limited to: antibiotics (therapeutic or prophylactic) such as, but not limited to, ampicillin, clarithromycin, tetracycline, penicillin, cephalosporins, streptomycin, kanamycin, and erythromycin; antivirals such as, but not limited to, amantadine, rimantadine, acyclovir, and ribavirin; immunoglobulin; plasma; immunologic enhancing drugs such as, but not limited to, levami sole and isoprinpsme; biologics such as, but not limited to, gammaglobulin, transfer factor, interleukins, and interferons; hormones such as, but not limited to, thymic; and other immunologic agents such as, but not limited to, B cell stimulators (e.g., BAFF/BlyS), cytokines (e.g., IL-2, IL-4
  • second active agents that may be used for the treatment, prevention and/or management of CNS disorders include, but are not limited to: a dopamine agonist or antagonist, such as, but not limited to, Levodopa, L-DOPA, cocaine, ⁇ -methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline, fenodolpam mesylate, cabergoline, pramipexole dihydrochloride, ropinorole, amantadine hydrochloride, selegiline hydrochloride, carbidopa, pergolide mesylate, Sinemet CR, and Symmetrel; a MAO inhibitor, such as, but not limited to, iproniazid, clorgyline, phenelzine and isocarboxazid; a COMT inhibitor, such as, but not limited to, tolcapone and entacapone; a choline
  • second active agents that may be used for the treatment, prevention and/or management of CNS injuries and related syndromes include, but are not limited to, immunomodulatory agents, immunosuppressive agents, antihypertensives, anticonvulsants, fibrinolytic agents, antiplatelet agents, antipsychotics, antidepressants, benzodiazepines, buspirone, amantadine, and other known or conventional agents used in patients with CNS injury/damage and related syndromes.
  • steroids e.g., glucocorticoids, such as, but not limited to, methylprednisolone, dexamethasone and betamethasone
  • an anti-inflammatory agent including, but not limited to, naproxen sodium, diclofenac sodium, diclofenac potassium, celecoxib, sulindac, oxaprozin, diflunisal, etodolac, meloxicam, ibuprofen, ketoprofen, nabumetone, refecoxib, methotrexate, leflunomide, sulfasalazine, gold salts, RHo-D Immune Globulin, mycophenylate mofetil, cyclosporine, azathioprine, tacrolimus, basiliximab, daclizumab, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, ols
  • an anti-inflammatory agent including,
  • second active agent examples include, but are not limited to, a tricyclic antidepressant agent, a selective serotonin reuptake inhibitor, an antiepileptic agent (gabapentin, pregabalin, carbamazepine, oxcarbazepine, levitiracetam, topiramate), an antiaryhthmic agent, a sodium channel blocking agent, a selective inflammatory mediator inhibitor, an opioid agent, a second immunomodulatory compound, a combination agent, and other known or conventional agents used in sleep therapy.
  • a tricyclic antidepressant agent a selective serotonin reuptake inhibitor
  • an antiepileptic agent gabapentin, pregabalin, carbamazepine, oxcarbazepine, levitiracetam, topiramate
  • an antiaryhthmic agent a sodium channel blocking agent
  • a selective inflammatory mediator inhibitor an opioid agent
  • a second immunomodulatory compound a combination agent
  • Specific examples include, but are not limited to, Neurontin, oxycontin, morphine, topiramate, amitryptiline, nortryptiline, carbamazepine, Levodopa, L-DOPA, cocaine, ⁇ -methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline, fenodolpam mesylate, cabergoline, pramipexole dihydrochloride, ropinorole, amantadine hydrochloride, selegiline hydrochloride, carbidopa, pergolide mesylate, Sinemet CR, Symmetrel, iproniazid, clorgyline, phenelzine, isocarboxazid, tolcapone, entacapone, physostigmine saliclate, physostigmine sulfate, physostig
  • second active agents that may be used for the treatment, prevention and/or management of hemoglobinopathy and related disorders include, but are not limited to: interleukins, such as IL-2 (including recombinant IL-II (“rIL2”) and canarypox IL-2), IL-10, IL-12, and IL-18; interferons, such as interferon alfa-2a, interferon alfa-2b, interferon alfa-n1, interferon alfa-n3, interferon beta-I a, and interferon gamma-I b; and G-CSF; hydroxyurea; butyrates or butyrate derivatives; nitrous oxide; HEMOXINTM (NIPRISANTM; see U.S.
  • interleukins such as IL-2 (including recombinant IL-II (“rIL2”) and canarypox IL-2), IL-10, IL-12, and IL-18
  • interferons such as interferon alf
  • Gardos channel antagonists such as clotrimazole and triaryl methane derivatives
  • Deferoxamine protein C
  • transfusions of blood, or of a blood substitute such as HemospanTM or HemospanTM PS (Sangart).
  • Administration of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and the second active agents to a patient can occur simultaneously or sequentially by the same or different routes of administration.
  • the suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated.
  • a preferred route of administration for compounds of this invention is oral.
  • Preferred routes of administration for the second active agents or ingredients of the invention are known to those of ordinary skill in the art. See, e.g., Physicians' Desk Reference, 1755-1760 (56th ed., 2002).
  • the second active agent is administered intravenously or subcutaneously and once or twice daily in an amount of from about 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg.
  • the specific amount of the second active agent will depend on the specific agent used, the type of disease being treated or managed, the severity and stage of disease, and the amount(s) of compounds of the invention and any optional additional active agents concurrently administered to the patient.
  • the invention encompasses a method of reducing, treating and/or preventing adverse or undesired effects associated with conventional therapy including, but not limited to, surgery, chemotherapy, radiation therapy, hormonal therapy, biological therapy and immunotherapy.
  • Compounds of the invention and other active ingredients can be administered to a patient prior to, during, or after the occurrence of the adverse effect associated with conventional therapy.
  • the prophylactic or therapeutic agents of the invention are cyclically administered to a patient. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.
  • a compound of the invention is administered daily in a single or divided doses in a four to six week cycle with a rest period of about a week or two weeks.
  • the invention further allows the frequency, number, and length of dosing cycles to be increased.
  • another specific embodiment of the invention encompasses the administration of a compound of the invention for more cycles than are typical when it is administered alone.
  • a compound of the invention is administered for a greater number of cycles that would typically cause dose-limiting toxicity in a patient to whom a second active ingredient is not also being administered.
  • a compound of the invention is administered daily and continuously for three or four weeks at a dose of from about 0.1 mg to about 500 mg per day, followed by a break of one or two weeks.
  • the dose can be from about 1 mg to about 300 mg, from about 0.1 mg to about 150 mg, from about 1 mg to about 200 mg, from about 10 mg to about 100 mg, from about 0.1 mg to about 50 mg, from about 1 mg to about 50 mg, from about 10 mg to about 50 mg, from about 20 mg to about 30 mg, or from about 1 mg to about 20 mg, followed by a break.
  • a compound of the invention and a second active ingredient are administered orally, with administration of the compound of the invention occurring 30 to 60 minutes prior to the second active ingredient, during a cycle of four to six weeks.
  • the combination of a compound of the invention and a second active ingredient is administered by intravenous infusion over about 90 minutes every cycle.
  • the number of cycles during which the combinatorial treatment is administered to a patient will be from about one to about 24 cycles, more typically from about two to about 16 cycles, and even more typically from about four to about three cycles.
  • compositions can be used in the preparation of individual, single unit dosage forms.
  • Pharmaceutical compositions and dosage forms of the invention comprise a compound of the invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • Pharmaceutical compositions and dosage forms of the invention can further comprise one or more excipients.
  • compositions and dosage forms of the invention can also comprise one or more additional active ingredients.
  • additional active ingredients are disclosed in Section 4.3, above.
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), topical (e.g., eye drops or other ophthalmic preparations), transdermal or transcutaneous administration to a patient.
  • mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
  • parenteral e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial
  • topical e.g., eye drops or other ophthalmic preparations
  • transdermal or transcutaneous administration e.g., transcutaneous administration to a patient.
  • dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; powders; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; eye drops or other ophthalmic preparations suitable for topical administration; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • suspensions e.g., aqueous or non-aqueous liquid suspensions, oil-in-water e
  • composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
  • a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease.
  • a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease.
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients.
  • Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
  • oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms.
  • the suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. For example, the decomposition of some active ingredients may be accelerated by some excipients such as lactose, or when exposed to water.
  • lactose-free means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.
  • Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmacopeia (USP) 25-NF20 (2002).
  • lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts.
  • Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • the invention further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose.
  • Such compounds which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
  • antioxidants such as ascorbic acid, pH buffers, or salt buffers.
  • the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients.
  • typical dosage forms of the invention comprise a compound of the invention in an amount of from about 0.10 to about 500 mg.
  • Typical dosage forms comprise a compound of the invention in an amount of about 0.1, 1, 2, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • Typical dosage forms comprise the second active ingredient in an amount of 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg.
  • the specific amount of the second active agent will depend on the specific agent used, the type of cancer being treated or managed, and the amount(s) of a compound of the invention and any optional additional active agents concurrently administered to the patient.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredients in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
  • Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
  • tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment.
  • Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions.
  • a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • a preferred solid oral dosage form of the invention comprises a compound of the invention, anhydrous lactose, microcrystalline cellulose, polyvinylpyrrolidone, stearic acid, colloidal anhydrous silica, and gelatin.
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference.
  • Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
  • the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.
  • Controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
  • Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • water for Injection USP Water for Injection USP
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
  • cyclodextrin and its derivatives can be used to increase the solubility of an immunomodulatory compound of the invention and its derivatives. See, e.g., U.S. Pat. No. 5,134,127, which is incorporated herein by reference.
  • Topical and mucosal dosage forms of the invention include, but are not limited to, sprays, aerosols, solutions, emulsions, suspensions, eye drops or other ophthalmic preparations, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels.
  • Suitable excipients e.g., carriers and diluents
  • other materials that can be used to provide topical and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form solutions, emulsions or gels, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990).
  • the pH of a pharmaceutical composition or dosage form may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration.
  • This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • kits encompassed by this invention can further comprise additional active ingredients such as oblimersen (Genasense®), melphalan, G-CSF, GM-CSF, EPO, topotecan, dacarbazine, irinotecan, taxotere, IFN, COX-2 inhibitor, pentoxifylline, ciprofloxacin, dexamethasone, IL2, IL8, IL18, Ara-C, vinorelbine, isotretinoin, 13 cis-retinoic acid, or a pharmacologically active mutant or derivative thereof, or a combination thereof.
  • additional active ingredients include, but are not limited to, those disclosed herein (see, e.g., section 4.3).
  • Kits of the invention can further comprise devices that are used to administer the active ingredients.
  • devices include, but are not limited to, syringes, drip bags, patches, and inhalers.
  • Kits of the invention can further comprise cells or blood for transplantation as well as pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
  • the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol
  • 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.7 g, 4.3 mmol) was added to a stirred suspension of 3-[4-(aminomethyl)-1-oxo-1,3-dihydro-isoindol-2-yl]piperidine-2,6-dione hydrochloride (0.6 g, 1.9 mmol) in acetonitrile (50 mL). After stirring for 30 minutes, phenylacetyl chloride (0.4 g, 2.3 mmol) was added. The mixture was stirred at room temperature for 17 hours.
  • 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.4 g, 2.9 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.6 g, 1.9 mmol) in acetonitrile (100 mL). The mixture was heated for 30 minutes, then cooled to room temperature. Cyclohexyl isocyanate (0.4 g, 2.9 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was filtered and the solid was stirred with water (25 mL) to give 0.9 g of crude product.
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes, and benzoyl chloride (0.4 g, 3.2 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was stirred with 2N HCl (30 mL) and CH 2 Cl 2 (80 mL).
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 2-Furoyl chloride (0.4 g, 3.2 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH 2 Cl 2 (60 mL) and 2N HCl (30 mL).
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. n-Butyryl chloride (0.3 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH 2 Cl 2 (60 mL) and 2NHCl (30 mL).
  • 1,8 Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 3-Chlorobenzoyl chloride (0.6 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was stirred with CH 2 Cl 2 (60 mL) and 2N HCl (30 mL).
  • 1,8-Diazabicyclo[5,4,0]-unded-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. Propyl isocyanate (0.3 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH 2 Cl 2 (60 mL) and 2N HCl (30 mL).
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (1.1 g, 7.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 3-Nicotinoyl chloride (0.5 g, 2.5 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with water (40 mL).
  • 3-Cyanophenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 min, the mixture was warmed to room temperature and stirred overnight. The reaction was quenched with methanol (1 mL) and concentrated. The residue was stirred with 1N HCl (30 mL) for 30 minutes and filtered.
  • 3-Chlorophenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour and filtered.
  • Triethylamine (0.7 g, 7.4 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and isonicotinoyl chloride hydrochloride (0.5 g, 2.5 mmol) in THF (30 mL) at 5-10° C. After stirring for 10 minutes at 5° C., the mixture was stirred at room temperature overnight.
  • Triethylamine (0.7 g, 7.4 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and picolinoyl chloride hydrochloride (0.5 g, 2.5 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with H 2 O (30 mL).
  • Benzyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL).
  • 3,4-Dichlorophenyl isocyanate (0.5 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL).
  • Step 1 A solution of 3-aminopyridine (1.5 g, 15.5 mmol) in acetonitrile (20 mL) was added to a stirred solution of N,N′-disuccinimidyl carbonate (4.0 g, 15.5 mmol) in acetonitrile (150 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in CH 2 Cl 2 (120 mL). The CH 2 Cl 2 solution was washed with saturated NaHCO 3 (40 mL), H 2 O (40 mL), brine (40 mL), and dried (MgSO 4 ). Solvent was removed to give pyridin-3-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (1.3 g, 36%), which was used in next step without purification.
  • Step 2 Pyridin-3-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (0.5 g, 2.1 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and 1,8-diazabicyclo[5,4,0]undec-7-ene (0.4 g, 2.3 mmol) in acetonitrile (100 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with water (30 mL).
  • Triethylamine (0.6 g, 5.9 mmol) was added slowly to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and dimethylcarbamoyl chloride (0.3 g, 3.2 mmol) in THF (100 mL). The mixture was stirred at room temperature overnight. Another portion of dimethylcarbamoyl chloride (0.3 g) and 1,8-diazabicyclo[5,4,0]-undec-7-ene (0.6 g) was added and stirred for another day.
  • Triethylamine (0.5 g, 5.2 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and m-toluoyl chloride (0.5 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (20 mL).
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (2.6 g, 16.8 mmol) was added to a stirred solution of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6 dione hydrochloride (2.0 g, 6.5 mmol) in DMF (100 mL). After stirring for 10 minutes, 1-hydrocybenztriazole (1.1 g, 7.8 mmol) and N-BOC- ⁇ -alanine (1.4 g, 7.1 mmol) were added.
  • Triethylamine (0.5 g, 5.0 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and methoxyacetyl chloride (0.3 g, 2.7 mmol) in THF (30 mL) at room temperature. The mixture was stirred at room temperature overnight. Reaction mixture was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 30 minutes and filtered.
  • Step 2 Dimethylamine/THF (2M, 6.1 mL, 12.3 mmol) was added to a stirred solution of 2-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (1.0 g, 3.1 mmol) in DMF (30 mL). The resulting solution was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH 2 Cl 2 (15 mL). The mixture was filtered, and the solid was dissolved in H 2 O (10 mL). 4N HCl (1.5 mL) was added and stirred for 30 minutes.
  • 3,4-Dimethylphenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour then filtered.
  • Cyclohexyl isothiocyanate (0.4 g, 2.5 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature for 6 days. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 1 hour.
  • Methyl iodide (30.2 g, 213 mmol) was added to a stirred mixture of 3-nitrophthalic acid (15.0 g, 71.0 mmol) and sodium bicarbonate (23.9 g, 284 mmol) in DMF (150 mL) at room temperature, and the mixture was then heated in an oil bath set to 60° C. for 4 hours. The mixture was then poured into 700 mL of ice water.
  • Step 1 To a stirred solution of dimethyl 3-aminophthalate (1.1 g, 5.0 mmol) in CH 2 Cl 2 (40 mL) was added cyclopropanecarboxaldehyde (0.70 g, 10.0 mmol) and acetic acid (1.7 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (3.2 g, 15 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 50 mL of CH 2 Cl 2 , washed with water (2 ⁇ 100 mL), saturated aqueous sodium bicarbonate (100 mL), and brine (100 mL), and dried (MgSO 4 ). Upon evaporation of the solvent, 1.2 g of a yellow oil was obtained.
  • Step 1 To a stirred solution of dimethyl 3-aminophthalate (4.2 g, 20 mmol) in CH 2 Cl 2 (100 mL), were added glyoxylic acid (3.7 g, 40 mmol) and acetic acid (6.9 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (12 g, 60 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was washed with 0.1N HCl (3 ⁇ 100 mL) and brine (100 mL), and dried (MgSO 4 ). The solvent was evaporated leaving an oily residue, which was dissolved in sat. aq. sodium bicarbonate (50 mL).
  • Step 3 The product from step 2 and rac- ⁇ -aminoglutarimide hydrochloride (2.1 g, 13 mmol) were dissolved in pyridine (60 mL), and the resulting mixture was heated to reflux for 6 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in sat. aq. sodium bicarbonate (100 mL) and washed with ethyl acetate (3 ⁇ 100 mL). The aqueous phase was acidified to pH 2-3 (conc. HCl), and the resulting precipitate was isolated by filtration and washed with additional water (30 mL), and then ethyl acetate (50 mL).
  • 3-Bromo-2-methylbenzoic acid (2.15 g, 10.0 mmol) was dissolved in 100 mL of 0.5N KOH. To this clear solution, was added KMnO 4 . The resulting mixture was heated to 70° C. for 16 hours. To the reaction mixture was added ethanol (30 mL), resulting in formation of a black precipitate of MnO 2 . NaHSO 3 (3.0 g, 29 mmol) was added, followed by the slow addition of conc. HCl, until a clear, colorless, homogeneous solution was obtained. The solution was acidified further to pH 2-3 to give a white precipitate.
  • Step 1 A mixture of 3-(2-methoxy-1-methylethylamino)phthalic acid dimethyl ester (0.47 g, 1.7 mmol) and 5N KOH (4 mL) in methanol (10 mL) was stirred at room temperature for 26 hours. The solvent was removed under vacuum, and water (30 mL) was added. The mixture was washed with diethyl ether (2 ⁇ 50 mL), and the aqueous phase was acidified to pH 2 (conc. HCl) and extracted with ethyl acetate (3 ⁇ 75 mL). The combined ethyl acetate extracts were washed with brine (100 mL), dried (MgSO 4 ), and the solvent was evaporated.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.32 g, 2.0 mmol) were dissolved in pyridine (20 mL), and the resulting mixture was heated to reflux for 8 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH 2 Cl 2 (100 mL), washed with water (3 ⁇ 100 mL) and brine (100 mL), and dried (MgSO 4 ), and the solvent was evaporated in vacuo.
  • Step 1 A mixture of 3-(indan-5-ylamino)phthalic acid dimethyl ester (0.80 g, 2.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified (HCl) and extracted with ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ), and evaporated, providing 0.14 g.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.082 g, 0.5 mmol) in pyridine (5 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2 ⁇ 100 mL) and water (2 ⁇ 100 mL), and evaporated.
  • Step 1 A mixture of 3-(2,5-dimethoxyphenylamino)phthalic acid dimethyl ester (0.71 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified (HCl) and extracted with ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ), and evaporated, providing 0.48 g.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) in pyridine (10 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2 ⁇ 100 mL) and water (2 ⁇ 100 mL), and evaporated.
  • Step 1 A mixture of 3-(2-phenoxyphenylamino)phthalic acid dimethyl ester (0.85 g, 2.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified (HCl) and extracted with ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ), and evaporated, providing 0.72 g.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.32 g, 2.0 mmol) in pyridine (10 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2 ⁇ 100 mL) and water (2 ⁇ 100 mL), and evaporated.
  • Step 1 A mixture of 3-(4-dimethylaminophenylamino)phthalic acid dimethyl ester (0.70 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • N,N-Dimethylethanolamine (0.80 g, 9.0 mmol) was added to a mixture of powdered KOH (0.50 g, 9.0 mmol) and Aliquat 336 (0.36 g, 0.9 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (1.28 g, 7.5 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (50 mL), and the organic layer was extracted with dilute aqueous HCl (2 ⁇ 50 mL).
  • Step 1 A mixture of 3-[4-(2-dimethylaminoethoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester (0.72 g, 1.8 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • N,N-Dimethylethanolamine (0.80 g, 9.0 mmol) was added to a mixture of powdered KOH (0.50 g, 9.0 mmol) and Aliquat 336 (0.36 g, 0.9 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 2-fluoro-4-methoxy-1-nitrobenzene (1.28 g, 7.5 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (50 mL), and the organic layer was extracted with dilute aqueous HCl (2 ⁇ 50 mL).
  • Step 1 A mixture of 3-[2-(2-dimethylaminoethoxy)-4-methoxyphenylamino]phthalic acid dimethyl ester (0.20 g, 0.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.10 g, 0.6 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2 ⁇ 100 mL), basified (sat. Na 2 CO 3 ), and extracted with methylene chloride (3 ⁇ 100 mL). The combined organic layers were washed with water (3 ⁇ 100 mL), dried (MgSO 4 ), and evaporated. The residue was triturated with ether and filtered, providing 0.10 g of the product, in 44% yield for the final 2 steps.
  • Step 3 4-[4-(2-Dimethylaminoethoxy)-2-methoxyphenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (0.10 g, 0.2 mmol) was dissolved in methylene chloride (30 mL) and a 2M solution of hydrogen chloride in ether (0.4 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum.
  • Step 1 A mixture of 3-[2-methoxy-4-(2-morpholin-4-ylethoxy)phenylamino]phthalic acid dimethyl ester (1.0 g, 2.2 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.36 g, 2.2 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2 ⁇ 100 mL), basified (saturated Na 2 CO 3 ), and extracted with methylene chloride (3 ⁇ 100 mL). The combined organic layers were washed with water (3 ⁇ 100 mL), dried (MgSO 4 ), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, providing 0.3 g of the product, in 27% yield over 2 steps.
  • Step 3 The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (30 mL) and a 2M solution of hydrogen chloride in ether (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum.
  • Triethylamine (5 mL) was added to a solution of 3-methoxy-4-nitrobenzyl alcohol (2.5 g, 13.6 mmol) in 50 mL of methylene chloride, and the mixture was cooled to 0° C. under nitrogen. Methanesulfonyl chloride (1.9 g, 16.3 mmol) was added dropwise and the mixture stirred at this temperature for 1 hour. Triethylamine (5 mL) was added, followed by dimethylamine hydrochloride (1.6 g, 20.4 mmol). After 5 minutes, the cooling bath was removed, and the mixture stirred at ambient temperature for 2.5 hours.
  • the mixture was diluted with methylene chloride (75 mL) and washed with water (3 ⁇ 75 mL), and extracted into dilute aqueous HCl (3 ⁇ 75 mL).
  • the combined aqueous extracts were washed with methylene chloride (3 ⁇ 75 mL), basified (3N NaOH), and extracted into methylene chloride (3 ⁇ 75 mL).
  • Step 1 A mixture of 3-(4-dimethylaminomethyl-2-methoxyphenylamino)phthalic acid dimethyl ester (0.9 g, 2.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.39 g, 2.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2 ⁇ 100 mL), basified (saturated Na 2 CO 3 ), and extracted with methylene chloride (3 ⁇ 100 mL). The combined organic layers were washed with water (3 ⁇ 100 mL), dried (MgSO 4 ), and evaporated.
  • 3-Dimethylaminopropanol (1.45 g, 14.0 mmol) was added to a mixture of powdered KOH (0.79 g, 14.0 mmol) and Aliquat 336 (0.57 g, 1.4 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (2.0 g, 11.7 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (80 mL), and the organic layer was extracted with dilute aqueous HCl (2 ⁇ 50 mL).
  • Step 1 A mixture of 3-[4-(3-dimethylaminopropoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester (0.6 g, 1.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.23 g, 1.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2 ⁇ 100 mL), basified (saturated Na 2 CO 3 ), and extracted with methylene chloride (3 ⁇ 100 mL). The combined organic layers were washed with water (3 ⁇ 100 mL), dried (MgSO 4 ), and evaporated. The residue was triturated in diethyl ether and filtered, providing 0.2 g of the product, in 29% yield over 2 steps.
  • Step 3 The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (25 mL) and a 2M solution of hydrogen chloride in ether (0.8 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum.
  • Step 1 A mixture of 3-[4-(2-dimethylamino-ethoxy)-phenylamino]-phthalic acid dimethyl ester (0.50 g, 1.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.21 g, 1.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH 2 Cl 2 (3 ⁇ 75 mL), and was basified (sat. Na 2 CO 3 ) and then extracted into ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 130 mg as an orange solid.
  • N,N-Dimethylethanolamine (1.6 g, 18 mmol) was added to a mixture of powdered KOH (1.0 g, 18 mmol) and Aliquat 336 (0.72 g, 1.8 mmol), and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-isopropoxy-1-nitrobenzene (3.0 g, 15 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (100 mL) and dilute aqueous HCl (100 mL), and the organic layer was extracted with dilute aqueous HCl (2 ⁇ 100 mL).
  • Step 1 A mixture of 3-[4-(2-dimethylamino-ethoxy)-2-isopropoxy-phenylamino]-phthalic acid dimethyl ester (1.1 g, 2.7 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.45 g, 2.7 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH 2 Cl 2 (3 ⁇ 75 mL), and was basified (sat. Na 2 CO 3 ) and then extracted into ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 260 mg as an orange solid.
  • a 60% dispersion of sodium hydride (0.86 g, 22 mmol) was added to a mixture of copper bromide (2.6 g, 17.9 mmol) and phenol (1.7 g, 17.9 mmol) in pyridine (300 mL). After the effervescence subsided, the mixture was heated to reflux for 30 minutes. 3-Iodo-4-nitroanisole (5.0 g, 17.9 mmol) was added and stirring proceeded under nitrogen for 20 hours. The mixture was cooled and the reaction was quenched with saturated ammonium chloride (1 mL). The mixture was evaporated in vacuo.
  • the mixture was cooled and evaporated under vacuum, and the residue was partitioned between ethyl acetate (100 mL) and water (150 mL), and the aqueous phase was extracted with ethyl acetate (100 mL).
  • the combined organic layers were washed with water (3 ⁇ 150 mL) and extracted into dilute aqueous HCl (3 ⁇ 75 mL).
  • the combined aqueous extracts were washed with ethyl acetate (2 ⁇ 100 mL) and basified (NaOH), and the resulting mixture was extracted with ethyl acetate (3 ⁇ 100 mL).
  • Step 1 A mixture of 3-[4-(2-dimethylamino-ethoxy)-2-phenoxy-phenylamino]-phthalic acid dimethyl ester (2.0 g, 4.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.70 g, 4.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH 2 Cl 2 (3 ⁇ 75 mL), and was basified (sat. Na 2 CO 3 ) and then extracted into ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (3 ⁇ 75 mL), dried (MgSO 4 ) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 260 mg as an orange solid.
  • Step 1 A mixture of 3-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (1.5 g, 3.6 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.59 g, 3.6 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was purified by ISCO silica gel flash chromatography in methylene chloride-methanol gradient, eluting 0.76 g at 93:7 methylene chloride-methanol, as an orange solid.
  • Step 1 A mixture of 3-[3-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (1.6 g, 3.9 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 2 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.36 g, 2.2 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue chromatographed in methylene chloride-methanol gradient, eluting the product at 93:7 methylene chloride-methanol.
  • Step 3 The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL) and a 4N solution of hydrogen chloride in dioxane (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo.
  • Step 1 A mixture of 3-[2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (0.6 g, 1.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.23 g, 1.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue chromatographed in methylene chloride-methanol gradient, eluting the product at 93:7 methylene chloride-methanol.
  • Step 3 The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL) and a 4N solution of hydrogen chloride in dioxane (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo.
  • Step 1 A mixture of 3-[2-fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (2.3 g, 5.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3 ⁇ 75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2 The product from Step 1 and rac- ⁇ -aminoglutarimide hydrochloride (0.87 g, 5.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was purified by ISCO silica gel flash chromatography in methylene chloride-methanol gradient, eluting the product at 92:8 methylene chloride-methanol. The appropriate fractions were pooled and treated with a 2N solution of hydrogen chloride in ethyl ether (10 mL). The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo.
  • N-Methylmorpholine (0.15 g, 1.5 mmol) was added to a stirred suspension of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.50 g, 1.5 mmol) in 50 mL THF under nitrogen at room temperature.
  • Ethyl chloroformate (0.16 g, 1.5 mmol) was then added.
  • cyclopropylamine (0.086 g, 1.5 mmol) was added, and stirring proceeded for 21 hours.
  • Step 1 To a stirred solution of dimethyl 3-aminophthalate (4.2 g, 20 mmol) in CH 2 Cl 2 (100 mL), were added glyoxylic acid (3.7 g, 40 mmol) and acetic acid (6.9 mL). The mixture was stirred for 5 minutes followed by addition of sodium triacetoxyborohydride (13 g, 60 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was washed with 0.1N HCl (3 ⁇ 100 mL) and brine (100 mL), and dried (MgSO 4 ). The solvent was evaporated leaving an oily residue, which was dissolved in sat. aq. sodium bicarbonate (50 mL).
  • Step 2 A sample of the product from step 1 (0.53 g, 2.0 mmol) was suspended in THF and cooled to 0° C. under nitrogen. N-Methylmorpholine (0.20 g, 2.0 mmol) was added, followed by ethyl chloroformate (0.22 g, 2.0 mmol). The mixture was stirred for 10 minutes, and then aniline (0.19 g, 2.0 mmol) was added. The mixture was stirred at room temperature for 2 hours and then at reflux for 1 hour. The solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL).
  • Step 3 The product from step 2 was added to a mixture of 5N KOH (3 mL) and methanol (20 mL), and the resulting mixture was stirred at room temperature for 18 hours. The solvent was evaporated, and the residue was dissolved in water (50 mL) and washed with ethyl acetate (50 mL). The aqueous phase was then acidified to pH 2-3 (conc. HCl) and then extracted with ethyl acetate (3 ⁇ 75 mL). The combined ethyl acetate extracts were washed with brine (100 mL) and dried (MgSO 4 ). The solvent was evaporated in vacuo, affording 0.41 g of the sample.
  • Step 4 The product from step 3 and rac- ⁇ -aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) were dissolved in pyridine (20 mL), and the resulting mixture was heated to reflux for 18 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH 2 Cl 2 (150 mL), washed with water (2 ⁇ 100 mL), sat. sodium bicarbonate (100 mL), and brine (100 mL), and dried (MgSO 4 ). The solution was treated with Norite ( ⁇ 1 g), stirred for 10 minutes, and filtered through Celite.
  • Step 1 To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH 2 Cl 2 (40 mL), were added 2-pyridinecarboxaldehyde (0.86 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 50 mL of CH 2 Cl 2 , washed with water (3 ⁇ 100 mL), saturated aqueous sodium bicarbonate (2 ⁇ 100 mL), and brine (100 mL), and dried (MgSO 4 ).
  • Step 2 A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (20 mL), washed with diethyl ether (2 ⁇ 100 mL), and acidified to pH 2-3 (conc. HCl), and then evaporated once more, giving a white solid.
  • Step 3 The product from step 2 and rac- ⁇ -aminoglutarimide hydrochloride (0.66 g, 4.0 mmol) were dissolved in pyridine (40 mL), and the resulting mixture was heated to reflux for 5 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH 2 Cl 2 (100 mL), washed with water (3 ⁇ 100 mL) and brine (100 mL), and dried (MgSO 4 ). The solution was treated with Norite ( ⁇ 2 g), stirred for 30 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow semi-solid.
  • This material was purified by preparative HPLC, running with 25:75 ACN—H 2 O, providing 0.72 g of the free base. This material was dissolved in 1:1 CH 2 Cl 2 -MeOH (30 mL) and treated with 4N HCl/dioxane (2 mL).
  • Step 1 To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH 2 Cl 2 (40 mL), were added 4-pyridinecarboxaldehyde (0.86 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 60 mL of CH 2 Cl 2 , washed with water (3 ⁇ 100 mL), saturated aqueous sodium bicarbonate (3 ⁇ 100 mL), and brine (100 mL), and dried (MgSO 4 ).
  • Step 2 A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (20 mL), washed with diethyl ether (2 ⁇ 100 mL), and acidified to pH 2-3 (conc. HCl), and then evaporated once more, and the resulting solid was dried under high vacuum overnight.
  • Step 3 The product from step 2 and rac- ⁇ -aminoglutarimide hydrochloride (0.66 g, 4.0 mmol) were dissolved in pyridine (30 mL), and the resulting mixture was heated to reflux for 5 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH 2 Cl 2 (125 mL), washed with water (3 ⁇ 100 mL) and brine (100 mL), and dried (MgSO 4 ). The solution was treated with Norite ( ⁇ 3 g), stirred for 10 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow solid, which was triturated with methanol (15 mL), filtered and dried.
  • This material was suspended in MeOH and treated with 2N HCl/diethyl ether. After stirring for 10 minutes, the solvent was evaporated, and the resulting residue was dissolved in water (100 mL) and washed with ethyl acetate. The aqueous phase was then neutralized (sat. aq. NaHCO 3 ) and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic extracts were washed with brine (100 mL), dried (MgSO 4 ) and then treated with 2N HCl/diethyl ether (2 mL).
  • Step 2 A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated and the resulting white solid was dissolved in water (50 mL), washed with diethyl ether (2 ⁇ 50 mL), and acidified to pH 2-3 (conc. HCl). The aqueous mixture was then extracted with ethyl acetate (3 ⁇ 75 mL). The combined organic extracts were washed with water (100 mL), brine (100 mL), and dried (MgSO 4 ) and evaporated, providing a light brown-yellow oil.
  • Step 3 The product from step 2 and ⁇ -methyl- ⁇ -aminoglutarimide hydrochloride (0.71 g, 4.0 mmol) were dissolved in pyridine (30 mL), and the resulting mixture was heated to reflux for 20 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH 2 Cl 2 (125 mL), washed with water (3 ⁇ 100 mL), 0.1N HCl (2 ⁇ 100 mL), and brine (100 mL), and dried (MgSO 4 ).
  • Step 2 2N HCl/ether solution (8.5 mL) was added to a stirred solution of [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamic acid t-butyl ester (2.3 g, 5.7 mmol) in ethyl acetate (20 mL). The mixture was stirred at room temperature overnight.
  • Step 3 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.2 g, 2.2 mmol) was added to a stirred suspension of 4-aminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.3 g, 1.0 mmol) in acetonitrile (40 mL). After stirring for 30 minutes, ethyl isocyanate (0.09 g, 1.3 mmol) was added, and the mixture was stirred at room temperature for 24 hours. The mixture was concentrated and the residue was dissolved in methylene chloride (60 mL).
  • 2-Methoxyphenyl isocyanate (0.4 g, 2.6 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.8 mmol) in THF (30 mL) at 5-10° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes.

Abstract

This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Description

  • This application claims priority to U.S. provisional No. 60/712,387, filed Aug. 31, 2005, the entirety of which is incorporated herein by reference.
    • 1. FIELD OF THE INVENTION
  • This invention relates to isoindole-imide compounds. Pharmaceutical compositions comprising the compounds and methods for treating, preventing and managing various disorders are also disclosed.
    • 2. BACKGROUND OF THE INVENTION
  • 2.1 Pathobiology of Cancer and Other Diseases
  • Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, or lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis). Clinical data and molecular biologic studies indicate that cancer is a multistep process that begins with minor preneoplastic changes, which may under certain conditions progress to neoplasia. The neoplastic lesion may evolve clonally and develop an increasing capacity for invasion, growth, metastasis, and heterogeneity, especially under conditions in which the neoplastic cells escape the host's immune surveillance. Roitt, I., Brostoff, J and Kale, D., Immunology, 17.1-17.12 (3rd ed., Mosby, St. Louis, Mo., 1993). There is an enormous variety of cancers which are described in detail in the medical literature. Examples includes cancer of the lung, colon, rectum, prostate, breast, brain, and intestine. The incidence of cancer continues to climb as the general population ages, as new cancers develop, and as susceptible populations (e.g., people infected with AIDS or excessively exposed to sunlight) grow. However, options for the treatment of cancer are limited. For example, in the case of blood cancers (e.g., multiple myeloma), few treatment options are available, especially when conventional chemotherapy fails and bone-marrow transplantation is not an option. A tremendous demand therefore exists for new methods and compositions that can be used to treat patients with cancer.
  • Many types of cancers are associated with new blood vessel formation, a process known as angiogenesis. Several of the mechanisms involved in tumor-induced angiogenesis have been elucidated. The most direct of these mechanisms is the secretion by the tumor cells of cytokines with angiogenic properties. Examples of these cytokines include acidic and basic fibroblastic growth factor (a,b-FGF), angiogenin, vascular endothelial growth factor (VEGF), and TNF-α. Alternatively, tumor cells can release angiogenic peptides through the production of proteases and the subsequent breakdown of the extracellular matrix where some cytokines are stored (e.g., b-FGF). Angiogenesis can also be induced indirectly through the recruitment of inflammatory cells (particularly macrophages) and their subsequent release of angiogenic cytokines (e.g., TNF-α, bFGF).
  • A variety of other diseases and disorders are also associated with, or characterized by, undesired angiogenesis. For example, enhanced or unregulated angiogenesis has been implicated in a number of diseases and medical conditions including, but not limited to, ocular neovascular diseases, choroidal neovascular diseases, retina neovascular diseases, rubeosis (neovascularization of the angle), viral diseases, genetic diseases, inflammatory diseases, allergic diseases, and autoimmune diseases. Examples of such diseases and conditions include, but are not limited to: diabetic retinopathy; retinopathy of prematurity; corneal graft rejection; neovascular glaucoma; retrolental fibroplasia; and proliferative vitreoretinopathy.
  • Accordingly, compounds that can control angiogenesis or inhibit the production of certain cytokines, including TNF-α, may be useful in the treatment and prevention of various diseases and conditions.
  • 2.2 Methods of Treating Cancer
  • Current cancer therapy may involve surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient (see, e.g., Stockdale, 1998, Medicine, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV). Recently, cancer therapy could also involve biological therapy or immunotherapy. All of these approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of a patient or may be unacceptable to the patient.
  • Additionally, surgery may not completely remove neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue. Radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent. Although hormonal therapy can be effective, it is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of cancer cells. Biological therapies and immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.
  • With respect to chemotherapy, there are a variety of chemotherapeutic agents available for treatment of cancer. A majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division. Gilman et al., Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Tenth Ed. (McGraw Hill, New York).
  • Despite availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks. Stockdale, Medicine, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10, 1998. Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous side effects including severe nausea, bone marrow depression, and immunosuppression. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even if those agents act by different mechanism from those of the drugs used in the specific treatment. This phenomenon is referred to as pleiotropic drug or multidrug resistance. Because of the drug resistance, many cancers prove or become refractory to standard chemotherapeutic treatment protocols.
  • Other diseases or conditions associated with, or characterized by, undesired angiogenesis are also difficult to treat. However, some compounds such as protamine, hepain and steroids have been proposed to be useful in the treatment of certain specific diseases. Taylor et al., Nature 297:307 (1982); Folkman et al., Science 221:719 (1983); and U.S. Pat. Nos. 5,001,116 and 4,994,443.
  • Still, there is a significant need for safe and effective methods of treating, preventing and managing cancer and other diseases and conditions, particularly for diseases that are refractory to standard treatments, such as surgery, radiation therapy, chemotherapy and hormonal therapy, while reducing or avoiding the toxicities and/or side effects associated with the conventional therapies.
    • 3. SUMMARY OF THE INVENTION
  • This invention is directed, in part, to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates (e.g., hydrates), prodrugs, or stereoisomers thereof.
  • This invention also encompasses methods of treating and managing various diseases or disorders. The methods comprise administering to a patient in need of such treatment or management a therapeutically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • The invention also encompasses methods of preventing various diseases and disorders, which comprise administering to a patient in need of such prevention a prophylactically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, or prodrug thereof.
  • This invention also encompasses pharmaceutical compositions, single unit dosage forms, dosing regimens and kits which comprise a compound of this invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
    • 4. DETAILED DESCRIPTION OF THE INVENTION
  • In one embodiment, this invention encompasses isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof. In another embodiment, this invention encompasses methods of treating, managing, and preventing various diseases and disorders, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof. Examples of diseases and disorders are described herein.
  • In particular embodiments, a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is administered in combination with another drug (“second active agent”) or treatment. Second active agents include small molecules and large molecules (e.g., proteins and antibodies), examples of which are provided herein, as well as stem cells. Methods, or therapies, that can be used in combination with the administration of compounds of this invention include, but are not limited to, surgery, blood transfusions, immunotherapy, biological therapy, radiation therapy, and other non-drug based therapies presently used to treat, prevent or manage various disorders described herein.
  • This invention also encompasses pharmaceutical compositions (e.g., single unit dosage forms) that can be used in methods disclosed herein. Particular pharmaceutical compositions comprise a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and optionally a second active agent.
  • 4.1 Compounds
  • In one embodiment, this invention encompasses compounds of formula (I):
    Figure US20070049618A1-20070301-C00001
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
    X is O or S;
    R1 is H or methyl;
    R2 is: (C2-C6)alkyl, excluding cycloalkyl; (C4-C6)cycloalkyl; (C1-C4)alkoxy;
      • (C1-C6)alkyl, substituted with (C1-C4)alkoxy;
      • (C0-C1)alkyl-phenyl, wherein the phenyl is optionally substituted with one or more of halogen, (C1-C4)alkoxy, (C1-C4)alkyl, or cyano;
      • (C0-C1)alkyl-(5 to 6 membered heteroaryl), wherein the heteroaryl is optionally substituted with one or more of (C1-C4)alkyl or halogen; or
      • (C0-C3)alkyl-NR3R4;
        R3 and R4 are each independently:
      • H; (C1-C6)alkyl; (C3-C6)cycloalkyl;
      • (C0-C1)alkyl-(C6-C10)aryl, wherein the aryl is optionally substituted with one or more of (C1-C4)alkoxy, halogen, methyl, cyano, or —O—CH2—O—;
      • (C0-C1)alkyl-(5 to 10 membered heteroaryl), wherein the heteroaryl is substituted with one or more of (C1-C4)alkoxy, halogen, or methyl; or C(O)R5; and
        R5 is (C1-C4)alkoxy or (C1-C2)alkyl-O—(C1-C2)alkyl;
        with the proviso that if one of R3 and R4 is H, then the other is not ethyl.
  • In one embodiment, X is O. In another embodiment, X is S. In another embodiment, R2 is phenyl, optionally substituted with one or more halogen.
  • In another embodiment, R2 is NHR4. In a specific embodiment, R4 is (C6-C10)aryl or 5 to 10 membered heteroaryl, both optionally substituted with one or more of (C1-C4)alkoxy, halogen, and methyl. In particular, the aryl or heteroaryl is phenyl, pyridyl, or naphthyl.
  • Examples of compounds of formula (I) include, but are not limited to, those listed in Table 1, below:
    TABLE 1
    Compounds of Formula I
    No. Structure Name
    1
    Figure US20070049618A1-20070301-C00002
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo2,3-dihydro-1H- isoindol-4-ylmethyl]-2- phenyl-acetamide
    2
    Figure US20070049618A1-20070301-C00003
         		1-Cyclohexyl-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    3
    Figure US20070049618A1-20070301-C00004
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- benzamide
    4
    Figure US20070049618A1-20070301-C00005
         		Furan-2-carboxylic acid[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    5
    Figure US20070049618A1-20070301-C00006
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-1-isoindol-4-ylmethyl]- butyramide
    6
    Figure US20070049618A1-20070301-C00007
         		3-Chloro-N-[2-(2,6-dioxo- piperidine-3-yl)-1-oxo-2,3- dihydro-1H-sioindol-4- ylmethyl]-benzamide
    7
    Figure US20070049618A1-20070301-C00008
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- propyl-urea
    8
    Figure US20070049618A1-20070301-C00009
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- nicotinamide
    9
    Figure US20070049618A1-20070301-C00010
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- phenyl-urea
    10
    Figure US20070049618A1-20070301-C00011
         		[2-(2,6-Dioxo-piperidin-3 - yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- carbamic acid tert-butyl ester
    11
    Figure US20070049618A1-20070301-C00012
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- methoxy-benzamide
    12
    Figure US20070049618A1-20070301-C00013
         		3-Cyano-N-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-benzamide
    13
    Figure US20070049618A1-20070301-C00014
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-4- methoxy-benzamide
    14
    Figure US20070049618A1-20070301-C00015
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-2- methoxy-benzamide
    15
    Figure US20070049618A1-20070301-C00016
         		1-[2-(2,6-Dioxo-pipderidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (3-methoxy-phenyl)-urea
    16
    Figure US20070049618A1-20070301-C00017
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (4-methoxy-phenyl)-urea
    17
    Figure US20070049618A1-20070301-C00018
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (2-methoxy-phenyl)-urea
    18
    Figure US20070049618A1-20070301-C00019
         		1-(3-Cyano-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-ylmethyl]-urea
    19
    Figure US20070049618A1-20070301-C00020
         		1-(3-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    20
    Figure US20070049618A1-20070301-C00021
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- isonicotinamide
    21
    Figure US20070049618A1-20070301-C00022
         		Pyridine-2-carboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    22
    Figure US20070049618A1-20070301-C00023
         		1-Benzyl-3-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-urea
    23
    Figure US20070049618A1-20070301-C00024
         		1-(3,4-Dichloro-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H-1- isoindol-4-ylmethyl]-urea
    24
    Figure US20070049618A1-20070301-C00025
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmehyl]-3- pyridin-3-yl-urea
    25
    Figure US20070049618A1-20070301-C00026
         		3-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- 1,1-dimethyl-urea
    26
    Figure US20070049618A1-20070301-C00027
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- methyl-benzamide
    27
    Figure US20070049618A1-20070301-C00028
         		(2-{[2-(2,6-Dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-carbamoyl}- ethyl)-carbamic acid t-butyl ester
    28
    Figure US20070049618A1-20070301-C00029
         		3-Amino-N-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-propionamide Hydrochloride
    29
    Figure US20070049618A1-20070301-C00030
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-2- methoxy-acetamide
    30
    Figure US20070049618A1-20070301-C00031
         		2-Dimethylamino-N-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide Hydrochloride
    31
    Figure US20070049618A1-20070301-C00032
         		(3-{[2-(2,6-Dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-carbamoyl}- propyl)-carbamic acid t- butyl ester
    32
    Figure US20070049618A1-20070301-C00033
         		4-Amino-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-butyramide hydrochloride
    33
    Figure US20070049618A1-20070301-C00034
         		1-(4-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    34
    Figure US20070049618A1-20070301-C00035
         		1-(3,4-Dimethyl-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    35
    Figure US20070049618A1-20070301-C00036
         		1-Cyclohexyl-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- thiourea
    36
    Figure US20070049618A1-20070301-C00037
         		3,4-Dichloro-N-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide
    37
    Figure US20070049618A1-20070301-C00038
         		1-(3-Chloro-4- methylphenyl)-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]urea
    38
    Figure US20070049618A1-20070301-C00039
         		1-[2-(2,6-Dioxopiperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-3- naphthalen-1-yl-urea
    39
    Figure US20070049618A1-20070301-C00040
         		1-[2-(2,6-Dioxopiperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-3- naphthalen-2-yl-urea
  • In another embodiment, this invention encompasses compounds of formula
    Figure US20070049618A1-20070301-C00041
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
    • R1 is H or methyl; and
    • R2 is: (C6-C10)aryl, optionally substituted with one or more of: (C1-C8)alkyl, optionally substituted with NH2, NH(CH3), or N(CH3)2; (C1-C4)alkoxy, optionally substituted with NH2, NH(CH3), N(CH3)2, or 3 to 6 membered heterocycloalkyl; (C3-C6)cycloalkyl; (C5-C10)aryloxy; hydroxy; NH2; NH(CH3); N(CH3)2; —CH2—CH2—CH2—; halogen; or —O—CH2—O—;
      • (C3-C6)alkyl, optionally substituted with one or more of (C1-C4)alkoxy;
      • (C1-C2)alkyl, optionally substituted with carboxyl;
      • (C1-C6)alkyl-(C3-C6)cycloalkyl; or
      • 5 to 10 membered heterocycle;
        with the proviso that if R2 is pentyl, then R1 is methyl.
  • In one embodiment, R2 is phenyl, optionally substituted with one or more of (C1-C4)alkoxy or —O—CH2—O—. In another embodiment, R2 is phenyl substituted with one or more (C1-C4)alkoxy, substituted with N(CH3)2. In another embodiment, R2 is (C3-C6)alkyl, optionally substituted with one or more of (C1-C4)alkoxy.
  • Examples of compounds of formula (II) include, but are not limited to, those listed in Table 2, below:
    TABLE 2
    Compounds of Formula II
    No. Structure Name
    40
    Figure US20070049618A1-20070301-C00042
         		2-(2,6-Dioxopiperidin-3-yl)-4- phenylaminoisoindole-1,3- dione
    41
    Figure US20070049618A1-20070301-C00043
         		2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- methylenedioxyphenylamino) isoindole-1,3-dione
    42
    Figure US20070049618A1-20070301-C00044
         		2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- dimethoxyphenylamino) isoindole-1,3-dione
    43
    Figure US20070049618A1-20070301-C00045
         		2-(3-Methyl-2,6- dioxopiperidin-3-yl)-4- pentylaminoisoindole-1,3- dione
    44
    Figure US20070049618A1-20070301-C00046
         		4-(Cyclopropylmethylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    45
    Figure US20070049618A1-20070301-C00047
         		[2-(2,6-Dioxopiperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-yl-amino]acetic acid
    46
    Figure US20070049618A1-20070301-C00048
         		2-(2,6-Dioxopiperidin-3-yl)-4- (2-methoxy-1- methylethylamino)isoindole- 1,3-dione
    47
    Figure US20070049618A1-20070301-C00049
         		4-(4-ert-Butylphenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    48
    Figure US20070049618A1-20070301-C00050
         		4-(4-Isopropylphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    49
    Figure US20070049618A1-20070301-C00051
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-(indan-5-ylamino)-isoindole- 1,3-dione
    50
    Figure US20070049618A1-20070301-C00052
         		4-(2,4- Dimethoxyphenylamino)-2- (2,6-dioxopiperidin-3- yI)isoindole-1,3-dione
    51
    Figure US20070049618A1-20070301-C00053
         		2-(2,6-Dioxopiperidin-3-yl)-4- (4-methoxyphenylamino) isoindole-1,3-dione
    52
    Figure US20070049618A1-20070301-C00054
         		2-(2,6-Dioxopiperidin-3-yl)-4- (3-ethoxy-4- methoxyphenylamino)- isoindole-1,3-dione
    53
    Figure US20070049618A1-20070301-C00055
         		2-(2,6-Dioxopiperidin-3-yl)-4- (3-hydroxy-4- methoxyphenylainino)- isoindole-1,3-dione
    54
    Figure US20070049618A1-20070301-C00056
         		2-(2,6-Dioxopiperidin-3-yl)-4- (naphthalen-2-ylamino) isoindole-1,3-dione
    55
    Figure US20070049618A1-20070301-C00057
         		4-(4-Cyclohexylphenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    56
    Figure US20070049618A1-20070301-C00058
         		4-(2-Methoxyphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    57
    Figure US20070049618A1-20070301-C00059
         		4-(2,5- Dimethoxyphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    58
    Figure US20070049618A1-20070301-C00060
         		4-(2-Phenoxyphenylamino)-2- (2,6-dioxopipendin-3-yl) isoindole-1,3-dione
    59
    Figure US20070049618A1-20070301-C00061
         		4-(4- Dimethylaminophenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
    60
    Figure US20070049618A1-20070301-C00062
         		4-[4-(2- Dimethylaminoethoxy)-2- methoxyphenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione
    61
    Figure US20070049618A1-20070301-C00063
         		Dimethylaminoethoxy)-2- methoxyphenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione hydrochloride
    62
    Figure US20070049618A1-20070301-C00064
         		4-[2-(2-Dimethylaminoethoxy)- 4-methoxyphenylamino]-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione hydrochloride
    63
    Figure US20070049618A1-20070301-C00065
         		2-(2,6-Dioxopiperidin-3-yl)-4- [2-methoxy-4-(2-morpholin-4- ylethoxy)phenylamino]- isoindole-1,3-dione hydrochloride
    64
    Figure US20070049618A1-20070301-C00066
         		4-(4-Dimethylaminomethyl-2- methoxyphenylamino)-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione
    65
    Figure US20070049618A1-20070301-C00067
         		4-(4-Dimethylaminomethyl-2- methoxyphenylamino)-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione hydrochloride
    66
    Figure US20070049618A1-20070301-C00068
         		Dimethylaminopropoxy)-2- methoxyphenylamino]-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione hydrochloride
    67
    Figure US20070049618A1-20070301-C00069
         		4-[4-(2-Dimethylamino- ethoxy)-phenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione
    68
    Figure US20070049618A1-20070301-C00070
         		4-[4-(2-Dimethylamino- ethoxy)-2-isopropoxy- phenylamino]-2-(2,6-dioxo- piperidin-3-yl)-isoindole-1,3- dione
    69
    Figure US20070049618A1-20070301-C00071
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-(4-methoxy-2-phenoxy- phenylamino)-isoindole-1,3- dione
    70
    Figure US20070049618A1-20070301-C00072
         		4-[4-(2-Dimethylamino- ethoxy)-2-phenoxy- phenylamino]-2-(2,6-dioxo- piperidin-3-yl)-isoindole-1,3- dione
    71
    Figure US20070049618A1-20070301-C00073
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-[4-(2-morpholin-4-yl- ethoxy)-phenylamino]- isoindole-1,3-dione
    72
    Figure US20070049618A1-20070301-C00074
         		2-(2,6-Dioxo-piperidin-3-yl)- [3-(2-morpholin-4-yl- ethoxy)-phenylamino]- isoindole-1,3-dione
    73
    Figure US20070049618A1-20070301-C00075
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-methoxy-4-(2-piperidin- 1-yl-ethoxy)-phenylamino]- isoindole-1,3-dione
    74
    Figure US20070049618A1-20070301-C00076
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-methoxy-4-(2-pyrrolidin- 1-yl-ethoxy)-phenylamino]- isoindole-1,3-dione
    75
    Figure US20070049618A1-20070301-C00077
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-fluoro-4-(2-morpholin-4- yl-ethoxy)-phenylamino]- isoindole-1,3-dione
    76
    Figure US20070049618A1-20070301-C00078
         		4-(2,4-Dimethoxy- phenylamino)-2-[(3S)-3- methyl-2,6-dioxo-piperidin-3- yl]-isoindole-1,3-dione
    77
    Figure US20070049618A1-20070301-C00079
         		4-(Indan-5-ylamino)-2-[(3S)- 3-methyl-2,6-dioxo-piperidin- 3-yl]-isoindole-1,3-dione
    78
    Figure US20070049618A1-20070301-C00080
         		2-(2,6-Dioxo-piperidin-3-yl)- 4-(3-methoxy-phenylamino)- isoindole-1,3-dione
  • In another embodiment, this invention encompasses compounds of formula
    Figure US20070049618A1-20070301-C00081
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
    • R1 is H or methyl; and
    • R2 is: amino, optionally substituted with one or more of (C1-C6)alkyl, (C3-C6)cycloalkyl, or phenyl; 3 to 6 membered heterocycloalkyl; or (C1-C4)alkoxy.
  • In one specific embodiment, R2 is —NH(CH3) or —N(CH3)2. In another embodiment, R2 is (C3-C6)cycloalkyl.
  • Examples of compounds of formula (III) include, but are not limited to, those listed in Table 3, below:
    TABLE 3
    Compounds of Formula III
    No. Structure Name
    79
    Figure US20070049618A1-20070301-C00082
         		2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide
    80
    Figure US20070049618A1-20070301-C00083
         		[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]acetic acid methyl ester
    81
    Figure US20070049618A1-20070301-C00084
         		2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide
    82
    Figure US20070049618A1-20070301-C00085
         		N-Cyclopropyl-2-[2-(2,6- dioxopiperidin-3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylamino]acetamide
    83
    Figure US20070049618A1-20070301-C00086
         		4-(2-(Azetidin-1-yl)-2- oxoethylamino)-2-(2,6-dioxo piperidin-3-yl)isoindoline-1,3- dione
    84
    Figure US20070049618A1-20070301-C00087
         		2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-phenyl-acetamide
  • In another embodiment, this invention encompasses compounds of formula (IV): or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof:
    Figure US20070049618A1-20070301-C00088
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein R1 is H or methyl; and R2 is 5 to 6 membered heteroaryl;
    with the proviso that if R2 is furan or thiophene, then R1 is methyl; and
    with the proviso that if R2 is pyridine, then the pyridine is not connected to the core at the 3 position.
  • In one specific embodiment, R2 is not pyridine.
  • Examples of compounds of formula IV include, but are not limited to, those listed in Table 4, below:
    TABLE 4
    Compounds of Formula IV
    No. Structure Name
    85
    Figure US20070049618A1-20070301-C00089
         		2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-2-yl- methyl)amino]isoindole-1,3-dione hydrochloride
    86
    Figure US20070049618A1-20070301-C00090
         		2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-4-yl- methyl)amino]isoindole-1,3-dione hydrochloride
    87
    Figure US20070049618A1-20070301-C00091
         		[(Furan-2-ylmethyl)amino]-2- (3-methyl-2,6-dioxopiperidin-3- yl)isoindole-1,3-dione
  • In another embodiment, this invention encompasses compounds of formula (V):
    Figure US20070049618A1-20070301-C00092
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof:
    wherein:
    R1 is H or methyl; and
    R2 is: H; methyl; ethyl;
      • phenyl, substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, cyano, or —O—CH2—O—;
      • naphthyl, optionally substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, or cyano; or
      • 5 to 10 membered heteroaryl, optionally substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, or cyano;
        with the proviso that if R2 is ethyl, then R1 is methyl; and
        with the proviso that if R2 is pyridine, then the pyridine is not connected to the core at the 3 position.
  • In one specific embodiment, R2 is phenyl, optionally substituted with one or more of methyl, halogen, (C1-C4)alkoxy, cyano, and —O—CH2—O—. In another embodiment, R2 is naphthyl. In another embodiment, R2 is not pyridine.
  • Examples of compounds of formula (V) include, but are not limited to, those listed in Table 5, below:
    TABLE 5
    Compounds of Formula V
    No. Structure Name
    88
    Figure US20070049618A1-20070301-C00093
         		1-Ethyl-3-[2-(3-methyl- 2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    89
    Figure US20070049618A1-20070301-C00094
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(3-methoxy- phenyl)-urea
    90
    Figure US20070049618A1-20070301-C00095
         		1-(3-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    91
    Figure US20070049618A1-20070301-C00096
         		1-(3-Cyano-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea
    92
    Figure US20070049618A1-20070301-C00097
         		1-[2-(2,6-Dioxo-piperidin- dihydro-1H-isoindol-4- ylmethyl]-3-(4-methoxy- phenyl)-urea
    93
    Figure US20070049618A1-20070301-C00098
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(2-methoxy- phenyl)-urea
    94
    Figure US20070049618A1-20070301-C00099
         		1-(3,4- Methylenedioxyphenyl)-3- [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4- ylmethyl]urea
    95
    Figure US20070049618A1-20070301-C00100
         		1-(3-Chloro-4- methylphenyl)-3-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]urea
    96
    Figure US20070049618A1-20070301-C00101
         		1-(3,4-dichlorophenyl)-3- [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4- ylmethyl]urea
    97
    Figure US20070049618A1-20070301-C00102
         		1-[2-(2,6-Dioxopiperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-naphthalen-1- yl-urea
    98
    Figure US20070049618A1-20070301-C00103
         		1-[2-(2,6-Dioxopiperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-naphthalen-2- yl-urea
    99
    Figure US20070049618A1-20070301-C00104
         		1-(3,4-Dimethyl-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- urea
    100
    Figure US20070049618A1-20070301-C00105
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-m-tolyl-urea
    101
    Figure US20070049618A1-20070301-C00106
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-pyridin-2-yl- urea
    102
    Figure US20070049618A1-20070301-C00107
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-p-tolyl-urea
    103
    Figure US20070049618A1-20070301-C00108
         		1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-o-tolyl-urea
    104
    Figure US20070049618A1-20070301-C00109
         		[2-(2,6-Dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- urea
  • In another embodiment, this invention encompasses compounds of formula (VI):
    Figure US20070049618A1-20070301-C00110
    and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, wherein:
    R1 is H or methyl; and
    R2 is: N(CH3)2;
      • (C0-C1)alkyl-(C6-C10)aryl, substituted with one or more of: methyl, itself optionally substituted with one or more halogen; (C1-C4)alkoxy, itself optionally substituted with one or more halogen; or halogen;
      • (C0-C1)alkyl-(5 to 10 membered heteroaryl), optionally substituted with one or more of (C1-C4)alkyl, (C1-C4)alkoxy, or halogen; or
      • (5 to 6 membered heteroaryl)-phenyl, wherein the heteroaryl and phenyl are each independently optionally substituted with one or more of (C1-C4)alkyl or (C1-C4)alkoxy;
        with the proviso that R2 is not unsubstituted pyridine, furan, or thiophene.
  • In one specific embodiment, R2 is phenyl, substituted with one or more of methyl, (C1-C4)alkoxy, and halogen. In another embodiment, R2 is pyrazine, pyrimidine, quinoxaline, or isoquinoline, optionally substituted with one or more of (C1-C4)alkyl and halogen. In another embodiment, R2 is 5 membered heteroaryl, substituted with one of more (C1-C4)alkyl.
  • Examples of compounds of formula (VI) include, but are not limited to, those listed in Table 6, below:
    TABLE 6
    Compounds of Formula VI
    No. Structure Name
    105
    Figure US20070049618A1-20070301-C00111
         		3-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-1,1-dimethyl- urea
    106
    Figure US20070049618A1-20070301-C00112
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-methoxy- benzamide
    107
    Figure US20070049618A1-20070301-C00113
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-methyl- benzamide
    108
    Figure US20070049618A1-20070301-C00114
         		3,4-Dichloro-N-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl- methyl]benzamide
    109
    Figure US20070049618A1-20070301-C00115
         		Isoquinoline-3-carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro- isoindol-4-ylmethyl]amide
    110
    Figure US20070049618A1-20070301-C00116
         		5-Butylpyridine-2- carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide
    111
    Figure US20070049618A1-20070301-C00117
         		6-Bromopyridine-2- carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide
    112
    Figure US20070049618A1-20070301-C00118
         		6-Methylpyridine-2- carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide
    113
    Figure US20070049618A1-20070301-C00119
         		Pyrazine-2-carboxylic acid [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- H-isoindol-4-yl- methyl]amide
    114
    Figure US20070049618A1-20070301-C00120
         		Quinoxaline-2-carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide
    115
    Figure US20070049618A1-20070301-C00121
         		Pyrimidine-5-carboxylic acid[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro- isoindol-4-ylmethyl]amide
    116
    Figure US20070049618A1-20070301-C00122
         		2,5-Dichloro-N-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl- methyl]nicotinamide
    117
    Figure US20070049618A1-20070301-C00123
         		6-(3-Ethoxy-4- methoxyphenyl)pyridine-2- carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide
    118
    Figure US20070049618A1-20070301-C00124
         		1H-Indole-2-carboxylic acid[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-amide
    119
    Figure US20070049618A1-20070301-C00125
         		1,5-Dimethyl-1H-pyrazole- 3-carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    120
    Figure US20070049618A1-20070301-C00126
         		5-Methyl-isoxazole-3- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    121
    Figure US20070049618A1-20070301-C00127
         		1-Methyl-1H-pyrrole-2- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    122
    Figure US20070049618A1-20070301-C00128
         		3-Methyl-3H-imidazole-4- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    123
    Figure US20070049618A1-20070301-C00129
         		N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4- trifluoromethyl-benzamide
    124
    Figure US20070049618A1-20070301-C00130
         		5-Phenyl- [1,3,4]oxadiazole-2- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethylamide
    125
    Figure US20070049618A1-20070301-C00131
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3- trifluoromethyl-benzamide
    126
    Figure US20070049618A1-20070301-C00132
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3,4-difluoro- benzamide
    127
    Figure US20070049618A1-20070301-C00133
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-fluoro- benzamide
    128
    Figure US20070049618A1-20070301-C00134
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-methyl- benzamide
    129
    Figure US20070049618A1-20070301-C00135
         		3,5-Dichloro-N-[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide
    130
    Figure US20070049618A1-20070301-C00136
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3,5-difluoro- benzamide
    131
    Figure US20070049618A1-20070301-C00137
         		4-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-benzamide
    132
    Figure US20070049618A1-20070301-C00138
         		2-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-benzamide
    133
    Figure US20070049618A1-20070301-C00139
         		3-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-4-methyl- benzamide
    134
    Figure US20070049618A1-20070301-C00140
         		Benzofuran-2-carboxylic acid[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-amide
    135
    Figure US20070049618A1-20070301-C00141
         		2-(3,4-Dichloro-phenyl)-N- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- acetamide
    136
    Figure US20070049618A1-20070301-C00142
         		2-(3-Chloro-phenyl)-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide
    137
    Figure US20070049618A1-20070301-C00143
         		Benzo[1,3]dioxole-5- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    138
    Figure US20070049618A1-20070301-C00144
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4-yl- methyl]-3,4-dimethoxy- benzamide
    139
    Figure US20070049618A1-20070301-C00145
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4- trifluoromethoxy- benzamide
    140
    Figure US20070049618A1-20070301-C00146
         		N-[2-(2,6-Dioxo-piperidin- dihydro-1H-isoindol-4- ylmethyl]-3- trifluoromethoxy- benzamide
    141
    Figure US20070049618A1-20070301-C00147
         		4-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide
    142
    Figure US20070049618A1-20070301-C00148
         		3-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide
    143
    Figure US20070049618A1-20070301-C00149
         		2-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide
    144
    Figure US20070049618A1-20070301-C00150
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-fluoro- benzamide
    145
    Figure US20070049618A1-20070301-C00151
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(4-fluoro- phenyl)-acetamide
    146
    Figure US20070049618A1-20070301-C00152
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-fluoro- phenyl)-acetamide
    147
    Figure US20070049618A1-20070301-C00153
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(2-fluoro- phenyl)-acetamide
    148
    Figure US20070049618A1-20070301-C00154
         		2-(3,5-Difluoro-phenyl)-N- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isindol-4-ylmethyl]- acetamide
    149
    Figure US20070049618A1-20070301-C00155
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- trifluoromethoxy-phenyl)- acetamide
    150
    Figure US20070049618A1-20070301-C00156
         		2-(3,5-Bis-trifluoromethyl- phenyl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide
    151
    Figure US20070049618A1-20070301-C00157
         		(N-[2-(2,6-Dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-2-(4- trifluoromethyl-phenyl)- acetamide
    152
    Figure US20070049618A1-20070301-C00158
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- trifluoromethyl-phenyl)- acetamide
    153
    Figure US20070049618A1-20070301-C00159
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3- trifluoromethoxy-phenyl)- acetamide
    154
    Figure US20070049618A1-20070301-C00160
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-fluoro-4- methyl-phenyl)-acetamide
    155
    Figure US20070049618A1-20070301-C00161
         		2-(3,5-Dimethoxy-phenyl)- N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-acetamide
    156
    Figure US20070049618A1-20070301-C00162
         		2-(4-Chloro-phenyl)-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide
    157
    Figure US20070049618A1-20070301-C00163
         		2-Benzo[1,3]dioxo-5-yl-N- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- acetamide
    158
    Figure US20070049618A1-20070301-C00164
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridinyl-2-yl- acetamide
    159
    Figure US20070049618A1-20070301-C00165
         		N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridinyl-3-yl- acetamide
    160
    Figure US20070049618A1-20070301-C00166
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridin-4-yl- acetamide
    161
    Figure US20070049618A1-20070301-C00167
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-naphthalen-1- yl-acetamide
    162
    Figure US20070049618A1-20070301-C00168
         		2-(4,5-Dimethyl-furan-2- yl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide
    163
    Figure US20070049618A1-20070301-C00169
         		2-(2,5-Dimethyl-furan-3- yl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide
    164
    Figure US20070049618A1-20070301-C00170
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]2-(6-methoxy- benzofuran-3-yl)- acetamide
    165
    Figure US20070049618A1-20070301-C00171
         		2-{2,5-Dimethyl-1,3- thiazol-4-yl)-N-[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide
    166
    Figure US20070049618A1-20070301-C00172
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-methyl- isoxazol-5-yl)-acetamide
    167
    Figure US20070049618A1-20070301-C00173
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(1-methyl-1H- indol-3-yl)-acetamide
    168
    Figure US20070049618A1-20070301-C00174
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-thiophen-2-yl- acetamide
    169
    Figure US20070049618A1-20070301-C00175
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-thiophen-2-yl- acetamide
    170
    Figure US20070049618A1-20070301-C00176
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-fluoro-4- trifluoromethyl-benzamide
    171
    Figure US20070049618A1-20070301-C00177
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-fluoro-4- trifluoromethyl-benzamide
    172
    Figure US20070049618A1-20070301-C00178
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-fl uoro-3- trifluoromethyl-benzamide
    173
    Figure US20070049618A1-20070301-C00179
         		N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-fluoro-3- trifluoromethyl-benzamide
    174
    Figure US20070049618A1-20070301-C00180
         		Benzo[b]thiophene-5- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    175
    Figure US20070049618A1-20070301-C00181
         		4-Methyl-oxazole-5- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
    176
    Figure US20070049618A1-20070301-C00182
         		4-Methyl-2-phenyl- thiazole-5-carboxylic acid yl)-1,3-dioxo-2,3-dihydro- [2-(2,6-dioxo-piperidin-3- 1H-isoindol-4- ylmethylamide
    177
    Figure US20070049618A1-20070301-C00183
         		Isoxazole-5-carboxylic acid[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 23-dihydro-1H-isoindol-4- ylmethyl]-amide
    178
    Figure US20070049618A1-20070301-C00184
         		Thiazole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-Isoindol-4-ylmethyl]- amide
    179
    Figure US20070049618A1-20070301-C00185
         		Benzo[c]isoxazole-3- carboxylic acid[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide
  • This invention also encompasses the compounds of the following formula, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof.
    TABLE 7
    180
    Figure US20070049618A1-20070301-C00186
         		cyclopropanecarboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- amide
    181
    Figure US20070049618A1-20070301-C00187
         		2-amino-N-[2-(3-methyl-2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl]-acetamide
    182
    Figure US20070049618A1-20070301-C00188
         		3-{4-[(Benzofuran-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione
    183
    Figure US20070049618A1-20070301-C00189
         		3-{4-[(4,5-Dimethyl-furan-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione
    184
    Figure US20070049618A1-20070301-C00190
         		3-{4-[(5-Methyl-furan-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione
  • In specific embodiments, this invention encompasses a stereomerically pure (R) isomer and a stereomerically pure (S) isomer of the compounds listed above.
  • This invention also encompasses encompasses, which has the following structure:
  • and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof.
  • In specific embodiments, this invention encompasses a stereomerically pure (R) isomer and a stereomerically pure (S) isomer of 2-amino-N-[2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide, and a racemic mixture thereof.
  • As used herein, and unless otherwise specified, the term “pharmaceutically acceptable salt” refers to salts prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids. Suitable non-toxic acids include inorganic and organic acids such as, but not limited to, acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, gluconic, glutamic, glucorenic, galacturonic, glycidic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, propionic, phosphoric, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, p-toluenesulfonic and the like. Suitable are hydrochloric, hydrobromic, phosphoric, and sulfuric acids.
  • As used herein, and unless otherwise specified, the term “solvate” means a compound of the present invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.
  • As used herein, and unless otherwise specified, the term “prodrug” means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide the compound. Examples of prodrugs include, but are not limited to, compounds that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Other examples of prodrugs include compounds that comprise —NO, —NO2, —ONO, or —ONO2 moieties. Prodrugs can typically be prepared using well-known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York 1985).
  • As used herein, and unless otherwise specified, the terms “biohydrolyzable carbamate,” “biohydrolyzable carbonate,” “biohydrolyzable ureide” and “biohydrolyzable phosphate” mean a carbamate, carbonate, ureide and phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted in vivo to the biologically active compound. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • As used herein, and unless otherwise specified, the term “stereoisomer” encompasses all enantiomerically/stereomerically pure and enantiomerically/stereomerically enriched compounds of this invention.
  • As used herein and unless otherwise indicated, the term “stereomerically pure” means a composition that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound. For example, a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.
  • As used herein and unless otherwise indicated, the term “stereomerically enriched” means a composition that comprises greater than about 55% by weight of one stereoisomer of a compound, greater than about 60% by weight of one stereoisomer of a compound, preferably greater than about 70% by weight, more preferably greater than about 80% by weight of one stereoisomer of a compound.
  • As used herein, and unless otherwise indicated, the term “enantiomerically pure” means a stereomerically pure composition of a compound having one chiral center. Similarly, the term “enantiomerically enriched” means a stereomerically enriched composition of a compound having one chiral center.
  • As used herein, and unless otherwise indicated, the term “alkyl” refers to a saturated straight chain or branched hydrocarbon having number of carbon atoms as specified herein. Representative saturated straight chain alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like.
  • As used herein, and unless otherwise specified, the term “alkoxy” refers to —O-(alkyl), wherein alkyl is defined herein. Examples of alkoxy include, but are not limited to, —OCH3, —OCH2CH3, —O(CH2)2CH3, —O(CH2)3CH3, —O(CH2)4CH3, and —O(CH2)5CH3.
  • As used herein, the term “aryl” means a carbocyclic aromatic ring containing from 6 to 14 ring atoms. The ring atoms of a carbocyclic aryl group are all carbon atoms. Aryl ring structures include compounds having one or more ring structures such as mono-, bi-, or tricyclic compounds as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl and the like. Specifically, the aryl group is a monocyclic ring or bicyclic ring. Representative aryl groups include phenyl, anthracenyl, fluorenyl, indenyl, azulenyl, phenanthrenyl and naphthyl.
  • As used herein, and unless otherwise specified, the term “heteroaryl” means an aromatic ring containing from 5 to 14 ring atoms, of which at least one (e.g., one, two, or three) is a heteroatom (e.g., nitrogen, oxygen, or sulfur). Heteroaryl ring structures include compounds having one or more ring structures such as mono-, bi-, or tricyclic compounds, as well as fused heterocyclic moieties. Examples of heteroaryls include, but are not limited to, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl, thiophenyl, thiazolyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, isoquinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl, quinoxalinyl, acridinyl, pyrimidyl, oxazolyl, benzo[1,3]dioxole and 2,3-dihydro-benzo[1,4]dioxine.
  • The term “heterocycle” means a monocyclic or polycyclic ring comprising carbon and hydrogen atoms, optionally having 1 or 2 multiple bonds, and the ring atoms contain at least one heteroatom, specifically 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. Heterocycle ring structures include, but are not limited to compounds having one or more ring structures such as mono-, bi-, or tri-cyclic compounds. Specific heterocycles are monocyclic or bicyclic. Representative heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl and tetrahydrothiopyranyl. A heterocyclic ring can be unsubstituted or substituted.
  • It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.
  • 4.2 Methods of Treatment, Prevention and Management
  • This invention encompasses methods of treating, preventing, and/or managing various diseases or disorders using a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof.
  • Examples of diseases or disorders include, but are not limited to, cancer, disorders associated with angiogenesis, pain including Complex Regional Pain Syndrome (“CRPS”), Macular Degeneration (“MD”) and related syndromes, skin diseases, pulmonary disorders, asbestos-related disorders, parasitic diseases, immunodeficiency disorders, CNS disorders, CNS injury, atherosclerosis and related disorders, dysfunctional sleep and related disorders, hemoglobinopathy and related disorders (e.g., anemia), TNFα related disorders, and other various diseases and disorders.
  • As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” refer to the eradication or amelioration of a disease or disorder, or of one or more symptoms associated with the disease or disorder. In certain embodiments, the terms refer to minimizing the spread or worsening of the disease or disorder resulting from the administration of one or more prophylactic or therapeutic agents to a subject with such a disease or disorder.
  • As used herein, and unless otherwise specified, the terms “prevent,” “preventing” and “prevention” refer to the prevention of the onset, recurrence or spread of a disease or disorder, or of one or more symptoms thereof.
  • As used herein, and unless otherwise specified, the terms “manage,” “managing” and “management” refer to preventing or slowing the progression, spread or worsening of a disease or disorder, or of one or more symptoms thereof. Often, the beneficial effects that a subject derives from a prophylactic or therapeutic agent do not result in a cure of the disease or disorder.
  • As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or disorder, or to delay or minimize one or more symptoms associated with the disease or disorder. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or disorder. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.
  • As used herein, and unless otherwise specified, a “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease or disorder, or prevent its recurrence. A prophylactically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
  • Examples of cancer and precancerous conditions include, but are not limited to, those described in U.S. Pat. Nos. 6,281,230 and 5,635,517 to Muller et al., in various U.S. patent applications to Zeldis, including application Ser. Nos. 10/411,649, filed Apr. 11, 2003 (Treatment of Myelodysplastic Syndrome); 10/438,213 filed May 15, 2003 (Treatment of Various Types of Cancer); and 10/411,656, filed Apr. 11, 2003 (Treatment of Myeloproliferative Diseases). Examples also include those described in PCT/US04/14004, filed May 5, 2004. All of these references are incorporated herein in their entireties by reference.
  • Specific examples of cancer include, but are not limited to, cancers of the skin, such as melanoma; lymph node; breast; cervix; uterus; gastrointestinal tract; lung; ovary; prostate; colon; rectum; mouth; brain; head and neck; throat; testes; kidney; pancreas; bone; spleen; liver; bladder; larynx; nasal passages; and AIDS-related cancers. The compounds are particularly useful for treating cancers of the blood and bone marrow, such as multiple myeloma and acute and chronic leukemias, for example, lymphoblastic, myelogenous, lymphocytic, and myelocytic leukemias. The compounds of the invention can be used for treating, preventing or managing either primary or metastatic tumors.
  • Other specific cancers include, but are not limited to, advanced malignancy, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastase, glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, recurrent malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C & D colorectal cancer, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karotype acute myeloblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T-Cell lymphoma, cutaneous B-Cell lymphoma, diffuse large B-Cell lymphoma, low grade follicular lymphoma, metastatic melanoma (localized melanoma, including, but not limited to, ocular melanoma), malignant mesothelioma, malignant pleural effusion mesothelioma syndrome, peritoneal carcinoma, papillary serous carcinoma, gynecologic sarcoma, soft tissue sarcoma, scleroderma, cutaneous vasculitis, Langerhans cell histiocytosis, leiomyosarcoma, fibrodysplasia ossificans progressive, hormone refractory prostate cancer, resected high-risk soft tissue sarcoma, unrescectable hepatocellular carcinoma, Waldenstrom's macroglobulinemia, smoldering myeloma, indolent myeloma, fallopian tube cancer, androgen independent prostate cancer, androgen dependent stage 1V non-metastatic prostate cancer, hormone-insensitive prostate cancer, chemotherapy-insensitive prostate cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, and leiomyoma. In a specific embodiment, the cancer is metastatic. In another embodiment, the cancer is refractory or resistance to chemotherapy or radiation.
  • In one specific embodiment, this invention encompasses methods of treating, preventing or managing various forms of leukemias such as chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia and acute myeloblastic leukemia, including leukemias that are relapsed, refractory or resistant, as disclosed in U.S. publication no. 2006/0030594, published Feb. 9, 2006, which is incorporated in its entirety by reference.
  • The term “leukemia” refers malignant neoplasms of the blood-forming tissues. The leukemia includes, but is not limited to, chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia and acute myeloblastic leukemia. The leukemia can be relapsed, refractory or resistant to conventional therapy. The term “relapsed” refers to a situation where patients who have had a remission of leukemia after therapy have a return of leukemia cells in the marrow and a decrease in normal blood cells. The term “refractory or resistant” refers to a circumstance where patients, even after intensive treatment, have residual leukemia cells in their marrow.
  • In another specific embodiment, this invention encompasses methods of treating, preventing or managing various types of lymphomas, including Non-Hodgkin's lymphoma (NHL). The term “lymphoma” refers a heterogenous group of neoplasms arising in the reticuloendothelial and lymphatic systems. “NHL” refers to malignant monoclonal proliferation of lymphoid cells in sites of the immune system, including lymph nodes, bone marrow, spleen, liver and gastrointestinal tract. Examples of NHL include, but are not limited to, mantle cell lymphoma, MCL, lymphocytic lymphoma of intermediate differentiation, intermediate lymphocytic lymphoma, ILL, diffuse poorly differentiated lymphocytic lymphoma, PDL, centrocytic lymphoma, diffuse small-cleaved cell lymphoma, DSCCL, follicular lymphoma, and any type of the mantle cell lymphomas that can be seen under the microscope (nodular, diffuse, blastic and mentle zone lymphoma).
  • Examples of diseases and disorders associated with, or characterized by, undesired angiogenesis include, but are not limited to, inflammatory diseases, autoimmune diseases, viral diseases, genetic diseases, allergic diseases, bacterial diseases, ocular neovascular diseases, choroidal neovascular diseases, retina neovascular diseases, and rubeosis (neovascularization of the angle). Specific examples of the diseases and disorders associated with, or characterized by, undesired angiogenesis include, but are not limited to, endometriosis, Crohn's disease, heart failure, advanced heart failure, renal impairment, endotoxemia, toxic shock syndrome, osteoarthritis, retrovirus replication, wasting, meningitis, silica-induced fibrosis, asbestos-induced fibrosis, veterinary disorder, malignancy-associated hypercalcemia, stroke, circulatory shock, periodontitis, gingivitis, macrocytic anemia, refractory anemia, and 5q-deletion syndrome.
  • Examples of pain include, but are not limited to those described in U.S. patent application Ser. No. 10/693,794, filed Oct. 23, 2003, which is incorporated herein by reference. Specific types of pain include, but are not limited to, nociceptive pain, neuropathic pain, mixed pain of nociceptive and neuropathic pain, visceral pain, migraine, headache and post-operative pain.
  • Examples of nociceptive pain include, but are not limited to, pain associated with chemical or thermal burns, cuts of the skin, contusions of the skin, osteoarthritis, rheumatoid arthritis, tendonitis, and myofascial pain.
  • Examples of neuropathic pain include, but are not limited to, CRPS type I, CRPS type II, reflex sympathetic dystrophy (RSD), reflex neurovascular dystrophy, reflex dystrophy, sympathetically maintained pain syndrome, causalgia, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, trigeminal neuralgia, post herpetic neuralgia, cancer related pain, phantom limb pain, fibromyalgia, chronic fatigue syndrome, spinal cord injury pain, central post-stroke pain, radiculopathy, diabetic neuropathy, post-stroke pain, luetic neuropathy, and other painful neuropathic conditions such as those induced by drugs such as vincristine and velcade.
  • As used herein, the terms “complex regional pain syndrome,” “CRPS” and “CRPS and related syndromes” mean a chronic pain disorder characterized by one or more of the following: pain, whether spontaneous or evoked, including allodynia (painful response to a stimulus that is not usually painful) and hyperalgesia (exaggerated response to a stimulus that is usually only mildly painful); pain that is disproportionate to the inciting event (e.g., years of severe pain after an ankle sprain); regional pain that is not limited to a single peripheral nerve distribution; and autonomic dysregulation (e.g., edema, alteration in blood flow and hyperhidrosis) associated with trophic skin changes (hair and nail growth abnormalities and cutaneous ulceration).
  • Examples of MD and related syndromes include, but are not limited to, those described in U.S. patent publication no. 2004/0091455, published May 13, 2004, which is incorporated herein by reference. Specific examples include, but are not limited to, atrophic (dry) MD, exudative (wet) MD, age-related maculopathy (ARM), choroidal neovascularisation (CNVM), retinal pigment epithelium detachment (PED), and atrophy of retinal pigment epithelium (RPE).
  • Examples of skin diseases include, but are not limited to, those described in U.S. application Ser. No. 11/085,905, filed Mar. 22, 2005, which is incorporated herein by reference. Specific examples include, but are not limited to, keratoses and related symptoms, skin diseases or disorders characterized with overgrowths of the epidermis, acne, and wrinkles.
  • As used herein, the term “keratosis” refers to any lesion on the epidermis marked by the presence of circumscribed overgrowths of the horny layer, including but not limited to actinic keratosis, seborrheic keratosis, keratoacanthoma, keratosis follicularis (Darier disease), inverted follicular keratosis, palmoplantar keratoderma (PPK, keratosis palmaris et plantaris), keratosis pilaris, and stucco keratosis. The term “actinic keratosis” also refers to senile keratosis, keratosis senilis, verruca senilis, plana senilis, solar keratosis, keratoderma or keratoma. The term “seborrheic keratosis” also refers to seborrheic wart, senile wart, or basal cell papilloma. Keratosis is characterized by one or more of the following symptoms: rough appearing, scaly, erythematous papules, plaques, spicules or nodules on exposed surfaces (e.g., face, hands, ears, neck, legs and thorax), excrescences of keratin referred to as cutaneous horns, hyperkeratosis, telangiectasias, elastosis, pigmented lentigines, acanthosis, parakeratosis, dyskeratoses, papillomatosis, hyperpigmentation of the basal cells, cellular atypia, mitotic figures, abnormal cell-cell adhesion, dense inflammatory infiltrates and small prevalence of squamous cell carcinomas.
  • Examples of skin diseases or disorders characterized with overgrowths of the epidermis include, but are not limited to, any conditions, diseases or disorders marked by the presence of overgrowths of the epidermis, including but not limited to, infections associated with papilloma virus, arsenical keratoses, sign of Leser-Trélat, warty dyskeratoma (WD), trichostasis spinulosa (TS), erythrokeratodermia variabilis (EKV), ichthyosis fetalis (harlequin ichthyosis), knuckle pads, cutaneous melanoacanthoma, porokeratosis, squamous cell carcinoma, confluent and reticulated papillomatosis (CRP), acrochordons, cutaneous horn, cowden disease (multiple hamartoma syndrome), dermatosis papulosa nigra (DPN), epidermal nevus syndrome (ENS), ichthyosis vulgaris, molluscum contagiosum, prurigo nodularis, and acanthosis nigricans (AN).
  • Examples of pulmonary disorders include, but are not limited to, those described in U.S. provisional application No. 60/565,172, filed Apr. 23, 2004, which is incorporated herein by reference. Specific examples include pulmonary hypertension and related disorders. Examples of pulmonary hypertension and related disorders include, but are not limited to: primary pulmonary hypertension (PPH); secondary pulmonary hypertension (SPH); familial PPH; sporadic PPH; precapillary pulmonary hypertension; pulmonary arterial hypertension (PAH); pulmonary artery hypertension; idiopathic pulmonary hypertension; thrombotic pulmonary arteriopathy (TPA); plexogenic pulmonary arteriopathy; functional classes I to IV pulmonary hypertension; and pulmonary hypertension associated with, related to, or secondary to, left ventricular dysfunction, mitral valvular disease, constrictive pericarditis, aortic stenosis, cardiomyopathy, mediastinal fibrosis, anomalous pulmonary venous drainage, pulmonary venoocclusive disease, collagen vasular disease, congenital heart disease, HIV virus infection, drugs and toxins such as fenfluramines, congenital heart disease, pulmonary venous hypertension, chronic obstructive pulmonary disease, interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorder, chronic exposure to high altitude, neonatal lung disease, alveolar-capillary dysplasia, sickle cell disease, other coagulation disorder, chronic thromboemboli, connective tissue disease, lupus including systemic and cutaneous lupus, schistosomiasis, sarcoidosis or pulmonary capillary hemangiomatosis.
  • Examples of asbestos-related disorders include, but not limited to, those described in U.S. publication no. 2005/0100529, published May 12, 2005, which is incorporated herein by reference. Specific examples include, but are not limited to, mesothelioma, asbestosis, malignant pleural effusion, benign exudative efflusion, pleural plaques, pleural calcification, diffuse pleural thickening, rounded atelectasis, fibrotic masses, and lung cancer.
  • Examples of parasitic diseases include, but are not limited to, those described in U.S. provisional application No. 60/626,975, filed Nov. 12, 2004, which is incorporated herein by reference. Parasitic diseases include diseases and disorders caused by human intracellular parasites such as, but not limited to, P. falcifarium, P. ovale, P. vivax, P. malariae, L. donovari, L. infantum, L. aethiopica, L. major, L. tropica, L. mexicana, L. braziliensis, T. Gondii, B. microti, B. divergens, B. coli, C. parvum, C. cayetanensis, E. histolytica, I. belli, S. mansonii, S. haematobium, Trypanosoma ssp., Toxoplasma ssp., and O. volvulus. Other diseases and disorders caused by non-human intracellular parasites such as, but not limited to, Babesia bovis, Babesia canis, Banesia Gibsoni, Besnoitia darlingi, Cytauxzoon felis, Eimeria ssp., Hammondia ssp., and Theileria ssp., are also encompassed. Specific examples include, but are not limited to, malaria, babesiosis, trypanosomiasis, leishmaniasis, toxoplasmosis, meningoencephalitis, keratitis, amebiasis, giardiasis, cryptosporidiosis, isosporiasis, cyclosporiasis, microsporidiosis, ascariasis, trichuriasis, ancylostomiasis, strongyloidiasis, toxocariasis, trichinosis, lymphatic filariasis, onchocerciasis, filariasis, schistosomiasis, and dermatitis caused by animal schistosomes.
  • Examples of immunodeficiency disorders include, but are not limited to, those described in U.S. provisional application No. 60/631,870, filed Dec. 1, 2004. Specific examples include, but not limited to, adenosine deaminase deficiency, antibody deficiency with normal or elevated Igs, ataxia-tenlangiectasia, bare lymphocyte syndrome, common variable immunodeficiency, Ig deficiency with hyper-IgM, Ig heavy chain deletions, IgA deficiency, immunodeficiency with thymoma, reticular dysgenesis, Nezelof syndrome, selective IgG subclass deficiency, transient hypogammaglobulinemia of infancy, Wistcott-Aldrich syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency.
  • Examples of CNS disorders include, but are not limited to, those described in U.S. provisional application No. 60/533,862, filed Dec. 30, 2003, and the co-pending U.S. application Ser. No. 11/022,075, filed Dec. 23, 2004, both of which are incorporated herein by reference. Specific examples include, but are not limited to, include, but are not limited to, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Parkinson Disease, Huntington's Disease, Multiple Sclerosis other neuroimmunological disorders such as Tourette Syndrome, delerium, or disturbances in consciousness that occur over a short period of time, and amnestic disorder, or discreet memory impairments that occur in the absence of other central nervous system impairments.
  • Examples of CNS injuries and related syndromes include, but are not limited to, those described in U.S. provisional application No. 60/630,599, filed Nov. 23, 2004, which is incorporated herein by reference. Specific examples include, but are not limited to, CNS injury/damage and related syndromes, include, but are not limited to, primary brain injury, secondary brain injury, traumatic brain injury, focal brain injury, diffuse axonal injury, head injury, concussion, post-concussion syndrome, cerebral contusion and laceration, subdural hematoma, epidermal hematoma, post-traumatic epilepsy, chronic vegetative state, complete SCI, incomplete SCI, acute SCI, subacute SCI, chronic SCI, central cord syndrome, Brown-Sequard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, neurogenic shock, spinal shock, altered level of consciousness, headache, nausea, emesis, memory loss, dizziness, diplopia, blurred vision, emotional lability, sleep disturbances, irritability, inability to concentrate, nervousness, behavioral impairment, cognitive deficit, and seizure.
  • Other disease or disorders include, but not limited to, viral, genetic, allergic, and autoimmune diseases. Specific examples include, but not limited to, HIV, hepatitis, adult respiratory distress syndrome, bone resorption diseases, chronic pulmonary inflammatory diseases, dermatitis, cystic fibrosis, septic shock, sepsis, endotoxic shock, hemodynamic shock, sepsis syndrome, post ischemic reperfusion injury, meningitis, psoriasis, fibrotic disease, cachexia, graft versus host disease, graft rejection, auto-immune disease, rheumatoid spondylitis, Crohn's disease, ulcerative colitis, inflammatory-bowel disease, multiple sclerosis, systemic lupus erythrematosus, ENL in leprosy, radiation damage, cancer, asthma, or hyperoxic alveolar injury.
  • Examples of atherosclerosis and related conditions include, but are not limited to, those disclosed in U.S. publication no. 2002/0054899, published May 9, 2002, which is incorporated herein by reference. Specific examples include, but are not limited to, all forms of conditions involving atherosclerosis, including restenosis after vascular intervention such as angioplasty, stenting, atherectomy and grafting. All forms of vascular intervention are contemplated by the invention including diseases of the cardiovascular and renal system, such as, but not limited to, renal angioplasty, percutaneous coronary intervention (PCI), percutaneous transluminal coronary angioplasty (PTCA), carotid percutaneous transluminal angioplasty (PTA), coronary by-pass grafting, angioplasty with stent implantation, peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries, and surgical intervention using impregnated artificial grafts. The following chart provides a listing of the major systemic arteries that may be in need of treatment, all of which are contemplated by the invention:
    Artery Body Area
    Axillary Shoulder and axilla
    Brachial Upper arm
    Brachiocephalic Head, neck, and arm
    Celiac Divides into left gastric, splenic, and hepatic arteries
    Common carotid Neck
    Common iliac Divides into external and internal iliac arteries
    Coronary Heart
    Deep femoral Thigh
    Digital Fingers
    Dorsalis pedis Foot
    External carotid Neck and external head regions
    External iliac Femoral artery
    Femoral Thigh
    Gastric Stomach
    Hepatic Liver, gallbladder, pancreas, and duodenum
    Inferior mesenteric Descending colon, rectum, and pelvic wall
    Internal carotid Neck and internal head regions
    Internal iliac Rectum, urinary bladder, external genitalia, buttocks
    muscles, uterus and vagina
    Left gastric Esophagus and stomach
    Middle sacral Sacrum
    Ovarian Ovaries
    Palmar arch Hand
    Peroneal Calf
    Popliteal Knee
    Posterior tibial Calf
    Pulmonary Lungs
    Radial Forearm
    Renal Kidney
    Splenic Stomach, pancreas, and spleen
    Subclavian Shoulder
    Superior mesenteric Pancreas, small intestine,
    ascending and transverse colon
    Testicular Testes
    Ulnar Forearm
  • Examples of dysfunctional sleep and related syndromes include, but are not limited to, those disclosed in U.S. provisional application No. 60/559,261, filed Apr. 1, 2004, and U.S. application Ser. No. 11/093,848, filed Mar. 30, 2005, both of which are incorporated herein by reference. Specific examples include, but are not limited to, snoring, sleep apnea, insomnia, narcolepsy, restless leg syndrome, sleep terrors, sleep walking sleep eating, and dysfunctional sleep associated with chronic neurological or inflammatory conditions. Chronic neurological or inflammatory conditions, include, but are not limited to, Complex Regional Pain Syndrome, chronic low back pain, musculoskeletal pain, arthritis, radiculopathy, pain associated with cancer, fibromyalgia, chronic fatigue syndrome, visceral pain, bladder pain, chronic pancreatitis, neuropathies (diabetic, post-herpetic, traumatic or inflammatory), and neurodegenerative disorders such as Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's Disease, bradykinesia; muscle rigidity; parkinsonian tremor; parkinsonian gait; motion freezing; depression; defective long-term memory, Rubinstein-Taybi syndrome (RTS); dementia; postural instability; hypokinetic disorders; synuclein disorders; multiple system atrophies; striatonigral degeneration; olivopontocerebellar atrophy; Shy-Drager syndrome; motor neuron disease with parkinsonian features; Lewy body dementia; Tau pathology disorders; progressive supranuclear palsy; corticobasal degeneration; frontotemporal dementia; amyloid pathology disorders; mild cognitive impairment; Alzheimer disease with parkinsonism; Wilson disease; Hallervorden-Spatz disease; Chediak-Hagashi disease; SCA-3 spinocerebellar ataxia; X-linked dystonia parkinsonism; prion disease; hyperkinetic disorders; chorea; ballismus; dystonia tremors; Amyotrophic Lateral Sclerosis (ALS); CNS trauma and myoclonus.
  • Examples of hemoglobinopathy and related disorders include, but are not limited to, those described in U.S. application Ser. No. 11/004,736, filed Dec. 2, 2004, which is incorporated herein by reference. Specific examples include, but are not limited to, hemoglobinopathy, sickle cell anemia, and any other disorders related to the differentiation of CD34+ cells.
  • Examples of TNFα related disorders include, but are not limited to, those described in WO 98/03502 and WO 98/54170, both of which are incorporated herein in their entireties by reference. Specific examples include, but are not limited to: endotoxemia or toxic shock syndrome; cachexia; adult respiratory distress syndrome; bone resorption diseases such as arthritis; hypercalcemia; Graft versus Host Reaction; cerebral malaria; inflammation; tumor growth; chronic pulmonary inflammatory diseases; reperfusion injury; myocardial infarction; stroke; circulatory shock; rheumatoid arthritis; Crohn's disease; HIV infection and AIDS; NFκB related disorders such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions, septic shock, septis, endotoxic shock, graft versus host disease, wasting, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythromatosis, ENL in leprosy, HIV, AIDS, and opportunistic infections in AIDS; cAMP related disorders such as septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, oncogenic or cancerous conditions, asthma, autoimmune disease, radiation damages, and hyperoxic alveolar injury; viral infections, such as those caused by the herpes viruses; viral conjunctivitis; or atopic dermatitis.
  • In other embodiments, the use of compounds of this invention in various immunological applications, in particular, as vaccine adjuvants, particularly anticancer vaccine adjuvants, as disclosed in U.S. Provisional Application No. 60/712,823, filed Sep. 1, 2005, which is incorporated herein in its entirety by reference, is also encompassed. This aspect of the invention also relates to the uses of compounds of this invention in combination with vaccines to treat or prevent cancer or infectious diseases, and other various uses of immunomodulatory compounds such as reduction or desensitization of allergic reactions.
  • Doses of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, vary depending on factors such as: specific indication to be treated, prevented, or managed; age and condition of a patient; and amount of second active agent used, if any. Generally, a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, may be used in an amount of from about 0.1 mg to about 500 mg per day, and can be adjusted in a conventional fashion (e.g., the same amount administered each day of the treatment, prevention or management period), in cycles (e.g., one week on, one week off), or in an amount that increases or decreases over the course of treatment, prevention, or management.
  • In other embodiments, the dose can be from about 1 mg to about 300 mg, from about 0.1 mg to about 150 mg, from about 1 mg to about 200 mg, from about 10 mg to about 100 mg, from about 0.1 mg to about 50 mg, from about 1 mg to about 50 mg, from about 10 mg to about 50 mg, from about 20 mg to about 30 mg, or from about 1 mg to about 20 mg.
  • 4.3 Second Active Agents
  • A compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, can be combined with other pharmacologically active compounds (“second active agents”) in methods and compositions of the invention. It is believed that certain combinations may work synergistically in the treatment of particular types diseases or disorders, and conditions and symptoms associated with such diseases or disorders. A compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, can also work to alleviate adverse effects associated with certain second active agents, and vice versa.
  • One or more second active ingredients or agents can be used in the methods and compositions of the invention. Second active agents can be large molecules (e.g., proteins) or small molecules (e.g., synthetic inorganic, organometallic, or organic molecules).
  • Examples of large molecule active agents include, but are not limited to, hematopoietic growth factors, cytokines, and monoclonal and polyclonal antibodies. Specific examples of the active agents are anti-CD40 monoclonal antibodies (such as, for example, SGN-40); histone deacetlyase inhibitors (such as, for example, SAHA and LAQ 824); heat-shock protein-90 inhibitors (such as, for example, 17-AAG); insulin-like growth factor-1 receptor kinase inhibitors; vascular endothelial growth factor receptor kinase inhibitors (such as, for example, PTK787); insulin growth factor receptor inhibitors; lysophosphatidic acid acyltransrerase inhibitors; IkB kinase inhibitors; p38MAPK inhibitors; EGFR inhibitors (such as, for example, gefitinib and erlotinib HCL); HER-2 antibodies (such as, for example, trastuzumab (Herceptin®) and pertuzumab (Omnitarg™)); VEGFR antibodies (such as, for example, bevacizumab (Avastin™)); VEGFR inhibitors (such as, for example, flk-1 specific kinase inhibitors, SU5416 and ptk787/zk222584); P13K inhibitors (such as, for example, wortmannin); C-Met inhibitors (such as, for example, PHA-665752); monoclonal antibodies (such as, for example, rituximab (Rituxan®), tositumomab (Bexxar®), edrecolomab (Panorex®) and G250); and anti-TNF-α antibodies. Examples of small molecule active agents include, but are not limited to, small molecule anti-cancer agents and antibiotics (e.g., clarithromycin).
  • Specific second active compounds that can be combined with compounds of this invention vary depending on the specific indication to be treated, prevented or managed.
  • For instance, for the treatment, prevention or management of cancer, second active agents include, but are not limited to: semaxanib; cyclosporin; etanercept; doxycycline; bortezomib; acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; celecoxib; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; iproplatin; irinotecan; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; taxotere; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicin hydrochloride.
  • Other second agents include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clathromycin; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; doxorubicin; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imatinib (Gleeve®), imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; Erbitux, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; oblimersen (Genasense®); O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin, pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
  • Specific second active agents include, but are not limited to, 2-methoxyestradiol, telomestatin, inducers of apoptosis in multiple myeloma cells (such as, for example, TRAIL), bortezomib, statins, semaxanib, cyclosporin, etanercept, doxycycline, bortezomib, oblimersen (Genasense®), remicade, docetaxel, celecoxib, melphalan, dexamethasone (Decadron®), steroids, gemcitabine, cisplatinum, temozolomide, etoposide, cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, tamoxifen, topotecan, methotrexate, Arisa®, taxol, taxotere, fluorouracil, leucovorin, irinotecan, xeloda, CPT-11, interferon alpha, pegylated interferon alpha (e.g., PEG INTRON-A), capecitabine, cisplatin, thiotepa, fludarabine, carboplatin, liposomal daunorubicin, cytarabine, doxetaxol, pacilitaxel, vinblastine, IL-2, GM-CSF, dacarbazine, vinorelbine, zoledronic acid, palmitronate, biaxin, busulphan, prednisone, bisphosphonate, arsenic trioxide, vincristine, doxorubicin (Doxil®), paclitaxel, ganciclovir, adriamycin, estramustine sodium phosphate (Emcyt®), sulindac, and etoposide.
  • Similarly, examples of specific second agents according to the indications to be treated, prevented, or managed can be found in the following references, all of which are incorporated herein in their entireties: U.S. Pat. Nos. 6,281,230 and 5,635,517; U.S. application Ser. Nos. 10/411,649, 10/483,213, 10/411,656, 10/693,794, 10/699,154, and 10/981,189; and U.S. provisional application Nos. 60/554,923, 60/565,172, 60/626,975, 60/630,599, 60/631,870, and 60/533,862.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of pain include, but are not limited to, conventional therapeutics used to treat or prevent pain such as antidepressants, anticonvulsants, antihypertensives, anxiolytics, calcium channel blockers, muscle relaxants, non-narcotic analgesics, opioid analgesics, anti-inflammatories, cox-2 inhibitors, immunomodulatory agents, alpha-adrenergic receptor agonists or antagonists, immunosuppressive agents, corticosteroids, hyperbaric oxygen, ketamine, other anesthetic agents, NMDA antagonists, and other therapeutics found, for example, in the Physician's Desk Reference 2003. Specific examples include, but are not limited to, salicylic acid acetate (Aspirin®), celecoxib (Celebrex®), Enbrel®, ketamine, gabapentin (Neurontin®), phenyloin (Dilantin®), carbamazepine (Tegretol®), oxcarbazepine (Trileptal®), valproic acid (Depakene®), morphine sulfate, hydromorphone, prednisone, griseofulvin, penthonium, alendronate, dyphenhydramide, guanethidine, ketorolac (Acular®), thyrocalcitonin, dimethylsulfoxide (DMSO), clonidine (Catapress®), bretylium, ketanserin, reserpine, droperidol, atropine, phentolamine, bupivacaine, lidocaine, acetaminophen, nortriptyline (Pamelor®), amitriptyline (Elavil®), imipramine (Tofranil®), doxepin (Sinequan®), clomipramine (Anafranil®), fluoxetine (Prozac®), sertraline (Zoloft®), nefazodone (Serzone®), venlafaxine (Effexor®), trazodone (Desyrel®), bupropion (Wellbutrin®), mexiletine, nifedipine, propranolol, tramadol, lamotrigine, ziconotide, ketamine, dextromethorphan, benzodiazepines, baclofen, tizanidine and phenoxybenzamine.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of MD and related syndromes include, but are not limited to, a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound, or a combination thereof. Specific examples include, but are not limited to, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2α, pentoxifylline, tin etiopurpurin, motexafin lutetium, 9-fluoro-11,21-dihydroxy-16,17-1-methylethylidinebis(oxy)pregna-1,4-diene-3,20-dione, latanoprost (see U.S. Pat. No. 6,225,348), tetracycline and its derivatives, rifamycin and its derivatives, macrolides, metronidazole (U.S. Pat. Nos. 6,218,369 and 6,015,803), genistein, genistin, 6′-O-Mal genistin, 6′-O—Ac genistin, daidzein, daidzin, 6′-O-Mal daidzin, 6′-O—Ac daidzin, glycitein, glycitin, 6′-O-Mal glycitin, biochanin A, formononetin (U.S. Pat. No. 6,001,368), triamcinolone acetomide, dexamethasone (U.S. Pat. No. 5,770,589), thalidomide, glutathione (U.S. Pat. No. 5,632,984), basic fibroblast growth factor (bFGF), transforming growth factor b (TGF-b), brain-derived neurotrophic factor (BDNF), plasminogen activator factor type 2 (PAI-2), EYE101 (Eyetech Pharmaceuticals), LY333531 (Eli Lilly), Miravant, and RETISERT implant (Bausch & Lomb). All of the references cited above are incorporated herein in their entireties by reference.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of skin diseases include, but are not limited to, keratolytics, retinoids, α-hydroxy acids, antibiotics, collagen, botulinum toxin, interferon, and immunomodulatory agents. Specific examples include, but are not limited to, 5-fluorouracil, masoprocol, trichloroacetic acid, salicylic acid, lactic acid, ammonium lactate, urea, tretinoin, isotretinoin, antibiotics, collagen, botulinum toxin, interferon, corticosteroid, transretinoic acid and collagens such as human placental collagen, animal placental collagen, Dermalogen, AlloDerm, Fascia, Cymetra, Autologen, Zyderm, Zyplast, Resoplast, and Isolagen.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of pulmonary hepertension and related disorders include, but are not limited to, anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, vasodilators, prostacyclin analogues, endothelin antagonists, phosphodiesterase inhibitors (e.g., PDE V inhibitors), endopeptidase inhibitors, lipid lowering agents, thromboxane inhibitors, and other therapeutics known to reduce pulmonary artery pressure. Specific examples include, but are not limited to, warfarin (Coumadin), a diuretic, a cardiac glycoside, digoxin-oxygen, diltiazem, nifedipine, a vasodilator such as prostacyclin (e.g., prostaglandin I2 (PGI2), epoprostenol (EPO, Floran®), treprostinil (Remodulin®), nitric oxide (NO), bosentan (Tracleer®), amlodipine, epoprostenol (Floran®), treprostinil (Remodulin®), prostacyclin, tadalafil (Cialis®), simvastatin (Zocor®), omapatrilat (Vanlev®), irbesartan (Avapro®), pravastatin (Pravachol®), digoxin, L-arginine, iloprost, betaprost, and sildenafil (Viagra®).
  • Examples of second active agents that may be used for the treatment, prevention and/or management of asbestos-related disorders include, but are not limited to, anthracycline, platinum, alkylating agent, oblimersen (Genasense®), cisplatinum, cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, tamoxifen, topotecan, methotrexate, taxotere, irinotecan, capecitabine, cisplatin, thiotepa, fludarabine, carboplatin, liposomal daunorubicin, cytarabine, doxetaxol, pacilitaxel, vinblastine, IL-2, GM-CSF, dacarbazine, vinorelbine, zoledronic acid, palmitronate, biaxin, busulphan, prednisone, bisphosphonate, arsenic trioxide, vincristine, doxorubicin (Doxil®), paclitaxel, ganciclovir, adriamycin, bleomycin, hyaluronidase, mitomycin C, mepacrine, thiotepa, tetracycline and gemcitabine.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of parasitic diseases include, but are not limited to, chloroquine, quinine, quinidine, pyrimethamine, sulfadiazine, doxycycline, clindamycin, mefloquine, halofantrine, primaquine, hydroxychloroquine, proguanil, atovaquone, azithromycin, suramin, pentamidine, melarsoprol, nifurtimox, benznidazole, amphotericin B, pentavalent antimony compounds (e.g., sodium stiboglucuronate), interfereon gamma, itraconazole, a combination of dead promastigotes and BCG, leucovorin, corticosteroids, sulfonamide, spiramycin, IgG (serology), trimethoprim, and sulfamethoxazole.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of immunodeficiency disorders include, but are not limited to: antibiotics (therapeutic or prophylactic) such as, but not limited to, ampicillin, clarithromycin, tetracycline, penicillin, cephalosporins, streptomycin, kanamycin, and erythromycin; antivirals such as, but not limited to, amantadine, rimantadine, acyclovir, and ribavirin; immunoglobulin; plasma; immunologic enhancing drugs such as, but not limited to, levami sole and isoprinpsme; biologics such as, but not limited to, gammaglobulin, transfer factor, interleukins, and interferons; hormones such as, but not limited to, thymic; and other immunologic agents such as, but not limited to, B cell stimulators (e.g., BAFF/BlyS), cytokines (e.g., IL-2, IL-4, and IL-5), growth factors (e.g., TGF-α), antibodies (e.g., anti-CD40 and IgM), oligonucleotides containing unmethylated CpG motifs, and vaccines (e.g., viral and tumor peptide vaccines).
  • Examples of second active agents that may be used for the treatment, prevention and/or management of CNS disorders include, but are not limited to: a dopamine agonist or antagonist, such as, but not limited to, Levodopa, L-DOPA, cocaine, α-methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline, fenodolpam mesylate, cabergoline, pramipexole dihydrochloride, ropinorole, amantadine hydrochloride, selegiline hydrochloride, carbidopa, pergolide mesylate, Sinemet CR, and Symmetrel; a MAO inhibitor, such as, but not limited to, iproniazid, clorgyline, phenelzine and isocarboxazid; a COMT inhibitor, such as, but not limited to, tolcapone and entacapone; a cholinesterase inhibitor, such as, but not limited to, physostigmine saliclate, physostigmine sulfate, physostigmine bromide, meostigmine bromide, neostigmine methylsulfate, ambenonim chloride, edrophonium chloride, tacrine, pralidoxime chloride, obidoxime chloride, trimedoxime bromide, diacetyl monoxim, endrophonium, pyridostigmine, and demecarium; an anti-inflammatory agent, such as, but not limited to, naproxen sodium, diclofenac sodium, diclofenac potassium, celecoxib, sulindac, oxaprozin, diflunisal, etodolac, meloxicam, ibuprofen, ketoprofen, nabumetone, refecoxib, methotrexate, leflunomide, sulfasalazine, gold salts, Rho-D Immune Globulin, mycophenylate mofetil, cyclosporine, azathioprine, tacrolimus, basiliximab, daclizumab, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, methotrexate, colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone or betamethasone and other glucocorticoids; and an antiemetic agent, such as, but not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxypemdyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and a mixture thereof.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of CNS injuries and related syndromes include, but are not limited to, immunomodulatory agents, immunosuppressive agents, antihypertensives, anticonvulsants, fibrinolytic agents, antiplatelet agents, antipsychotics, antidepressants, benzodiazepines, buspirone, amantadine, and other known or conventional agents used in patients with CNS injury/damage and related syndromes. Specific examples include, but are not limited to: steroids (e.g., glucocorticoids, such as, but not limited to, methylprednisolone, dexamethasone and betamethasone); an anti-inflammatory agent, including, but not limited to, naproxen sodium, diclofenac sodium, diclofenac potassium, celecoxib, sulindac, oxaprozin, diflunisal, etodolac, meloxicam, ibuprofen, ketoprofen, nabumetone, refecoxib, methotrexate, leflunomide, sulfasalazine, gold salts, RHo-D Immune Globulin, mycophenylate mofetil, cyclosporine, azathioprine, tacrolimus, basiliximab, daclizumab, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, methotrexate, colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone; a cAMP analog including, but not limited to, db-cAMP; an agent comprising a methylphenidate drug, which comprises l-threo-methylphenidate, d-threo-methylphenidate, dl-threo-methylphenidate, l-erythro-methylphenidate, d-erythro-methylphenidate, dl-erythro-methylphenidate, and a mixture thereof; and a diuretic agent such as, but not limited to, mannitol, furosemide, glycerol, and urea.
  • Examples of second active agent that may be used for the treatment, prevention and/or management of dysfunctional sleep and related syndromes include, but are not limited to, a tricyclic antidepressant agent, a selective serotonin reuptake inhibitor, an antiepileptic agent (gabapentin, pregabalin, carbamazepine, oxcarbazepine, levitiracetam, topiramate), an antiaryhthmic agent, a sodium channel blocking agent, a selective inflammatory mediator inhibitor, an opioid agent, a second immunomodulatory compound, a combination agent, and other known or conventional agents used in sleep therapy. Specific examples include, but are not limited to, Neurontin, oxycontin, morphine, topiramate, amitryptiline, nortryptiline, carbamazepine, Levodopa, L-DOPA, cocaine, α-methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline, fenodolpam mesylate, cabergoline, pramipexole dihydrochloride, ropinorole, amantadine hydrochloride, selegiline hydrochloride, carbidopa, pergolide mesylate, Sinemet CR, Symmetrel, iproniazid, clorgyline, phenelzine, isocarboxazid, tolcapone, entacapone, physostigmine saliclate, physostigmine sulfate, physostigmine bromide, meostigmine bromide, neostigmine methylsulfate, ambenonim chloride, edrophonium chloride, tacrine, pralidoxime chloride, obidoxime chloride, trimedoxime bromide, diacetyl monoxim, endrophonium, pyridostigmine, demecarium, naproxen sodium, diclofenac sodium, diclofenac potassium, celecoxib, sulindac, oxaprozin, diflunisal, etodolac, meloxicam, ibuprofen, ketoprofen, nabumetone, refecoxib, methotrexate, leflunomide, sulfasalazine, gold salts, RHo-D Immune Globulin, mycophenylate mofetil, cyclosporine, azathioprine, tacrolimus, basiliximab, daclizumab, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, methotrexate, colchicine, allopurinol, probenecid, sulfinpyrazone, benzbromarone, betamethasone and other glucocorticoids, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and a mixture thereof.
  • Examples of second active agents that may be used for the treatment, prevention and/or management of hemoglobinopathy and related disorders include, but are not limited to: interleukins, such as IL-2 (including recombinant IL-II (“rIL2”) and canarypox IL-2), IL-10, IL-12, and IL-18; interferons, such as interferon alfa-2a, interferon alfa-2b, interferon alfa-n1, interferon alfa-n3, interferon beta-I a, and interferon gamma-I b; and G-CSF; hydroxyurea; butyrates or butyrate derivatives; nitrous oxide; HEMOXIN™ (NIPRISAN™; see U.S. Pat. No. 5,800,819); Gardos channel antagonists such as clotrimazole and triaryl methane derivatives; Deferoxamine; protein C; and transfusions of blood, or of a blood substitute such as Hemospan™ or Hemospan™ PS (Sangart).
  • Administration of a compound of this invention, or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and the second active agents to a patient can occur simultaneously or sequentially by the same or different routes of administration. The suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated. A preferred route of administration for compounds of this invention is oral. Preferred routes of administration for the second active agents or ingredients of the invention are known to those of ordinary skill in the art. See, e.g., Physicians' Desk Reference, 1755-1760 (56th ed., 2002).
  • In one embodiment of the invention, the second active agent is administered intravenously or subcutaneously and once or twice daily in an amount of from about 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg. The specific amount of the second active agent will depend on the specific agent used, the type of disease being treated or managed, the severity and stage of disease, and the amount(s) of compounds of the invention and any optional additional active agents concurrently administered to the patient.
  • As discussed elsewhere herein, the invention encompasses a method of reducing, treating and/or preventing adverse or undesired effects associated with conventional therapy including, but not limited to, surgery, chemotherapy, radiation therapy, hormonal therapy, biological therapy and immunotherapy. Compounds of the invention and other active ingredients can be administered to a patient prior to, during, or after the occurrence of the adverse effect associated with conventional therapy.
  • 4.4 Cycling Therapy
  • In certain embodiments, the prophylactic or therapeutic agents of the invention are cyclically administered to a patient. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.
  • Consequently, in one specific embodiment of the invention, a compound of the invention is administered daily in a single or divided doses in a four to six week cycle with a rest period of about a week or two weeks. The invention further allows the frequency, number, and length of dosing cycles to be increased. Thus, another specific embodiment of the invention encompasses the administration of a compound of the invention for more cycles than are typical when it is administered alone. In yet another specific embodiment of the invention, a compound of the invention is administered for a greater number of cycles that would typically cause dose-limiting toxicity in a patient to whom a second active ingredient is not also being administered.
  • In one embodiment, a compound of the invention is administered daily and continuously for three or four weeks at a dose of from about 0.1 mg to about 500 mg per day, followed by a break of one or two weeks. In other embodiments, the dose can be from about 1 mg to about 300 mg, from about 0.1 mg to about 150 mg, from about 1 mg to about 200 mg, from about 10 mg to about 100 mg, from about 0.1 mg to about 50 mg, from about 1 mg to about 50 mg, from about 10 mg to about 50 mg, from about 20 mg to about 30 mg, or from about 1 mg to about 20 mg, followed by a break.
  • In one embodiment of the invention, a compound of the invention and a second active ingredient are administered orally, with administration of the compound of the invention occurring 30 to 60 minutes prior to the second active ingredient, during a cycle of four to six weeks. In another embodiment of the invention, the combination of a compound of the invention and a second active ingredient is administered by intravenous infusion over about 90 minutes every cycle.
  • Typically, the number of cycles during which the combinatorial treatment is administered to a patient will be from about one to about 24 cycles, more typically from about two to about 16 cycles, and even more typically from about four to about three cycles.
  • 4.5 Pharmaceutical Compositions and Dosage Forms
  • Pharmaceutical compositions can be used in the preparation of individual, single unit dosage forms. Pharmaceutical compositions and dosage forms of the invention comprise a compound of the invention, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. Pharmaceutical compositions and dosage forms of the invention can further comprise one or more excipients.
  • Pharmaceutical compositions and dosage forms of the invention can also comprise one or more additional active ingredients. Examples of optional second, or additional, active ingredients are disclosed in Section 4.3, above.
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), topical (e.g., eye drops or other ophthalmic preparations), transdermal or transcutaneous administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; powders; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; eye drops or other ophthalmic preparations suitable for topical administration; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • The composition, shape, and type of dosage forms of the invention will typically vary depending on their use. For example, a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease. These and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. For example, the decomposition of some active ingredients may be accelerated by some excipients such as lactose, or when exposed to water. Active ingredients that comprise primary or secondary amines are particularly susceptible to such accelerated decomposition. Consequently, this invention encompasses pharmaceutical compositions and dosage forms that contain little, if any, lactose other mono- or di-saccharides. As used herein, the term “lactose-free” means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.
  • Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmacopeia (USP) 25-NF20 (2002). In general, lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts. Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, N.Y., 1995, pp. 379-80. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • The invention further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose. Such compounds, which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers. Like the amounts and types of excipients, the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients. However, typical dosage forms of the invention comprise a compound of the invention in an amount of from about 0.10 to about 500 mg. Typical dosage forms comprise a compound of the invention in an amount of about 0.1, 1, 2, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • Typical dosage forms comprise the second active ingredient in an amount of 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg. Of course, the specific amount of the second active agent will depend on the specific agent used, the type of cancer being treated or managed, and the amount(s) of a compound of the invention and any optional additional active agents concurrently administered to the patient.
  • 4.5.1 Oral Dosage Forms
  • Pharmaceutical compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredients in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of preparation desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • For example, a tablet can be prepared by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • Examples of excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AVICEL RC-581, AVICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, Pa.), and mixtures thereof. An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103™ and Starch 1500 LM.
  • Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form. Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention. The amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof. Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL200, manufactured by W.R. Grace Co. of Baltimore, Md.), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Plano, Tex.), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, Mass.), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • A preferred solid oral dosage form of the invention comprises a compound of the invention, anhydrous lactose, microcrystalline cellulose, polyvinylpyrrolidone, stearic acid, colloidal anhydrous silica, and gelatin.
  • 4.5.2 Delayed Release Dosage Forms
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference. Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • All controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.
  • Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • 4.5.3 Parenteral Dosage Forms
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms of the invention. For example, cyclodextrin and its derivatives can be used to increase the solubility of an immunomodulatory compound of the invention and its derivatives. See, e.g., U.S. Pat. No. 5,134,127, which is incorporated herein by reference.
  • 4.5.4 Topical and Mucosal Dosage Forms
  • Topical and mucosal dosage forms of the invention include, but are not limited to, sprays, aerosols, solutions, emulsions, suspensions, eye drops or other ophthalmic preparations, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels.
  • Suitable excipients (e.g., carriers and diluents) and other materials that can be used to provide topical and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied. With that fact in mind, typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form solutions, emulsions or gels, which are non-toxic and pharmaceutically acceptable. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990).
  • The pH of a pharmaceutical composition or dosage form may also be adjusted to improve delivery of one or more active ingredients. Similarly, the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery. Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery. In this regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent. Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • 4.6 Kits
  • Typically, active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration. This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • A typical kit of the invention comprises a dosage form of a compound of the invention. Kits encompassed by this invention can further comprise additional active ingredients such as oblimersen (Genasense®), melphalan, G-CSF, GM-CSF, EPO, topotecan, dacarbazine, irinotecan, taxotere, IFN, COX-2 inhibitor, pentoxifylline, ciprofloxacin, dexamethasone, IL2, IL8, IL18, Ara-C, vinorelbine, isotretinoin, 13 cis-retinoic acid, or a pharmacologically active mutant or derivative thereof, or a combination thereof. Examples of the additional active ingredients include, but are not limited to, those disclosed herein (see, e.g., section 4.3).
  • Kits of the invention can further comprise devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, drip bags, patches, and inhalers.
  • Kits of the invention can further comprise cells or blood for transplantation as well as pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
    • 5. EXAMPLES
  • Certain embodiments of the invention are illustrated by the following non-limiting examples.
    • 5.1 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-PHENYL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00191
  • 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.7 g, 4.3 mmol) was added to a stirred suspension of 3-[4-(aminomethyl)-1-oxo-1,3-dihydro-isoindol-2-yl]piperidine-2,6-dione hydrochloride (0.6 g, 1.9 mmol) in acetonitrile (50 mL). After stirring for 30 minutes, phenylacetyl chloride (0.4 g, 2.3 mmol) was added. The mixture was stirred at room temperature for 17 hours. Solvent was removed and the residue was stirred with water (40 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-phenyl-acetamide (0.41 g, 54%) as a white solid: mp 236-238° C.; 1H NMR (DMSO-d6) δ 1.94-1.98 (m, 1H, CH2), 2.15-2.19 (m, 1H, CH2), 2.49-2.63 (m, 1H, CH2), 2.85-2.99 (m, 1H, CH2), 3.47 (s, 2H, CH2), 4.23-4.43 (m, 4H, 2CH2), 5.07-5.14 (dd, J=5.1 and 13.2 Hz, 1H, CH), 7.18-7.33 (m, 5H, Ar), 7.46-7.64 (m, 3H, Ar), 8.61 (t, J=5.6 Hz, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.51, 31.14, 42.23, 46.08, 51.47, 121.70, 126.34, 128.22, 128.95, 130.73, 131.69, 134.49, 136.16, 140.09, 167.99, 170.18, 170.87, 172.81; Anal. calcd. for C22H21N3O4+0.07H2O: C, 67.29; H, 5.43; N, 10.70. Found: C, 66.94; H, 5.22; N, 10.63.
    • 5.2 1-CYCLOHEXYL-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00192
  • 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.4 g, 2.9 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.6 g, 1.9 mmol) in acetonitrile (100 mL). The mixture was heated for 30 minutes, then cooled to room temperature. Cyclohexyl isocyanate (0.4 g, 2.9 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was filtered and the solid was stirred with water (25 mL) to give 0.9 g of crude product. The crude product was recrystallized from methanol to give 1-cyclohexyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.12 g, 16%) as a white solid: mp 309-311° C.; 1H NMR (DMSO-d6) δ 0.97-1.75 (m, 10H), 1.99-2.04 (m, 1H), 2.32-2.64 (m, 3H), 2.86-2.98 (m, 1H), 4.27-4.51 (m, 4H), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 5.86 (d, J=7.9 Hz, 1H), 6.26 (t, J=5.5 Hz, 1H, NH), 7.47-7.62 (m, 3H, Ar), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.64, 24.44, 25.29, 31.16, 33.32, 46.09, 47.50, 47.85, 51.47, 121.36, 128.18, 130.26, 131.61, 136.28, 139.77, 157.20, 168.09, 170.97, 172.82; Anal. calcd. for C21H26N4O4: C, 63.30; H, 6.58; N, 14.06. Found: C, 63.18; N, 6.58; N, 13.99.
    • 5.3 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00193
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes, and benzoyl chloride (0.4 g, 3.2 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was stirred with 2N HCl (30 mL) and CH2Cl2 (80 mL). The solid was collected to give N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide (0.5 g, 68%) as a white solid: mp 228-230° C.; 1H NMR (DMSO-d6) δ 2.01-2.05 (m, 1H), 2.33-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.48 (d, J=17.3 Hz, 1H), 4.53 (d, J=22.1 Hz, 1H), 4.55 (s, 2H), 5.12-5.19 (dd, J=5.0 and 13.2 Hz, 1H, CH), 7.44-7.65 (m, 6H, Ar), 7.87 (d, J=7.1 Hz, 2H, Ar), 9.11 (t, J=5.7 Hz, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.61, 31.20, 46.30, 51.60, 121.67, 127.25, 128.35, 130.67, 131.36, 131.63, 134.07, 134.74, 140.16, 166.37, 168.10, 171.04, 172.88; Anal. calcd. for C21H19N3O4: C, 66.83; H, 5.07; N, 11.13. Found: C, 66.58; H, 5.08; N, 11.12.
    • 5.4 FURAN-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00194
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 2-Furoyl chloride (0.4 g, 3.2 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH2Cl2 (60 mL) and 2N HCl (30 mL). The mixture was filtered, and the solid was slurried with ethanol (20 mL) to give furan-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.5 g, 58%) as a white solid: mp 219-221° C.; 1H NMR (DMSO-d6) δ 2.00-2.05 (m, 1H), 2.30-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.39-4.49 (m, 3H), 4.53 (d, J=17.3 Hz, 1H), 5.11-5.18 (dd, J=5.0 and 13.1 Hz, 1H, CH), 6.62-6.63 9m, 1H), 7.14 (d, J=3.4 Hz, 1H), 7.47-7.65 (m, 3H, Ar), 7.84 (s, 1H), 8.00 (t, J=5.8 Hz, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.59, 31.18, 38.72, 46.24, 51.58, 111.87, 113.69, 121.70, 128.32, 130.74, 131.61, 134.55, 140.11, 145.15, 147.61, 157.84, 168.05, 171.01, 172.85; Anal. calcd. for C19H17N3O5: C, 62.12; H, 4.66; N, 11.44. Found: C, 61.91; H, 4.64; N, 11.38.
    • 5.5 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BUTYRAMIDE
  • Figure US20070049618A1-20070301-C00195
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. n-Butyryl chloride (0.3 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH2Cl2 (60 mL) and 2NHCl (30 mL). Solid was collected and slurried with ethanol (20 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-butyramide (0.5 g, 67%) as a white solid: mp 244-246° C.; 1H NMR (DMSO-d6) δ 0.85 (t, J=7.4 Hz, 3H, CH3), 1.40-1.60 (m, 2H), 1.99-2.14 (m, 3H), 2.34-2.65 (m, 2H), 2.86-2.98 (m, 1H), 4.32-4.53 (m, 4H), 5.11-5.18 (dd, J=4.9 and 13.2 Hz, 1H, CH), 7.48-7.64 (m, 3H, Ar), 8.13 (t, J=5.1 Hz, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 13.67; 18.65, 22.61, 31.19, 37.16, 38.93, 46.15, 51.54, 121.62, 128.29, 130.60, 131.63, 134.82, 140.08, 168.08, 171.02, 172.01, 172.88; Anal. calcd. for C18H21N3O4: C, 62.96; H, 6.16; N, 12.24. Found: C, 63.08; H, 6.06; N, 12.08.
    • 5.6 3-CHLORO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-SIOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00196
  • 1,8 Diazabicyclo[5,4,0]-undec-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 3-Chlorobenzoyl chloride (0.6 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was stirred with CH2Cl2 (60 mL) and 2N HCl (30 mL). The mixture was filtered and the solid was slurried with ethanol (20 mL) to give 3-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide (0.8 g, 96%) as a white solid: mp 266-268° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.37-2.66 (m, 2H), 2.86-2.99 (m, 1H), 4.48 (d, J=17.3 Hz, 1H), 4.53 (d, J=21.1 Hz, 1H), 4.55 (s, 2H), 5.12-5.20 (dd, J=5.0 and 13.2 Hz, 1H, CH), 7.48-7.66 (m, 5H, Ar), 7.87 (d, J=7.7 Hz, 1H, Ar), 7.93 (d, J=1.3 Hz, 1H, Ar), 9.23 (t, J=5.6 Hz, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.60, 31.20, 39.66, 46.28, 51.60, 121.76, 126.07, 127.08, 128.38, 130.40, 130.77, 131.22, 131.65, 133.23, 134.37, 136.01, 140.21, 164.94, 168.07, 171.04, 172.88; Anal. calcd. for C21H18N3O4Cl: C, 61.24; H, 4.41; N, 10.20; Cl, 8.61. Found: C, 60.92; H, 4.21; N, 10.01; Cl, 8.92.
    • 5.7 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-PROPYL-UREA
  • Figure US20070049618A1-20070301-C00197
  • 1,8-Diazabicyclo[5,4,0]-unded-7-ene (0.8 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. Propyl isocyanate (0.3 g, 3.2 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH2Cl2 (60 mL) and 2N HCl (30 mL). The mixture was filtered and the solid was slurried with methanol (40 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-propyl-urea (0.3 g, 31%) as a white solid: mp 298-300° C.; 1H NMR (DMSO-d6) δ 0.82 (t, J=7.3 Hz, 3H, CH3), 1.32-1.41 (m, 2H), 1.99-2.04 (m, 1H), 2.37-2.65 (m, 2H), 2.86-2.99 (m, 3H), 4.29 (d, J=6.0 Hz, 2H), 4.37 (d, J=17.3 Hz, 1H), 4.45 (d, J=17.3 Hz, 1H), 5.11-5.18 (dd, J=5.1 and 13.2 Hz, 1H, CH), 6.00 (t, J=5.5 Hz, 1H, NH), 6.38 (t, J=5.9 Hz, 1H, NH), 7.47-7.62 (m, 3H, Ar), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 11.31, 22.62, 23.24, 31.18, 41.16, 46.13, 51.50, 121.36, 128.19, 130.24, 131.58, 136.29, 139.80, 157.97, 168.13, 171.01, 172.87; Anal. calcd. for C18H22N4O4: C, 60.32; H, 6.19; N, 15.63. Found: C, 59.93; H, 6.27; N, 15.40.
    • 5.8 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-NICOTINAMIDE
  • Figure US20070049618A1-20070301-C00198
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (1.1 g, 7.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (100 mL). The mixture was stirred for 30 minutes. 3-Nicotinoyl chloride (0.5 g, 2.5 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with water (40 mL). The mixture was filtered and the solid was slurried with hot methanol (25 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3 dihydro-1H-idoindol-4-ylmethyl]-nicotinamide (0.4 g, 51%): mp 259-261° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.34-2.65 (m, 2H), 2.86-3.01 (m, 1H), 4.41-4.62 (m, 4H, 2CH2), 5.13-5.20 (dd, J=4.8 and 13.1 Hz, 1H, CH), 7.50-7.67 (m, 4H, Ar), 8.21 (d, J=7.9 Hz, 1H, Ar), 8.73 (d, J=4.2 Hz, 1H, Ar), 9.05 (s, 1H, Ar), 9.30 (t, J=5.1 Hz, 1H, NH), 11.04 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.58, 31.19, 46.27, 51.60, 121.77, 123.48, 128.37, 129.56, 130.77, 131.67, 134.30, 135.02, 140.22, 148.41, 151.99, 164.97, 168.05, 171.02, 172.37; Anal. calcd. for C20H18N4O4: C, 63.49; H, 4.79; N, 14.81. Found: C, 63.19; H, 4.75; N, 14.68.
    • 5.9 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-PHENYL-UREA
  • Figure US20070049618A1-20070301-C00199
  • A suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.7 mmol) in THF (30 mL) was cooled to 4° C. Phenyl isocyanate (0.3 g, 2.7 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL). The solid was collected and slurried with ethanol (10 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-phenyl-urea (0.7 g, 89%) as a white solid: mp 328-330° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.36-2.64 (m, 2H), 2.86-2.98 (m, 1H), 4.37-4.58 (m, 4H, 2CH2), 5.12-5.19 (dd, J=5.0 and 13.2 Hz, 1H, CH), 6.71 (t, J=5.7 Hz, 1H, NH), 6.89 (t, J=7.3 Hz, 1H, Ar), 7.21 (t, J=7.6 Hz, 2H, Ar), 7.38 (d, J=7.6 Hz, 2H, Ar), 7.48-7.65 (m, 3H, Ar), 8.61 (s, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.57, 31.18, 39.67, 46.20, 51.58, 117.80, 121.20, 121.54, 128.29, 128.62, 130.33, 131.64, 135.59, 139.90, 140.29, 155.22, 168.09, 171.01, 172.84; Anal. calcd. for C21H20N4O4: C, 64.28; H, 5.14; N, 14.28. Found: C, 64.36; H, 4.96; N, 14.17.
    • 5.10 [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
  • Figure US20070049618A1-20070301-C00200
  • Di-tert-butyl dicarbonate (0.6 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.5 g, 5.3 mmol) in THF (30 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with water (40 mL). The mixture was filtered, and the solid was slurried with hot ethanol (20 mL) to give [2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamic acid tert-butyl ester (0.7 g, 91%) as a white solid: mp 239-241° C.; 1H NMR (DMSO-d6) δ 1.38 (s, 9H, 3CH3), 2.00-2.05 (m, 1H), 2.31-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.21 (d, J=5.5 Hz, 2H, CH2), 4.37 (d, J=17.3 Hz, 1H), 4.45 (d, J=17.3 Hz, 1H), 5.11-5.18 (dd, J=4.8 and 13.0 Hz, 1H, CH), 7.48-7.62 (m, 4H, Ar and NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.64, 28.17, 31.15, 40.36, 46.02, 51.48, 78.01, 121.56, 128.23, 130.37, 131.60, 135.25, 139.84, 155.69, 168.05, 170.98, 172.81; Anal. calcd. for C19H23N3O5: C, 61.12; H, 6.21; N, 11.25. Found: C, 60.90; H, 6.19; N, 11.21.
    • 5.11 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-METHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00201
  • A suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and m-anisoyl chloride (0.4 g, 2.5 mmol) in THF 30 mL) was cooled to 5° C. Triethylamine (0.5 g, 4.8 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated, and the residue was stirred with 1N HCl (40 mL). The mixture was filtered, and the solid was slurried with hot ethanol (20 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-methoxy-benzamide (0.8 g, 93%) as a white solid: mp 244-246° C.; 1H NMR (DMSO-d6) δ 2.01-2.07 (m, 1H), 2.36-2.65 (m, 2H), 2.86-3.00 (m, 1H), 3.80 (s, 3H, CH3), 4.41-4.61 (m, 4H, 2CH2), 5.12-5.19 (dd, J=5.1 and 13.2 Hz, 1H, CH), 7.08-7.12 (m, 1H, Ar), 7.35-7.65 (m, 6H, Ar), 9.09 (t, J=5.6 Hz, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.59, 31.17, 46.29, 51.59, 55.24, 112.41, 117.19, 119.44, 121.65, 128.31, 129.46, 130.67, 131.61, 134.68, 135.46, 140.12, 159.18, 166.08, 168.06, 171.00, 172.82; Anal. calcd. for C22H21N3O5: C, 64.86; H, 5.20; N, 10.31. Found: C, 64.62; H, 5.06; N, 10.23.
    • 5.12 3-CYANO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00202
  • A suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and m-cyanobenzoyl chloride (0.4 g, 2.5 mmol) in THF (30 mL) was cooled to 5° C. Triethylamine (0.5 g, 4.8 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated, and the residue was stirred with 1N HCl (40 mL). The mixture was filtered, and the solid was slurried with warmed ethanol (20 mL) to give 3-cyano-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide (0.8 g, 92%) as a white solid: mp 282-284° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.34-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.41-4.62 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.8 and 13 Hz, 1H, CH), 7.48-7.74 (m, 4H, Ar), 8.01 (d, J=7.7 Ha, 1H, Ar), 8.17 (d, J=7.9 Hz, 1H, Ar), 8.31 (s, 1H, Ar), 9.28 (t, J=5.0 Hz, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.69, 31.17, 46.26, 51.60, 111.50, 118.26, 121.79, 128.35, 129.80, 130.82, 130.89, 131.65, 132.08, 134.14, 134.79, 135.00, 140.25, 164.54, 168.02, 170.98, 172.81; Anal. calcd. for C22H18N4O4: C, 65.67; H, 4.51; N, 13.92. Found: C, 65.38; H, 4.42; N, 13.77.
    • 5.13 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-METHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00203
  • A suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and p-anisoyl chloride (0.4 g, 2.5 mmol) in THF (30 mL) was cooled to 5° C. Triethylamine (0.5 g, 4.8 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL). The mixture was filtered, and the solid was slurried with ethanol (15 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-methoxy-benzamide (0.8 g, 90%) as a white solid: mp 289-291° C.; 1H NMR (DMSO-d6) δ 2.01-2.05 (m, 1H), 2.32-2.65 (m, 2H), 2.86-3.00 (m, 1H), 3.81 (s, 3H, OCH3), 4.40-4.60 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 7.02 (d, J=8.6 Hz, 2H, Ar), 7.46-7.64 (m, 3H, Ar), 7.85 (d, J=8.7 Hz, 2H, Ar), 8.93 (t, J=5.3 Hz, 1H, NH), 11.00 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.58, 31.17, 46.28, 51.59, 55.32, 113.51, 121.57, 126.25, 128.27, 129.06, 130.64, 131.58, 134.93, 140.07, 161.63, 165.81, 168.07, 170.98, 172.81; Anal. calcd. for C22H21N3O5: C, 64.86; H, 5.20; N, 10.31. Found: C, 64.51; H, 5.04; N, 10.09.
    • 5.14 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-METHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00204
  • A suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and o-anisoyl chloride (0.4 g, 2.5 mmol) in THF (30 mL) was cooled to 5° C. Triethylamine (0.5 g, 4.8 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL), and the mixture was concentrated. The residue was stirred with 1N HCl (30 mL) and filtered. The solid was slurried with ethanol (15 mL) to give N-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-methoxy-benzamide (0.8 g, 94%) as a white solid: mp 236-238° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.32-2.66 (m, 2H), 2.86-3.01 (m, 1H), 3.88 (s, 3H, OCH3), 4.39-4.61 (m, 4H, 2CH2), 5.12-5.19 (dd, J=4.9 and 13.1 Hz, 1H, CH), 7.02 (t, J=7.4 Hz, 1H, Ar), 7.16 (d, J=8.3 Hz, 1H, Ar), 7.44-7.72 (m, 5H, Ar), 8.77 (t, J=5.6 Hz, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.60, 31.17, 46.20, 51.55, 55.82, 111.93, 120.41, 121.51, 123.10, 128.24, 130.22, 130.43, 131.57, 132.17, 134.89, 139.94, 156.87, 165.34, 168.09, 171.00, 172.83; Anal. calcd. for C22H21N3O5: C, 64.86; H, 5.20; N, 10.31. Found: C, 64.59; H, 5.01; N, 10.17.
    • 5.15 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(3-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00205
  • A stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.7 mmol) in THF (30 mL) was cooled to 5° C. 3-Methoxyphenyl isocyanate (0.4 g, 2.7 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL). The mixture was filtered, and the solid was slurried with warmed methanol (15 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-(3-methoxy-phenyl)-urea (0.8 g, 95%) as a white solid: mp 340-342° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.33-2.64 (m, 2H), 2.86-3.00 (m, 1H), 3.69 (s, 3H, OCH3), 4.36-4.57 (m, 4H, 2CH2), 5.11-5.18 (dd, J=5.0 and 13.2 Hz, 1H, CH), 6.45-6.50 (m, 1H, Ar), 6.70 (t, J=5.7 Hz, 1H, NH), 6.89 (d, J=8.3 Hz, 1H, Ar), 7.08-7.14 (m, 2H, Ar), 7.48-7.64 (m, 3H, Ar), 8.63 (s, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.56, 31.17, 39.65, 46.19, 51.57, 54.81, 103.57, 106.63, 110.14, 121.52, 128.28, 129.34, 130.29, 131.62, 135.55, 139.87, 141.50, 155.12, 159.60, 168.07, 170.99, 172.81; Anal. calcd. for C22H22N4O5: C, 62.55; H, 5.25; N, 13.26. Found: C, 62.41; H, 5.04; N, 13.25.
    • 5.16 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(4-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00206
  • A stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.7 mmol) in THF (30 mL) was cooled to 5° C. 4-Methoxyphenyl isocyanate (0.4 g, 2.7 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL), and then concentrated. The residue was stirred with 1N HCl (30 mL) for one hour then filtered. The solid was slurried with hot methanol (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-(4-methoxy-phenyl)-urea (0.8 g, 93%) as a white solid: mp 320-322° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.36-2.64 (m, 2H), 2.86-3.00 (m, 1H), 3.68 (s, 3H, OCH3), 4.35-4.57 (m, 4H, 2CH2), 5.12-5.19 (dd, J=4.6 and 13.0 Hz, 1H, CH), 6.61 (t, J=5.5 Hz, 1H, NH), 6.83 (d, J=8.9 Hz, 2H, Ar), 7.27 (d, J=8.9 Hz, 2H, Ar), 7.47-7.64 (m, 3H, Ar), 8.40 (s, 1H, NH), 11.03 (s, 1H); 13C NMR (DMSO-d6) δ 22.58, 31.18, 46.20, 51.58, 55.11, 113.86, 119.70, 121.49, 128.27, 130.34, 131.62, 133.36, 135.76, 139.88, 154.08, 155.47, 168.10, 171.00, 172.84; Anal. calcd. for C22H22N4O5: C, 62.55; H, 5.25; N, 13.26. Found: C, 62.61; H, 4.95; N, 13.59.
    • 5.17 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(2-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00207
  • A stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.7 mmol) in THF (30 mL) was cooled to 5° C. 2-Methoxyphenyl isocyanate (0.4 g, 2.7 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL), and then concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour and then filtered. The solid was slurried with hot methanol (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-(2-methoxy-phenyl)-urea (0.8 g, 89%) as a white solid: mp 187-189° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.31-2.64 (m, 2H), 2.86-3.00 (m, 1H), 3.82 (s, 3H, OCH3), 4.36-4.58 (m, 4H, 2CH2), 5.11-5.18 (dd, J=5.0 and 13.2 Hz, 1H, CH), 6.98-6.82 (m, 3H, Ar), 7.38 (t, J=5.6 Hz, 1H, NH), 7.48-7.66 (m, 3H, Ar), 8.04-8.08 (m, 2H), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.56, 31.18, 39.63, 46.18, 51.60, 55.64, 110.58, 118.07, 120.44, 121.19, 128.35, 129.21, 130.40, 131.69, 135.36, 139.99, 147.36, 155.14, 168.07, 171.00, 172.84; Anal. calcd. for C22H22N4O5+0.35H2O: C, 61.63; H, 5.34; N, 13.07. Found: C, 61.34; H, 5.15; N, 12.78.
    • 5.18 1-(3-CYANO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00208
  • 3-Cyanophenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 min, the mixture was warmed to room temperature and stirred overnight. The reaction was quenched with methanol (1 mL) and concentrated. The residue was stirred with 1N HCl (30 mL) for 30 minutes and filtered. The solid was slurried with hot methanol (15 mL) to give 1-(3-cyano-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.33 g, 38%) as a white solid: mp 330-333° C.; 1H NMR (DMSO-d6) δ 2.01-2.05 (m, 1H), 2.37-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.37-4.58 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 6.92 (t, J=5.5 Hz, 1H, NH), 7.32-7.65 (m, 6H, Ar), 7.93 (s, 1H, Ar), 9.00 (s, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.55, 31.17, 39.67, 46.18, 51.57, 111.41, 118.91, 120.24, 121.59, 122.36, 124.64, 128.30, 130.02, 130.35, 131.63, 135.27, 139.92, 141.21, 154.98, 168.05, 171.00, 172.82; Anal. calcd. for C22H19N5O4+0.1H2O: C, 63.03; H, 4.62; N, 16.71. Found: C, 62.69; H, 4.48; N, 16.41.
    • 5.19 1-(3-CHLORO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00209
  • 3-Chlorophenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour and filtered. The solid was slurried with hot methanol (15 mL) to give 1-(3-chloro-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.8 g, 91%): mp 250-252° C.; 1H NMR (DMSO-d6) δ 2.00-2.05 (m, 1H), 2.37-2.65 (m, 2H), 2.86-2.98 (m, 1H), 4.37 (d, J=5.3 Hz, 2H, CH2), 4.44 (d, J=17.2 Hz, 1H), 4.51 (d, J=17.3 Hz, 1H), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 6.82 (t, J=5.4 Hz, 1H, NH), 6.92-6.95 (m, 1H, Ar), 7.18-7.27 (m, 2H, Ar), 7.48-7.65 (m, 4H, Ar), 8.84 (s, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.57, 31.18, 39.68, 46.20, 51.59, 116.15, 117.13, 120.78, 121.57, 128.30, 130.21, 130.35, 131.64, 133.06, 135.37, 139.90, 141.86, 154.99, 168.07, 171.00, 172.82; Anal. calcd. for C21H19N4O4Cl: C, 59.09; H, 4.49; N, 13.13; Cl, 8.31. Found: C, 59.06; H, 4.39; N, 13.24; Cl, 7.95.
    • 5.20 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ISONICOTINAMIDE
  • Figure US20070049618A1-20070301-C00210
  • Triethylamine (0.7 g, 7.4 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and isonicotinoyl chloride hydrochloride (0.5 g, 2.5 mmol) in THF (30 mL) at 5-10° C. After stirring for 10 minutes at 5° C., the mixture was stirred at room temperature overnight. The mixture was filtered, and the solid was slurried with hot methanol (30 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-isonicotinamide (0.5 g, 63%): mp 282-284° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.38-2.66 (m, 2H), 2.86-2.98 (m, 1H), 4.41-4.64 (m, 4H, 2CH2), 5.12-5.19 (dd, J=4.6 and 13.0 Hz, 1H, CH), 7.48-7.67 (m, 3H, Ar), 7.78-7.80 (d, J=4.8 Hz, 2H, Ar), 8.73-8.75 (m, d, J=4.8 Hz, 2H, Ar), 9.39 (s, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.59, 31.18, 39.67, 46.27, 51.61, 121.25, 121.83, 128.38, 130.76, 131.68, 134.11, 140.24, 140.98, 150.27, 164.87, 168.03, 171.00, 172.84; Anal. calcd. for C20H18N4O4: C, 63.49; H, 4.79; N, 14.81. Found: C, 63.22; H, 4.73; N, 14.62.
    • 5.21 PYRIDINE-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00211
  • Triethylamine (0.7 g, 7.4 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and picolinoyl chloride hydrochloride (0.5 g, 2.5 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with H2O (30 mL). The mixture was filtered, and the solid was slurried with hot methanol (15 mL) to give pyridine-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.6 g, 78%): mp 254-256° C.; 1H NMR (DMSO-d6) δ 2.01-2.06 (m, 1H), 2.32-2.66 (m, 2H), 2.86-3.01 (m, 1H), 4.43-4.65 (m, 4H, 2CH2), 5.12-5.19 (dd, J=4.7 and 13.0 Hz, 1H, CH), 7.45-7.64 (m, 4H, Ar), 7.97-8.07 (m, 2H, Ar), 8.65 (d, J=4.2 Hz, 1H, Ar), 9.51 (t, J=5.8 Hz, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.59, 31.17, 46.30, 51.57, 121.63, 122.02, 126.60, 128.28, 130.77, 131.58, 134.73, 137.79, 140.08, 148.44, 149.80, 164.16, 168.06, 170.99, 172.82; Anal. calcd. for C20H18N4O4: C, 63.49; H, 4.79; N, 14.81. Found: C, 63.32; H, 4.66; N, 14.80.
    • 5.22 1-BENZYL-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00212
  • Benzyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL). The mixture was filtered, and the solid was slurried with hot methanol (15 mL) to give 1-benzyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.8 g, 88%) as a white solid: mp 304-306° C., 1H NMR (DMSO-d6) δ 1.97-2.02 (m, 1H), 2.30-2.34 (m, 1H), 2.50-2.65 (m, 1H), 2.85-2.98 (m, 1H), 4.21-4.52 (m, 6H), 5.09-5.16 (dd, J=4.5 and 13.0 Hz, 1H, CH), 6.51-6.53 (m, 2H), 7.23-7.61 (m, 8H), 11.01 (s, 1H), 13C NMR (DMSO-d6) δ 22.56, 31.18, 40.01, 42.96, 46.14, 51.52, 121.38, 126.52, 126.95, 128.17, 130.23, 131.60, 136.11, 139.80, 140.78, 157.95, 168.09, 170.95, 172.82; Anal. calcd. for C22H22N4O4: C, 65.01; H, 5.46; N, 13.78. Found: C, 64.90; H, 5.53; N, 13.46.
    • 5.23 1-(3,4-DICHLORO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00213
  • 3,4-Dichlorophenyl isocyanate (0.5 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL). The mixture was filtered, and the solid was slurried with hot methanol (20 mL) to give 1-(3,4-dichloro-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.6 g, 67%) as a white solid: mp 253-255° C.; 1H NMR (DMSO-d6) δ 2.00-2.05 (m, 1H), 2.37-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.36-4.58 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 6.89 (t, J=5.6 Hz, 1H, NH), 7.24-7.84 (m, 6H, Ar), 8.96 (s, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.56, 31.17, 39.69, 46.19, 51.58, 117.86, 118.83, 121.58, 122.37, 128.29, 130.38, 130.86, 131.64, 135.27, 139.91, 140.56, 154.87, 168.05, 170.98, 172.81; Anal. calcd. for C21H18N4O4Cl2: C, 54.68; H, 3.93; N, 12.15; Cl, 15.37. Found: C, 54.52; H, 3.78; N, 11.89; Cl, 15.28.
    • 5.24 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-PYRIDIN-3-YL-UREA
  • Figure US20070049618A1-20070301-C00214
  • Step 1: A solution of 3-aminopyridine (1.5 g, 15.5 mmol) in acetonitrile (20 mL) was added to a stirred solution of N,N′-disuccinimidyl carbonate (4.0 g, 15.5 mmol) in acetonitrile (150 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (120 mL). The CH2Cl2 solution was washed with saturated NaHCO3 (40 mL), H2O (40 mL), brine (40 mL), and dried (MgSO4). Solvent was removed to give pyridin-3-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (1.3 g, 36%), which was used in next step without purification.
  • Step 2: Pyridin-3-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (0.5 g, 2.1 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and 1,8-diazabicyclo[5,4,0]undec-7-ene (0.4 g, 2.3 mmol) in acetonitrile (100 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with water (30 mL). The mixture was filtered, and the solid was slurried with hot methanol (15 mL) to give 1-[2-(2,6-dioxo-phenyl-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-pyridin-3-yl-urea (0.5 g, 60%) as a white solid: mp 273-275° C.; 1H NMR (DMSO-d6) δ 2.00-2.05 (m, 1H), 2.33-2.65 (m, 2H), 2.85-3.00 (m, 1H), 4.38-4.58 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.9 and 13.1 Hz, 1H, CH), 6.87 (t, J=5.4 Hz, 1H, NH), 7.22-7.27 (w, 1H, Ar), 7.48-7.65 (m, 3H, Ar), 7.86 (d, J=8.3 Hz, 1H, Ar), 8.11 (d, J=2.9 Hz, 1H, Ar), 8.54 (s, 1H, Ar), 8.80 (s, 1H, NH), 11.00 (s, 1H, NH); 13C NMR (DSMO-d6) δ 22.56, 31.17, 46.19, 51.57, 121.57, 123.43, 124.62, 128.29, 130.34, 131.64, 135.37, 136.96, 139.69, 139.90, 142.25, 155.16, 168.06, 170.99, 172.81; Anal. calcd. for C20H19N5O4: C, 61.06; H, 4.87; N, 17.80. Found: C, 60.74, 4.75; N, 17.66.
    • 5.25 3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-1,1-DIMETHYL-UREA
  • Figure US20070049618A1-20070301-C00215
  • Triethylamine (0.6 g, 5.9 mmol) was added slowly to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and dimethylcarbamoyl chloride (0.3 g, 3.2 mmol) in THF (100 mL). The mixture was stirred at room temperature overnight. Another portion of dimethylcarbamoyl chloride (0.3 g) and 1,8-diazabicyclo[5,4,0]-undec-7-ene (0.6 g) was added and stirred for another day. The mixture was concentrated, and the residue was stirred with 1N HCl (15 mL). The mixture was filtered, and the solid was slurried with hot methanol (10 mL) to give 3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-1,1-dimethyl-urea (0.3 g, 46%) as a white solid: mp 169-171° C.; 1H NMR (DMSO-d6) δ 1.99-2.04 (m, 1H), 2.32-2.64 (m, 2H), 2.80 (s, 6H, 2CH3), 2.85-3.00 (m, 1H), 4.27 (d, J=5.6 Hz, 2H, CH2), 4.40 (d, J=17.3 Hz, 1H), 4.47 (d, J=17.3 Hz, 1H), 5.10-5.17 (dd, J=5.0 and 13.2 Hz, 1H, CH), 6.94 (t, J=5.6 Hz, 1H, NH), 7.44-7.64 (m, 3H, Ar), 11.02 (s, 1H); 13C NMR (DMSO-d6) δ 22.58, 31.18, 35.88, 46.20, 51.55, 121.20, 128.08, 130.38, 131.39, 136.35, 139.77, 158.08, 168.15, 171.00, 172.83; Anal. calcd. for C17H20N4O4: C, 59.29; H, 5.85; N, 16.27. Found: C, 59.05; H, 5.91; N, 15.92.
    • 5.26 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-METHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00216
  • Triethylamine (0.5 g, 5.2 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and m-toluoyl chloride (0.5 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (20 mL). The mixture was filtered, and the solid was slurried with hot methanol (15 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-methyl-benzamide (0.7 g, 86%) as a white solid: mp 253-255° C.; 1H NMR (DMSO-d6) δ 2.01-2.05 (m, 1H), 2.35 (s, 3H, CH3), 2.35-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.40-4.61 (m, 4H, 2CH2), 5.12-5.19 (dd, J=5.0 and 13.2 Hz, 1H, CH), 7.34-7.70 (m, 7H, Ar), 9.05 (t, J=5.6 Hz, 1H, NH), 11.03 (s, 1H, NH); 13C NMR (DMSO-d6) δ 20.90, 22.59, 31.17, 46.28, 51.58, 121.62, 124.36, 127.76, 128.20, 128.30, 130.66, 131.60, 131.86, 134.07, 134.75, 137.59, 140.11, 166.45, 168.06, 170.99, 172.82; Anal. calcd. for C22H21N3O4: C, 67.51; H, 5.41; N, 10.74. Found: C, 67.52; H, 5.35; N, 10.71.
    • 5.27 (2-{[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-CARBAMOYL}-ETHYL)-CARBAMIC ACID T-BUTYL ESTER
  • Figure US20070049618A1-20070301-C00217
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (2.6 g, 16.8 mmol) was added to a stirred solution of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6 dione hydrochloride (2.0 g, 6.5 mmol) in DMF (100 mL). After stirring for 10 minutes, 1-hydrocybenztriazole (1.1 g, 7.8 mmol) and N-BOC-β-alanine (1.4 g, 7.1 mmol) were added. The reaction was initiated by addition of 1-[3-(dimethylamino0propyl]-3-ethylcarbodiimide hydrochloride (1.9 g, 9.7 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with H2O (40 mL) and CH2Cl2 (120 mL). The solid was collected to give (2-{[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamoyl}-ethyl)-carbamic acid t-butyl ester (2.1 g, 73%) as a white solid: mp 203-205° C.; 1H NMR (DMSO-d6) δ 1.36 (s, 9H, 3CH3), 1.99-2.04 (m, 1H), 2.27-2.64 (m, 2H), 2.85-2.98 (m, 1H), 3.00-3.18 (m, 2H), 4.31 (d, J=5.3 Hz, 2H, CH2), 4.33-4.53 (dd, J=17.3 and 37.3 Hz, 2H, CH2), 5.10-5.17 (dd, J=4.8 and 13.1 Hz, 1H, CH), 6.79 (t, 1H, NH), 7.47-7.52 (m, 2H, Ar), 7.61-7.64 (m, 1H, Ar), 8.43 (t, J=5.3 Hz, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.54, 28.19, 31.17, 35.60, 36.67, 46.15, 51.55, 77.77, 121.60, 128.24, 130.56, 131.61, 134.56, 140.04, 155.43, 168.02, 170.43, 170.95, 172.80; Anal. calcd. for C22H28N4O6: C, 59.45; H, 6.35; N, 12.60. Found: C, 59.16; H, 6.31; N, 12.50.
    • 5.28 3-AMINO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-PROPIONAMIDE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00218
  • 4N HCl/dioxane (3.4 mL) was added to a stirred solution of (2-{[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamoyl}-ethyl)-carbamic acid t-butyl ester (1.5 g, 3.4 mmol) in CH2Cl2 (50 mL) and DMF (25 mL). The mixture was stirred at room temperature for 7 days. The mixture was filtered to give 3-amino-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-propionamide hydrochloride (1.0 g, 74%) as a white solid: mp 249-251° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.37-2.65 (m, 4H, 2CH2), 2.86-2.99 (m, 3H), 4.34-4.57 (m, 4H, 2CH2), 5.11-5.18 (dd, J=4.8 and 13.1 Hz, 1H, CH), 7.46-7.64 (m, 3H, Ar), 8.02 (s, 3H, NH3), 8.78 (t, J=5.3 Hz, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.57, 31.17, 31.94, 35.09, 39.02, 46.21, 51.57, 121.71, 128.27, 130.81, 131.65, 134.28, 140.14, 167.99, 169.47, 170.96, 172.83; Anal. calcd. for C17H21N4O4CL: C, 52.38; H, 5.69; N, 14.37; Cl, 9.09. Found: C, 52.31; H, 5.56; N, 14.19; Cl, 9.01.
    • 5.29 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-METHOXY-ACETAMIDE
  • Figure US20070049618A1-20070301-C00219
  • Triethylamine (0.5 g, 5.0 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and methoxyacetyl chloride (0.3 g, 2.7 mmol) in THF (30 mL) at room temperature. The mixture was stirred at room temperature overnight. Reaction mixture was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 30 minutes and filtered. The solid was slurried with ethanol (15 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-methoxy-acetamide (0.4 g, 57%) as a white solid: mp 232-234° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.32-2.64 (m, 2H), 2.85-3.00 (m, 1H), 3.31 (s, 3H, CH3), 3.87 (s, 2H, CH2), 4.35 (d, J=6.2 Hz, 2H, CH2), 4.41 (d, J=17.3 Hz, 1H), 4.49 (d, J=17.3 Hz, 1H), 5.10-5.17 (dd, J=5.0 and 13.2 Hz, 1H, CH), 7.45-7.64 (m, 3H, Ar), 8.46 (t, J=5.8 Hz, 1H, NH), 11.00 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.57, 31.16, 38.42, 46.18, 51.54, 58.61, 71.46, 121.60, 128.23, 130.69, 131.56, 134.65, 140.01, 168.03, 169.20, 170.97, 172.82, Anal. calcd. for C17H19N3O5: C, 59.12; H, 5.55; N, 12.17. Found: C, 59.10; H, 5.51; N, 12.05.
    • 5.30 2-DIMETHYLAMINO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00220
  • Step 1: Triethylamine (0.7 g, 6.5 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.8 g, 2.6 mmol) in THF (50 mL). After stirring for 5 minutes, chloroacetyl chloride (0.4 g, 3.6 mmol) was added slowly. The resulting brown suspension was refluxed overnight. The mixture was cooled and quenched with methanol (1 mL). The mixture was concentrated, and the solid was stirred with 0.5N HCl (30 mL). The mixture was filtered, and the solid was slurried with ethanol (15 mL) to give 2-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.7 g, 76%): 1H NMR (DMSO-d6) δ 1.99-2.04 (m, 1H), 2.35-2.65 (m, 2H), 2.85-2.94 (m, 1H), 4.19 (s, 2H, CH2), 5.10-5.18 (dd, J=5.1 and 13.3 Hz, 1H, CH), 7.50-7.66 (m, 3H), 8.80 (t, J=5.7 Hz, 1H, NH), 11.01 (s, 1H, NH).
  • Step 2: Dimethylamine/THF (2M, 6.1 mL, 12.3 mmol) was added to a stirred solution of 2-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (1.0 g, 3.1 mmol) in DMF (30 mL). The resulting solution was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with CH2Cl2 (15 mL). The mixture was filtered, and the solid was dissolved in H2O (10 mL). 4N HCl (1.5 mL) was added and stirred for 30 minutes. The resulting solution was concentrated, and the residue was evaporated with ethanol (3×10 mL). The residue was slurried with ether (15 mL) and ethanol (5 mL). The mixture was filtered to give 2-dimethylamino-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide hydrochloride (0.7 g, 54%) as a white solid: mp 273-275° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.33-2.65 (m, 2H), 2.81 (s, 6H, 2CH3), 2.87-3.01 (m, 1H), 4.02 (s, 2H, CH2), 4.36 (d, J=17.4 Hz, 1H), 4.43 (d, J=4.6 Hz, 2H, CH2), 4.55 (d, J=17.4 Hz, 1H), 5.12-5.19 (dd, J=5.0 and 13.1 Hz, 1H, CH), 7.48-7.67 (m, 3H, Ar), 9.41 (t, J=5.7 Hz, 1H, NH), 10.08 (s, 1H, NH), 11.04 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.60, 31.16, 39.06, 43.05, 46.19, 51.55, 57.07, 121.95, 128.32, 130.87, 131.72, 133.59, 140.25, 164.43, 167.93, 170.94, 172.84; Anal. calcd. for C18H23N4O4Cl+0.34H2O: C, 53.92; H, 5.95; N, 13.94; Cl, 8.84. Found: C, 54.06; H, 6.08; N, 13.72; Cl, 9.06.
    • 5.31 (3-{[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-CARBAMOYL}-PROPYL)-CARBAMIC ACID T-BUTYL ESTER
  • Figure US20070049618A1-20070301-C00221
  • 1,8-Diazabicyclo[5,4,0]-undec-7-ene (1.8 g, 11.8 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (1.4 g, 4.5 mmol) in DMF (50 mL). After stirring for 10 minutes, 1-hydroxbenzotriazole (0.7 g, 5.4 mmol) and N-BOC-γ-aminobutyric acid (1.1 g, 5.4 mmol) were added. The reaction was initiated by addition of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.3 g, 6.8 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with EtOAc (50 mL) and H2O (40 mL) for 30 minutes. The mixture was filtered, and dried to give (3-{[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamoyl}-propyl-carbamic acid t-butyl ester (1.6 g, 77%) as a white solid: mp 199-201° C.; 1H NMR (DMSO-d6) δ 1.37 (s, 9H, 3CH3), 1.58-1.66 (m, 2H, CH2), 1.99-2.16 (m, 3H), 2.36-2.49 (m, 1H), 2.58-2.64 (m, 1H), 2.86-2.94 (m, 3H), 4.31 (d, J=5.6 Hz, 2H, CH2), 4.38 (d, J=17.3 Hz, 1H), 4.46 (d, J=17.3 Hz, 1H), 5.10-5.18 (dd, J=5.0 and 13.1 Hz, 1H, CH), 6.81 (t, J=5.4 Hz, 1H, NH), 7.48-7.64 (m, 3H, Ar), 8.37 (t, J=5.7 Hz, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.56, 25.72, 28.23, 31.18, 32.63, 38.95, 46.15, 51.56, 77.04, 121.60, 128.27, 130.55, 131.61, 134.70, 140.06, 155.55, 168.04, 170.97, 171.90, 172.82; Anal. calcd. for C23H30N4O6: C, 60.25; H, 6.59; N, 12.22. Found: C, 60.12; H, 6.55; N, 12.15.
    • 5.32 4-AMINO-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BUTYRAMIDE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00222
  • 2N HCl/ether (4 mL) was added to a stirred solution of (3-{[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamoyl}-propyl)-carbamic acid t-butyl ester (1 g, 2.2 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 7 days. The mixture was diluted with CH2Cl2 (20 mL) and filtered to give 4-amino-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-butyramide hydrochloride (0.8 g, 87%) as a white solid: mp 268-270° C.; 1H NMR (DMSO-d6) δ 1.74-1.86 (m, 2H, CH2), 2.00-2.04 (m, 1H), 2.24-2.79 (m, 6H), 2.86-2.98 (m, 1H), 4.32-4.39 (m, 3H), 4.49 (d, J=17.5 Hz, 1H), 5.10-5.18 (dd, J=5.0 and 12.5 Hz, 1H, CH), 7.49-7.64 (m, 3H, Ar), 8.01 (b, 3H, NH3), 8.61 (t, J=5.0 Hz, 1H, NH), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.59, 23.10, 31.18, 31.87, 38.40, 38.98, 46.20, 51.57, 121.64, 128.28, 130.64, 131.63, 134.61, 140.09, 168.03, 170.99, 171.37, 172.85; Anal. calcd. for C18H23N4O4Cl: C, 54.75; H, 5.87; N, 14.19; Cl, 8.98. Found: C, 54.50; H, 5.81; N, 13.90; Cl, 8.92.
    • 5.33 1-(4-CHLORO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00223
  • 4-Chlorophenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and concentrated. The residue was stirred with 1NHCl (30 mL) for 30 minutes. The mixture was filtered, and the solid was slurried with hot acetone (10 mL) to give 1-(4-chloro-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.7 g, 73%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.33-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.36-4.58 (m, 4H, 2CH2), 5.11-5.18 (dd, J=5.0 and 12.5 Hz, 1H, CH), 6.77 (t, J=5.0 Hz, 1H, NH), 7.27 (d, J=10.0 Hz, 2H, Ar), 7.40 (d, J=10 Hz, 2H, Ar), 7.47-7.64 (m, 3H, Ar), 8.77 (s, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.57, 31.18, 39.68, 45.19, 51.58, 119.29, 121.56, 124.66, 128.30, 128.44, 130.35, 131.64, 135.46, 139.31, 139.92, 155.08, 168.07, 171.00, 172.84; Anal. calcd. for C21H19N4O4Cl: C, 59.09; H, 4.49; N, 13.13; Cl, 8.31. Found: C, 58.85; H, 4.35; N, 12.97; Cl, 8.19.
    • 5.34 1-(3,4-DIMETHYL-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00224
  • 3,4-Dimethylphenyl isocyanate (0.4 g, 2.7 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and then concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour then filtered. The solid was slurried with hot acetone (10 mL) for 30 minutes to give 1-(3,4-dimethyl-phenyl)-3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.8 g, 91%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.11 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.32-2.64 (m, 2H), 2.85-3.00 (m, 1H), 4.34-4.57 (m, 4H, 2CH2), 5.11-5.18 (dd, J=5.0 and 12.5 Hz, 1H, CH), 6.64 (t, J=5.0 Hz, 1H, NH), 6.94-7.15 (m, 3H, Ar), 7.47-7.64 (m, 3H, Ar), 8.39 (s, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 18.59, 19.60, 22.57, 31.18, 39.69, 46.19, 51.57, 115.45, 119.25, 121.51, 128.28, 128.76, 129.49, 130.34, 131.63, 135.71, 136.09, 137.95, 139.88, 155.29, 168.09, 171.00, 172.84; Anal. calcd. for C23H24N4O4: C, 65.70; H, 5.75; N, 13.32. Found: C, 65.36; H, 5.61; N, 13.10.
    • 5.35 1-CYCLOHEXYL-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-THIOUREA
  • Figure US20070049618A1-20070301-C00225
  • Cyclohexyl isothiocyanate (0.4 g, 2.5 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and triethylamine (0.3 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature for 6 days. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 1 hour. The mixture was filtered, and the solid was slurried with hot methanol (20 mL) to give 0.5 g of crude product. The crude product was purified by prep. HPLC to give 1-cyclohexyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-thiourea (0.3 g, 29%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 1.10-1.34 (m, 5H), 1.52-1.63 (m, 3H), 1.82-1.85 (m, 2H), 2.00-2.05 (m, 1H), 2.32-2.39 (m, 1H), 2.58-2.65 (m, 1H), 2.86-3.00 (m, 1H), 4.31 (b, 1H), 4.38 (d, J=17.3 Hz, 1H), 4.47 (d, J=17.4 Hz, 1H), 4.77 (d, J=5.0 Hz, 2H), 5.11-5.19 (dd, J=5.0 and 13.2 Hz, 1H), 7.49-7.73 (m, 5H), 11.02 (s, 1H), 13C NMR (DMSO-d6) δ 22.65, 24.44, 25.12, 31.15, 32.24, 43.89, 46.21, 51.48, 51.91, 121.55, 128.20, 130.35, 131.68, 134.92, 139.74, 168.02, 170.97, 172.82; Anal. calcd. for C21H26N4O3S: C, 60.85; H, 6.32; N, 13.52; S, 7.74. Found: C, 60.51; H, 6.05; N, 13.33; S, 7.79.
    • 5.36 3,4-DICHLORO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00226
  • Triethylamine (0.5 g, 5.3 mmol) was added to a stirred suspension of 3-(4-aminomethyl-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.7 g, 2.1 mmol) and 3,4-dichlorobenzoyl chloride (0.6 g, 2.9 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL) and concentrated. The residue was stirred with 1N HCl (40 mL) for 1 hour then filtered. The solid was slurried with hot acetone (25 mL) to give 3,4-dichloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide (0.6 g, 62%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.01-2.08 (m, 1H), 2.33-2.65 (m, 2H), 2.86-3.00 (m, 1H), 4.40-4.61 (m, 4H, 2CH2), 5.11-5.19 (dd, J=5.0 and 13.2 Hz, 1H, CH), 7.47-7.88 (m, 5H, Ar), 8.12 (d, J=1.9 Hz, 1H, Ar), 9.26 (t, J=5.6 Hz, 1H, NH), 11.02 (s, 1H, NH); 13C NMR (DMSO-d6) δ 22.56, 31.16, 39.73, 46.25, 51.58, 121.78, 127.60, 128.34, 129.22, 130.73, 130.81, 131.27, 131.65, 134.16, 134.33, 140.23, 164.09, 168.01, 170.98, 172.81; Anal. calcd. for C21H17N3O4Cl2: C, 56.52; H, 3.84; N, 9.42; Cl, 15.89. Found: C, 56.42; H, 3.79; N, 9.21; Cl, 15.85.
    • 5.37 1-(3-CHLORO-4-METHYLPHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]UREA
  • Figure US20070049618A1-20070301-C00227
  • A mixture of 3-(4-aminomethyl-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.50 g, 1.6 mmol), 3-chloro-4-methylphenyl isocyanate (0.26 g, 1.6 mmol) and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at this temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed, eluting with 95:5 methylene chloride-methanol, to provide 0.35 g of the product in 50% yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.00-2.04 (m, 1H), 2.22 (s, 3H), 2.36-2.43 (m, 1H), 2.57-2.64 (m, 1H), 2.86-2.98 (m, 1H), 4.36 (d, J=5.6 Hz, 2H), 4.40 (d, J=17.3 Hz, 1H), 4.54 (d, J=17.3 Hz, 1H), 5.15 (dd, J=13.1 Hz, J=5.0 Hz, 1H), 6.77 (t, J=5.6 Hz, 1H), 7.09-7.19 (m, 2H), 7.48-7.57 (m, 2H), 7.61-7.64 (m, 2H), 8.72 (s, 1H), 11.01 (s, 1H); 13C NMR (DMSO-d6) δ 18.7, 22.6, 31.2, 39.7, 46.2, 51.6, 116.5, 117.7, 121.6, 127.5, 128.3, 130.4, 131.0, 131.7, 133.0, 135.5, 139.5, 139.9, 155.1, 168.1, 171.0, 172.8; Anal. calcd for C22H21ClN4O4.0.2H2O: C, 59.45; H, 4.85; N, 12.60. Found: C, 59.28; H, 4.83; N, 12.39.
    • 5.38 1-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-NAPHTHALEN-1-YL-UREA
  • Figure US20070049618A1-20070301-C00228
  • A heterogeneous mixture of 3-(4-aminomethyl-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.50 g, 1.6 mmol), 1-naphthyl isocyanate (0.26 g, 1.6 mmol), and triethylamine (4.9 g, 4.9 mmol) in 25 mL THF was stirred under nitrogen at ambient temperature for 18 hours. The solvent was removed under vacuum. The residue was triturated with 3% aqueous HCl (100 mL) for 1 hour and then filtered, and the filter was washed with additional 3% HCl. The resulting solid was dried, triturated with 30 mL refluxing acetone for 1 hour and filtered, and the filter was washed with additional hot acetone. The resulting solid was dried and then triturated with 30 mL refluxing acetonitrile, filtered, and dried, to provide 0.40 g of the product in 56% yield: 1H NMR (DMSO-d6) δ 2.00-2.09 (m, 1H), 2.35-2.42 (m, 1H), 2.57-2.63 (m, 1H), 2.86-2.98 (m, 1H), 4.44 (d, J=17.2 Hz, 1H), 4.46 (d, J=5.8 Hz, 2H), 4.58 (d, J=17.2 Hz, 1H), 5.16 (dd, J=13.1 Hz, J=5.1 Hz, 1H), 7.11 (t, J=5.8 Hz, 1H), 7.09-7.67 (m, 7H), 7.90 (dd, J=6.6 Hz, J=2.9 Hz, 1H), 7.95 (d, J=7.4 Hz, 1H), 8.09 (t, J=9.0 Hz, 1H), 8.66 (s, 1H), 11.03 (s, 1H); 13C NMR (DMSO-d6) δ 22.6, 31.2, 40.0, 46.2, 51.6, 117.0, 121.4, 121.6, 122.4, 125.5, 125.8, 125.9, 128.3, 128.4, 130.4, 131.7, 133.7, 134.9, 135.5, 140.0, 155.7, 168.1, 171.0, 172.8; Anal. calcd for C25H22N4O4: C, 67.86; H, 5.01; N, 12.66. Found: C, 67.64; H, 4.99; N, 12.28.
    • 5.39 1-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-NAPHTHALEN-2-YL-UREA
  • Figure US20070049618A1-20070301-C00229
  • A heterogeneous mixture of 3-(4-aminomethyl-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione hydrochloride (0.50 g, 1.6 mmol), 2-naphthyl isocyanate (0.26 g, 1.6 mmol), and triethylamine (4.9 g, 4.9 mmol) in 25 mL THF was stirred under nitrogen at ambient temperature for 18 hours. The solvent was removed under vacuum. The residue was triturated with 3% aqueous HCl (100 mL) for 1 hour and then filtered, and the filter was washed with additional 3% HCl. The resulting solid was dried, triturated with 30 mL refluxing acetone for 1 hour, and filtered, and the filter was washed with additional hot acetone. The resulting solid was dried and then triturated with 30 mL refluxing acetonitrile, filtered, and dried, to provide 0.45 g of the product in 63% yield: 1H NMR (DMSO-d6) δ 2.01-2.08 (m, 1H), 2.38-2.45 (m, 1H), 2.57-2.65 (m, 1H), 2.86-2.93 (m, 1H), 4.41 (d, J=5.0 Hz, 2H), 4.43 (d, J=17.4 Hz, 1H), 4.57 (d, J=17.4 Hz, 1H), 5.16 (dd, J=13.2 Hz, J=5.1 Hz, 1H), 6.83 (t, J=5.8 Hz, 1H), 7.28-7.79 (m, 9H), 8.02 (d, J=1.8 Hz, 1H), 8.85 (s, 1H), 11.03 (s, 1H); 13C NMR (DMSO-d6) δ 22.6, 31.2, 39.8, 46.2, 51.6, 112.8, 119.6, 121.6, 123.6, 126.2, 126.8, 127.4, 128.2, 128.3, 128.8, 130.4, 131.7, 133.8, 135.6, 138.0, 139.9, 155.3, 168.1, 171.0, 172.8; Anal. calcd for C25H22N4O4.0.2H2O: C, 67.31; H, 5.06; N, 12.56. Found: C, 67.37; H, 4.90; N, 12.53.
    • 5.40 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-PHENYLAMINOISOINDOLE-1,3-DIONE 50.40.1 3-Nitrophthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00230
  • Methyl iodide (30.2 g, 213 mmol) was added to a stirred mixture of 3-nitrophthalic acid (15.0 g, 71.0 mmol) and sodium bicarbonate (23.9 g, 284 mmol) in DMF (150 mL) at room temperature, and the mixture was then heated in an oil bath set to 60° C. for 4 hours. The mixture was then poured into 700 mL of ice water. After the ice melted, the mixture was extracted with ethyl acetate (3×150 mL) and the organic phases were washed with water (7×500 mL), dried (MgSO4) and evaporated, providing 16.2 g of the product as a pale yellow solid in 95% yield: 1H NMR (CDCl3) δ 3.95 (s, 3H), 4.02 (s, 3H), 7.69 (t, J=8.1 Hz, 1H), 8.36 (m, 2H).
    • 5.40.2 3-Aminophthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00231
  • A mixture of 3:1 ethanol-conc. HCl (200 mL) was cooled to 0° C. and then 3-nitrophthalic acid dimethyl ester (15.0 g, 62.8 mmol) was added. Maintaining the cooling, tin chloride (70.8 g, 314 mmol) was added portionwise, over a period of 15 minutes. Following completion of the addition, the cooling bath was removed, and stirring proceeded at room temperature. After 2 hours, the mixture was neutralized by the addition of solid sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate (3×150 mL) and the combined extracts were washed with water (5×250 mL), were dried (MgSO4) and evaporated, providing 11.3 g of the product as a yellow oil in 86% yield: 1H NMR (CDCl3) δ 3.84 (s, 3H), 3.86 (s, 3H), 5.20 (br, 2H), 6.78 (dd, J=8.5 Hz, J=1.0 Hz, 1H), 6.90 (dd, 1H, J=7.3 Hz, J=1.0 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H).
    • 5.40.3 3-Iodophthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00232
  • A solution of 3-aminophthalic acid dimethyl ester (9.5 g, 45.4 mmol) in 1:1 water-conc. HCl (300 mL) was cooled to 0° C., during which a precipitate formed. A solution of NaNO2 (3.5 g, 50.0 mmol) in 10 mL water was then added slowly, maintaining the temperature between 0-5° C. throughout the addition. Following completion of the addition, the mixture was stirred at the same temperature for 10 minutes, before adding a solution of KI (11.3 g, 68.3 mmol) in 30 mL of 1:1 water-conc. HCl. This solution was added all at once, and then the reaction flask was transferred immediately to an oil bath preheated to 65° C. The mixture was stirred with heating for 10 minutes, and was then cooled in an ice bath. The mixture was extracted with CH2Cl2 (3×150 mL), and the combined organic extracts were washed with water (3×150 mL), dried (MgSO4), and evaporated, and the residue was chromatographed using hexanes-ethyl acetate gradient. The product, which eluted at 17:3 hexanes-ethyl acetate, was a light purple solid, and was then triturated with hexanes to give 9.7 g (67%) of the final product after drying, as a colorless solid: 1H NMR (CDCl3) δ 3.90 (s, 3H), 3.99 (s, 3H), 7.19 (t, J=7.9 Hz, 1H), 8.02 (d, J=7.9 Hz, 2H).
    • 5.40.4 3-Phenylaminophthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00233
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), aniline (0.31 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and then filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.60 g of the product at 4:1 hexanes-ethyl acetate, in 83% yield: 1H NMR (CDCl3) δ 3.87 (s, 3H), 3.89 (s, 3H), 7.03-7.16 (m, 4H), 7.29-7.40 (m, 4H), 8.06 (br, 1H).
    • 5.40.5 3-Phenylaminophthalic Acid
  • Figure US20070049618A1-20070301-C00234
  • A mixture of 3-phenylaminophthalic acid dimethyl ester (0.60 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 2.5 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.52 g of the product in 97% yield: 1H NMR (DMSO-d6) δ 6.92 (t, J=7.3 Hz, 1H), 7.06-7.09 (m, 2H), 7.18-7.29 (m, 3H), 7.33-7.42 (m, 2H), 7.98 (s, 1H).
    • 5.40.6 2-(2,6-Dioxopiperidin-3-yl)-4-Phenylaminoisoindole-1,3-Dione
  • Figure US20070049618A1-20070301-C00235
  • A mixture of 3-phenylaminophthalic acid (0.52 g, 2.0 mmol) and rac-α-aminoglutarimide hydrochloride (0.33 g, 2.0 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.60 g of the product at 4:6 hexanes-ethyl acetate, in 83% yield: mp 214-216° C.; 1H NMR (DMSO-d6) δ 1.99-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.84-2.97 (m, 1H), 5.13 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 7.11-7.16 (m, 1H), 7.25 (d, J=7.0 Hz, 1H), 7.31-7.45 (m, 5H), 7.61 (t, J=7.8 Hz, 1H), 8.45 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 112.0, 113.4, 119.4, 121.9, 124.0, 129.4, 132.5, 136.2, 139.4, 142.8, 167.0, 168.3, 170.0, 172.8; Anal. calcd for C19H15N3O4: C, 65.32; H, 4.33; N, 12.03. Found: C, 64.93; H, 4.33; N, 11.79.
    • 5.41 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(3,4-METHYLENE DIOXYPHENYLAMINO)ISOINDOLE-1,3-DIONE 5.41.1 3-(3,4-Methylenedioxyphenylamino)phthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00236
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 3,4-methylenedioxyaniline (0.43 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and then filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.69 g of the product at 85:15 hexanes-ethyl acetate, in 67% yield: 1H NMR (CDCl3) δ 3.87 (s, 3H), 3.88 (s, 3H), 5.97 (s, 2H), 6.63 (dd, J=8.2 Hz, J=2.1 Hz, 1H), 6.70 (d, J=2.1 Hz, 1H), 6.78 (d, J=8.2 Hz, 1H), 6.98 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 7.13 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 7.25 (t, J=7.9 Hz, 1H), 8.06 (br, 1H).
    • 5.41.2 3-(3,4-Methylenedioxyphenylamino)phthalic Acid
  • Figure US20070049618A1-20070301-C00237
  • A mixture of 3-(3,4-methylenedioxyphenylamino)phthalic acid dimethyl ester (0.63 g, 1.9 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 2 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.50 g of the product in 88% yield: 1H NMR (DMSO-d6) δ 5.99 (s, 2H), 6.59 (dd, J=8.7 Hz, J=2.1 Hz, 1H), 6.77 (d, J=2.1 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 7.04 (dd, J=7.3 Hz, J=0.9 Hz, 1H), 7.13 (dd, J=8.5 Hz, J=0.9 Hz, 1H), 7.31 (t, J=7.9 Hz, 1H), 7.95 (s, 1H).
    • 5.41.3 2-(2,6-Dioxopiperidin-3-yl)-4-(3,4-Methylene dioxyphenylamino)Isoindole-1,3-Dione
  • Figure US20070049618A1-20070301-C00238
  • A mixture of 3-(3,4-methylenedioxyphenylamino)phthalic acid (0.50 g, 1.7 mmol) and rac-α-aminoglutarimide hydrochloride (0.29 g, 1.7 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.52 g of the product at 95:5 methylene chloride-methanol, in 80% yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.57-2.63 (m, 2H), 2.83-2.96 (m, 1H), 5.11 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 6.04 (s, 2H), 6.80 (dd, J=8.3 Hz, J=1.9 Hz, 1H), 6.92-6.95 (m, 2H), 7.16-7.22 (m, 2H), 7.56 (t, J=7.8 Hz, 1H), 8.25 (s, 1H), 11.12 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 101.3, 105.5, 108.6, 110.9, 112.7, 116.7, 118.9, 132.3, 133.2, 136.2, 144.1, 144.5, 147.9, 167.1, 168.3, 170.0, 172.8; Anal. calcd for C20H15N3O6.0.2H2O: C, 60.51; H, 3.91; N, 10.58. Found: C, 60.49; H, 3.62; N, 10.50.
    • 5.42 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(3,4-DIMETHOXYPHENYL AMINO)ISOINDOLE-1,3-DIONE 5.42.1 3-(3,4-Dimethoxyphenylamino)Phthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00239
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 3,4-dimethoxyaniline (0.48 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and then filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.80 g of the product at 65:35 hexanes-ethyl acetate, in 74% yield: 1H NMR (CDCl3) δ 3.84 (s, 3H), 3.87 (s, 3H), 3.89 (s, 6H), 6.71-6.77 (m, 2H), 6.85 (d, J=8.3 Hz, 1H), 6.98 (d, J=6.9 Hz, 1H), 7.14 (d, J=7.7 Hz, 1H), 7.25 (t, J=7.9 Hz, 1H), 8.08 (br, 1H).
    • 5.42.2 3-(3,4-Dimethoxyphenylamino)Phthalic Acid
  • Figure US20070049618A1-20070301-C00240
  • A mixture of 3-(3,4-dimethoxyphenylamino)phthalic acid dimethyl ester (0.80 g, 2.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.59 g of the product in 81% yield: 1H NMR (DMSO-d6) δ 3.72 (s, 6H), 6.68 (dd, J=8.6 Hz, J=2.4 Hz, 1H), 6.81 (d, J=2.4 Hz, 1H), 6.90 (d, J=8.6 Hz, 1H), 7.00 (d, J=7.3 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.30 (t, J=7.9 Hz, 1H), 7.98 (br, 1H).
    • 5.42.3 2-(2,6-Dioxopiperidin-3-yl)-4-(3,4-Dimethoxyphenyl amino)Isoindole-1,3-Dione
  • Figure US20070049618A1-20070301-C00241
  • A mixture of 3-(3,4-dimethoxyphenylamino)phthalic acid (0.59 g, 1.9 mmol) and rac-α-aminoglutarimide hydrochloride (0.32 g, 1.9 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.64 g of the product at 96:4 methylene chloride-methanol, in 85% yield: mp >215-217° C.; 1H NMR (CDCl3) δ 2.15-2.19 (m, 1H), 2.74-2.96 (m, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 4.97 (dd, J=11.8 Hz, J=5.1 Hz, 1H), 6.78-6.81 (m, 1H), 6.85-6.91 (m, 2H), 7.16-7.21 (m, 2H), 7.45 (t, J=7.8 Hz, 1H), 7.87 (s, 1H), 8.07 (s, 1H); 13C NMR (CDCl3) δ 22.8, 31.4, 49.0, 56.0, 56.2, 108.6, 110.9, 111.8, 113.2, 116.5, 118.5, 131.7, 132.4, 135.9, 145.2, 147.1, 149.8, 167.4, 168.2, 169.4, 170.8; Anal. calcd for C21H19N3O6: C, 61.61; H, 4.68; N, 10.26. Found: C, 61.47; H, 4.52; N, 10.12.
    • 5.43 2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-4-PENTYLAMINO ISOINDOLE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00242
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH2Cl2 (40 mL), was added pentanal (0.67 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 60 mL of CH2Cl2, washed with water (2×100 mL), saturated aqueous sodium bicarbonate (2×100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated, providing 1.1 g of a light yellow oil.
  • Step 2: A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (50 mL), washed with diethyl ether (2×100 mL), and acidified to pH 2-3 (conc. HCl). The aqueous mixture was then extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), and dried (MgSO4) and evaporated, providing a yellow oil.
  • Step 3: The product from step 2 and α-methyl-α-aminoglutarimide hydrochloride (0.71 g, 4.0 mmol) were dissolved in pyridine (40 mL), and the resulting mixture was heated to reflux for 4 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (120 mL), washed with water (2×100 mL), 0.1N HCl (2×100 mL), brine (100 mL), and was dried (MgSO4). The solvent was evaporated in vacuo, and the resulting yellow solid was triturated in diethyl ether (10 mL), providing 0.63 g of product in 44% overall yield (3 steps): mp 96-98° C.; 1H NMR (DMSO-d6) δ 0.87 (t, J=5.9 Hz, 3H), 1.32 (m, 4H), 1.57 (m, 2H), 1.88 (s, 3H), 1.96-2.07 (m, 1H), 2.48-2.79 (m, 3H), 3.26 (q, J=6.4 Hz, 2H), 6.56 (t, J=5.5 Hz, 1H), 6.94 (d, J=7.0 Hz, 1H), 7.04 (d, J=8.5 Hz, 1H), 7.55 (t, J=7.8 Hz, 1H), 11.00 (s, 1H); 13C NMR (DMSO-d6) δ 13.90, 20.97, 21.87, 28.35, 28.52, 28.63, 29.26, 41.77, 58.39, 108.72, 109.91, 116.89, 131.99, 136.18, 146.24, 167.98, 169.91, 172.17, 172.46; Anal. calcd for C19H23N3O4: C, 63.85; H, 6.49; N, 11.76. Found: C, 63.63; H, 6.27; N, 11.68.
    • 5.44 4-(CYCLOPROPYLMETHYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00243
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (1.1 g, 5.0 mmol) in CH2Cl2 (40 mL) was added cyclopropanecarboxaldehyde (0.70 g, 10.0 mmol) and acetic acid (1.7 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (3.2 g, 15 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 50 mL of CH2Cl2, washed with water (2×100 mL), saturated aqueous sodium bicarbonate (100 mL), and brine (100 mL), and dried (MgSO4). Upon evaporation of the solvent, 1.2 g of a yellow oil was obtained.
  • Step 2: A mixture of the product from step 1 and 5N KOH (10 mL) in methanol (15 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (30 mL), washed with diethyl ether (2×50 mL), acidified to pH 2-3 (conc. HCl), and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried (MgSO4), and evaporated, providing a yellow solid, which was dried under high vacuum to afford 0.81 g of a yellow solid.
  • Step 3: The product from step 2 and rac-α-aminoglutarimide hydrochloride (0.73 g, 4.5 mmol) were dissolved in pyridine (20 mL), and the resulting mixture was heated to reflux for 18 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (100 mL), washed with water (3×100 mL) and brine (100 mL), and dried (MgSO4). The solution was treated with Norite (˜2 g), stirred for 15 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow solid, which was chromatographed eluting with 9:1 methylene chloride-ethyl acetate. The resulting material was further purified by preparative HPLC, eluting with 3:2 water-acetonitrile and providing 0.59 g of the product as a yellow solid, in 36% overall yield (3 steps): mp 162-164° C.; 1H NMR (DMSO-d6) δ 0.25-0.35 (m, 2H), 0.46-0.53 (m, 2H), 1.06-1.16 (m, 1H), 2.02-2.09 (m, 1H), 2.50-2.63 (m, 2H), 2.82-2.97 (m, 1H), 3.18 (t, J=6.3 Hz, 2H), 5.06 (dd, J=12.5 Hz, J=5.4 Hz, 1H), 6.58 (t, J=5.6 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 7.13 (d, J=8.6 Hz, 1H), 7.58 (t, J=7.9 Hz, 1H), 11.11 (s, 1H); 13C NMR (DMSO-d6) δ 3.21, 10.61, 22.13, 30.95, 46.22, 48.54, 108.97, 110.47, 117.36, 132.10, 136.23, 146.38, 167.26, 168.97, 170.04, 172.76; Anal. calcd for C17H17N3O4.0.97H2O: C, 61.77; H, 5.29; N, 12.71. Found: C, 61.39; H, 5.24; N, 12.55.
    • 5.45 [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]ACETIC ACID
  • Figure US20070049618A1-20070301-C00244
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (4.2 g, 20 mmol) in CH2Cl2 (100 mL), were added glyoxylic acid (3.7 g, 40 mmol) and acetic acid (6.9 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (12 g, 60 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was washed with 0.1N HCl (3×100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated leaving an oily residue, which was dissolved in sat. aq. sodium bicarbonate (50 mL). This aqueous solution was washed with ethyl acetate (3×50 mL) and then acidified to pH 2-3 (conc. HCl). This mixture was extracted with ethyl acetate (3×100 mL), and the combined extracts were washed with brine (100 mL), and dried (MgSO4). Evaporation provided 3.4 g of an off-white solid (63%).
  • Step 2: A mixture of the product from step 1 and 5N KOH (30 mL) was stirred overnight at room temperature. The mixture was then acidified to pH 2-3 (conc. HCl). The solvent was evaporated in vacuo to give a yellow solid residue that was used without further purification.
  • Step 3: The product from step 2 and rac-α-aminoglutarimide hydrochloride (2.1 g, 13 mmol) were dissolved in pyridine (60 mL), and the resulting mixture was heated to reflux for 6 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in sat. aq. sodium bicarbonate (100 mL) and washed with ethyl acetate (3×100 mL). The aqueous phase was acidified to pH 2-3 (conc. HCl), and the resulting precipitate was isolated by filtration and washed with additional water (30 mL), and then ethyl acetate (50 mL). The solid was triturated with 50 mL of ethyl acetate overnight, filtered and dried under high vacuum, providing 3.6 g of the product in 84% yield (final 2 steps): 1H NMR (DMSO-d6) δ 1.98-2.07 (m, 1H), 2.47-2.62 (m, 2H), 2.83-2.95 (m, 1H), 4.11 (d, J=5.4 Hz, 2H), 5.08 (dd, J=12.3 Hz, J=5.1 Hz, 1H), 6.84 (br, 1H), 6.99 (d, J=8.5 Hz, 1H), 7.07 (d, J=7.0 Hz, 1H), 7.58 (t, J=8.4 Hz, 1H), 11.12 (s, 1H), 12.93 (br, 1H).
    • 5.46 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(2-METHOXY-1-METHYLETHYL AMINO)ISOINDOLE-1,3-DIONE 5.46.1 3-Bromophthalic Acid
  • Figure US20070049618A1-20070301-C00245
  • 3-Bromo-2-methylbenzoic acid (2.15 g, 10.0 mmol) was dissolved in 100 mL of 0.5N KOH. To this clear solution, was added KMnO4. The resulting mixture was heated to 70° C. for 16 hours. To the reaction mixture was added ethanol (30 mL), resulting in formation of a black precipitate of MnO2. NaHSO3 (3.0 g, 29 mmol) was added, followed by the slow addition of conc. HCl, until a clear, colorless, homogeneous solution was obtained. The solution was acidified further to pH 2-3 to give a white precipitate. The mixture was extracted with ethyl acetate (3×100 mL), and the combined extracts were washed with brine (150 mL), and dried (MgSO4). The solvent was evaporated, providing 2.5 g of the product as a white solid (100%): 1H NMR (DMSO-d6) δ 7.47 (t, J=7.9 Hz, 1H), 7.92 (t, J=7.3 Hz, 2H), 13.49 (br, 2H).
    • 5.46.2 3-Bromophthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00246
  • To a stirred solution of 3-bromophthalic acid (2.5 g, 10 mmol) in DMF (20 mL), were added iodomethane (3.1 g, 22 mmol) and sodium bicarbonate (1.8 g, 22 mmol). The mixture was heated to 70° C. with stirring for 26 hours. The solvent was evaporated in vacuo, and the residue was partitioned between diethyl ether (100 mL) and water (100 mL). The organic phase was washed with sat. sodium bicarbonate (100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated in vacuo, and dried under high vacuum to afford 2.4 g (86%) of the product as a white solid: 1H NMR (DMSO-d6) δ 3.84 (s, 3H), 3.86 (s, 3H), 7.57 (t, J=8.0 Hz, 1H), 8.01 (d, J=8.1 Hz, 2H).
    • 5.46.3 3-(2-Methoxy-1-Methylethylamino)Phthalic Acid Dimethyl Ester
  • Figure US20070049618A1-20070301-C00247
  • To a stirred solution of 3-Bromophthalic acid dimethyl ester (0.82 g, 3.0 mmol) in toluene (20 mL), were added S-BINAP (56 mg, 0.09 mmol), Pd2(dba)3 (55 mg, 0.06 mmol), Cs2CO3 (1.37 g, 4.2 mmol), and 1-methoxy-2-propanamine (0.32 g, 3.6 mmol), and the resulting mixture was heated to reflux with stirring under nitrogen for 24 hours. The mixture was allowed to cool to room temperature, and diethyl ether was added (70 mL). The mixture was filtered, and the filtrate was evaporated in vacuo. The residue was chromatographed eluting with 17:3 hexanes-ethyl acetate. The resulting material was further purified by preparative HPLC, eluting with 11:9 water-acetonitrile, and providing 0.32 g of the product in 38% yield: 1H NMR (DMSO-d6) δ1.14 (d, J=6.4 Hz, 3H), 3.29 (s, 3H), 3.37 (d, J=4.8 Hz, 2H), 3.74 (s, 3H), 3.77 (s, 3H), 3.74-3.80 (m, 1H), 6.53 (d, J=7.8 Hz, 1H), 6.76 (d, J=7.3 Hz, 1H), 6.99 (d, J=8.6 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H).
    • 5.46.4 2-(2,6-Dioxopiperidin-3-yl)-4-(2-Methoxy-1-Methylethylamino) Isoindole-1,3-Dione
  • Figure US20070049618A1-20070301-C00248
  • Step 1: A mixture of 3-(2-methoxy-1-methylethylamino)phthalic acid dimethyl ester (0.47 g, 1.7 mmol) and 5N KOH (4 mL) in methanol (10 mL) was stirred at room temperature for 26 hours. The solvent was removed under vacuum, and water (30 mL) was added. The mixture was washed with diethyl ether (2×50 mL), and the aqueous phase was acidified to pH 2 (conc. HCl) and extracted with ethyl acetate (3×75 mL). The combined ethyl acetate extracts were washed with brine (100 mL), dried (MgSO4), and the solvent was evaporated.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.32 g, 2.0 mmol) were dissolved in pyridine (20 mL), and the resulting mixture was heated to reflux for 8 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (100 mL), washed with water (3×100 mL) and brine (100 mL), and dried (MgSO4), and the solvent was evaporated in vacuo. Following trituration with diethyl ether (30 mL), 350 mg of the product was obtained as a yellow solid (64% yield, two steps): mp 193-195° C.; 1H NMR (DMSO-d6) δ 1.19 (d, J=6.3 Hz, 3H), 2.01-2.06 (m, 1H), 2.62-2.45 (m, 2H), 2.82-2.94 (m, 1H), 3.30 (s, 3H), 3.43 (d, J=4.2 Hz, 2H), 3.97 (m, 1H), 5.06 (dd, J=12.4 Hz, J=5.0 Hz, 1H), 6.39 (d, J=8.4 Hz, 1H), 7.04 (d, J=7.0 Hz, 1H), 7.16 (d, J=8.6 Hz, 1H), 7.59 (t, 7.8 Hz, 1H), 11.12 (s, 1H); 13C NMR (DMSO-d6) δ 17.45, 22.12, 30.96, 46.87, 48.55, 58.52, 75.18, 109.14, 110.66, 117.55, 132.11, 136.31, 145.74, 167.19, 169.11, 170.05, 172.77; Anal. calcd for C17H19N3O5: C, 59.12; H, 5.55; N, 12.17. Found: C, 58.83; H, 5.44; N, 12.01.
    • 5.47 4-(4-tert-BUTYLPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.47.1 3-(4-tert-Butylphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00249
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-tert-butylaniline (0.46 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.78 g of the product at 85:15 hexanes-ethyl acetate, in 74% yield: 1H NMR (CDCl3) δ 1.32 (s, 9H), 3.86 (s, 3H), 3.88 (s, 3H), 7.01-7.11 (m, 3H), 7.27-7.36 (m, 4H), 8.07 (br, 1H).
    • 5.47.2 3-(4-tert-Butylphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00250
  • A mixture of 3-(4-tert-butylphenylamino)phthalic acid dimethyl ester (0.70 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated. The brown residue was dissolved in 15 mL of 1:1 hexanes-ether. Addition of 35 mL hexanes resulted in precipitation of the product as a bright yellow solid, providing 0.50 g in 78% yield: 1H NMR (CDCl3) δ 1.33 (s, 9H), 7.11-7.15 (m, 3H), 7.33-7.39 (m, 4H).
    • 5.47.3 4-(4-tert-Butylphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00251
  • A mixture of 3-(4-tert-butylphenylamino)phthalic acid (0.50 g, 1.6 mmol) and rac-α-aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 1:1 hexanes-ethyl acetate, eluting 0.60 g of the product, in 92% yield: mp 228-230° C.; 1H NMR (CDCl3) δ 1.34 (s, 9H), 2.14-2.19 (m, 1H), 2.73-2.96 (m, 3H), 4.96 (dd, J=11.9 Hz, J=5.1 Hz, 1H), 7.16-7.22 (m, 3H), 7.33-7.49 (m, 4H), 7.98 (s, 1H), 8.07 (s, 1H); 13C NMR (CDCl3) δ 22.8, 31.3, 31.4, 34.5, 49.0, 111.2, 113.4, 118.6, 122.7, 126.5, 132.5, 135.8, 136.1, 144.4, 148.1, 167.4, 168.4, 169.3, 171.1; Anal. calcd for C23H23N3O4.0.25H2O: C, 67.39; H, 5.78; N, 10.25. Found: C, 67.42; H, 5.65; N, 10.15.
    • 5.48 4-(4-ISOPROPYLPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.48.1 3-(4-Isopropylphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00252
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-isopropylaniline (0.42 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.70 g of the product at 85:15 hexanes-ethyl acetate, in 70% yield: 1H NMR (CDCl3) δ 1.25 (s, J=6.8 Hz, 6H), 2.90 (m, 1H), 3.86 (s, 3H), 3.88 (s, 3H), 7.01-7.13 (m, 3H), 7.27-7.34 (m, 4H), 8.07 (br, 1H).
    • 5.48.2 3-(4-Isopropylphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00253
  • A mixture of 3-(4-isopropylphenylamino)phthalic acid dimethyl ester (0.70 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.64 g in quantitative yield: 1H NMR (DMSO-d6) δ 1.18 (d, J=6.9 Hz, 6H), 2.84 (m, 1H), 7.02-7.06 (m, 2H), 7.08-7.18 (m, 3H), 7.26-7.37 (m, 2H), 7.99 (br, 1H).
    • 5.48.3 4-(4-Isopropylphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00254
  • A mixture of 3-(4-isopropylphenylamino)phthalic acid (0.64 g, 2.1 mmol) and rac-α-aminoglutarimide hydrochloride (0.35 g, 2.1 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 1:1 hexanes-ethyl acetate, eluting 0.74 g of the product, in 89% yield: mp 138-140° C.; 1H NMR (DMSO-d6) δ 1.21 (d, J=6.9 Hz, 6H), 2.04-2.08 (m, 1H), 2.52-2.64 (m, 2H), 2.84-2.94 (m, 2H), 5.13 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 7.19-7.30 (m, 5H), 7.35 (d, J=8.5 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 8.35 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 23.9, 31.0, 32.9, 48.7, 111.3, 113.0, 119.0, 122.5, 127.2, 132.4, 136.2, 136.9, 143.3, 144.5, 167.1, 168.4, 170.0, 172.8; Anal. calcd for C22H21N3O4: C, 67.51; H, 5.41; N, 10.74. Found: C, 67.27; H, 5.36; N, 10.64.
    • 5.49 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(INDAN-5-YLAMINO)-ISOINDOLE-1,3-DIONE 5.49.1 3-(Indan-5-ylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00255
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 5-aminoindan (0.42 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.82 g of the product at 85:15 hexanes-ethyl acetate, in 82% yield: 1H NMR (CDCl3) δ 2.09 (m, 2H), 2.88 (t, J=7.4 Hz, 4H), 3.86 (s, 3H), 3.88 (s, 3H), 6.93 (dd, J=7.9 Hz, J=1.8 Hz, 1H), 6.99-7.06 (m, 2H), 7.12-7.21 (m, 1H), 7.25-7.29 (m, 1H), 7.40-7.71 (m, 1H), 8.07 (br, 1H).
    • 5.49.2 2-(2,6-Dioxo-piperidin-3-yl)-4-(indan-5-ylamino)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00256
  • Step 1: A mixture of 3-(indan-5-ylamino)phthalic acid dimethyl ester (0.80 g, 2.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.14 g.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.082 g, 0.5 mmol) in pyridine (5 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 1:1 hexanes-ethyl acetate, eluting 0.14 g of the product, in 15% yield for the final two steps: mp 230-232° C.; 1H NMR (CDCl3) δ 2.05-2.19 (m, 3H), 2.72-2.95 (m, 7H), 4.96 (dd, J=12.0 Hz, J=5.1 Hz, 1H), 7.02 (d, J=7.9 Hz, 1H), 7.11 (s, 1H), 7.19 (d, J=7.2 Hz, 1H), 7.23 (d, J=7.9 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.5 Hz, J=7.2 Hz, 1H), 7.96 (s, 1H), 8.02 (s, 1H); 13C NMR (CDCl3) δ 22.8, 25.7, 31.4, 32.4, 33.0, 49.0, 110.1, 113.2, 118.6, 119.6, 121.4, 125.2, 132.4, 135.8, 136.8, 141.4, 144.8, 146.0, 167.4, 168.4, 169.3, 170.8; Anal. calcd for C23H19N3O4: C, 67.86; H, 4.92; N, 10.79. Found: C, 67.69; H, 4.91; N, 10.61.
    • 5.50 4-(2,4-DIMETHOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.50.1 3-(2,4-Dimethoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00257
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2,4-dimethoxyaniline (0.48 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.87 g of the product at 70:30 hexanes-ethyl acetate, in 81% yield: 1H NMR (CDCl3) δ 3.81 (s, 6H), 3.87 (s, 6H), 6.46 (dd, J=8.6 Hz, J=2.6 Hz, 1H), 6.54 (d, J=2.6 Hz, 1H), 6.98 (dd, J=7.3 Hz, J=0.9 Hz, 1H), 7.09 (dd, J=8.0 Hz, J=0.9 Hz, 1H), 7.16 (d, J=8.6 Hz, 1H), 7.23 (t, J=7.3 Hz, 1H), 7.92 (br, 1H).
    • 5.50.2 3-(2,4-Dimethoxyphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00258
  • A mixture of 3-(2,4-dimethoxyphenylamino)phthalic acid dimethyl ester (0.85 g, 2.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.76 g in 97% yield: 1H NMR (CDCl3) δ 3.82 (s, 3H), 3.84 (s, 3H), 6.52 (dd, J=8.6 Hz, J=2.5 Hz, 1H), 6.57 (d, J=2.5 Hz, 1H), 7.11 (d, J=8.6 Hz, 1H), 7.22-7.26 (m, 2H), 7.52 (t, J=7.8 Hz, 1H), 7.61 (br, 1H).
    • 5.50.3 4-(2,4-Dimethoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00259
  • A mixture of 3-(2,4-dimethoxyphenylamino)phthalic acid (0.75 g, 2.4 mmol) and rac-α-aminoglutarimide hydrochloride (0.40 g, 2.4 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.64 g of the product at 25:75 hexanes-ethyl acetate, in 67% yield: mp 208-210° C.; 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.54-2.64 (m, 2H), 2.83-2.92 (m, 1H), 3.78 (s, 3H), 3.79 (s, 3H), 5.12 (dd, J=12.7 Hz, J=5.4 Hz, 1H), 6.57 (dd, J=8.6 Hz, J=2.6 Hz, 1H), 6.71 (d, J=2.6 Hz, 1H), 7.00 (d, J=8.6 Hz, 1H), 7.15 (d, J=7.0 Hz, 1H), 7.29 (d, J=8.7 Hz, 1H), 7.54 (t, J=7.9 Hz, 1H), 7.95 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 55.4, 55.7, 99.5, 104.7, 110.4, 112.2, 118.3, 120.1, 125.2, 132.1, 136.1, 144.2, 153.7, 157.9, 167.2, 168.9, 170.1, 172.8; Anal. calcd for C21H19N3O6.0.3H2O: C, 60.81; H, 4.76; N, 10.13. Found: C, 60.87; H, 4.64; N, 10.00.
    • 5.51 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(4-METHOXYPHENYLAMINO) ISOINDOLE-1,3-DIONE 5.51.1 3-(4-Methoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00260
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), p-anisidine (0.38 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.80 g of the product at 70:30 hexanes-ethyl acetate, in 82% yield: 1H NMR (CDCl3) δ 3.81 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 6.86-6.96 (m, 3H), 7.05-7.12 (m, 3H), 7.23 (t, J=7.6 Hz, 1H), 8.11 (br, 1H).
    • 5.51.2 3-(4-Methoxyphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00261
  • A mixture of 3-(4-methoxyphenylamino)phthalic acid dimethyl ester (0.80 g, 2.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.61 g in 85% yield: 1H NMR (DMSO-d6) δ 3.74 (s, 3H), 6.89-6.99 (m, 3H), 7.03-7.12 (m, 3H), 7.29 (t, J=8.0 Hz, 1H), 8.01 (br, 1H).
    • 5.51.3 2-(2,6-Dioxopiperidin-3-yl)-4-(4-methoxyphenylamino)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00262
  • A mixture of 3-(4-methoxyphenylamino)phthalic acid (0.52 g, 1.8 mmol) and rac-α-aminoglutarimide hydrochloride (0.30 g, 1.8 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, eluting 0.58 g of the product, in 84% yield: mp 228-230° C.; 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.52-2.64 (m, 2H), 2.83-2.96 (m, 1H), 3.77 (s, 3H), 5.12 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 6.96-7.00 (m, 2H), 7.12-7.17 (m, 2H), 7.24-7.28 (m, 2H), 7.54 (t, J=7.9 Hz, 1H), 8.24 (s, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 55.3, 110.6, 112.4, 114.7, 118.5, 125.3, 131.8, 132.4, 136.1, 144.3, 156.6, 167.1, 168.4, 170.0, 172.8; Anal. calcd for C20H17N3O5: C, 63.32; H, 4.52; N, 11.08. Found: C, 63.31; H, 4.47; N, 10.83.
    • 5.52 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(3-ETHOXY-4-METHOXYPHENYLAMINO)-ISOINDOLE-1,3-DIONE 5.52.1 2-Ethoxy-1-methoxy-4-nitrobenzene
  • Figure US20070049618A1-20070301-C00263
  • A mixture of 2-methoxy-5-nitrophenol (5.3 g, 31.3 mmol), iodoethane (14.6 g, 93.9 mmol), and potassium carbonate (43.2 g, 310 mmol) in acetone (100 mL) was heated to reflux for 4 hours. The reaction mixture was cooled, and the solvent was evaporated in vacuo. The residue was dissolved in water (250 mL) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL) and dried (MgSO4), and the solvent was evaporated under vacuum, providing 5.8 g of the product, in 99% yield: 1H NMR (CDCl3) δ 1.51 (t, J=7.0 Hz, 3H), 3.97 (s, 3H), 4.18 (q, J=7.0 Hz, 2H), 6.22 (dd, J=8.4 Hz, J=2.4 Hz, 1H), 6.31 (d, J=2.4 Hz, 1H), 6.70 (d, J=8.4 Hz, 1H).
    • 5.52.2 3-Ethoxy-4-methoxy-phenylamine
  • Figure US20070049618A1-20070301-C00264
  • A mixture of 2-ethoxy-1-methoxy-4-nitrobenzene (1.5 g, 7.6 mmol) and 5% Pd—C (0.3 g) in 30 mL of ethyl acetate was hydrogenated under 50 psi of hydrogen gas for 14 hours. The mixture was filtered through Celite and the filtrate was evaporated, providing 1.25 g of the product, in 98% yield: 1H NMR (CDCl3) δ 1.44 (t, J=7.0 Hz, 3H), 3.27 (br, 2H), 3.79 (s, 3H), 4.04 (q, J=7.0 Hz, 2H), 6.90 (d, J=8.9 Hz, 1H), 7.74 (d, J=2.5 Hz, 1H), 7.90 (dd, J=8.9 Hz, J=2.5 Hz, 1H).
    • 5.52.3 3-(3-Ethoxy-4-methoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00265
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 3-ethoxy-4-methoxyaniline (0.51 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.90 g of the product at 70:30 hexanes-ethyl acetate, in 80% yield: 1H NMR (CDCl3) δ 1.45 (t, J=7.0 Hz, 1H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.05 (q, J=7.0 Hz, 2H), 6.71-6.74 (m, 2H), 6.84 (d, J=7.4 Hz, 1H), 6.96 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.13 (dd, J=8.5 Hz, J=1.0 Hz, 1H), 7.24 (t, J=7.4 Hz, 1H), 8.07 (s, 1H).
    • 5.52.4 3-(3-Ethoxy-4-methoxyphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00266
  • A mixture of 3-(3-ethoxy-4-methoxyphenylamino)phthalic acid dimethyl ester (0.85 g, 2.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.68 g of the product, in 87% yield: 1H NMR (DMSO-d6) δ 1.31 (t, J=6.9 Hz, 3H), 3.73 (s, 3H), 3.96 (q, J=6.9, 2H), 6.69 (dd, J=8.6 Hz, J=2.4 Hz, 1H), 6.78 (d, J=2.4 Hz, 1H), 6.90 (d, J=8.6 Hz, 1H), 7.00 (d, J=7.2 Hz, 1H), 7.15 (d, J=8.0 Hz, 1H), 7.30 (t, J=7.9 Hz, 1H), 7.97 (s, 1H).
    • 5.52.5 2-(2,6-Dioxopiperidin-3-yl)-4-(3-ethoxy-4-methoxyphenylamino)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00267
  • A mixture of 3-(3-ethoxy-4-methoxyphenylamino)phthalic acid (0.85 g, 2.6 mmol) and rac-α-aminoglutarimide hydrochloride (0.43 g, 2.6 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, eluting 0.72 g of the product, in 67% yield: mp 162-164° C.; 1H NMR (CDCl3) δ 1.46 (t, J=7.0 Hz, 3H), 2.11-2.18 (m, 1H), 2.72-2.94 (m, 3H), 3.89 (s, 3H), 4.06 (q, J=7.0 Hz, 3H), 4.96 (dd, J=12.0 Hz, J=5.0 Hz, 1H), 6.76-6.89 (m, 3H), 7.14-7.19 (m, 2H), 7.43 (t, J=7.8 Hz, 1H), 7.86 (s, 1H), 8.43 (s, 1H); 13C NMR (CDCl3) δ 14.7, 22.8, 31.4, 49.0, 56.2, 64.5, 109.9, 110.8, 112.1, 113.1, 116.4, 118.5, 131.7, 132.4, 135.9, 145.2, 147.4, 149.1, 167.5, 168.4, 169.4, 171.1; Anal. calcd for C22H21N3O6: C, 62.41; H, 5.00; N, 9.92. Found: C, 62.16; H, 4.89; N, 9.72.
    • 5.53 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(3-HYDROXY-4-METHOXYPHENYL-AMINO)-ISOINDOLE-1,3-DIONE 5.53.1 tert-Butyl-(2-methoxy-5-nitrophenoxy)dimethylsilane
  • Figure US20070049618A1-20070301-C00268
  • A mixture of 2-methoxy-5-nitrophenol (3.0 g, 17.8 mmol), tert-butyldimethylsilyl chloride (3.2 g, 21.4 mmol), and ethyldiisopropylamine (5.8 g, 44.5 mmol) in DMF (50 mL) was stirred at room temperature for 3 hours. The mixture was poured into water (100 mL) and extracted with methylene chloride (3×100 mL). The combined organic extracts were washed with water (5×100 mL) and dried (MgSO4), and the solvent was evaporated under vacuum. The residue was recrystallized from ethanol-water, providing 3.2 g of the product as white crystals, in 64% yield: 1H NMR (CDCl3) δ 0.19 (s, 6H), 1.01 (s, 9H), 3.91 (s, 3H), 6.89 (d, J=8.9 Hz, 1H), 7.71 (d, J=2.8 Hz, 1H), 7.89 (dd, J=8.9 Hz, J=2.8 Hz, 1H).
    • 5.53.2 3-(tert-Butyldimethylsilanyloxy)-4-methoxyphenylamine
  • Figure US20070049618A1-20070301-C00269
  • A mixture of tert-butyl-(2-methoxy-5-nitrophenoxy)dimethylsilane (3.0 g, 10.6 mmol) and 5% Pd—C (0.3 g) in 30 mL of ethyl acetate was hydrogenated under 50 psi of hydrogen gas for 14 hours. The mixture was filtered through Celite and the filtrate was evaporated. The residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 2.0 g of the product at 85:15 hexanes-ethyl acetate, in 74% yield: 1H NMR (CDCl3) δ 0.15 (s,6H), 0.99 (s, 9H), 3.37 (br, 2H), 3.72 (s, 3H), 6.23-6.29 (m, 2H), 6.68 (d, J=8.1 Hz, 1H).
    • 5.53.3 3-[3-(tert-Butyldimethylsilanyloxy)-4-methoxyphenylamino]phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00270
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 3-(tert-butyldimethylsilanyloxy)-4-methoxyphenylamine (0.79 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 1.0 g of the product at 90:10 hexanes-ethyl acetate, in 71% yield: 1H NMR (CDCl3) δ 0.16 (s, 6H), 0.98 (s, 9H), 3.81 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 6.69-6.75 (m, 2H), 6.82 (d, J=8.2 Hz, 1H), 6.95 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 7.12 (dd, J=7.0 Hz, J=1.1 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 8.04 (s, 1H).
    • 5.53.4 3-(3-Hydroxy-4-methoxyphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00271
  • A mixture of 3-[3-(tert-butyldimethylsilanyloxy)-4-methoxyphenylamino]phthalic acid dimethyl ester (1.0 g, 2.2 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 2 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.65 g of the product, in 96% yield: 1H NMR (DMSO-d6) δ 3.73 (s, 3H), 6.54 (dd, J=8.5 Hz, J=2.5 Hz, 1H), 6.60 (d, J=2.5 Hz, 1H), 6.86 (d, J=8.5 Hz, 1H), 6.98 (d, J=7.3 Hz, 1H), 7.13 (d, J=7.7 Hz, 1H), 7.30 (t, J=7.9 Hz, 1H), 7.93 (s, 1H).
    • 5.53.5 2-(2,6-Dioxopiperidin-3-yl)-4-(3-hydroxy-4-methoxyphenylamino)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00272
  • A mixture of 3-(3-hydroxy-4-methoxyphenylamino)phthalic acid (0.60 g, 2.0 mmol) and rac-α-aminoglutarimide hydrochloride (0.33 g, 2.0 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), was dried (MgSO4) and evaporated. The residue was triturated in 1:1 acetonitrile-water (15 mL) and filtered, and the resulting solid was washed with additional 1:1 acetonitrile-water and dried under high vacuum, providing 0.45 g of the product, in 58% yield: mp 225-227° C.; 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.52-2.63 (m, 2H), 2.83-2.92 (m, 1H), 3.77 (s, 3H), 5.11 (dd, J=12.5 Hz, J=5.4 Hz, 1H), 6.69-6.76 (m, 2H), 6.94 (d, J=8.5 Hz, 1H), 7.14-7.23 (m, 2H), 7.56 (t, J=7.8 Hz, 1H), 8.15 (s, 1H), 9.21 (s, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.6, 55.9, 110.7, 111.5, 112.5, 113.0, 114.2, 118.8, 132.1, 132.3, 136.1, 144.2, 145.2, 147.2, 167.1, 168.4, 170.0, 172.8; Anal. calcd for C20H17N3O6: C, 60.76; H, 4.33; N, 10.63. Found: C, 60.76; H, 4.11; N, 10.42.
    • 5.54 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-(NAPHTHALEN-2-YLAMINO)ISOINDOLE-1,3-DIONE 5.54.1 3-(Naphthalen-2-ylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00273
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-aminonaphthalene (0.44 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.78 g of the product at 85:15 hexanes-ethyl acetate, in 75% yield: 1H NMR (CDCl3) δ 3.89 (s, 3H), 3.90 (s, 3H), 7.14 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.27-7.50 (m, 5H), 7.55 (d, J=1.8 Hz, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.77-7.82 (m, 2H), 8.20 (br, 1H).
    • 5.54.2 3-(Naphthalen-2-ylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00274
  • A mixture of 3-(naphthalen-2-ylamino)phthalic acid dimethyl ester (0.75 g, 2.2 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.64 g in 93% yield: 1H NMR (DMSO-d6) δ 7.29-7.54 (m, 7H), 7.68 (d, J=8.1 Hz, 1H), 7.76-7.81 (m, 2H), 8.16 (br, 1H).
    • 5.54.3 2-(2,6-Dioxopiperidin-3-yl)-4-(naphthalen-2-ylamino)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00275
  • A mixture of 3-(naphthalen-2-ylamino)phthalic acid (0.62 g, 1.8 mmol) and rac-α-aminoglutarimide hydrochloride (0.33 g, 2.0 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, eluting 0.74 g of the product, in 92% yield: mp 235-237° C.; 1H NMR (DMSO-d6) δ 2.06-2.11 (m, 1H), 2.54-2.64 (m, 2H), 2.85-3.00 (m, 1H), 3.77 (s, 3H), 5.15 (dd, J=12.7 Hz, J=5.3 Hz, 1H), 7.29 (d, J=6.3 Hz, 1H), 7.39-7.52 (m, 3H), 7.57-7.69 (m, 2H), 7.80-7.95 (m, 4H), 8.66 (s, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.8, 112.5, 113.8, 117.0, 120.0, 122.1, 124.8, 126.6, 127.0, 127.6, 129.2, 130.0, 132.5, 133.7, 136.2, 137.3, 142.5, 167.0, 168.2, 170.0, 172.8; Anal. calcd for C23H17N3O4.0.1H2O: C, 68.86; H, 4.32; N, 10.47. Found: C, 68.73; H, 4.01; N, 10.36.
    • 5.55 4-(4-CYCLOHEXYLPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.55.1 3-(4-Cyclohexylphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00276
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-cyclohexylaniline (0.54 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.90 g of the product at 90:10 hexanes-ethyl acetate, in 78% yield: 1H NMR (CDCl3) δ 1.27-1.44 (m, 6H), 1.73-1.85 (m, 4H), 2.45-2.55 (m, 1H), 3.86 (s, 3H), 3.88 (s, 3H), 7.00-7.10 (m, 3H), 7.15-7.18 (m, 2H), 7.23-7.34 (m, 2H), 8.07 (br, 1H).
    • 5.55.2 3-(4-Cyclohexylphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00277
  • A mixture of 3-(4-cyclohexylphenylamino)phthalic acid dimethyl ester (0.85 g, 2.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.70 g in 90% yield: 1H NMR (DMSO-d6) δ 1.14-1.44 (s, 5H), 1.67-1.78 (m, 5H), 2.35-2.45 (m, 1H), 7.00-7.04 (m, 2H), 7.08-7.14 (m, 3H), 7.26-7.37 (m, 2H), 7.98 (s, 1H).
    • 5.55.3 4-(4-Cyclohexylphenylamino)-2-(2,6-dioxopiperidin-3-vi)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00278
  • A mixture of 3-(4-cyclohexylphenylamino)phthalic acid (0.80 g, 2.4 mmol) and rac-α-aminoglutarimide hydrochloride (0.39 g, 2.4 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 1:1 hexanes-ethyl acetate, eluting 0.86 g of the product, in 86% yield: mp 219-221° C.; 1H NMR (DMSO-d6) δ 1.10-1.46 (m, 5H), 1.67-1.80 (m, 5H), 2.04-2.07 (m, 1H), 2.40-2.50 (m, 1H), 2.53-2.64 (m, 2H), 2.83-2.90 (m, 1H), 5.12 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 7.19-7.24 (m, 5H), 7.35 (d, J=8.6 Hz, 1H), 7.58 (t, J=7.9 Hz, 1H), 8.34 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 25.6, 26.4, 31.0, 34.0, 43.2, 48.7, 111.3, 113.0, 119.0, 122.4, 127.6, 132.4, 136.2, 136.9, 143.3, 143.7, 167.1, 168.4, 170.0, 172.8; Anal. calcd for C25H25N3O4: C, 69.59; H, 5.84; N, 9.74. Found: C, 69.38; H, 5.85; N, 9.41.
    • 5.56 4-(2-METHOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.56.1 3-(2-Methoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00279
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-methoxyaniline (0.38 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.75 g of the product at 75:25 hexanes-ethyl acetate, in 77% yield: 1H NMR (CDCl3) δ 3.88 (s, 9H), 6.89-7.00 (m, 3H), 7.14 (d, J=7.0 Hz, 1H), 7.27-7.34 (m, 2H), 7.46 (d, J=8.1 Hz, 1H), 7.99 (br, 1H).
    • 5.56.2 3-(2-Methoxyphenylamino)phthalic acid
  • Figure US20070049618A1-20070301-C00280
  • A mixture of 3-(2-methoxyphenylamino)phthalic acid dimethyl ester (0.74 g, 2.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.61 g in 91% yield: 1H NMR (DMSO-d6) δ 3.83 (s, 3H), 6.89-7.11 (m, 4H), 7.24 (dd, J=7.5 Hz, J=1.5 Hz, 1H), 7.33-7.41 (m, 2H), 7.96 (s, 1H).
    • 5.56.3 4-(2-Methoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00281
  • A mixture of 3-(2-methoxyphenylamino)phthalic acid (0.55 g, 1.9 mmol) and rac-α-aminoglutarimide hydrochloride (0.31 g, 1.9 mmol) in pyridine (10 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, eluting 0.66 g of the product, in 92% yield: mp 223-225° C.; 1H NMR (CDCl3) δ 2.13-2.20 (m, 1H), 2.73-2.95 (m, 3H), 3.88 (s, 3H), 4.97 (dd, J=11.9 Hz, J=5.0 Hz, 1H), 6.94-7.00 (m, 2H), 7.09-7.15 (m, 1H), 7.21-7.26 (m, 1H), 7.38-7.52 (m, 3H), 8.08 (s, 1H), 8.15 (s, 1H); 13C NMR (CDCl3) δ 22.8, 31.4, 49.0, 55.7, 111.4, 112.1, 113.6, 118.8, 120.6, 121.1, 124.8, 128.2, 132.5, 135.7, 143.6, 151.4, 167.4, 168.1, 169.1, 170.8; Anal. calcd for C20H17N3O5.0.1H2O: C, 63.02; H, 4.55; N, 11.02. Found: C, 62.91; H, 4.42; N, 10.71.
    • 5.57 4-(2,5-DIMETHOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.57.1 3-(2,5-Dimethoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00282
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2,5-dimethoxyaniline (0.48 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.73 g of the product at 80:20 hexanes-ethyl acetate, in 68% yield: 1H NMR (CDCl3) δ 3.74 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 6.48 (dd, J=8.8 Hz, J=2.9 Hz, 1H), 6.83 (d, J=8.8 Hz, 1H), 6.87 (d, J=2.9 Hz, 1H), 7.19 (dd, J=7.7 Hz, J=0.9 Hz, 1H), 7.34 (t, J=7.9 Hz, 1H), 7.55 (dd, J=8.5 Hz, J=0.9 Hz, 1H), 7.95 (br, 1H).
    • 5.57.2 4-(2,5-Dimethoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00283
  • Step 1: A mixture of 3-(2,5-dimethoxyphenylamino)phthalic acid dimethyl ester (0.71 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.48 g.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) in pyridine (10 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, providing 0.42 g of the product, in 68% yield: mp 231-233° C.; 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.82-2.92 (m, 1H), 3.78 (s, 3H), 3.79 (s, 3H), 5.13 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 6.70 (dd, J=8.9 Hz, J=2.6 Hz, 1H), 7.03-7.07 (m, 2H), 7.26 (d, J=7.0 Hz, 1H), 7.45 (d, J=8.5 Hz, 1H), 7.65 (t, J=7.8 Hz, 1H), 8.31 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 55.4, 56.2, 107.3, 108.4, 111.9, 112.6, 113.4, 119.2, 128.6, 132.2, 136.4, 142.2, 144.9, 153.3, 167.0, 168.8, 170.0, 172.8; Anal. calcd for C21H19N3O6: C, 61.61; H, 4.68; N, 10.26. Found: C, 61.46; H, 4.50; N, 10.23.
    • 5.58 4-(2-PHENOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.58.1 3-(2-Phenoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00284
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-phenoxyaniline (0.57 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.86 g of the product at 80:20 hexanes-ethyl acetate, in 73% yield: 1H NMR (CDCl3) δ 3.75 (s, 3H), 3.86 (s, 3H), 6.93-7.03 (m, 4H), 7.06-7.12 (m, 2H), 7.17 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.29-7.38 (m, 4H), 7.46 (d, J=8.4 Hz, 1H), 7.89 (s, 1H).
    • 5.58.2 4-(2-Phenoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00285
  • Step 1: A mixture of 3-(2-phenoxyphenylamino)phthalic acid dimethyl ester (0.85 g, 2.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified (HCl) and extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 0.72 g.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.32 g, 2.0 mmol) in pyridine (10 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.85 g of the product at 98:2 methylene chloride-methanol, in 93% yield: mp 219-221° C.; 1H NMR (CDCl3) δ 2.07-2.17 (m, 1H), 2.63-2.92 (m, 3H), 4.92 (dd, J=12.0 Hz, J=5.4 Hz, 1H), 6.95-7.01 (m, 3H), 7.07-7.15 (m, 2H), 7.22-7.33 (m, 4H), 7.40-7.52 (m, 3H), 8.07 (s, 1H), 8.13 (s, 1H); 13C NMR (CDCl3) δ 22.7, 31.4, 48.9, 112.3, 113.9, 118.4, 119.0, 119.7, 122.6, 123.6, 123.9, 125.2, 129.8, 130.5, 132.5, 135.7, 143.4, 149.2, 156.6, 167.3, 168.0, 168.9, 170.8; Anal. calcd for C25H19N3O5: C, 68.02; H, 4.34; N, 9.52. Found: C, 68.00; H, 4.13; N, 9.43.
    • 5.59 4-(4-DIMETHYLAMINOPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.59.1 3-(4-Dimethylaminophenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00286
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), N,N-dimethyl-1,4-phenylenediamine (0.42 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a hexanes-ethyl acetate gradient, eluting 0.73 g of the product at 70:30 hexanes-ethyl acetate, in 71% yield: 1H NMR (CDCl3) δ 2.95 (s, 6H), 3.86 (s, 3H), 3.88 (s, 3H), 6.71-6.76 (m, 2H), 6.88 (d, J=7.4 Hz, 1H), 7.00-7.09 (m, 3H), 7.20 (t, J=7.9 Hz, 1H), 8.10 (br, 1H).
    • 5.59.2 4-(4-Dimethylaminophenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00287
  • Step 1: A mixture of 3-(4-dimethylaminophenylamino)phthalic acid dimethyl ester (0.70 g, 2.1 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.35 g, 2.1 mmol) in pyridine (10 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (150 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, eluting 0.50 g. This material was purified further by reverse phase preparative HPLC, eluting with 1:1 acetonitrile-water, and providing 90 mg (11% yield for the final two steps): mp >260° C.; 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.53-2.63 (m, 2H), 2.83-3.00 (m, 7H), 5.11 (dd, J=12.6 Hz, J=5.5 Hz, 1H), 6.76-6.79 (m, 2H), 7.04-7.17 (m, 4H), 7.52 (t, J=7.8 Hz, 1H), 8.11 (s, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 40.3, 48.6, 110.0, 111.9, 113.1, 118.3, 125.5, 127.6, 132.3, 136.1, 145.0, 148.4, 167.2, 168.6, 170.1, 172.8; Anal. calcd for C21H20N4O4.0.2H2O: C, 62.65; H, 5.13; N, 13.85. Found: C, 62.85; H, 4.78; N, 13.67.
    • 5.60 4-[4-(2-DIMETHYLAMINOETHOXY)-2-METHOXYPHENYL AMINO]-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.60.1 4-Fluoro-2-methoxy-1-nitrobenzene
  • Figure US20070049618A1-20070301-C00288
  • A mixture of 5-fluoro-2-nitrophenol (5.0 g, 31.8 mmol), iodomethane (13.5 g, 95.4 mmol), and potassium carbonate (16.7 g, 159 mmol) in acetone (80 mL) was heated to reflux for 4 hours. The mixture was cooled and evaporated under vacuum, and the residue was dissolved in ethyl acetate (200 mL) and washed with water (3×250 mL), dried (MgSO4), and evaporated, providing 5.25 g, in 97% yield: 1H NMR (CDCl3) δ 3.97 (s, 3H), 6.69-6.82 (m, 2H), 7.97 (dd, J=8.9 Hz, J=6.0 Hz, 1H).
    • 5.60.2 [2-(3-Methoxy-4-nitrophenoxy)ethyl]dimethylamine
  • Figure US20070049618A1-20070301-C00289
  • N,N-Dimethylethanolamine (0.80 g, 9.0 mmol) was added to a mixture of powdered KOH (0.50 g, 9.0 mmol) and Aliquat 336 (0.36 g, 0.9 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (1.28 g, 7.5 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (50 mL), and the organic layer was extracted with dilute aqueous HCl (2×50 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 1.1 g as a yellow oil, in 62% yield: 1H NMR (CDCl3) δ 2.34 (s, 6H), 2.75 (t, J=5.5 Hz, 2H), 3.93 (s, 3H), 4.12 (t, J=5.5 Hz, 2H), 6.51 (dd, J=9.1 Hz, J=2.5 Hz, 1H), 6.60 (d, J=2.5 Hz, 1H), 8.00 (d, J=9.1 Hz, 1H).
    • 5.60.3 4-(2-Dimethylaminoethoxy)-2-methoxyphenylamine
  • Figure US20070049618A1-20070301-C00290
  • A mixture of [2-(3-Methoxy-4-nitrophenoxy)ethyl]dimethylamine (1.0 g, 4.2 mmol) and 5% Pd—C (0.2 g) in ethyl acetate (75 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 0.80 g of the product as a light gold oil, in 91% yield: 1H NMR (CDCl3) δ 2.33 (s, 6H), 2.69 (t, J=5.8 Hz, 2H), 3.82 (s, 3H), 4.00 (t, J=5.8 Hz, 2H), 6.35 (dd, J=8.3 Hz, J=2.6 Hz, 1H), 6.50 (d, J=2.6 Hz, 1H), 6.63 (d, J=8.3 Hz, 1H).
    • 5.60.4 3-[4-(2-Dimethylaminoethoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00291
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-(2-dimethylaminoethoxy)-2-methoxyphenylamine (0.65 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.75 g of the product at 96:4 methylene chloride-methanol, in 60% yield: 1H NMR (CDCl3) δ 2.35 (s, 6H), 2.73 (t, J=5.7 Hz, 2H), 3.80 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.06 (t, J=5.7 Hz, 2H), 6.46 (dd, J=8.6 Hz, J=2.7 Hz, 1H), 6.59 (d, J=2.7 Hz, 1H), 6.98 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.08-7.16 (m, 2H), 7.22 (t, J=7.5 Hz, 1H), 7.93 (br, 1H).
    • 5.60.5 4-[4-(2-Dimethylaminoethoxy)-2-methoxyphenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00292
  • Step 1: A mixture of 3-[4-(2-dimethylaminoethoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester (0.72 g, 1.8 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.30 g, 1.8 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2×100 mL), basified (saturated Na2CO3), and extracted with methylene chloride (3×100 mL). The combined organic layers were washed with water (3×100 mL), dried (MgSO4), and evaporated. The residue was triturated with ether and filtered, providing 0.45 g of the product, in 52% yield for the final 2 steps: 1H NMR (DMSO-d6) δ 2.00-2.08 (m, 1H), 2.22 (s, 6H), 2.53-2.65 (m, 4H), 2.83-2.90 (m, 1H), 3.79 (s, 3H), 4.07 (t, J=5.8 Hz, 2H), 5.11 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 6.58 (dd, J=8.6 Hz, J=2.4 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 7.01 (d, J=8.6 Hz, 1H), 7.15 (d, J=7.0 Hz, 1H), 7.28 (d, J=8.6 Hz, 1H), 7.55 (t, J=7.8 Hz, 1H), 7.95 (s, 1H), 11.15 (s, 1H).
    • 5.61 4-[4-(2-DIMETHYLAMINOETHOXY)-2-METHOXYPHENYL AMINO]-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00293
  • 4-[4-(2-Dimethylaminoethoxy)-2-methoxyphenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (0.45 g, 1.0 mmol) was dissolved in 9:1 methylene chloride-methanol (30 mL) and a 2 M solution of hydrogen chloride in ether (2.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum. The residue was triturated with ether and filtered, providing 0.49 g, in quantitative yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.57-2.64 (m, 2H), 2.84-2.91 (m, 7H), 3.50 (t, J=4.6 Hz, 2H), 3.81 (s, 3H), 4.39 (t, J=4.6 Hz, 2H), 5.11 (dd, J=13.4 Hz, J=5.2 Hz, 1H), 6.65 (dd, J=8.6 Hz, J=2.0 Hz, 1H), 6.80 (d, J=2.0 Hz, 1H), 7.04 (d, J=8.4 Hz, 1H), 7.17 (d, J=7.0 Hz, 1H), 7.34 (d, J=8.6 Hz, 1H), 7.56 (t, J=7.8 Hz, 1H), 8.00 (s, 1H), 10.57 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 42.7, 48.7, 55.2, 55.9, 62.7, 100.4, 105.7, 110.6, 112.4, 118.3, 121.1, 124.8, 132.1, 136.2, 144.0, 153.4, 155.9, 167.1, 168.8, 170.0, 172.8; Anal. calcd for C24H27ClN4O6.0.1 Et2O.0.8H2O: C, 55.85; H, 5.69; N, 10.68. Found: C, 55.80; H, 5.32; N, 10.38.
    • 5.62 4-[2-(2-DIMETHYLAMINOETHOXY)-4-METHOXYPHENYL AMINO]-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.62.1 2-Fluoro-4-methoxy-1-nitrobenzene
  • Figure US20070049618A1-20070301-C00294
  • A mixture of 3-fluoro-4-nitrophenol (5.0 g, 31.8 mmol), iodomethane (13.5 g, 95.4 mmol), and potassium carbonate (16.7 g, 159 mmol) in acetone (80 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum, and the partitioned between water (75 mL) and methylene chloride (75 mL) and the aqueous phase was extracted with methylene chloride (2×75 mL). The combined organic phases were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 5.30 g, in 97% yield: 1H NMR (CDCl3) δ 3.90 (s, 3H), 6.70-6.79 (m, 2H), 8.09 (t, J=9.1 Hz, 1H).
    • 5.62.2 [2-(5-Methoxy-2-nitrophenoxy)ethyl]dimethylamine
  • Figure US20070049618A1-20070301-C00295
  • N,N-Dimethylethanolamine (0.80 g, 9.0 mmol) was added to a mixture of powdered KOH (0.50 g, 9.0 mmol) and Aliquat 336 (0.36 g, 0.9 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 2-fluoro-4-methoxy-1-nitrobenzene (1.28 g, 7.5 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (50 mL), and the organic layer was extracted with dilute aqueous HCl (2×50 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 1.3 g as a yellow oil, in 74% yield: 1H NMR (CDCl3) δ 2.36 (s, 6H), 2.81 (t, J=5.8 Hz, 2H), 3.86 (s, 3H), 4.17 (t, J=5.8 Hz, 2H), 6.47-6.54 (m, 2H), 6.97 (d, J=9.0 Hz, 1H).
    • 5.62.3 2-(2-Dimethylaminoethoxy)-4-methoxyphenylamine
  • Figure US20070049618A1-20070301-C00296
  • A mixture of [2-(5-methoxy-2-nitrophenoxy)ethyl]dimethylamine (1.2 g, 5.0 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (75 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 0.94 g of the product, in 90% yield: 1H NMR (CDCl3) δ 2.34 (s, 6H), 2.75 (t, J=5.8 Hz, 2H), 3.74 (s, 3H), 4.08 (t, J=5.8 Hz, 2H), 6.36 (dd, J=8.4 Hz, J=2.5 Hz, 1H), 6.47 (d, J=2.5 Hz, 1H), 6.65 (d, J=8.4 Hz, 1H).
    • 6.62.4 3-[2-(2-Dimethylaminoethoxy)-4-methoxyphenylamino]phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00297
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-(2-dimethylaminoethoxy)-4-methoxyphenylamine (0.65 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.82 g of the product at 95:5 methylene chloride-methanol. This material was dissolved in methylene chloride (100 mL) and extracted with dilute aqueous HCl (3×75 mL). The combined aqueous extracts were washed with methylene chloride (3×75 mL), made basic (Na2CO3), and extracted into methylene chloride (3×75 mL). The organic phases were dried (MgSO4) and evaporated, providing 0.25 g, in 20% yield: 1H NMR (CDCl3) δ 2.28 (s, 6H), 2.70 (t, J=5.8 Hz, 2H), 3.80 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.06 (t, J=5.8 Hz, 2H), 6.46 (dd, J=8.6 Hz, J=2.5 Hz, 1H), 6.54 (d, J=2.7 Hz, 1H), 7.00 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 7.09-7.23 (m, 3H), 7.87 (br, 1H).
    • 5.62.5 4-[2-(2-Dimethylaminoethoxy)-4-methoxyphenylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00298
  • Step 1: A mixture of 3-[2-(2-dimethylaminoethoxy)-4-methoxyphenylamino]phthalic acid dimethyl ester (0.20 g, 0.5 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.10 g, 0.6 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2×100 mL), basified (sat. Na2CO3), and extracted with methylene chloride (3×100 mL). The combined organic layers were washed with water (3×100 mL), dried (MgSO4), and evaporated. The residue was triturated with ether and filtered, providing 0.10 g of the product, in 44% yield for the final 2 steps.
  • Step 3: 4-[4-(2-Dimethylaminoethoxy)-2-methoxyphenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (0.10 g, 0.2 mmol) was dissolved in methylene chloride (30 mL) and a 2M solution of hydrogen chloride in ether (0.4 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum. The residue was triturated with ether and filtered, providing 0.10 g, in quantitative yield: mp 210-212° C.; 1H NMR (DMSO-d6) δ 2.04-2.08 (m, 1H), 2.57-2.71 (m, 8H), 2.83-2.91 (m, 1H), 3.38 (m, 2H), 3.80 (s, 3H), 4.41 (m, 2H), 5.11 (dd, J=15.4 Hz, J=5.3 Hz, 1H), 6.64 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 6.19 (d, J=2.4 Hz, 1H), 7.06 (d, J=8.5 Hz, 1H), 7.17 (d, J=7.0 Hz, 1H), 7.35 (d, J=8.6 Hz, 1H), 7.56 (t, J=7.8 Hz, 1H), 8.01 (s, 1H), 10.43 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 43.0, 48.7, 55.5, 55.6, 63.4, 100.7, 105.6, 110.6, 112.4, 118.5, 120.7, 125.8, 132.1, 136.2, 144.4, 152.1, 157.8, 167.1, 168.8, 170.0, 172.8; Anal. calcd for C24H27ClN4O6.0.5H2O: C, 56.31; H, 5.51; N, 10.94. Found: C, 56.24; H, 5.34; N, 10.72.
    • 5.63 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-[2-METHOXY-4-(2-MORPHOLIN-4-YLETHOXY)PHENYLAMINO]ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.63.1 4-[2-(3-Methoxy-4-nitrophenoxy)ethyl]morpholine
  • Figure US20070049618A1-20070301-C00299
  • 4-(2-Hydroxyethyl)morpholine (0.98 g, 9.0 mmol) was added to a mixture of powdered KOH (0.50 g, 9.0 mmol) and Aliquat 336 (0.36 g, 0.9 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (1.28 g, 7.5 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (50 mL), and the organic layer was extracted with dilute aqueous HCl (2×50 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 1.2 g as a yellow oil, in 57% yield: 1H NMR (CDCl3) δ 2.58 (t, J=4.6 Hz, 6H), 2.83 (t, J=5.6 Hz, 2H), 3.74 (t, J=4.6 Hz, 4H), 3.94 (s, 3H), 4.17 (t, J=5.6 Hz, 2H), 6.51 (dd, J=9.1 Hz, J=2.4 Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 8.00 (d, J=9.1 Hz, 1H).
    • 5.63.2 2-Methoxy-4-(2-morpholin-4-ylethoxy)phenylamine
  • Figure US20070049618A1-20070301-C00300
  • A mixture of 4-[2-(3-methoxy-4-nitrophenoxy)ethyl]morpholine (1.2 g, 4.3 mmol) and 5% Pd—C (0.2 g) in ethyl acetate (75 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 0.95 g of the product as a light grey oil, in 87% yield: 1H NMR (CDCl3) δ 2.57 (t, J=4.6 Hz, 4H), 2.77 (t, J=5.7 Hz, 2H), 3.74 (t, J=4.6 Hz, 4H), 3.82 (s, 3H), 4.05 (t, J=5.7 Hz, 2H), 6.34 (dd, J=8.4 Hz, J=2.5 Hz, 1H), 6.47 (d, J=2.5 Hz, 1H), 6.63 (d, J=8.4 Hz, 1H).
    • 5.63.3 3-[2-Methoxy-4-(2-morpholin-4-ylethoxy)phenylamino]phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00301
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-methoxy-4-(2-morpholin-4-ylethoxy)phenylamine (0.78 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting 1.0 g of the product at 95:5 methylene chloride-methanol, in 72% yield: 1H NMR (CDCl3) δ 2.59 (t, J=4.6 Hz, 4H), 2.81 (t, J=5.7 Hz, 2H), 3.75 (t, J=4.6 Hz, 4H), 3.81 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.11 (t, J=5.7 Hz, 2H), 6.45 (dd, J=8.6 Hz, J=2.6 Hz, 1H), 6.56 (d, J=2.6 Hz, 1H), 6.98 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.08-7.17 (m, 2H), 7.22 (t, J=7.5 Hz, 1H), 7.93 (br, 1H).
    • 5.63.4 2-(2,6-Dioxopiperidin-3-yl)-4-[2-methoxy-4-(2-morpholin-4-ylethoxy)phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00302
  • Step 1: A mixture of 3-[2-methoxy-4-(2-morpholin-4-ylethoxy)phenylamino]phthalic acid dimethyl ester (1.0 g, 2.2 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.36 g, 2.2 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2×100 mL), basified (saturated Na2CO3), and extracted with methylene chloride (3×100 mL). The combined organic layers were washed with water (3×100 mL), dried (MgSO4), and evaporated. The residue was chromatographed in 95:5 methylene chloride-methanol, providing 0.3 g of the product, in 27% yield over 2 steps.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (30 mL) and a 2M solution of hydrogen chloride in ether (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum. The residue was triturated with ether and filtered, providing 0.3 g, in quantitative yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.03-2.13 (m, 1H), 2.57-2.71 (m, 2H), 2.84-2.95 (m, 1H), 3.38 (t, J=7.0 Hz, 2H), 3.42-3.55 (m, 4H), 3.80-3.92 (m, 7H), 4.47 (s, 2H), 5.10 (d, J=8.4 Hz, 1H), 6.64 (d, J=7.6 Hz, 1H), 6.79 (s, 1H), 7.03 (d, J=7.9 Hz, 1H), 7.16 (d, J=6.1 Hz, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.55 (t, J=6.9 Hz, 1H), 7.98 (s, 1H), 11.13 (s, 1H), 11.62 (br, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 51.7, 54.8, 55.9, 62.7, 63.2, 100.4, 105.7, 110.6, 112.4, 118.3, 121.0, 124.8, 132.1, 136.2, 144.0, 153.5, 155.9, 167.1, 168.8, 170.0, 172.8; Anal. calcd for C26H29ClN4O7H2O: C, 55.47; H, 5.55; N, 9.95. Found: C, 55.40; H, 5.24; N, 9.66.
    • 5.64 4-(4-DIMETHYLAMINOMETHYL-2-METHOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE 5.64.1 (3-Methoxy-4-nitrobenzyl)dimethylamine
  • Figure US20070049618A1-20070301-C00303
  • Triethylamine (5 mL) was added to a solution of 3-methoxy-4-nitrobenzyl alcohol (2.5 g, 13.6 mmol) in 50 mL of methylene chloride, and the mixture was cooled to 0° C. under nitrogen. Methanesulfonyl chloride (1.9 g, 16.3 mmol) was added dropwise and the mixture stirred at this temperature for 1 hour. Triethylamine (5 mL) was added, followed by dimethylamine hydrochloride (1.6 g, 20.4 mmol). After 5 minutes, the cooling bath was removed, and the mixture stirred at ambient temperature for 2.5 hours. The mixture was diluted with methylene chloride (75 mL) and washed with water (3×75 mL), and extracted into dilute aqueous HCl (3×75 mL). The combined aqueous extracts were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted into methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 1.8 g of the product, in 65% yield: 1H NMR (CDCl3) δ 2.26 (s, 6H), 3.45 (s, 2H), 3.97 (s, 3H), 6.95 (d, J=8.2 Hz, 1H), 7.12 (s, 1H), 7.82 (d, J=8.2 Hz, 1H).
    • 5.64.2 4-Dimethylaminomethyl-2-methoxyphenylamine
  • Figure US20070049618A1-20070301-C00304
  • A mixture of (3-methoxy-4-nitrobenzyl)dimethylamine (1.5 g, 7.1 mmol) and 5% Pd—C (0.2 g) in ethyl acetate (75 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 1.2 g of the product as a light grey oil, in 93% yield: 1H NMR (CDCl3) δ 2.22 (s, 6H), 3.32 (s, 2H), 3.74 (br, 2H), 3.86 (s, 3H), 6.62-6.67 (m, 2H), 6.78 (s, 1H).
    • 5.64.3 3-(4-Dimethylaminomethyl-2-methoxyphenylamino)phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00305
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-dimethylaminomethyl-2-methoxyphenylamine (0.56 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.9 g of the product at 92:8 methylene chloride-methanol, in 78% yield: 1H NMR (CDCl3) δ 2.31 (s, 6H), 3.47 (s, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 3.90 (s, 3H), 6.80 (dd, J=8.0 Hz, J=1.4 Hz, 1H), 6.99 (s, 1H), 7.14 (dd, J=7.3 Hz, J=0.9 Hz, 1H), 7.20 (d, J=8.0 Hz, 1H), 7.31 (t, J=7.9 Hz, 1H), 7.45 (dd, J=8.5 Hz, J=0.9 Hz, 1H), 7.99 (br, 1H).
    • 5.64.4 4-(4-Dimethylaminomethyl-2-methoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00306
  • Step 1: A mixture of 3-(4-dimethylaminomethyl-2-methoxyphenylamino)phthalic acid dimethyl ester (0.9 g, 2.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.39 g, 2.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2×100 mL), basified (saturated Na2CO3), and extracted with methylene chloride (3×100 mL). The combined organic layers were washed with water (3×100 mL), dried (MgSO4), and evaporated. The residue was triturated in diethyl ether and filtered, providing 0.45 g of the product, in 43% yield over 2 steps: 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.11 (s, 6H), 2.53-2.64 (m, 2H), 2.82-2.92 (m, 1H), 3.38 (s, 2H), 3.84 (s, 3H), 5.12 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 6.91 (d, J=8.8 Hz, 1H), 7.05 (s, 1H), 7.22 (d, J=7.1 Hz, 1H), 7.34-7.41 (m, 2H), 7.62 (t, J=7.9 Hz, 1H), 8.24 (s, 1H), 11.14 (s, 1H).
    • 5.65 4-(4-DIMETHYLAMINOMETHYL-2-METHOXYPHENYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00307
  • 4-(4-Dimethylaminomethyl-2-methoxyphenylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (0.42 g, 1.0 mmol) was dissolved in 9:1 methylene chloride-methanol (75 mL) and a 2 M solution of hydrogen chloride in ether (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum. The residue was triturated with ether and filtered, providing 0.44 g, in quantitative yield: mp >260° C.; 1H NMR (DMSO-d6) δ 1.96-2.14 (m, 1H), 2.53-2.68 (m, 8H), 2.84-2.95 (m, 1H), 3.90 (s, 3H), 4.24 (s, 2H), 5.13 (d, J=7.8 Hz, 1H), 7.13 (d, J=7.1 Hz, 1H), 7.28 (d, J=5.7 Hz, 1H), 7.25-7.66 (m, 4H), 8.41 (s, 1H), 11.11 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 41.4, 48.8, 56.1, 59.4, 112.3, 113.7, 114.3, 119.3, 123.5, 126.1, 129.0, 132.2, 136.4, 141.7, 150.0, 167.0, 168.8, 170.0, 172.8; Anal. calcd for C23H25ClN4O5.0.5H2O.0.1 Et2O: C, 57.44; H, 5.56; N, 11.45. Found: C, 57.44; H, 5.48; N, 11.08.
    • 5.66 4-[4-(3-DIMETHYLAMINOPROPOXY)-2-METHOXYPHENYL AMINO]-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.66.1 [3-(3-Methoxy-4-nitrophenoxy)propyl]dimethylamine
  • Figure US20070049618A1-20070301-C00308
  • 3-Dimethylaminopropanol (1.45 g, 14.0 mmol) was added to a mixture of powdered KOH (0.79 g, 14.0 mmol) and Aliquat 336 (0.57 g, 1.4 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (2.0 g, 11.7 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (80 mL) and dilute aqueous HCl (80 mL), and the organic layer was extracted with dilute aqueous HCl (2×50 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 2.1 g as a yellow oil, in 71% yield: 1H NMR (CDCl3) δ 1.98 (q, J=6.8 Hz, 6H), 2.25 (s, 6H), 2.45 (t, J=7.0 Hz, 2H), 3.74 (t, J=4.6 Hz, 4H), 3.94 (s, 3H), 4.10 (t, J=6.4 Hz, 2H), 6.48-6.53 (m, 2H), 7.99 (d, J=8.8 Hz, 1H).
    • 5.66.2 4-(3-Dimethylaminopropoxy)-2-methoxyphenylamine
  • Figure US20070049618A1-20070301-C00309
  • A mixture of [3-(3-methoxy-4-nitrophenoxy)propyl]dimethylamine (2.0 g, 7.7 mmol) and 5% Pd—C (0.4 g) in ethyl acetate (75 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 1.7 g of the product as a light grey oil, in 97% yield: 1H NMR (CDCl3) δ 1.86-1.98 (m, 2H), 2.25 (s, 6H), 2.44 (t, J=7.3 Hz, 2H), 3.44 (br, 2H), 3.82 (s, 3H), 3.94 (t, J=6.5 Hz, 2H), 6.35 (dd, J=8.4 Hz, J=2.6 Hz, 1H), 6.46 (d, J=2.6 Hz, 1H), 6.62 (d, J=8.4 Hz, 1H).
    • 5.66.3 3-[4-(3-Dimethylaminopropoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00310
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-(3-dimethylaminopropoxy)-2-methoxyphenylamine (0.70 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.6 g of the product at 94:6 methylene chloride-methanol, in 46% yield: 1H NMR (CDCl3) δ 1.98 (p, J=6.8 Hz, 2H), 2.30 (s, 6H), 2.51 (t, J=7.3 Hz, 2H), 3.81 (s, 3H), 3.87 (s, 6H), 4.02 (t, J=6.4 Hz, 2H), 6.45 (dd, J=8.6 Hz, J=2.6 Hz, 1H), 6.54 (d, J=2.6 Hz, 1H), 6.97 (dd, J=7.3 Hz, J=1.0 Hz, 1H), 7.09 (dd, J=8.5 Hz, J=1.0 Hz, 1H), 7.14 (d, J=8.6 Hz, 1H), 7.21 (t, J=7.5 Hz, 1H), 7.92 (br, 1H).
    • 5.66.4 4-[4-(3-Dimethylaminopropoxy)-2-methoxyphenylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00311
  • Step 1: A mixture of 3-[4-(3-dimethylaminopropoxy)-2-methoxyphenylamino]phthalic acid dimethyl ester (0.6 g, 1.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.23 g, 1.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between methylene chloride (100 mL) and water (150 mL). The aqueous phase was washed with methylene chloride (2×100 mL), basified (saturated Na2CO3), and extracted with methylene chloride (3×100 mL). The combined organic layers were washed with water (3×100 mL), dried (MgSO4), and evaporated. The residue was triturated in diethyl ether and filtered, providing 0.2 g of the product, in 29% yield over 2 steps.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (25 mL) and a 2M solution of hydrogen chloride in ether (0.8 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated under vacuum. The residue was triturated with ether and filtered, providing 0.2 g, in quantitative yield: mp 225-227° C.; 1H NMR (DMSO-d6) δ 1.94-2.22 (m, 3H), 2.56-2.62 (m, 2H), 2.77 (s, 6H), 2.82-2.92 (m, 1H), 3.21 (t, J=7.0 Hz, 2H), 3.79 (s, 3H), 4.09 (t, J=7.0 Hz, 2H), 5.11 (dd, J=12.3 Hz, J=4.6 Hz, 1H), 6.59 (d, J=7.9 Hz, 1H), 6.72 (s, 1H), 7.01 (d, J=8.4 Hz, 1H), 7.15 (d, J=6.8 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.55 (t, J=7.5 Hz, 1H), 7.96 (s, 1H), 10.70 (br, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 23.9, 31.0, 42.1, 48.7, 54.0, 55.8, 65.3, 100.1, 105.4, 110.5, 112.3, 118.3, 120.4, 125.0, 132.1, 136.1, 144.1, 153.5, 156.8, 167.1, 168.8, 170.0, 172.8; Anal. calcd for C25H29ClN4O6H2O: C, 56.13; H, 5.84; N, 10.47. Found: C, 55.91; H, 5.62; N, 10.31.
    • 5.67 4-[4-(2-DIMETHYLAMINO-ETHOXY)-PHENYLAMINO]-2-(2.6 DIOXO-PIPERIDIN-3-YL)-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.67.1 Dimethyl-[2-(4-nitro-phenoxy)-ethyl]-amine
  • Figure US20070049618A1-20070301-C00312
  • A mixture of 4-nitrophenol (3.5 g, 25 mmol), 2-(dimethylamino)ethyl chloride hydrochloride (3.6 g, 25 mmol), and potassium carbonate (13.2 g, 125 mmol) in acetone (100 mL) was heated to reflux for 30 hours. The solvent was removed under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (150 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (3×150 mL) and extracted with dilute aqueous HCl (2×125 mL). These extracts were washed with CH2Cl2 (2×150 mL), made basic (NaOH) and extracted into ethyl acetate (3×75 mL). These organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 3.0 g as a pale yellow solid, in 57% yield; 1H NMR (CDCl3) δ 2.35 (s, 6H), 2.76 (t, J=5.6 Hz, 2H), 4.15 (t, J=5.6 Hz, 2H), 6.96-7.00 (m, 2H), 8.17-8.22 (m, 2H).
    • 5.67.2 4-(2-Dimethylamino-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00313
  • A mixture of dimethyl-[2-(4-nitro-phenoxy)-ethyl]-amine (3.0 g, 14 mmol) and 5% Pd—C (0.4 g) in ethyl acetate (70 mL) was hydrogenated under 50 psi hydrogen for 20 hours. The mixture was filtered through Celite and the filtrate was evaporated in vacuo, providing 2.6 g, in quantitative yield; 1H NMR (CDCl3) δ 2.32 (s, 6H), 2.69 (t, J=5.8 Hz, 2H), 3.99 (t, J=5.8 Hz, 2H), 6.00-6.66 (m, 2H), 6.73-6.78 (m, 2H).
    • 5.67.3 3-[4-(2-Dimethylamino-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00314
  • A mixture of 4-(2-dimethylamino-ethoxy)-phenylamine (0.56 g, 3.1 mmol), 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 16 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 0.53 g of the product at 95:5 methylene chloride-methanol, in 46% yield, as a pale yellow solid; 1H NMR (CDCl3) δ 2.34 (s, 3H), 2.73 (t, J=5.7 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 4.06 (t, J=5.7 Hz, 2H), 6.89-6.96 (m, 3H), 7.06-7.23 (m, 3H), 7.33-7.50 (m, 1H), 8.09 (s, 1H).
    • 5.67.4 4-[4-(2-Dimethylamino-ethoxy)-phenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00315
  • Step 1: A mixture of 3-[4-(2-dimethylamino-ethoxy)-phenylamino]-phthalic acid dimethyl ester (0.50 g, 1.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.21 g, 1.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH2Cl2 (3×75 mL), and was basified (sat. Na2CO3) and then extracted into ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 130 mg as an orange solid.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL), and a 2N solution of HCl in ethyl ether (0.6 mL) was added dropwise. The mixture stirred at room temperature for 1 hour and was then evaporated, providing 0.13 g as an orange solid, in 21% yield over 3 steps: mp >260° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=2.50 (95.99%); 1H NMR (DMSO-d6) δ 2.04-2.12 (m, 1H), 2.53-2.64 (m, 2H), 2.84-2.97 (m, 7H), 3.39 (t, J=4.8 Hz, 2H), 4.37 (t, J=4.8 Hz, 2H), 5.12 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 7.06 (d, J=8.8 Hz, 2H), 7.16-7.20 (m, 2H), 7.30 (d, J=8.8 Hz, 2H), 7.57 (t, J=7.8 Hz, 1H), 8.30 (s, 1H), 10.53 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 42.7, 48.7, 55.3, 62.6, 110.9, 112.7, 115.6, 118.6, 125.0, 132.4, 132.7, 136.2, 144.0, 154.7, 167.1, 168.4, 170.0, 172.8; Anal. calcd For C23H25ClN4O5.0.7H2O: C, 56.89; H, 5.48; N, 11.54. Found: C, 57.02; H, 5.28; N, 11.15.
    • 5.68 4-[4-(2-DIMETHYLAMINO-ETHOXY)-2-ISOPROPOXY-PHENYLAMINO]-2-(2,6-DIOXO-PIPERIDIN-3-YL)-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.68.1 4-Fluoro-2-isopropoxy-1-nitro-benzene
  • Figure US20070049618A1-20070301-C00316
  • A mixture of 5-fluoro-2-nitrophenol (2.5 g, 15.9 mmol), 2-iodopropane (5.4 g, 31.8 mmol), and potassium carbonate (4.2 g, 39.8 mmol) in acetone (40 mL) was heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum, and the residue was partitioned between ethyl acetate (100 mL) and water (150 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (3×150 mL), dried (MgSO4), and evaporated, providing 3.2 g, in quantitative yield; 1H NMR (CDCl3) δ 1.42 (d, J=6.0 Hz, 6H), 4.63 (septet, J=6.0 Hz, 6H), 6.64-6.72 (m, 1H), 6.76 (dd, J=9.8 Hz, J=2.5 Hz, 1H), 7.88 (dd, J=8.9 Hz, J=6.1 Hz, 1H).
    • 5.68.2 [2-(3-Isopropoxy-4-nitro-phenoxy)-ethyl]-dimethyl-amine
  • Figure US20070049618A1-20070301-C00317
  • N,N-Dimethylethanolamine (1.6 g, 18 mmol) was added to a mixture of powdered KOH (1.0 g, 18 mmol) and Aliquat 336 (0.72 g, 1.8 mmol), and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-isopropoxy-1-nitrobenzene (3.0 g, 15 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (100 mL) and dilute aqueous HCl (100 mL), and the organic layer was extracted with dilute aqueous HCl (2×100 mL). The combined aqueous phases were washed with methylene chloride (3×150 mL), basified (3N NaOH), and extracted with methylene chloride (3×100 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 2.2 g as a yellow oil, in 55% yield; 1H NMR (CDCl3) δ 1.40 (d, J=6.1 Hz, 6H), 2.34 (s, 6H), 2.74 (t, J=5.6 Hz, 2H), 4.10 (t, J=5.6 Hz, 2H), 4.61 (septet, J=6.1 Hz, 1H), 6.48 (dd, J=9.1 Hz, J=2.5 Hz, 1H), 6.57 (d, J=2.5 Hz, 1H), 7.91 (d, J=9.1 Hz, 1H).
    • 5.68.3 4-(2-Dimethylamino-ethoxy)-2-isopropoxy-phenylamine
  • Figure US20070049618A1-20070301-C00318
  • A mixture of [2-(3-isopropoxy-4-nitrophenoxy)ethyl]dimethylamine (2.0 g, 7.5 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (70 mL) was shaken under 50 psi of hydrogen for 24 hours. The mixture was filtered through Celite and evaporated, providing 1.7 g of the product as a light gold oil, in 98% yield; 1H NMR (CDCl3) δ 1.34 (d, J=6.0 Hz, 6H), 2.32 (s, 6H), 2.68 (t, J=5.8 Hz, 2H), 3.48 (br, 2H), 3.98 (t, J=5.8 Hz, 2H), 4.48 (septet, J=6.0 Hz, 1H), 6.35 (dd, J=8.4 Hz, J=2.5 Hz, 1H), 6.50 (d, J=2.5 Hz, 1H), 6.63 (d, J=8.4 Hz, 1H).
    • 5.68.4 3-[4-(2-Dimethylamino-ethoxy)-2-isopropoxy-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00319
  • A mixture of 3-iodophthalic acid dimethyl ester (2.0 g, 6.2 mmol), 4-(2-dimethylaminoethoxy)-2-isopropoxyphenylamine (1.5 g, 6.2 mmol), Pd2(dba)3 (0.26 g, 0.28 mmol), rac-BINAP (0.12 g, 0.19 mmol), and cesium carbonate (2.8 g, 8.6 mmol), in 12 mL toluene was heated to reflux under nitrogen for 24 hours. The reaction mixture was cooled, diluted with CH2Cl2 (20 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (60 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 1.3 g of the product at 96:4 methylene chloride-methanol, in 47% yield; 1H NMR (CDCl3) δ 1.31 (d, J=6.1 Hz, 6H), 2.96 (d, J=4.8 Hz, 6H), 3.41-3.47 (m, 2H), 3.87 (s, 6H), 4.47-4.51 (m, 3H), 6.45 (dd, J=8.7 Hz, J=2.6 Hz, 1H), 6.56 (d, J=2.6 Hz, 1H), 7.07 (dd, J=6.0 Hz, J=2.5 Hz, 1H), 7.18 (d, J=8.7 Hz, 1H), 7.20-7.18 (m, 2H), 7.90 (s, 1H).
    • 5.68.5 4-[4-(2-Dimethylamino-ethoxy)-2-isopropoxy-phenylamino]-2 (2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00320
  • Step 1: A mixture of 3-[4-(2-dimethylamino-ethoxy)-2-isopropoxy-phenylamino]-phthalic acid dimethyl ester (1.1 g, 2.7 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.45 g, 2.7 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH2Cl2 (3×75 mL), and was basified (sat. Na2CO3) and then extracted into ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 260 mg as an orange solid.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL), and a 2N solution of HCl in ethyl ether (0.3 mL) was added dropwise. The mixture stirred at room temperature for 1 hour and was then evaporated, providing 0.16 g as an orange solid, in 12% yield over 3 steps: mp 247-249° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=4.02 (96.99%); 1H NMR (DMSO-d6) δ 1.25 (d, J=5.9 Hz, 1H), 2.05-2.10 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.91 (m, 7H), 3.49 (t, J=4.8 Hz, 2H), 4.38 (t, J=4.8 Hz, 2H), 4.65 (septet, J=5.9 Hz, 1H), 5.13 (dd, J=12.4 Hz, J=5.2 Hz, 1H), 6.64 (dd, J=8.7 Hz, J=2.2 Hz, 1H), 6.82 (d, J=2.2 Hz, 1H), 7.17-7.25 (m, 2H), 7.38 (d, J=8.7 Hz, 1H), 7.60 (t, J=7.8 Hz, 1H), 8.13 (s, 1H), 10.54 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.8, 22.1, 31.0, 42.7, 48.7, 55.2, 62.7, 71.0, 102.8, 106.2, 110.9, 112.6, 118.5, 122.7, 123.2, 132.1, 136.2, 143.4, 150.7, 155.2, 167.1, 168.9, 170.0, 172.8; Anal. calcd For C26H31ClN4O6.0.6H2O: C, 57.64; H, 5.99; N, 10.34. Found: C, 57.62; H, 5.87; N, 10.25.
    • 5.69 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-(4-METHOXY-2-PHENOXY-PHENYLAMINO)-ISOINDOLE-1,3-DIONE 5.69.1 4-Methoxy-1-nitro-2-phenoxy-benzene
  • Figure US20070049618A1-20070301-C00321
  • A 60% dispersion of sodium hydride (0.86 g, 22 mmol) was added to a mixture of copper bromide (2.6 g, 17.9 mmol) and phenol (1.7 g, 17.9 mmol) in pyridine (300 mL). After the effervescence subsided, the mixture was heated to reflux for 30 minutes. 3-Iodo-4-nitroanisole (5.0 g, 17.9 mmol) was added and stirring proceeded under nitrogen for 20 hours. The mixture was cooled and the reaction was quenched with saturated ammonium chloride (1 mL). The mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate (250 mL) and washed with dilute aqueous HCl (2×200 mL), saturated sodium carbonate (2×200 mL) and water (200 mL), and was evaporated in vacuo. The residue was purified by ISCO silica gel flash chromatography in hexanes-ethyl acetate gradient, eluting 2.8 g of the product at 7:3 hexanes-ethyl acetate, in 64% yield; 1H NMR (CDCl3) δ 3.78 (s, 3H), 6.43 (d, J=2.3 Hz, 1H), 6.68 (dd, J=9.2, J=2.3 Hz, 1H), 7.03-7.07 (m, 2H), 7.19 (t, J=7.3 Hz, 1H), 7.37-7.41 (m, 2H), 8.07 (d, J=9.2 Hz, 1H).
    • 5.69.2 4-Methoxy-2-phenoxy-phenylamine
  • Figure US20070049618A1-20070301-C00322
  • A mixture 4-methoxy-1-nitro-2-phenoxy-benzene (1.3 g, 5.3 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (100 mL) was shaken under 50 psi of hydrogen for 20 hours. The mixture was filtered through Celite and evaporated, providing 1.1 g of the product as a light gold oil; 1H NMR (CDCl3) δ 3.70 (s, 3H), 6.49 (d, J=2.6 Hz, 1H), 6.59 (dd, J=8.6 Hz, J=2.6 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.96-7.00 (m, 2H), 7.07 (t, J=7.3 Hz, 1H), 7.28-7.35 (m, 2H).
    • 5.69.3 3-(4-Methoxy-2-phenoxy-phenylamino)-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00323
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 4-methoxy-2-phenoxy-phenylamine (0.67 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 16 hours. The reaction mixture was cooled, diluted with CH2Cl2 (10 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (30 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a hexanes-ethyl acetate gradient, eluting 0.9 g of the product at 8:2 hexanes-ethyl acetate, in 71% yield; 1H NMR (CDCl3) δ 3.74 (s, 3H), 3.76 (s, 3H), 3.84 (s, 3H), 6.60 (d, J=2.9 Hz, 1H), 6.69 (dd, J=8.7 Hz, J=2.9 Hz, 1H), 6.85-6.89 (m, 2H), 6.97-7.07 (m, 2H), 7.09 (dd, J=8.5 Hz, J=1.0 Hz, 1H), 7.22-7.29 (m, 4H), 7.84 (s, 1H).
    • 5.69.4 3-(4-Methoxy-2-phenoxy-phenylamino)-phthalic acid
  • Figure US20070049618A1-20070301-C00324
  • A mixture of 3-(4-methoxy-2-phenoxy-phenylamino)-phthalic acid dimethyl ester (0.80 g, 2.0 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with CH2Cl2 (2×100 mL), and acidified (HCl). The resulting mixture was extracted with ethyl acetate (4×50 mL) and the combined extracts were washed with water (3×100 mL), dried (MgSO4) and evaporated, providing 0.69 g, in 93% yield; 1H NMR (DMSO-d6) δ 3.71 (s, 3H), 6.58 (d, J=2.7, 1H), 6.80 (dd, J=8.8 Hz, J=2.7 Hz, 1H), 6.88-6.94 (m, 3H), 7.03-7.10 (m, 2H), 7.27-7.36 (m, 4H), 8.07 (s, 1H).
    • 5.69.5 2-(2,6-Dioxo-piperidin-3-yl)-4-(4-methoxy-2-phenoxy-phenylamino)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00325
  • A mixture of 3-(4-methoxy-2-phenoxy-phenylamino)-phthalic acid (0.60 g, 1.6 mmol) and rac-α-aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) in pyridine (10 mL) were heated to reflux for 20 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (100 mL) and washed with dilute aqueous HCl (3×100 mL) and water (100 mL), and then evaporated under vacuum. The residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 0.66 g of the product, an orange solid, at 95:5 methylene chloride-methanol, in 89% yield: mp 142-144° C.; HPLC, Waters Symmetry C-18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 60/40 CH3CN/0.1% H3PO4, 4.71 min (96.79%); 1H NMR (DMSO-d6) δ 1.98-2.04 (m, 1H), 2.49-2.61 (m, 2H), 2.81-2.90 (m, 1H), 3.73 (s, 3H), 5.06 (dd, J=12.8 Hz, J=5.3 Hz, 1H), 6.58 (d, J=2.8 Hz, 1H), 6.84 (dd, J=8.8, J=2.8 Hz, 1H), 6.90-6.94 (m, 2H), 7.04-7.10 (m, 2H), 7.16 (d, J=7.0 Hz, 1H), 7.27-7.34 (m, 2H), 7.45 (d, J=8.7 Hz, 1H), 7.57 (dd, J=8.3 Hz, J=7.4 Hz, 1H), 7.95 (s, 1H), 11.10 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 30.9, 48.6, 55.5, 105.9, 109.6, 110.7, 112.6, 117.9, 118.7, 122.8, 123.5, 127.2, 129.9, 132.0, 136.0, 144.0, 151.1, 156.2, 157.8, 167.1, 168.5, 169.9, 172.8; Anal. calcd For C26H21N3O6.0.3H2O: C, 65.49; H, 4.55; N, 8.84. Found: C, 65.43; H, 4.29; N, 8.73.
    • 5.70 4-[4-(2-DIMETHYLAMINO-ETHOXY)-2-PHENOXY-PHENYLAMINO]-2-(2,6-DIOXO-PIPERIDIN-3-YL)-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.70.1 [2-(3-Fluoro-4-nitro-phenoxy)-ethyl]-dimethyl-amine
  • Figure US20070049618A1-20070301-C00326
  • A mixture of 3-fluoro-4-nitrophenol (3.0 g, 19 mmol), 2-(dimethylamino)ethyl chloride hydrochloride (3.0 g, 21 mmol) and potassium carbonate (5.4 g, 39 mmol) in 2-butanone (75 mL) was heated to reflux for 20 hours. An additional portion of 2-(dimethylamino)ethyl chloride hydrochloride (2.0 g, 14 mmol) was added, and stirring at reflux proceeded for 24 hours. The mixture was cooled and evaporated under vacuum, and the residue was partitioned between ethyl acetate (100 mL) and water (150 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (3×150 mL) and extracted into dilute aqueous HCl (3×75 mL). The combined aqueous extracts were washed with ethyl acetate (2×100 mL) and basified (NaOH), and the resulting mixture was extracted with ethyl acetate (3×100 mL). The combined extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 2.9 g as a yellow oil, in 67% yield; 1H NMR (CDCl3) δ 2.34 (s, 6H), 2.76 (t, J=5.5 Hz, 2H), 4.13 (t, J=5.5 Hz, 2H), 6.72-6.81 (m, 2H), 8.09 (t, J=9.1 Hz, 1H).
    • 5.70.2 Dimethyl-[2-(4-nitro-3-phenoxy-phenoxy)-ethyl]-amine
  • Figure US20070049618A1-20070301-C00327
  • A mixture of [2-(3-fluoro-4-nitro-phenoxy)-ethyl]-dimethyl-amine (2.8 g, 12 mmol) and phenol (1.4 g, 15 mmol) in DMF (100 mL) was treated with potassium carbonate (3.4 g, 25 mmol) and the mixture heated at 110° C. under N2 with stirring. After 4 hours, the mixture was cooled to ambient temperature. The mixture was evaporated in vacuo, and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic phases were washed with 10% potassium carbonate (2×100 mL) and water (2×100 mL), and were then extracted with dilute aqueous HCl (3×75 mL). The combined aqueous extracts were washed with CH2Cl2 (2×100 mL), basified (NaOH), and extracted into ethyl acetate (3×75 mL). The combined organic phases were washed with water (2×100 mL), dried (MgSO4) and evaporated, providing 3.1 g, in 84% yield; 1H NMR (CDCl3) δ 2.29 (s, 6H), 2.67 (t, J=5.8 Hz, 2H), 4.00 (t, J=5.8 Hz, 2H), 6.46 (d, J=2.6 Hz, 1H), 6.68 (dd, J=9.2 Hz, J=2.6 Hz, 1H), 7.03-7.07 (m, 2H), 7.18-7.22 (m, 1H), 7.35-7.42 (m, 2H), 8.06 (d, J=9.2 Hz, 1H).
    • 5.70.3 4-(2-Dimethylamino-ethoxy)-2-phenoxy-phenylamine
  • Figure US20070049618A1-20070301-C00328
  • A mixture dimethyl-[2-(4-nitro-3-phenoxy-phenoxy)-ethyl]-amine (3.0 g, 9.9 mmol) and 5% Pd—C (0.6 g) in ethyl acetate (100 mL) was shaken under 50 psi of hydrogen for 20 hours. The mixture was filtered through Celite and evaporated, providing 2.7 g of the product, in quantitative yield; 1H NMR (CDCl3) δ 2.30 (s, 6H), 2.65 (t, J=5.7 Hz, 2H), 3.93 (t, J=5.7 Hz, 2H), 6.51 (d, J=2.6 Hz, 1H), 6.60 (dd, J=8.6 Hz, J=2.9 Hz, 1H), 6.74 (d, J=8.6 Hz, 1H), 6.95-7.00 (m, 2H), 7.06 (t, J=7.3 Hz, 1H), 7.28-7.34 (m, 2H).
    • 5.70.4 3-[4-(2-Dimethylamino-ethoxy)-2-phenoxy-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00329
  • A mixture of 3-iodophthalic acid dimethyl ester (2.0 g, 6.2 mmol), 4-(2-dimethylamino-ethoxy)-2-phenoxy-phenylamine (1.9 g, 6.2 mmol), Pd2(dba)3 (0.26 g, 0.28 mmol), rac-BINAP (0.12 g, 0.19 mmol), and cesium carbonate (2.8 g, 8.6 mmol), in 12 mL toluene was heated to reflux under nitrogen for 16 hours. The reaction mixture was cooled, diluted with CH2Cl2 (20 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (60 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 2.2 g of the product, an orange solid, at 95:5 methylene chloride-methanol, in 76% yield; 1H NMR (CDCl3) δ 2.31 (s, 6H), 2.69 (t, J=5.6 Hz, 2H), 3.74 (s, 3H), 3.84 (s, 3H), 3.99 (t, J=5.6 Hz, 2H), 6.61 (d, J=2.6 Hz, 1H), 6.69 (dd, J=8.5 Hz, J=2.8 Hz, 1H), 6.86-6.90 (m, 2H), 6.98 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 7.01-7.07 (m, 1H), 7.11 (dd, J=8.6 Hz, J=1.1 Hz, 1H), 7.22-7.30 (m, 4H), 7.85 (s, 1H).
    • 5.70.5 4-[4-(2-Dimethylamino-ethoxy)-2-phenoxy-phenylamino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00330
  • Step 1: A mixture of 3-[4-(2-dimethylamino-ethoxy)-2-phenoxy-phenylamino]-phthalic acid dimethyl ester (2.0 g, 4.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.70 g, 4.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (75 mL). The aqueous phase was washed with CH2Cl2 (3×75 mL), and was basified (sat. Na2CO3) and then extracted into ethyl acetate (3×75 mL). The combined organic extracts were washed with water (3×75 mL), dried (MgSO4) and evaporated, and the residue was triturated with ethyl ether and filtered, providing 260 mg as an orange solid.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL), and a 2N solution of HCl in ethyl ether (4.3 mL) was added dropwise. The mixture stirred at room temperature for 1 hour and was then evaporated, providing 0.98 g of the product as an orange solid, in 41% yield over 3 steps: mp >400° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=5.50 (96.24%); 1H NMR (DMSO-d6) δ 1.99-2.04 (m, 1H), 2.51-2.61 (m, 2H), 2.80-2.94 (m, 7H), 3.46-3.56 (m, 2H), 4.33 (t, J=4.7 Hz, 2H), 5.07 (dd, J=12.6 Hz, J=5.1 Hz, 1H), 6.64 (d, J=2.6 Hz, 1H), 6.90 (dd, J=8.8 Hz, J=2.6 Hz, 1H), 6.93-6.97 (m, 2H), 7.07-7.14 (m, 2H), 7.18 (d, J=7.0 Hz, 1H), 7.30-7.37 (m, 2H), 7.50 (d, J=8.8 Hz, 1H), 7.59 (t, J=7.8 Hz, 1H), 8.04 (s, 1H), 10.50 (br, 1H), 11.11 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 30.9, 42.7, 48.6, 55.1, 62.7, 106.7, 110.0, 110.9, 112.7, 118.2, 118.7, 123.6, 123.8, 126.8, 130.0, 132.0, 136.1, 143.8, 151.0, 155.9, 156.0, 167.0, 168.6, 169.9, 172.8; Anal. calcd. For C29H29ClN4O6.0.85H2O: C, 60.02; H, 5.33; N, 9.65. Found: C, 60.02; H, 5.30; N, 9.30.
    • 5.71 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-[4-(2-MORPHOLIN-4-YL-ETHOXY)-PHENYLAMINO]-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.71.1 4-[2-(4-Nitro-phenoxy)-ethyl]-morpholine
  • Figure US20070049618A1-20070301-C00331
  • A mixture of 4-nitrophenol (3.5 g, 25 mmol), N-(2-chloroethyl)morpholine hydrochloride (4.7 g, 25 mmol), and potassium carbonate (13.2 g, 125 mmol) in acetone (100 mL) was heated to reflux for 18 hours. The solvent was removed under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (150 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (3×100 mL) and extracted with dilute aqueous HCl (2×125 mL). These extracts were washed with CH2Cl2 (2×125 mL), made basic (NaOH), and extracted into ethyl acetate (3×75 mL). These organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 3.4 g as a pale yellow solid, in 54% yield; 1H NMR (CDCl3) δ 2.59 (t, J=4.7 Hz, 4H), 2.84 (t, J=5.7 Hz, 2H), 3.74 (t, J=4.7 Hz, 4H), 4.20 (t, J=5.7 Hz, 2H), 6.97 (d, J=9.0 Hz, 2H), 8.20 (d, J=9.0 Hz, 2H).
    • 5.71.2 4-(2-Morpholin-4-yl-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00332
  • A mixture of 4-[2-(4-nitro-phenoxy)-ethyl]-morpholine (3.2 g, 13 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (70 mL) was hydrogenated under 50 psi hydrogen for 20 hours. The mixture was filtered through Celite, and the filtrate was evaporated in vacuo, providing 2.0 g, in 72% yield; 1H NMR (CDCl3) δ 2.57 (t, J=4.6 Hz, 4H), 2.77 (t, J=5.8 Hz, 2H), 3.74 (t, J=4.6 Hz, 4H), 4.04 (t, J=5.8 Hz, 2H), 6.63 (d, J=8.8 Hz, 2H), 6.75 (d, J=8.8 Hz, 2H).
    • 5.71.3 3-[4-(2-Morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00333
  • A mixture of 4-(2-morpholin-4-yl-ethoxy)-phenylamine (1.4 g, 6.2 mmol), 3-iodophthalic acid dimethyl ester (2.0 g, 6.2 mmol), Pd2(dba)3 (0.26 g, 0.28 mmol), rac-BINAP (0.12 g, 0.19 mmol), and cesium carbonate (2.8 g, 8.6 mmol), in 12 mL toluene was heated to reflux under nitrogen for 16 hours. The reaction mixture was cooled, diluted with CH2Cl2 (20 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (60 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 1.8 g of the product at 95:5 methylene chloride-methanol, in 70% yield, as a pale yellow solid; 1H NMR (CDCl3) δ 3.00-3.51 (m, 6H), 3.87 (s, 3H), 3.88 (s, 3H), 4.08-4.34 (m, 4H), 4.52-4.62 (m, 2H), 6.89 (d, J=8.7 Hz, 2H), 6.99 (d, J=7.1, 1H), 7.09-7.12 (m, 3H), 7.23-7.28 (m, 1H), 8.08 (s, 1H).
    • 5.71.4 2-(2,6-Dioxo-piperidin-3-yl)-4-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00334
  • Step 1: A mixture of 3-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (1.5 g, 3.6 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.59 g, 3.6 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was purified by ISCO silica gel flash chromatography in methylene chloride-methanol gradient, eluting 0.76 g at 93:7 methylene chloride-methanol, as an orange solid.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL), and a 4N solution of HCl in dioxane (1.5 mL) was added dropwise. The mixture stirred at room temperature for 1 hour and was then evaporated, providing 0.75 g as an orange solid, in 38% yield over 3 steps: mp 206-208° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=4.09 (97.99%); 1H NMR (DMSO-d6) δ 2.05-2.08 (m, 1H), 2.49-2.64 (m, 2H), 2.85-2.97 (m, 1H), 3.07-3.27 (m, 2H), 3.39-3.54 (m, 4H), 3.85-3.94 (m, 4H), 4.36-4.45 (m, 2H), 5.11 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 7.05 (d, J=8.7 Hz, 2H), 7.16-7.20 (m, 2H), 7.30 (d, J=8.7 Hz, 2H), 7.56 (t, J=7.8 Hz, 1H), 8.29 (s, 1H), 11.13 (s, 1H), 11.45 (br, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.6, 51.7, 54.9, 62.5, 63.1, 110.9, 112.1, 115.6, 118.6, 125.0, 132.4, 132.6, 136.1, 144.0, 154.7, 167.1, 168.4, 170.0, 172.8; Anal. calcd For C25H27ClN4O6.0.65H2O: C, 57.01; H, 5.42; N, 10.64. Found: C, 57.32; H, 5.30; N, 10.26.
    • 5.72 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-[3-(2-MORPHOLIN-4-YL-ETHOXY)-PHENYLAMINO]-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.72.1 4-[2-(3-Nitro-phenoxy)-ethyl]-morpholine
  • Figure US20070049618A1-20070301-C00335
  • A mixture of 3-nitrophenol (3.5 g, 25 mmol), N-(2-chloroethyl)morpholine hydrochloride (4.7 g, 25 mmol), and potassium carbonate (13.2 g, 125 mmol) in acetone (100 mL) was heated to reflux for 20 hours. The solvent was removed under vacuum. The residue was partitioned between water (150 mL) and ethyl acetate (150 mL) and the aqueous phase was extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (3×100 mL) and extracted with dilute aqueous HCl (2×125 mL). These extracts were washed with CH2Cl2 (2×125 mL), made basic (NaOH) and extracted into ethyl acetate (3×75 mL). These organic extracts were washed with water (3×75 mL), dried (MgSO4), and evaporated, providing 4.4 g, in 70% yield; 1H NMR (CDCl3) δ 2.59 (t, J=4.7 Hz, 4H), 2.84 (t, J=5.6 Hz, 2H), 3.75 (t, J=4.7 Hz, 4H), 4.19 (t, J=5.6 Hz, 2H), 7.22-7.25 (m, 1H), 7.43 (t, J=8.1 Hz, 1H), 7.76 (t, J=2.3 Hz, 1H), 7.82-7.85 (m, 1H).
    • 5.72.2 3-(2-Morpholin-4-yl-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00336
  • A mixture of 4-[2-(3-nitro-phenoxy)-ethyl]-morpholine (4.0 g, 13 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (100 mL) was hydrogenated under 50 psi hydrogen for 23 hours. The mixture was filtered through Celite, and the filtrate was evaporated in vacuo, providing 3.0 g, in 86% yield; 1H NMR (CDCl3) δ 2.58 (t, J=4.7 Hz, 4H), 2.78 (t, J=5.8 Hz, 2H), 3.65 (br, 2H), 3.73 (t, J=4.7 Hz, 4H), 4.07 (t, J=5.8 Hz, 2H), 6.24-6.34 (m, 3H), 7.05 (t, J=8.1 Hz, 1H).
    • 5.72.3 3-[3-(2-Morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00337
  • A mixture of 3-(2-morpholin-4-yl-ethoxy)-phenylamine (1.4 g, 6.1 mmol), 3-iodophthalic acid dimethyl ester (2.0 g, 6.2 mmol), Pd2(dba)3 (0.26 g, 0.28 mmol), rac-BINAP (0.12 g, 0.19 mmol), and cesium carbonate (2.8 g, 8.6 mmol), in 12 mL toluene was heated to reflux under nitrogen for 16 hours. The reaction mixture was cooled, diluted with CH2Cl2 (20 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (60 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 1.9 g of the product at 95:5 methylene chloride-methanol, in 73% yield; 1H NMR (CDCl3) δ 2.57 (t, J=4.6 Hz, 4H), 2.79 (t, J=5.7 Hz, 2H), 3.73 (t, J=4.6 Hz, 4H), 3.87 (s, 3H), 3.89 (s, 3H), 4.09 (t, J=5.7 Hz, 2H), 6.60 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 6.70 (t, J=2.1 Hz, 1H), 6.74 (dd, J=7.8 Hz, J=1.8 Hz, 1H), 7.11 (dd, J=7.4 Hz, J=1.0 Hz, 1H), 7.21 (t, J=8.1 Hz, 1H), 7.31 (t, J=8.0 Hz, 1H), 7.43 (dd, J=8.4 Hz, J=0.9 Hz, 1H), 7.98 (s, 1H).
    • 5.72.4 2-(2,6-Dioxo-piperidin-3-yl)-4-[3-(2-morpholin-4-yl-ethoxy)-phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00338
  • Step 1: A mixture of 3-[3-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (1.6 g, 3.9 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 2 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.64 g, 3.9 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue chromatographed in methylene chloride-methanol gradient, eluting 1.0 g at 93:7 methylene chloride-methanol, as an orange solid.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL), and a 4N solution of HCl in dioxane (2.0 mL) was added dropwise. The mixture stirred at room temperature for 1 hour and was then evaporated, providing 0.96 g as an orange solid, in 48% yield over 3 steps: mp 249-251° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=4.45 (99.53%); 1H NMR (DMSO-d6) δ 1.97-2.04 (m, 1H), 2.42-2.27 (m, 2H), 2.79-2.91 (m, 1H), 3.07-3.18 (m, 2H), 3.40-3.57 (m, 4H), 3.77-3.86 (m, 4H), 4.33-4.42 (m, 2H), 5.06 (dd, J=12.8 Hz, J=5.3 Hz, 1H), 6.69 (d, J=1.8 Hz, 1H), 6.89-6.92 (m, 2H), 7.20-7.28 (m, 2H), 7.46 (d, J=8.4 Hz, 1H), 7.58 (dd, J=8.6 Hz, J=7.1 Hz, 1H), 8.40 (s, 1H), 11.07 (s, 1H), 11.36 (br, 1H); 13C NMR (DMSO-d6) δ 22.1, 30.9, 48.7, 51.6, 54.8, 63.1, 66.3, 107.8, 110.1, 112.4, 113.7, 114.2, 119.9, 130.3, 132.4, 136.2, 140.9, 142.4, 158.4, 167.0, 168.2, 170.0, 172.8; Anal. calcd For C25H27ClN4O6.0.65H2O: C, 57.01; H, 5.42; N, 10.64. Found: C, 57.33; H, 5.42; N, 10.26.
    • 5.73 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-[2-METHOXY-4-(2-PIPERIDIN-1-YL-ETHOXY)-PHENYLAMINO]-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.73.1 1-[2-(3-Methoxy-4-nitro-phenoxy)-ethyl]-piperidine
  • Figure US20070049618A1-20070301-C00339
  • 1-Piperidineethanol (1.8 g, 14 mmol) was added to a mixture of powdered KOH (0.78 g, 14 mmol) and Aliquat 336 (0.56 g, 1.4 mmol), and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (2.0 g, 12 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (75 mL) and water (75 mL), and the organic phase was washed with water (75 mL) and extracted with dilute aqueous HCl (3×60 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 1.6 g, in 49% yield; 1H NMR (DMSO-d6) δ 1.48-1.53 (m, 6H), 2.40-2.44 (m, 4H), 2.67 (t, J=5.8 Hz, 2H), 3.93 (s, 3H), 4.21 (t, J=5.8 Hz, 2H), 6.67 (dd, J=9.3 Hz, J=1.5 Hz, 1H), 6.81 (d, J=1.5 Hz, 1H), 7.95 (d, J=9.3 Hz, 1H).
    • 5.73.2 2-Methoxy-4-(2-piperidin-1-yl-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00340
  • A mixture of 1-[2-(3-methoxy-4-nitro-phenoxy)-ethyl]-piperidine (1.5 g, 5.4 mmol) and 5% Pd—C (0.5 g) in ethyl acetate (70 mL) was shaken under 50 psi of hydrogen for 18 hours. The mixture was filtered through Celite and evaporated, providing 1.1 g of the product, in 81% yield: 1H NMR (DMSO-d6) δ 1.45-1.53 (m, 6H), 2.35-2.41 (m, 4H), 2.59 (t, J=6.0 Hz, 2H), 3.74 (s, 3H), 3.93 (t, J=6.0 Hz, 2H), 6.28 (dd, J=8.3 Hz, J=2.6 Hz, 1H), 6.45 (d, J=2.6 Hz, 1H), 6.63 (d, J=8.3 Hz, 1H).
    • 5.73.3 3-[2-Methoxy-4-(2-piperidin-1-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00341
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-methoxy-4-(2-piperidin-1-yl-ethoxy)-phenylamine (0.78 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 20 hours. The reaction mixture was cooled, diluted with CH2Cl2 (15 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (25 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 1.1 g of the product at 95:5 methylene chloride-methanol, in 78% yield; 1H NMR (DMSO-d6) δ 1.47-1.49 (m, 2H), 1.57-1.64 (m, 4H), 2.50-2.53 (m, 4H), 2.78 (t, J=6.2 Hz, 2H), 3.81 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.10 (t, J=6.2 Hz, 2H), 6.46 (dd, J=8.7 Hz, J=2.7 Hz, 1H), 6.56 (d, J=2.7 Hz, 1H), 6.98 (dd, J=7.2 Hz, J=1.2 Hz, 1H), 7.09-7.16 (m, 2H), 7.21-7.23 (m, 1H), 7.92 (br, 1H).
    • 5.73.4 2-(2,6-Dioxo-piperidin-3-yl)-4-[2-methoxy-4-(2-piperidin-1-yl-ethoxy)-phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00342
  • Step 1: A mixture of 3-[2-methoxy-4-(2-piperidin-1-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (1.0 g, 2.2 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.36 g, 2.2 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue chromatographed in methylene chloride-methanol gradient, eluting the product at 93:7 methylene chloride-methanol.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL) and a 4N solution of hydrogen chloride in dioxane (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo. The residue was triturated with ether and filtered, providing 0.63 g as an orange solid, in 53% yield over three steps: mp 210-212° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=4.22 (96.21%); 1H NMR (DMSO-d6) δ 1.37-1.91 (m, 6H), 2.05-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.85-3.02 (m, 3H), 3.46-3.53 (m, 4H), 3.82 (s, 3H), 4.48 (t, J=4.7 Hz, 2H), 5.12 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 6.65 (dd, J=8.6 Hz, J=2.3 Hz, 1H), 6.80 (d, J=2.1 Hz, 1H), 7.05 (d, J=8.7 Hz, 1H), 7.17 (d, J=6.9 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.57 (t, J=8.0 Hz, 1H), 8.00 (s, 1H), 10.85 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.1, 22.0, 22.2, 30.9, 48.6, 52.5, 54.5, 55.8, 62.6, 100.2, 105.6, 110.5, 112.3, 118.2, 120.9, 124.8, 132.0, 136.1, 143.9, 153.4, 155.9, 167.0, 168.8, 170.0, 172.7; Anal. calcd for C27H31ClN4O6.0.5H2O: C, 58.75; H, 5.84; N, 10.15. Found: C, 58.72; H, 5.90; N, 9.78.
    • 5.74 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-[2-METHOXY-4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINO]-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.74.1 1-[2-(3-Methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine
  • Figure US20070049618A1-20070301-C00343
  • 1-(2-Hydroxyethyl)pyrrolidine (1.6 g, 14 mmol) was added to a mixture of powdered KOH (0.78 g, 14 mmol) and Aliquat 336 (0.56 g, 1.4 mmol) and the resulting mixture was stirred for 5 minutes at 80° C. Then 4-fluoro-2-methoxy-1-nitrobenzene (2.0 g, 12 mmol) was added, and stirring proceeded at this temperature for 30 minutes. The mixture was cooled and partitioned between methylene chloride (75 mL) and water (75 mL), and the organic phase was washed with water (75 mL) and extracted with dilute aqueous HCl (3×60 mL). The combined aqueous phases were washed with methylene chloride (3×75 mL), basified (3N NaOH), and extracted with methylene chloride (3×75 mL). The combined organic extracts were washed with water (3×100 mL), dried (MgSO4), and evaporated, providing 2.4 g, in 76% yield; 1H NMR of the HCl salt (DMSO-d6) δ 1.83-2.01 (m, 4H), 3.04-3.19 (m, 4H), 3.58 (t, J=5.0 Hz, 2H), 3.94 (s, 3H), 4.51 (t, J=5.0 Hz, 2H), 6.74 (dd, J=9.0 Hz, J=2.4 Hz, 1H), 6.90 (d, J=2.4 Hz, 1H), 7.99 (d, J=9.0 Hz, 1H), 10.97 (br, 1H).
    • 5.74.2 2-Methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00344
  • A mixture of 1-[2-(3-methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine (2.2 g, 8.3 mmol) and 5% Pd—C (0.4 g) in ethyl acetate (70 mL) was shaken under 50 psi of hydrogen for 22 hours. The mixture was filtered through Celite and evaporated, providing 1.8 g of the product, in 89% yield; 1H NMR (DMSO-d6) δ 1.78-1.83 (m, 4H), 2.58-2.63 (m, 4H), 2.86 (t, J=6.0 Hz, 2H), 3.53 (by, 2H), 3.81 (s, 3H), 4.04 (t, J=6.0 Hz, 2H), 6.35 (dd, J=8.4 Hz, J=2.7 Hz, 1H), 6.49 (d, J=2.7 Hz, 1H), 6.61 (d, J=8.4 Hz, 1H).
    • 5.74.3 3-[2-Methoxy-4-(2-pyrrolidin-1-Yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00345
  • A mixture of 3-iodophthalic acid dimethyl ester (1.0 g, 3.1 mmol), 2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (0.73 g, 3.1 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol), rac-BINAP (0.058 g, 0.093 mmol), and cesium carbonate (1.4 g, 4.3 mmol), in 6 mL toluene was heated to reflux under nitrogen for 20 hours. The reaction mixture was cooled, diluted with CH2Cl2 (15 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (25 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 0.9 g of the product at 95:5 methylene chloride-methanol, in 69% yield; 1H NMR (DMSO-d6) δ 1.68-1.71 (m, 4H), 2.49-2.53 (m, 4H), 2.79 (t, J=5.9 Hz, 2H), 3.78 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.07 (t, J=5.9 Hz, 2H), 6.53 (dd, J=8.7 Hz, J=2.6 Hz, 1H), 6.69 (d, J=2.6 Hz, 1H), 6.92-6.98 (m, 2H), 7.14 (d, J=8.7 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 7.73 (s, 1H).
    • 5.74.4 2-(2,6-Dioxo-piperidin-3-yl)-4-[2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00346
  • Step 1: A mixture of 3-[2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (0.6 g, 1.4 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 3 hours. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.23 g, 1.4 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue chromatographed in methylene chloride-methanol gradient, eluting the product at 93:7 methylene chloride-methanol.
  • Step 3: The product from Step 2 was dissolved in 9:1 methylene chloride-methanol (20 mL) and a 4N solution of hydrogen chloride in dioxane (1.0 mL) was added. The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo. The residue was triturated with ether and filtered, providing 0.23 g as an orange solid, in 31% yield over three steps: mp 185-187° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=2.52 (95.82%); 1H NMR (DMSO-d6) δ 1.91-2.09 (m, 5H), 2.53-2.64 (m, 2H), 2.85-2.97 (m, 1H), 3.12 (t, J=5.0 Hz, 2H), 3.57-3.59 (m, 4H), 3.82 (s, 3H), 4.40 (t, J=5.0 Hz, 2H), 5.12 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 6.66 (dd, J=8.7 Hz, J=2.7 Hz, 1H), 6.82 (d, J=2.7 Hz, 1H), 7.05 (d, J=8.7 Hz, 1H), 7.17 (d, J=6.9 Hz, 1H), 7.34 (d, J=8.7 Hz, 1H), 7.57 (dd, J=8.4 Hz, J=7.2 Hz, 1H), 8.00 (s, 1H), 10.91 (br, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 22.5, 30.9, 48.6, 52.5, 53.6, 55.8, 63.6, 100.3, 105.6, 110.5, 112.3, 118.2, 120.9, 124.7, 132.0, 136.1, 143.9, 153.4, 155.9, 167.0, 168.8, 170.0, 172.7; Anal. calcd for C26H29ClN4O6.0.75H2O: C, 57.56; H, 5.67; N, 10.33. Found: C, 57.33; H, 5.67; N, 10.04.
    • 5.75 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-[2-FLUORO-4-(2-MORPHOLIN-4-YL-ETHOXY)-PHENYLAMINO]-ISOINDOLE-1,3-DIONE HYDROCHLORIDE 5.75.1 4-[2-(3-Fluoro-4-nitro-phenoxy)-ethyl]-morpholine
  • Figure US20070049618A1-20070301-C00347
  • A mixture of 3-fluoro-4-nitrophenol (1.6 g, 10 mmol), 4-(2-chloroethyl)morpholine hydrochloride (1.9 g, 10 mmol), and potassium carbonate (5.5 g, 52 mmol) in acetone (50 mL) was heated to reflux with stirring for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was partitioned between water (100 mL) and ethyl acetate (100 mL), and the organic phase was washed with water (100 mL) and brine (100 mL), was dried (MgSO4), and evaporated, providing 2.6 g, in 93% yield; 1H NMR (DMSO-d6) δ 2.47 (t, 4H, J=4.6), 2.71 (t, J=5.6 Hz, 2H), 3.57 (t, J=4.6, 4H), 4.25 (t, J=5.6 Hz, 2H), 6.99 (dd, J=9.3 Hz, J=2.7 Hz, 1H), 7.19-7.24 (m, 1H), 8.14 (t, J=9.3 Hz, 1H).
    • 5.75.2 2-Fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamine
  • Figure US20070049618A1-20070301-C00348
  • A mixture of 4-[2-(3-fluoro-4-nitro-phenoxy)-ethyl]-morpholine (2.4 g, 8.9 mmol) and 5% Pd—C (0.3 g) in ethyl acetate (70 mL) was shaken under 50 psi of hydrogen for 20 hours. The mixture was filtered through Celite and evaporated, providing 2.0 g of the product, in 94% yield; 1H NMR (DMSO-d6) δ 2.44 (t, J=4.5, 4H), 2.62 (t, J=5.8 Hz, 2H), 3.57 (t, J=4.5, 4H), 3.95 (t, J=5.8 Hz, 2H), 6.50-6.55 (m, 1H), 6.52-6.72 (m, 2H).
    • 5.75.3 3-[2-Fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00349
  • A mixture of 3-iodophthalic acid dimethyl ester (2.0 g, 6.2 mmol), 2-fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamine (1.5 g, 6.2 mmol), Pd2(dba)3 (0.26 g, 0.28 mmol), rac-BINAP (0.12 g, 0.19 mmol), and cesium carbonate (2.8 g, 8.6 mmol), in 12 mL toluene was heated to reflux under nitrogen for 18 hours. The reaction mixture was cooled, diluted with CH2Cl2 (15 mL), and filtered through Celite, and the filter was washed with additional CH2Cl2 (25 mL). The filtrate was evaporated in vacuo, and the residue was purified by ISCO silica gel flash chromatography using a methylene chloride-methanol gradient, eluting 2.5 g of the product at 95:5 methylene chloride-methanol, in 93% yield; 1H NMR (DMSO-d6) δ 2.47 (t, J=4.7, 4H), 2.69 (t, J=5.6 Hz, 2H), 3.58 (t, J=4.7, 4H), 3.80 (s, 6H), 4.10 (t, J=5.6 Hz, 2H), 6.76-6.83 (m, 2H), 6.97 (dd, J=12.6 Hz, J=2.7 Hz, 1H), 7.06 (dd, J=7.5 Hz, J=0.9 Hz, 1H), 7.23 (t, J=9.2 Hz, 1H), 7.34 (t, J=8.0 Hz, 1H), 7.69 (s, 1H).
    • 5.75.4 2-(2,6-Dioxo-piperidin-3-yl)-4-[2-fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamino]-isoindole-1,3-dione hydrochloride
  • Figure US20070049618A1-20070301-C00350
  • Step 1: A mixture of 3-[2-fluoro-4-(2-morpholin-4-yl-ethoxy)-phenylamino]-phthalic acid dimethyl ester (2.3 g, 5.3 mmol) and 3N NaOH (50 mL) in ethanol (100 mL) was heated to reflux for 90 minutes. The mixture was cooled, and the solvent was removed under vacuum. The residue was dissolved in water (100 mL), washed with ethyl acetate (3×75 mL), acidified to pH 2-3 (HCl) and evaporated, providing a crude product that was used directly in the next step.
  • Step 2: The product from Step 1 and rac-α-aminoglutarimide hydrochloride (0.87 g, 5.3 mmol) in pyridine (20 mL) were heated to reflux for 16 hours. The mixture was cooled and evaporated under vacuum. The residue was purified by ISCO silica gel flash chromatography in methylene chloride-methanol gradient, eluting the product at 92:8 methylene chloride-methanol. The appropriate fractions were pooled and treated with a 2N solution of hydrogen chloride in ethyl ether (10 mL). The mixture was stirred at room temperature for 1 hour, and was evaporated in vacuo. The residue was triturated with ether and filtered, providing 1.8 g as an orange solid, in 65% yield over two steps: mp 219-221° C.; HPLC, Waters Xterra RP18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 40/60 (CH3CN/0.1% HCO2NH4): tR=4.56 (98.82%); 1H NMR (DMSO-d6) δ 2.06-2.09 (m, 1H), 2.54-2.64 (m, 2H), 2.86-2.97 (m, 1H), 3.18-3.24 (m, 2H), 3.50-3.60 (m, 4H), 3.84-3.95 (m, 4H), 4.44-4.52 (m, 2H), 5.12 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 6.85 (dd, J=8.4 Hz, J=1.8 Hz, 1H), 6.93 (d, J=9.0 Hz, 1H), 7.11 (dd, J=12.3 Hz, J=1.8 Hz, 1H), 7.21 (d, J=7.2 Hz, 1H), 7.43 (t, J=9.2 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 8.18 (s, 1H), 11.14 (s, 1H), 11.39 (br, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 51.6, 54.7, 62.9, 63.1, 103.5 (d, J=23.4 Hz), 110.9, 111.5, 112.8, 118.6, 119.7, 130.3 (d, J=278 Hz), 136.2, 144.0, 155.5, 156.3, 158.8, 167.0, 168.4, 170.0, 172.8; Anal. calcd for C25H26ClFN4O6.1.6H2O: C, 59.25; H, 4.50; N, 10.91. Found: C, 59.06; H, 4.20; N, 10.80.
    • 5.76 4-(2,4-DIMETHOXY-PHENYLAMINO)-2-[(3S)-3-METHYL-2,6-DIOXO-PIPERIDIN-3-YL]-ISOINDOLE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00351
  • A mixture of 3-(2,4-dimethoxyphenylamino)phthalic acid (0.37 g, 1.2 mmol) and (3S)-3-amino-3-methyl-piperidine-2,6-dione hydrobromide (0.28 g, 1.2 mmol) in pyridine (10 mL) was heated to reflux for 24 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (100 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was purified by ISCO silica gel flash chromatography using a hexanes-ethyl acetate gradient, eluting 0.20 g of the product, an orange solid, at 50:50 hexanes-ethyl acetate, in 41% yield: mp 255-257° C.; HPLC, Waters Symmetry C-18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 65/35 (CH3CN/0.1% H3PO4): tR=2.72 (97.30%); 1H NMR (DMSO-d6) δ 1.91 (s, 3H), 2.05-2.08 (m, 1H), 2.59-2.73 (m, 3H), 3.79 (s, 6H), 6.57 (d, J=7.5 Hz, 1H), 6.71 (s, 1H), 6.97-7.08 (m, 2H), 7.27 (d, J=8.1 Hz, 1H), 7.52 (m, 1H), 7.94 (s, 1H), 11.01 (s, 1H); 13C NMR (DMSO-d6) δ 21.0, 28.6, 29.2, 55.4, 55.7, 58.5, 99.5, 104.7, 110.2, 111.8, 118.1, 120.1, 125.0, 131.9, 136.0, 144.0, 153.6, 157.9, 167.8, 169.8, 172.1, 172.4; Anal. calcd for C22H21N3O6.0.2H2O: C, 61.88; H, 5.05; N, 9.84. Found: C, 61.91; H, 5.01; N, 8.52.
    • 5.77 4-(INDAN-5-YLAMINO)-2-[(3S)-3-METHYL-2,6-DIOXO-PIPERIDIN-3-YL]-ISOINDOLE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00352
  • A mixture of 3-(indan-5-ylamino)-phthalic acid (0.62 g, 3.1 mmol) and (3S)-3-amino-3-methyl-piperidine-2,6-dione hydrobromide (0.50 g, 2.1 mmol) in pyridine (10 mL) was heated to reflux for 17 hours. The mixture was cooled and evaporated under vacuum. The residue was dissolved in ethyl acetate (100 mL), washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL), and evaporated. The residue was purified by ISCO silica gel flash chromatography using a hexanes-ethyl acetate gradient, eluting 0.37 g of the product, an orange solid, at 70:30 hexanes-ethyl acetate, in 45% yield: mp 200-202° C.; HPLC, Waters Symmetry C-18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 65/35 (CH3CN/0.1% H3PO4): tR=5.40 (99.54%); 1H NMR (DMSO-d6) δ 1.91 (s, 3H), 2.00-2.08 (m, 3H), 2.54-2.75 (m, 3H), 2.82-2.88 (m, 4H), 7.04-7.31 (m, 5H), 7.55 (t, J=7.8 Hz, 1H), 8.30 (s, 1H), 11.00 (s, 1H); 13C NMR (DMSO-d6) δ 21.0, 25.2, 28.6, 29.2, 31.8, 32.4, 58.5, 110.9, 112.4, 118.7, 120.7, 124.9, 132.2, 136.0, 137.2, 139.9, 143.4, 145.1, 167.8, 169.4, 172.2, 172.3; Anal. calcd for C23H21N3O4: C, 68.47; H, 5.25; N, 10.42. Found: C, 68.25; H, 5.12; N, 10.30.
    • 5.78 2-(2,6-DIOXO-PIPERIDIN-3-YL)-4-(3-METHOXY-PHENYLAMINO)-ISOINDOLE-1,3-DIONE 5.78.1 3-(3-Methoxy-phenylamino)-phthalic acid dimethyl ester
  • Figure US20070049618A1-20070301-C00353
  • A mixture of 3-iodo-phthalic acid dimethyl ester (1.0 g, 3.1 mmol), cesium carbonate (1.4 g, 4.3 mmol), Pd2(dba) (0.13 g, 0.14 mmol) and rac-BINAP (0.058 g, 0.093 mmol) in toluene (6 mL) was stirred at room temperature for 5 minutes. m-Anisidine (0.38 g, 3.1 mmol) was then added, and the reaction mixture was refluxed for 48 hours. The reaction mixture was diluted with methylene chloride (20 mL) and filtered through celite. The filter was washed with additional methylene chloride (25 mL). The combined filtrates were evaporated, and the residue was purified by ISCO silica gel flash chromatography using a hexanes-ethyl acetate gradient, eluting the product at 7:3 hexanes-ethyl acetate. It was then purified by preparative HPLC using an acetonitrile-water gradient, eluting the product at 6:4 acetonitrile:water to give the title product, 0.46 g in 47% yield; 1H NMR (CDCl3) δ 3.79 (s, 3H), 3.87 (s, 3H), 3.89 (s, 3H), 6.59-6.75 (m, 3H), 7.09-7.46 (m, 4H), 8.00 (s, 1H).
    • 5.78.2 3-(3-Methoxy-phenylamino)-phthalic acid
  • Figure US20070049618A1-20070301-C00354
  • A mixture of 3-(3-methoxy-phenylamino)-phthalic acid dimethyl ester (0.43 g, 1.4 mmol) and 3N NaOH (25 mL) in ethanol (50 mL) was heated to reflux for 2 hours and cooled to room temperature. The solvent was removed under vacuum and the residue was dissolved in water (50 mL), washed with CH2Cl2 (2×50 mL), and acidified with 6N HCl to pH 1-2. The resulting mixture was extracted with ethyl acetate (2×50 mL). The organic extracts were washed with water (2×50 mL) and dried (MgSO4). After filtration of the MgSO4, the solvent was evaporated in vacuo to give the product, 0.32 g, 82% yield; 1H NMR (DMSO-d6) δ 3.70 (s, 3H), 6.48 (dd, J=7.9 Hz, J=1.7 Hz, 1H), 6.62-6.64 (m, 2H), 7.11-7.44 (m, 4H), 7.92 (s, 1H), 13.12 (br, 2H).
    • 5.78.3 2-(2,6-Dioxo-piperidin-3-yl)-4-(3-methoxy-phenylamino)-isoindole-1,3-dione
  • Figure US20070049618A1-20070301-C00355
  • A mixture of 3-(3-methoxy-phenylamino)-phthalic acid (0.32 g, 1.1 mmol) and rac-α-aminoglutarimide hydrochloride (0.18 g, 1.1 mmol) in pyridine (10 mL) was heated to reflux for 15 hours. The reaction mixture was cooled, and the solvent was evaporated in vacuo. The residue was suspended in ethyl acetate (100 mL) and washed with dilute aqueous HCl (2×100 mL) and water (2×100 mL). Solvent was evaporated in vacuo. The residue was purified by ISCO silica gel flash chromatography using a methanol-methylene chloride gradient, eluting the product at 5:95 methanol-methylene chloride to give the title product (0.32 g, 76% yield): mp 210-212° C.; HPLC, Waters Symmetry C-18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 60/40 CH3CN/0.1% H3PO4, 2.70 (97.39%); 1H NMR (DMSO-d6) δ 2.04-2.08 (m, 1H), 2.49-2.64 (m, 2H), 2.84-2.94 (m, 1H), 3.75 (s, 3H), 5.13 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 6.71 (dd, J=8.4 Hz, J=2.2 Hz, 1H), 6.90-6.92 (m, 2H), 7.25-7.32 (m, 2H), 7.50 (d, J=8.4 Hz, 1H), 7.60-7.66 (m, 1H), 8.42 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.1, 31.0, 48.7, 55.1, 107.3, 109.6, 112.2, 113.6, 119.9, 130.2, 132.5, 136.2, 140.7, 142.6, 160.2, 167.0, 168.2, 170.0, 172.8; Anal. calcd for C20H17N3O5: C, 63.32; H, 4.52; N, 11.08. Found: C, 63.22; H, 4.51; N, 10.78.
    • 5.79 2-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]-N-METHYLACETAMIDE
  • Figure US20070049618A1-20070301-C00356
  • To a stirred solution of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.73 g, 2.2 mmol) in DMF (20 mL), were successively added HOBt (0.32 g, 2.4 mmol), DBU (0.38 g, 2.5 mmol), methylamine (0.062 g, 2.0 mmol) and EDC-CL (0.58 g, 3.0 mmol). The solution was stirred overnight at room temperature. The solvent was evaporated in vacuo, giving a yellow oil. The oil was dissolved in CH2Cl2 (100 mL), washed with water (3×50 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated in vacuo to give a yellow solid. This material was triturated with diethyl ether for 1 hour and then filtered, and the resulting solid was recrystallized from ethanol, and the recrystallized solid was rinsed with diethyl ether, providing 0.45 g (65%) of the product as a yellow solid: mp 239-241° C.; 1H NMR (DMSO-d6) δ 2.01-2.05 (m, 1H), 2.47-2.56 (m, 2H), 2.62 (d, J=4.5 Hz, 3H), 2.97-2.82 (m, 1H), 3.91 (d, J=5.6 Hz, 2H), 5.07 (dd, J=12.5 Hz, J=5.4 Hz, 1H), 6.86 (d, J=8.5 Hz, 1H), 6.95 (t, J=5.5 Hz, 1H), 7.07 (d, J=7.1 Hz, 1H), 7.60 (t, J=7.6 Hz, 1H), 8.00 (d, J=4.5 Hz, 1H), 11.10 (s, 1H); 13C NMR (DMSO-d6) δ 22.14, 25.53, 30.95, 45.16, 48.53, 109.87, 110.92, 117.38, 132.02, 136.19, 145.80, 167.28, 168.65, 168.87, 169.99, 172.76; Anal. calcd. for C16H16N4O5.0.15H2O.0.03 Et2O: C, 55.44; H, 4.79; N, 16.04. Found: C, 55.31; H, 4.56; N, 15.65.
    • 5.80 [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]ACETIC ACID METHYL ESTER
  • Figure US20070049618A1-20070301-C00357
  • To a stirred solution of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.66 g, 2.0 mmol) in DMF (20 mL), were added methyl iodide (0.34 g, 2.4 mmol) and potassium carbonate (0.33 g, 2.4 mmol). The mixture was stirred overnight at room temperature. The solvent was evaporated in vacuo, giving a yellow oil. The oil was dissolved in CH2Cl2 (100 mL), washed with sat. aq. sodium bicarbonate (100 mL), water (100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated in vacuo to give a yellow solid. This material was triturated with diethyl ether and then filtered, and the resulting solid was chromatographed, eluting with 9:1 methylene chloride-ethyl acetate. The resulting solid was triturated in 1:1 ethyl ether-water, filtered, and dried under high vacuum, providing 0.42 g (61%) of the product as a yellow solid: mp 210-212° C.; 1H NMR (DMSO-d6) δ 2.03-2.07 (m, 1H), 2.47-2.63 (m, 2H), 2.96-2.83 (m, 1H), 3.69 (s, 3H), 4.23 (d, J=6.0 Hz, 2H), 5.08 (dd, J=12.4 Hz, J=5.2 Hz, 1H), 6.91-7.11 (m, 3H), 7.61 (t, J=7.7 Hz, 1H), 11.12 (s, 1H); 13C NMR (DMSO-d6) δ 22.10, 30.96, 43.62, 48.51, 51.90, 109.76, 111.22, 117.65, 132.01, 136.09, 145.76, 167.21, 168.70, 170.12, 170.65, 172.77; Anal. calcd. for C16H15N3O6: C, 55.65; H, 4.38; N, 12.17. Found: C, 55.64; H, 4.28; N, 11.98.
    • 5.81 2-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]-N-METHYLACETAMIDE
  • Figure US20070049618A1-20070301-C00358
  • To a stirred solution of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.73 g, 2.2 mmol) in DMF (20 mL), were successively added HOBt (0.32 g, 2.4 mmol), DBU (0.38 g, 2.5 mmol), dimethylamine (90 mg, 2 mmol) and EDC-Cl (0.58 g, 3.0 mmol). The solution was stirred overnight at room temperature. The solvent was evaporated in vacuo, giving a yellow oil. The oil was dissolved in CH2Cl2 (200 mL), washed with water (3×100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated in vacuo to give a yellow solid. Following an ethanol trituration, the resulting solid was purified by preparative HPLC, giving 0.52 g of the product in 73% yield: mp 239-241° C.; 1H NMR (DMSO-d6) δ 2.02-2.06 (m, 1H), 2.47-2.63 (m, 2H), 2.83-3.01 (m, 7H), 4.15 (d, J=3.9 Hz, 2H), 5.08 (dd, J=12.6 Hz, J=5.3 Hz, 1H), 7.05-7.10 (m, 3H), 7.60 (t, J=8.1 Hz, 1H), 11.12 (s, 1H); 13C NMR (DMSO-d6) δ 22.12, 30.96, 35.04, 35.34, 45.53, 48.55, 109.48, 110.72, 118.13, 131.98, 136.12, 145.36, 167.31, 167.59, 168.75, 170.02, 172.76; Anal. calcd. for C17H18N4O5.0.3H2O: C, 56.13; H, 5.15; N, 15.40. Found: C, 56.17; H, 5.15; N, 15.26.
    • 5.82 N-CYCLOPROPYL-2-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]ACETAMIDE
  • Figure US20070049618A1-20070301-C00359
  • N-Methylmorpholine (0.15 g, 1.5 mmol) was added to a stirred suspension of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.50 g, 1.5 mmol) in 50 mL THF under nitrogen at room temperature. Ethyl chloroformate (0.16 g, 1.5 mmol) was then added. Following 30 minutes stirring at room temperature, cyclopropylamine (0.086 g, 1.5 mmol) was added, and stirring proceeded for 21 hours. The solvent was evaporated in vacuo, and the dark yellow residue was dissolved in ethyl acetate (200 mL) and washed with sat. sodium bicarbonate (2×100 mL), water (100 mL), 1N citric acid (2×100 mL), water (100 mL) and brine (100 mL). The organic phase was dried (MgSO4) and evaporated to provide 0.15 g (27%) of the product as a yellow solid: mp 240-242° C.; 1H NMR (DMSO-d6) δ 0.39-0.45 (m, 2H), 0.59-0.73 (m, 2H), 2.02-2.06 (m, 1H), 2.45-2.70 (m, 3H), 2.96-2.83 (m, 1H), 3.88 (d, J=5.3 Hz, 2H), 5.07 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 6.83-6.92 (m, 2H), 7.07 (d, J=7.0 Hz, 1H), 7.60 (t, J=7.9 Hz, 1H), 11.11 (s, 1H); 13C NMR (DMSO-d6) δ 5.57, 22.13, 22.26, 30.96, 44.92, 48.59, 109.77, 110.88, 117.42, 132.02, 136.17, 145.80, 167.28, 168.68, 169.46, 170.07, 172.77; Anal. calcd. for C18H18N4O5: C, 58.37; H, 4.90; N, 15.13. Found: C, 58.16; H, 4.64; N, 14.84.
    • 5.83 4-(2-(AZETIDIN-1-YL)-2-OXOETHYLAMINO)-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00360
  • To a stirred solution of [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]acetic acid (0.50 g, 1.5 mmol) in DMF (20 mL), were successively added HOBt (0.22 g, 1.7 mmol), DBU (0.63 g, 4.1 mmol), trimethylamine (0.15 g, 1.7 mmol) and EDC-Cl (0.38 g, 2.0 mmol). The solution was stirred overnight at room temperature. The solvent was evaporated in vacuo, and the residue was dissolved in ethyl acetate (200 mL), washed with water (100 mL), 0.1N HCl (100 mL), water (100 mL), and brine (100 mL), and was dried (MgSO4). The solvent was evaporated in vacuo, and the residue was chromatographed eluting with 3:2 ethyl acetate-methylene chloride, providing 0.15 g of the product in 27% yield: mp 272-274° C.; 1H NMR (DMSO-d6) δ 1.09-1.99 (m, 1H), 2.20-2.32 (m, 2H), 2.47-2.63 (m, 2H), 2.97-2.82 (m, 1H), 4.04-3.90 (m, 4H), 4.19 (t, J=7.5 Hz, 2H), 5.07 (dd, J=12.5 Hz, J=5.3 Hz, 1H), 6.86 (t, J=4.6 Hz, 1H), 6.99 (d, J=8.5 Hz, 1H), 7.07 (d, J=7.1 Hz, 1H), 7.60 (t, J=7.8 Hz, 1H), 11.12 (s, 1H); 13C NMR (DMSO-d6) δ 15.45, 22.11, 30.96, 41.82, 47.99, 48.56, 49.28, 109.58, 110.88, 117.90, 131.99, 136.13, 145.57, 167.28, 167.66, 168.75, 170.02, 172.77; Anal. calcd. for C19H20N4O5.0.15 EtOAc: C, 58.24; H, 5.05; N, 14.61. Found: C, 57.88; H, 4.81; N, 14.72.
    • 5.84 2-[2-(2,6-DIOXOPIPERIDIN-3-Y]L)-[3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLAMINO]-N-PHENYL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00361
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (4.2 g, 20 mmol) in CH2Cl2 (100 mL), were added glyoxylic acid (3.7 g, 40 mmol) and acetic acid (6.9 mL). The mixture was stirred for 5 minutes followed by addition of sodium triacetoxyborohydride (13 g, 60 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was washed with 0.1N HCl (3×100 mL) and brine (100 mL), and dried (MgSO4). The solvent was evaporated leaving an oily residue, which was dissolved in sat. aq. sodium bicarbonate (50 mL). This aqueous solution was washed with ethyl acetate (3×50 mL) and then acidified to pH 2-3 (conc. HCl). This mixture was extracted with ethyl acetate (3×100 mL). The combined extracts were washed with brine (100 mL), and dried (MgSO4). Evaporation provided 3.4 g of an off-white solid (63%).
  • Step 2: A sample of the product from step 1 (0.53 g, 2.0 mmol) was suspended in THF and cooled to 0° C. under nitrogen. N-Methylmorpholine (0.20 g, 2.0 mmol) was added, followed by ethyl chloroformate (0.22 g, 2.0 mmol). The mixture was stirred for 10 minutes, and then aniline (0.19 g, 2.0 mmol) was added. The mixture was stirred at room temperature for 2 hours and then at reflux for 1 hour. The solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was washed with water (3×100 mL), 0.1N HCl (50 mL), sat. sodium bicarbonate (100 mL) and brine (100 mL), and dried (MgSO4) and evaporated. The residue was chromatographed eluting with 7:3 hexanes-ethyl acetate, providing 0.51 g of the sample.
  • Step 3: The product from step 2 was added to a mixture of 5N KOH (3 mL) and methanol (20 mL), and the resulting mixture was stirred at room temperature for 18 hours. The solvent was evaporated, and the residue was dissolved in water (50 mL) and washed with ethyl acetate (50 mL). The aqueous phase was then acidified to pH 2-3 (conc. HCl) and then extracted with ethyl acetate (3×75 mL). The combined ethyl acetate extracts were washed with brine (100 mL) and dried (MgSO4). The solvent was evaporated in vacuo, affording 0.41 g of the sample.
  • Step 4: The product from step 3 and rac-α-aminoglutarimide hydrochloride (0.26 g, 1.6 mmol) were dissolved in pyridine (20 mL), and the resulting mixture was heated to reflux for 18 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (150 mL), washed with water (2×100 mL), sat. sodium bicarbonate (100 mL), and brine (100 mL), and dried (MgSO4). The solution was treated with Norite (˜1 g), stirred for 10 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow solid, which was purified by preparative HPLC, eluting with 7:3 water-acetonitrile, and providing 0.15 g as a yellow solid, 0.59 g of the product in 18% overall yield (final 3 steps): mp 267-268° C.; 1H NMR (DMSO-d6) δ 2.03-2.09 (m, 1H), 2.51-2.64 (m, 2H), 2.84-2.97 (m, 1H), 4.19 (d, J=5.3 Hz, 2H), 5.10 (dd, J=12.5 Hz, J=5.1 Hz, 1H), 6.95-7.10 (m, 4H), 7.32 (t, J=7.7 Hz, 2H), 7.60 (d, J=7.4 Hz, 3H), 10.22 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.15, 30.98, 45.62, 48.59, 109.81, 111.03, 117.60, 119.18, 123.40, 128.78, 132.06, 136.22, 138.70, 145.95, 167.30, 167.49, 168.74, 170.05, 172.80; Anal. calcd. for C21H18N4O5: C, 61.52; H, 4.52; N, 13.66. Found: C, 61.35; H, 4.29; N, 13.40.
    • 5.85 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-[(PYRIDIN-2-YLMETHYL) AMINO]ISOINDOLE-1,3-DIONE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00362
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH2Cl2 (40 mL), were added 2-pyridinecarboxaldehyde (0.86 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 50 mL of CH2Cl2, washed with water (3×100 mL), saturated aqueous sodium bicarbonate (2×100 mL), and brine (100 mL), and dried (MgSO4). The solvent was evaporated under vacuum. The resulting yellow oil was dissolved in diethyl ether and extracted with 0.1N HCl (2×100 mL). The combined extracts were washed with diethyl ether (2×100 mL) and then basified with saturated aqueous sodium carbonate. The combined aqueous phases were then extracted with diethyl ether (3×100 mL), and the combined ethereal extracts were washed with brine (100 mL), and dried (MgSO4). Upon evaporation of the solvent, 1.1 g (88%) of the sample was obtained.
  • Step 2: A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (20 mL), washed with diethyl ether (2×100 mL), and acidified to pH 2-3 (conc. HCl), and then evaporated once more, giving a white solid.
  • Step 3: The product from step 2 and rac-α-aminoglutarimide hydrochloride (0.66 g, 4.0 mmol) were dissolved in pyridine (40 mL), and the resulting mixture was heated to reflux for 5 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (100 mL), washed with water (3×100 mL) and brine (100 mL), and dried (MgSO4). The solution was treated with Norite (˜2 g), stirred for 30 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow semi-solid. This material was purified by preparative HPLC, running with 25:75 ACN—H2O, providing 0.72 g of the free base. This material was dissolved in 1:1 CH2Cl2-MeOH (30 mL) and treated with 4N HCl/dioxane (2 mL). After stirring for 10 minutes, the solvent was evaporated, and the resulting residue was recrystallized from ethanol (30 mL), providing 0.45 g of the product as a yellow solid, in 30% overall yield (3 steps): mp 254-256° C.; 1H NMR (DMSO-d6) δ 2.04-2.08 (m, 1H), 2.51-2.64 (m, 2H), 2.84-2.97 (m, 1H), 4.97 (s, 2H), 5.11 (dd, J=12.4 Hz, J=5.2 Hz, 1H), 7.10 (t, J=6.7 Hz, 2H), 7.56 (t, J=7.8 Hz, 2H), 7.86-7.79 (m, 2H), 8.37 (t, J=7.7 Hz, 1H), 8.81 (d, J=5.1 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.14, 30.97, 44.16, 48.61, 110.51, 111.62, 117.47, 124.27, 124.83, 132.28, 136.36, 143.39, 144.02, 145.29, 155.10, 167.18, 168.51, 170.04, 172.80; Anal. calcd. for C19H17ClN4O4.0.3H2O: C, 56.32; H, 4.23; N, 13.64. Found: C, 56.18; H, 4.37; N, 13.79.
    • 5.86 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-[(PYRIDIN-4-YLMETHYL) AMINO]ISOINDOLE-1,3-DIONE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00363
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH2Cl2 (40 mL), were added 4-pyridinecarboxaldehyde (0.86 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 60 mL of CH2Cl2, washed with water (3×100 mL), saturated aqueous sodium bicarbonate (3×100 mL), and brine (100 mL), and dried (MgSO4). The solvent was evaporated under vacuum. The resulting yellow oil was dissolved 0.2N HCl (60 mL). The aqueous solution was washed with diethyl ether (2×100 mL) and then basified with saturated aqueous sodium carbonate. The combined aqueous phases were then extracted with diethyl ether (3×100 mL), and the combined ethereal extracts were washed with brine (100 mL) and dried (MgSO4). Upon evaporation of the solvent, 0.58 g of the sample was obtained.
  • Step 2: A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated, and the resulting white solid was dissolved in water (20 mL), washed with diethyl ether (2×100 mL), and acidified to pH 2-3 (conc. HCl), and then evaporated once more, and the resulting solid was dried under high vacuum overnight.
  • Step 3: The product from step 2 and rac-α-aminoglutarimide hydrochloride (0.66 g, 4.0 mmol) were dissolved in pyridine (30 mL), and the resulting mixture was heated to reflux for 5 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (125 mL), washed with water (3×100 mL) and brine (100 mL), and dried (MgSO4). The solution was treated with Norite (˜3 g), stirred for 10 minutes, and filtered through Celite. The yellow filtrate was evaporated in vacuo to give a yellow solid, which was triturated with methanol (15 mL), filtered and dried. This material was suspended in MeOH and treated with 2N HCl/diethyl ether. After stirring for 10 minutes, the solvent was evaporated, and the resulting residue was dissolved in water (100 mL) and washed with ethyl acetate. The aqueous phase was then neutralized (sat. aq. NaHCO3) and extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried (MgSO4) and then treated with 2N HCl/diethyl ether (2 mL). The mixture was stirred for 10 minutes, and the solvent was removed under vacuum providing 0.25 g of the product as a yellow solid, in 16% overall yield (3 steps): mp 219-221° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.51-2.65 (m, 2H), 2.87-2.98 (m, 1H), 4.88 (s, 2H), 5.11 (dd, J=12.2 Hz, J=4.9 Hz, 1H), 6.89 (d, J=8.4 Hz, 1H), 7.10 (d, J=7.0 Hz, 1H), 7.49-7.55 (m, 2H), 8.04 (s, 2H), 9.05 (s, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 22.14, 30.96, 45.00, 48.59, 110.29, 111.46, 117.45, 132.35, 136.31, 141.53, 145.23, 159.69, 167.17, 168.49, 170.05, 172.81; Anal. calcd. for C19H17ClN4O4.0.35H2O.0.14 EtOAc: C, 56.01; H, 4.52; N, 13.36. Found: C, 55.65; H, 4.27; N, 13.36.
    • 5.87 4-[(FURAN-2-YLMETHYL)AMINO]-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE
  • Figure US20070049618A1-20070301-C00364
  • Step 1: To a stirred solution of dimethyl 3-aminophthalate (0.84 g, 4.0 mmol) in CH2Cl2 (40 mL), were added furfural (0.77 g, 8.0 mmol) and acetic acid (1.4 mL). The mixture was stirred for 5 minutes, followed by addition of sodium triacetoxyborohydride (2.5 g, 12 mmol). The mixture was stirred at ambient temperature overnight under an atmosphere of nitrogen. The reaction mixture was diluted with 60 mL of CH2Cl2 and washed with water (100 mL), saturated aqueous sodium bicarbonate (3×100 mL), and brine (100 mL), and dried (MgSO4). The solvent was evaporated, providing 0.97 g of the sample as a yellow oil.
  • Step 2: A mixture of the product from step 1 and 5N NaOH (8 mL) in methanol (20 mL) was stirred overnight. The solvent was evaporated and the resulting white solid was dissolved in water (50 mL), washed with diethyl ether (2×50 mL), and acidified to pH 2-3 (conc. HCl). The aqueous mixture was then extracted with ethyl acetate (3×75 mL). The combined organic extracts were washed with water (100 mL), brine (100 mL), and dried (MgSO4) and evaporated, providing a light brown-yellow oil.
  • Step 3: The product from step 2 and α-methyl-α-aminoglutarimide hydrochloride (0.71 g, 4.0 mmol) were dissolved in pyridine (30 mL), and the resulting mixture was heated to reflux for 20 hours. The mixture was cooled to ambient temperature, and the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (125 mL), washed with water (3×100 mL), 0.1N HCl (2×100 mL), and brine (100 mL), and dried (MgSO4). The solvent was evaporated in vacuo, and the resulting yellow solid was chromatographed eluting with 9:1 ethyl acetate-methylene chloride, providing 0.61 g of the product in 42% overall yield (3 steps): mp 158-160° C.; 1H NMR (DMSO-d6) δ 1.88 (s, 3H), 1.96-2.09 (m, 1H), 2.51-2.77 (m, 3H), 4.53 (d, J=5.8 Hz, 2H), 6.35-6.40 (m, 2H), 6.97-7.17 (m, 3H), 7.52-7.59 (m, 2H), 11.01 (s, 1H); 13C NMR (DMSO-d6) δ 20.99, 28.62, 29.24, 58.39, 107.41, 109.46, 110.43, 110.59, 117.35, 131.92, 135.97, 142.43, 145.61, 151.97, 167.92, 169.73, 172.21, 172.42; Anal. calcd. for C19H17N3O5: C, 62.07; H, 4.70; N, 11.22. Found: C, 62.12; H, 4.66; N, 11.44.
    • 5.88 1-ETHYL-3-[2-(3-METHYL-2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00365
  • Step 1: A mixture of 3-(t-butoxycarbonylamino-methyl)-phthalic acid (3.3 g, 11.2 mmol) and 3-amino-3-methyl-piperidine-2,6-dione hydrochloride (2.0 g, 11.2 mmol) in pyridine (40 mL) was refluxed for 17 hours. The mixture was cooled and concentrated. The residue was dissolved in EtOAc (200 mL) and water (50 mL). The organic layer was washed with water (40 mL), Sat. NaHCO3 (40 mL), water (40 mL), and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (Silica gel) to give [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamic acid t-butyl ester (2.3 g, 51%): 1H NMR (CDCl3) δ 1.43 (s, 9H, 3(CH3)), 2.08 (s, 3H, CH3), 2.10-2.15 (m, 1H), 2.69-2.84 (m, 3H), 4.62 (d, J=6.5 Hz, 2H, CH2), 5.46 (m, 1H, NH), 7.64-7.76 (m, 3H, Ar), 8.15 (s, 1H, NH).
  • Step 2: 2N HCl/ether solution (8.5 mL) was added to a stirred solution of [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-carbamic acid t-butyl ester (2.3 g, 5.7 mmol) in ethyl acetate (20 mL). The mixture was stirred at room temperature overnight. The mixture was filtered, and the solid was dried to gave 4-aminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.6 g, 80%) as a white solid: 1H NMR (DMSO-d6) δ 1.90 (s, 3H, CH3), 2.08 (m, 1H), 2.61-2.71 (m, 3H), 4.44 (M, 2H, CH2), 7.87-7.95 (m, 3H, Ar), 8.62 (s, 3H, NH3), 11.05 (s, 1H, NH); 13C NMR (DMSO-d6) δ 20.97, 28.52, 29.04, 36.98, 58.77, 123.14, 128.38, 131.10, 132.28, 134.64, 135.58, 167.31, 168.00, 171.93, 172.09.
  • Step 3: 1,8-Diazabicyclo[5,4,0]undec-7-ene (0.2 g, 2.2 mmol) was added to a stirred suspension of 4-aminomethyl-2-(3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.3 g, 1.0 mmol) in acetonitrile (40 mL). After stirring for 30 minutes, ethyl isocyanate (0.09 g, 1.3 mmol) was added, and the mixture was stirred at room temperature for 24 hours. The mixture was concentrated and the residue was dissolved in methylene chloride (60 mL). The methylene chloride solution was washed with water (2×30 mL) and brine (30 mL), and dried (MgSO4). Solvent was removed and purified by chromatography (silica gel) to give 1-ethyl-3-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.2 g, 55%) as a white solid: mp 220-222° C.; 1H NMR (DMSO-d6) δ 0.99 (t, J=7.1 Hz, 3H, CH3), 1.90 (s, 3H, CH3), 2.03-2.09 (m, 1H), 2.50-2.74 (m, 3H), 2.97-3.07 (m, 2H), 4.59 (d, J=5.8 Hz, 2H), 6.09 (t, J=5.0 Hz, 1H), 6.41 (t, J=5.6 Hz, 1H), 7.65-7.82(e, 3H, Ar), 11.01 (s, 1H, NH); 13C NMR (DMSO-d6) δ 15.59, 21.01, 28.58, 29.11, 34.16, 38.65, 58.69, 121.25, 126.64, 131.37, 133.26, 134.46, 140.79, 157.92, 167.78, 168.41, 172.14, 172.22; Anal. calcd. for C18H20N4O5+0.08H2O: C, 57.83; H, 5.44; N, 14.99. Found: C, 57.26; H, 5.21; N, 14.79.
    • 5.89 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(3-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00366
  • A suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.6 mmol) in THF (30 mL) was cooled to 5° C. 3-Methoxyphenyl isocyanate (0.4 g, 2.6 mmol) was added, and the mixture was stirred at room temperature 5 hours. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (80 mL). The CH2Cl2 solution was washed with 1N HCl (40 mL), water (40 mL), and brine (40 mL), and dried (MgSO4). Solvent was removed, and the solid was slurried with ethanol (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3 dihydro-1H-isoindol-4-ylmethyl]-3-(3-methoxy-phenyl)-urea (0.7 g, 80%) as a white solid: mp 160-162° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.50-2.65 (m, 2H), 2.85-2.99 (m, 1H), 3.69 (s, 3H, OCH3), 4.69 (d, J=5.2 Hz, 2H, CH2), 5.14-5.20 (dd, J=4.6 and 12.1 Hz, 1H, CH), 6.49 (d, J=7.9 Hz, 1H, Ar), 6.76-6.86 (m, 2H, Ar), 7.08-7.14 (m, 2H), 7.76-7.85 (m, 3H, Ar), 8.81 (s, 1H, NH), 11.16 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.99, 30.94, 38.72, 48.87, 54.82, 103.44, 106.70, 110.05, 121.86, 127.19, 129.36, 131.61, 133.62, 134.72, 140.23, 141.51, 155.15, 159.62, 167.01, 167.60, 169.82, 172.76; Anal. calcd. for C22H20N4O6: C, 60.55; H, 4.62; N, 12.84. Found: C, 60.18; H, 4.42; N, 12.63.
    • 5.90 1-(3-CHLORO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00367
  • A suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-sioindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.6 mmol) in THF (30 mL) was cooled to 5° C. 3-Chloro-phenyl isocyanate (0.4 g, 2.6 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (80 mL). The CH2Cl2 solution was washed with 1N HCl (40 mL), water (40 mL), and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was slurried with ethanol (10 mL) to give 1-(3-chloro-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.6 g, 65%) as a white solid: mp 193-195° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.49-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.70 (d, J=5.8 Hz, 2H, CH2), 5.13-5.20 (dd, J=5.3 and 12.5 Hz, 1H, CH), 6.84-6.96 (m, 2H), 7.16-7.27 (m, 2H), 7.66-7.68 (m, 1H), 7.75-7.88 (m, 3H), 9.04 (s, 1H, NH), 11.16 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.98, 30.93, 48.86, 116.07, 117.05, 120.79, 121.90, 127.21, 130.22, 131.60, 133.08, 133.64, 134.73, 139.98, 141.83, 155.02, 166.99, 167.59, 169.81, 172.75; Anal. calcd. for C21H17N4O5Cl+0.3C2H5OH: C, 57.06; H, 4.17; N, 12.32; Cl, 7.80. Found: C, 56.82; H, 4.21; N, 11.93; Cl, 7.46.
    • 5.91 1-(3-CYANO-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00368
  • A suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-sioindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.6 mmol) in THF (30 mL) was cooled to 5° C. 3-Cyano-phenyl isocyanate (0.4 g, 2.6 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (80 mL). The CH2Cl2 solution was washed with 1N HCl (2×25 mL), H2O (2×30 mL), and brine (30 mL), and dried (MgSO4). Solvent was removed, and the residue was slurried with ethanol (10 mL) to give 1-(3-cyano-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.7 g, 80%) as a white solid: mp 228-230° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.74 (d, J=5.8 Hz, 2H, CH2), 5.14-5.21 (dd, J=6.1 and 12.5 Hz, 1H, CH), 6.96 (t, J=5.9 Hz, 1H, NH), 7.36 (d, J=7.7 Hz, 1H, Ar), 7.43 (t, J=7.6 Hz, 1H, Ar), 7.57 (d, J=8.6 Hz, 1H, Ar), 7.76-7.94 (m, 4H, Ar), 9.20 (s, 1H, NH), 11.16 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.97, 30.92, 48.86, 111.44, 118.88, 120.19, 121.92, 122.29, 124.67, 127.22, 130.02, 131.60, 133.63, 134.73, 139.84, 141.17, 155.02, 166.97, 167.57, 169.80, 172.73; Anal. calcd. for C22H17N5O5+0.15H2O: C, 60.87; H, 4.02; N, 16.18. Found: C, 60.82; H, 3.94; N, 15.89.
    • 5.92 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(4-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00369
  • 4-Methoxyphenyl isocyanate (0.4 g, 2.6 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.8 mmol) in THF (30 mL) at 5-10° C. After 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL), and the mixture was concentrated. The residue was stirred with 1N HCl (30 mL) for one hour and then filtered. The solid was slurried with hot ethanol (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-(4-methoxy-phenyl)-urea (0.5 g, 59%) as a white solid: mp 205-207° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.49-2.65 (m, 2H), 2.84-2.97 (m, 1H), 3.68 (s, 3H, OCH3), 4.70 (d, J=5.7 Hz, 2H, CH2), 5.13-5.20 (dd, J=5.2 and 12.4 Hz, 1H, CH), 6.66 (t, J=5.7 Hz, 1H, NH), 6.79 (d, J=9.0 Hz, 2H, Ar), 7.27 (d, J=9.0 Hz, 2H, Ar), 7.75-7.88 (m, 3H, Ar), 8.59 (a, 1H, NH), 11.65 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.99, 30.94, 48.86, 55.10, 113.86, 119.50, 121.82, 127.15, 131.59, 133.38, 133.62, 134.70, 140.46, 154.03, 155.45, 167.02, 167.60, 169.84, 172.22; Anal. calcd. for C22H20N4O6: C, 60.55; H, 4.62; N, 12.84. Found: C, 60.43; H, 4.42; N, 12.58.
    • 5.93 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-(2-METHOXY-PHENYL)-UREA
  • Figure US20070049618A1-20070301-C00370
  • 2-Methoxyphenyl isocyanate (0.4 g, 2.6 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and triethylamine (0.3 g, 2.8 mmol) in THF (30 mL) at 5-10° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes. The solid was collected and slurried with hot methanol (15 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-(2-methoxy-phenyl)-urea (0.7 g, 80%) as a white solid: mp 214-216° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 3.83 (s, 3H, OCH3), 4.73 (d, J=5.7 Hz, 2H, CH2), 5.13-5.20 (dd, J=5.3 and 12.5 Hz, 1H, CH), 6.79-6.98 (m, 3H, Ar), 7.49 (t, H=5.7 Hz, 1H, NH), 7.77-7.89 (m, 3H, Ar), 8.04-8.08 (dd, J=1.4 and 7.3 Hz, 1H, Ar), 8.19 (s, 1H, NH), 11.15 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.99, 30.93, 48.86, 55.64, 110.59, 118.07, 120.42, 121.22, 121.88, 127.16, 129.20, 131.61, 133.65, 134.77, 140.112, 147.40, 155.24, 167.00, 167.50, 169.83, 172.76; Anal. calcd. for C22H20N4O6+0.66H2O: C, 58.94; H, 4.79; N, 12.50. Found: C, 59.24; H, 4.86; N, 12.74.
    • 5.94 1-(3,4-METHYLENEDIOXYPHENYL)-3-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]UREA
  • Figure US20070049618A1-20070301-C00371
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol), 3,4-methylenedioxyphenyl isocyanate (0.25 g, 1.6 mmol), and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at the same temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed, eluting with 95:5 methylene chloride-methanol, to provide 0.56 g of the product in 81% yield: mp 216-218° C.; 1H NMR (DMSO-d6) 62.05-2.09 (m, 1H), 2.50-2.58 (m, 2H), 2.84-2.91 (m, 1H), 4.69 (d, J=5.8 Hz, 2H), 5.16 (dd, J=12.4 Hz, d=5.1 Hz, 1H), 5.93 (s, 2H), 6.67-6.70 (m, 2H), 6.77 (d, J=8.4 Hz, 1H), 7.16 (d, J=1.6 Hz, 1H), 7.75-7.88 (m, 3H), 8.67 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.7, 48.9, 100.5, 100.6, 108.0, 110.4, 121.8, 127.2, 131.6, 133.6, 134.7, 134.8, 140.3, 141.5, 147.1, 155.3, 167.0, 167.6, 169.8, 172.8; Anal. calcd. for C22H18N4O5: C, 58.67; H, 4.03; N, 12.44. Found: C, 58.35; H, 3.95; N, 12.25.
    • 5.95 1-(3-CHLORO-4-METHYLPHENYL)-3-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]UREA
  • Figure US20070049618A1-20070301-C00372
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol), 3-chloro-4-methylphenyl isocyanate (0.26 g, 1.6 mmol), and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at the same temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed, eluting with 95:5 methylene chloride-methanol, to provide 0.63 g of the product in 90% yield: mp 238-240° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.22 (s, 3H), 2.49-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.70 (d, J=6.0 Hz, 2H), 5.17 (dd, J=12.5 Hz, d=5.3 Hz, 1H), 6.81 (t, J=6.0 Hz, 1H), 7.10 (dd, J=8.3 Hz, J=2.0 Hz, 1H), 7.18 (d, J=8.3 Hz, 1H), 7.65 (d, J=2.0 Hz, 1H), 7.75-7.85 (m, 3H), 8.90 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 18.7, 22.0, 30.9, 38.7, 48.9, 116.4, 117.6, 121.9, 127.2, 127.5, 131.0, 131.6, 133.0, 133.7, 134.7, 139.5, 140.1, 155.1, 167.0, 167.6, 169.8, 172.8; Anal. calcd. for C22H19ClN4O5.0.25H2O: C, 57.52; H, 4.27; N, 12.19. Found: C, 57.80; H, 4.33; N, 11.83.
    • 5.96 1-(3,4-DICHLOROPHENYL)-3-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]UREA
  • Figure US20070049618A1-20070301-C00373
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol), 3,4-dichlorophenyl isocyanate (0.29 g, 1.6 mmol), and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at the same temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed using a methylene chloride-methanol gradient, eluting with 97:3 methylene chloride-methanol, to provide 0.60 g of the product in 82% yield: mp 241-243° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.54-2.64 (m, 2H), 2.84-2.97 (m, 1H), 4.71 (d, J=6.0 Hz, 2H), 5.17 (dd, J=12.5 Hz, d=5.4 Hz, 1H), 6.92 (t, J=6.0 Hz, 1H), 7.25 (dd, J=8.8 Hz, J=2.5 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 7.75-7.88 (m, 4H), 9.15 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.8, 48.9, 117.8, 118.8, 121.9, 122.4, 127.2, 130.4, 130.9, 131.6, 133.7, 134.8, 139.9, 140.5, 154.9, 167.0, 167.6, 169.8, 172.8; Anal. calcd. for C21H16Cl2N4O5.0.25H2O: C, 52.57; H, 3.47; N, 11.68. Found: C, 52.78; H, 3.41; N, 11.37.
    • 5.97 1-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-NAPHTHALEN-1-YL-UREA
  • Figure US20070049618A1-20070301-C00374
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol), 1-naphthyl isocyanate (0.26 g, 1.6 mmol), and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at the same temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed, eluting with 95:5 methylene chloride-methanol, to provide 0.40 g of the product in 60% yield: mp 250-252° C.; 1H NMR (DMSO-d6) δ 2.06-2.11 (m, 1H), 2.51-2.65 (m, 2H), 2.85-2.97 (m, 1H), 4.78 (d, J=6.0 Hz, 2H), 5.18 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 7.23 (t, J=6.0, 1H), 7.41 (t, J=7.9 Hz, 1H), 7.49-7.58 (m, 3H), 7.80-7.91 (m, 4H), 7.98 (d, J=7.3, 1H), 8.12 (d, J=7.6 Hz, 1H), 8.81 (s, 1H), 11.20 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 31.0, 38.9, 48.9, 116.8, 121.4, 121.9, 122.3, 125.4, 125.7, 125.8, 125.9, 127.3, 128.3, 131.7, 133.7, 133.8, 134.8, 134.9, 140.2, 155.7, 167.0, 167.6, 169.8, 172.8; Anal. calcd. for C25H20N4O5.0.25H2O: C, 65.14; H, 4.48; N, 12.15. Found: C, 65.08; H, 4.48; N, 11.96.
    • 5.98 1-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-NAPHTHALEN-2-YL-UREA
  • Figure US20070049618A1-20070301-C00375
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol), 2-naphthyl isocyanate (0.26 g, 1.6 mmol), and diisopropylethylamine (0.40 g, 3.1 mmol) in 10 mL pyridine was warmed to 40° C. with stirring under N2, and the resulting solution was stirred at the same temperature for 2 hours. The mixture was cooled, and the solvent was evaporated under vacuum. The residue was chromatographed, eluting with 96:4 methylene chloride-methanol, to provide 0.46 g of the product in 70% yield: mp 201-203° C.; 1H NMR (DMSO-d6) δ 2.07-2.11 (m, 1H), 2.54-2.66 (m, 2H), 2.85-2.91 (m, 1H), 4.75 (d, J=6.0 Hz, 2H), 5.18 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 6.88 (t, J=6.0 Hz, 1H), 7.28-7.34 (m, 1H), 7.38-7.45 (m, 2H), 7.70-7.88 (m, 6H), 8.05 (d, J=1.6 Hz, 1H), 9.05 (s, 1H), 11.20 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 31.0, 38.8, 48.9, 112.7, 119.4, 121.9, 123.6, 126.2, 126.8, 127.2, 127.4, 128.3, 128.8, 131.7, 133.8, 134.8, 137.9, 140.2, 155.3, 167.0, 167.6, 169.8, 172.8; Anal. calcd. for C25H20N4O5.0.5H2O: C, 64.51; H, 4.54; N, 12.03. Found: C, 64.87; H, 4.88; N, 11.59.
    • 5.99 1-(3,4-DIMETHYL-PHENYL)-3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00376
  • 3,4-Dimethylphenyl isocyanate (0.4 g, 3.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.8 g, 2.3 mmol) and triethylamine (0.3 g, 3.2 mmol) in THF (40 mL) at 5° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes. The solid was collected and slurried with acetone (20 mL) to give 1-(3,4-dimethyl-phenyl)-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.8 g, 82%) as a white solid: mp 222-224° C.; 1H NMR (DMSO-d6) δ 2.05-2.08 (m, 1H), 2.12 (s, 3H), 2.14 (s, 3H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.70 (d, J=5.8 Hz, 2H), 5.13-5.20 (dd, J=5.3 and 12.6 Hz, 1H), 6.69 (t, J=5.9 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 7.08 (d, J=8.2 Hz, 1H), 7.17 (s, 1H), 7.75-7.88 (m, 3H), 8.57 (s, 1H), 11.14 (s, 1H); 13CNMR (DMSO-d6) δ 18.60, 19.61, 21.99, 30.94, 38.72, 48.86, 115.33, 119.13, 121.84, 127.18, 128.75, 129.51, 131.60, 133.68, 134.71, 136.11, 137.96, 140.40, 155.29, 167.03, 167.61, 169.84, 172.78; Anal. calcd. for C23H22N4O5: C, 63.59; H, 5.10; N, 12.90. Found: C, 63.21; H, 5.09; N, 12.74.
    • 5.100 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-M-TOLYL-UREA
  • Figure US20070049618A1-20070301-C00377
  • m-Tolyl isocyanate (0.4 g, 3.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.8 g, 2.3 mmol) and triethylamine (0.3 g, 3.2 mmol) in THF (40 mL) at 5° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes. The solid was collected and slurried with ether (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-m-tolyl-urea (0.7 g, 76%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.23 (s, 3H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.71 (d, J=6.0 Hz, 2H), 5.13-5.20 (dd, J=5.4 and 12.6 Hz, 1H), 6.70-6.77 (m, 2H), 7.05-7.17 (m, 2H), 7.25 (s, 1H), 7.75-7.88 (m, 3H), 8.70 (s, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 21.19, 21.99, 30.93, 38.71, 48.86, 114.90, 118.25, 121.85, 121.95, 127.18, 128.46, 131.60, 133.66, 134.71, 137.73, 140.18, 140.30, 155.22, 167.01, 167.59, 169.82, 172.76; Anal. calcd. for C22H20N4O5+0.5H2O: C, 61.53; H, 4.93; N, 13.05. Found: C, 61.87; H, 4.72; N, 12.92.
    • 5.101 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-PYRIDIN-2-YL-UREA
  • Figure US20070049618A1-20070301-C00378
  • Step 1: A solution of 2-aminopyridine (2.0 g, 21.3 mmol) in acetonitrile (20 mL) was added to a stirred suspension of N,N-disuccinimidyl carbonate (5.4 g, 21.3 mmol) in acetonitrile (150 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in methylene chloride (120 mL). The methylene chloride solution was washed with sat. NaHCO3 (40 mL), water (2×40 mL), brine (40 mL) and dried (MgSO4). Solvent was removed, and the residue was slurried with ether (30 mL) to give pyridin-2-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (2.5 g).
  • Step 2: 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.4 g, 2.4 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) in acetonitrile (50 mL). After stirring for 30 minutes, pyridin-2-yl-carbamic acid 2,5-dioxo-pyrrolidin-1-yl ester (0.7 g, 3.0 mmol) was added, and the mixture was stirred at room temperature overnight. The solid was collected and slurried with hot acetone (20 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-pyridin-2-yl-urea (0.5 g, 64%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.49-2.65 (m, 2H), 2.84-2.79 (m, 1H), 4.83 (d, J=6.1 Hz, 2H), 5.14-5.21 (dd, J=5.5 and 12.7 Hz, 1H), 6.91-6.96 (m, 1H), 7.33 (d, J=8.5 Hz, 1H), 7.64-7.88 (m, 4H), 8.17-8.20 (dd, J=1.3 and 5.0 Hz, 1H), 8.90 (t, J=5.7 Hz, 1H), 9.44 (s, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 21.96, 30.92, 38.67, 48.85, 93.31, 111.57, 116.91, 121.90, 127.20, 131.67, 133.43, 134.80, 138.23, 139.82, 146.69, 153.27, 154.93, 166.97, 167.49, 169.81, 172.75; Anal. calcd. for C20H17N5O5: C, 58.97; H, 4.21; N, 17.19. Found: C, 58.69; H, 4.10; N, 17.05.
    • 5.102 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-P-TOLYL-UREA
  • Figure US20070049618A1-20070301-C00379
  • p-Tolyl isocyanate (0.4 g, 3.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.8 g, 2.3 mmol) and triethylamine (0.3 g, 3.2 mmol) in THF (40 mL) at 5° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes. The solid was collected and slurried with hot ethanol (20 mL) to give 1-[2-(2,6-didoxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-p-tolyl-urea (0.8 g, 78%) as a white solid: mp 227-229° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.20 (s, 3H), 2.49-2.65 (m, 2H), 2.84-2.98 (m, 1H), 4.70 (d, J=6.0 Hz, 2H), 5.13-5.20 (dd, J=5.4 and 12.6 Hz, 1H), 6.71 (t, J=6.0 Hz, 1H), 7.03 (d, J=8.3 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 7.75-7.88 (m, 3H), 8.66 (s, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 20.26, 21.98, 30.93, 38.72, 48.85, 117.82, 121.83, 127.17, 129.01, 129.92, 131.60, 133.65, 134.70, 137.71, 140.34, 155.28, 167.02, 167.60, 169.83, 172.76; Anal. calcd. for C22H20N4O5: C, 62.85; H, 4.79; N, 13.33. Found: C, 62.61; H, 4.63; N, 13.26.
    • 5.103 1-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-O-TOLYL-UREA
  • Figure US20070049618A1-20070301-C00380
  • o-Tolyl isocyanate (0.4 g, 3.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.8 g, 2.3 mmol) and triethylamine (0.3 g, 3.2 mmol) in THF (40 mL) at 5° C. After stirring for 10 minutes at 5° C., the mixture was warmed to room temperature and stirred overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (30 mL) for 30 minutes. The solid was collected and slurried with hot acetone (15 mL) to give 1-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-o-tolyl-urea (0.7 g, 72%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.19 (s, 3H), 2.49-2.65 (m, 2H), 2.84-2.98 (m, 1H), 4.73 (d, J=5.9 Hz, 2H), 5.13-5.20 (dd, J=5.4 and 12.7 Hz, 1H), 6.85-7.19 (m, 4H), 7.77-7.92 (m, 5H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 13.90, 17.99, 26.93, 34.68, 44.86, 116.73, 117.88, 118.14, 122.03, 123.05, 123.18, 126.06, 127.61, 129.69, 130.75, 133.93, ‘36.25, 151.47, 163.00, 163.56, 165.83, 168.76; Anal. calcd. for C22H20N4O5: C, 62.85; H, 4.79; N, 13.33. Found: C, 62.76; H, 4.75; N, 13.12.
    • 5.104 [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-UREA
  • Figure US20070049618A1-20070301-C00381
  • Step 1: Potassium cyanate (1.9 g, 22.93 mmol) was added portionwise over 2 hours to a stirred solution of 3-aminomethyl-phthalic acid dimethyl ester hydrochloride (2.0 g, 7.7 mmol) in water (60 mL). After stirred for another 2 hours, the mixture was acidified to pH 4. The mixture was filtered to give 3-ureidomethyl-phthalic acid dimethyl ester (1.4 g, 70%): 1H NMR (DMSO-d6) δ 3.82 (s, 6H), 4.19 d, J=6.0 Hz, 2H), 5.63 (s, 2H), 6.38 (t, J=5.8 Hz, 1H), 7.54-7.62 (m, 2H), 7.78-7.81 (dd, J=2.2 and 6.4 Hz, 1H).
  • Step 2: A solution of sodium hydroxide (0.4 g, 10.5 mmol) in water (10 mL) was added to a stirred suspension of 3-ureidomethyl-phthalic acid dimethyl ester (1.4 g, 5.3 mmol) in ethanol (30 mL). The mixture was refluxed for one hour and then cooled to room temperature. The mixture was concentrated, and the residue was dissolved in water (30 mL). The mixture was acidified with 4N HCl to pH 1. The mixture was filtered to give 3-ureidomethyl-phthalic acid (1.0 g, 76%): 1H NMR (DMSO-d6) δ 4.22 (d, J=5.9 Hz, 2H, CH2), 5.68 (s, 2H, NH2), 6.40 (t, J=6.0 Hz, 1H, NH), 7.46-7.56 (m, 2H,Ar), 7.73 (d, J=6.9 Hz, 1H,Ar), 13.23 (b, 2H).
  • Step 3: A mixture of 3-ureidomethyl-phthalic acid (1.5 g, 6.1 mmol) and α-amino-glutarimide hydrochloride (1.0 g, 6.1 mmol) in pyridine (15 mL) was refluxed for 5 hours. The mixture was concentrated and the residue was stirred with water (20 mL). The solid was slurried with hot methanol to give [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea (0.7 g, 36%): mp 292-294° C.; 1H NMR (DMSO-d6) δ 2.04-2.08 (m, 1H), 2.50-2.63 (m, 2H), 2.83-2.98 (m, 1H), 4.61 (d, J=6.1 Hz, 2H, CH2), 5.11-5.18 (m, dd, J=5.3 and 12.5 Hz, 1H, CH), 5.71 (s, 2H, NH2), 6.57 (t, J=6.0 Hz, 1H,NH), 7.70-7.87 (m, 3H,Ar), 11.15 (s, 1H,NH); 13C NMR (DMSO-d6) δ 21.98, 30.92, 38.66, 48.82, 121.63, 126.95, 131.50, 133.32, 134.61, 141.06, 158.65, 167.04, 167.57, 169.82, 172.76; Anal. calcd. for C15H14N4O5: C, 54.44; H, 4.27; N, 16.96. Found: C, 54.47; H, 4.17; N, 16.76.
    • 5.105 3-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-1,1-DIMETHYL-UREA
  • Figure US20070049618A1-20070301-C00382
  • 1,8-Diazabicyclo[5,4,0]undec-7-ene (1.0 g, 6.8 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.0 g, 3.1 mmol) in acetonitrile (50 mL). The mixture was stirred for 30 minutes, then added slowly to a stirred solution of triphosgen (0.3 g, 1.1 mmol) in acetonitrile (20 mL) over 20 minutes. After stirring for another 10 minutes, a solution of dimethylamine/THF (2.0 M, 1.6 mL, 3.1 mmol) and diidopropylethylamine (0.5 g, 3.7 mmol) was added in one portion. The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in methylene chloride (80 mL). The methylene chloride solution was washed with 1N HCl (40 mL), water (40 mL), and brine (40 mL), and dried (MgSO4). Solvent was removed and purified by chromatography (silica gel) to give 3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-1,1-dimethyl-urea (0.4 g, 36%) as a white solid: mp 143-145° C.; 1H NMR (DMSO-d6) δ 2.04-2.08 (m, 1H), 2.50-2.63 (m, 2H), 2.84 (s, 6H, 2CH3), 2.84-2.96 (m, m, 1H), 4.68 (d, J=5.6 Hz, 2H, CH2), 5.11-5.18 (dd, J=5.2 and 121.5 Hz, 1H, CH), 6.98 (t, J=5.6 Hz, 1H, NH), 7.69-7.85 (m, 3H, Ar), 11.13 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.98, 30.93, 35.88, 39.30, 48.82, 121.45, 126.75, 131.38, 132.92, 134.56, 141.44, 148.14, 167.06, 167.63, 169.84, 172.75; Anal. calcd. for C17H18N4O5: C, 56.98; H, 5.06; N, 15.63. Found: C, 56.87; H, 5.16; N, 15.16.
    • 5.106 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-METHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00383
  • Triethylamine (0.5 g, 5.0 mmol) was added slowly to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and p-anisoyl chloride (0.5 g, 2.8 mmol) in THF (30 mL) at 5-10° C. After 10 minutes, the mixture was stirred at room temperature overnight. The reaction was quenched with methanol (1 mL), and the mixture was concentrated. The residue was stirred with 1N HCl (30 mL) for 1 hour then filtered. The solid was slurried with hot ethanol (15 mL) to give N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-methoxy-benzamide (0.6 g, 71%) as a white solid: mp 193-195° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 3.83 (s, 3H, OCH3), 4.93 (d, J=5.7 Hz, 2H, CH2), 5.14-5.21 (dd, J=5.4 and 12.7 Hz, 1H, CH), 7.04 (d, J=8.8 Hz, 2H, Ar), 7.69-7.86 (m, 3H, Ar), 7.89 (d, J=8.7 Hz, 2H, Ar), 9.01 (t, J=5.7 Hz, 1H, NH), 11.15 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.99, 30.94, 38.25, 48.87, 55.36, 113.57, 121.80, 126.10, 127.06, 129.15, 131.51, 133.00, 134.77, 139.63, 161.75, 166.08, 166.99, 167.56, 169.85, 172.77; Anal. calcd. for C22H19N3O6+0.34H2O: C, 61.81; H, 4.64; N, 9.83. Found: C, 61.77; H, 4.54; N, 9.63.
    • 5.107 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-METHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00384
  • Triethylamine (0.5 g, 5.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) and m-toluoyl chloride (0.4 g, 2.8 mmol) in THF (30 mL) at 5-10° C. After stirring at 5° C. for 10 minutes, the mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was stirred with 1N HCl (20 mL). The residue was dissolved in CH2Cl2 (80 mL), washed with H2O (30 mL) and brine (30 mL), and dried (MgSO4). Solvent was removed and the residue was purified by chromatography (silica gel) to N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3 dihydro-1H-isoindol-4-ylmethyl]-3-methyl-benzamide (0.5 g, 66%) as a white solid: mp 218-220° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.37 (s, 3H, CH3), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 4.94 (d, J=5.7 Hz, 2H, CH2), 5.14-5.21 (dd, J=5.4 and 12.7 Hz, 1H, CH), 7.37-7.41 (m, 2H, Ar), 7.72-7.86 (m, 5H, Ar), 9.10 (t, J=5.6 Hz, 1H, NH), 11.14 (s, 1H, NH); 13C NMR (DMSO-d6) δ 20.91, 21.98, 30.93, 38.30, 48.87, 121.82, 124.42, 127.10, 127.83, 128.24, 131.52, 131.98, 132.99, 133.92, 134.77, 137.64, 139.39, 166.71, 166.96, 167.53, 169.81, 172.73; Anal. calcd. for C22H19N3O5+0.04H2O: C, 65.06; H, 4.74; N, 10.35. Found: C, 64.75; H, 4.68; N, 10.02.
    • 5.108 3,4-DICHLORO-N-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]BENZAMIDE
  • Figure US20070049618A1-20070301-C00385
  • 3,4-Dichlorobenzoic acid (0.30 g, 1.6 mmol) was dissolved in 10 mL DMF and CDI (0.30 g, 1.9 mmol) was added. The mixture was stirred at 40° C. for 1 hour, and then 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.50 g, 1.6 mmol) and triethylamine (0.31 g, 3.1 mmol) were added. After an additional 90 minutes stirring at 40° C., the mixture was cooled. The solvent was evaporated, and the residue was dissolved in 60 mL CH2Cl2, and this solution was washed with water (2×60 mL), dried (MgSO4), and evaporated. The residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.49 g of the product with 98:2 methylene chloride-methanol, in 70% yield: mp 161-163° C.; 1H NMR (DMSO-d6) δ 2.06-2.09 (m, 1H), 2.51-2.58 (m, 2H), 2.84-2.91 (m, 1H), 4.94 (d, J=5.7 Hz, 2H), 5.17 (dd, J=12.6 Hz, d=5.3 Hz, 1H), 7.74-7.95 (m, 5H), 8.17 (d, J=1.9 Hz, 1H), 9.33 (t, J=5.7 Hz, 1H), 11.10 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.5, 48.9, 122.0, 127.2, 127.7, 129.3, 130.8, 131.3, 131.6, 133.3, 134.3, 134.9, 138.8, 164.4, 167.0, 167.5, 169.8, 172.8; Anal. calcd for C21H15Cl2N3O5: C, 54.80; H, 3.28; N, 9.13. Found: C, 54.85; H, 3.36; N, 8.95.
    • 5.109 ISOQUINOLINE-3-CARBOXYLIC ACID [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00386
  • A mixture of isoquinoline 3-carboxylic acid (0.39 g, 2.0 mmol) and thionyl chloride (10 mL) was heated to reflux for 1 hour. Excess thionyl chloride was removed under vacuum. To the acid chloride, was then added 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol), THF (30 mL) and triethylamine (0.61 g, 6.0 mmol), and the resulting mixture was stirred at reflux for 90 minutes. The solvent was evaporated and the crude residue was chromatographed using a methylene chloride-methanol gradient, eluting 0.67 g of the product with 96:4 methylene chloride-methanol, in 76% yield: mp 198-200° C.; 1H NMR (DMSO-d6) δ 2.07-2.11 (m, 1H), 2.53-2.66 (m, 2H), 2.85-2.97 (m, 1H), 5.02 (d, J=6.3 Hz, 2H), 5.19 (dd, J=12.6 Hz, d=5.3 Hz, 1H), 7.71-7.92 (m, 5H), 8.21 (d, J=7.8 Hz, 1H), 8.28 (d, J=7.8 Hz, 1H) 8.59 (s, 1H), 9.43 (s, 1H), 9.65 (t, J=6.3 Hz, 1H), 11.17 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 31.0, 38.5, 48.9, 120.0, 121.9, 127.2, 127.8, 128.0, 129.2, 129.3, 131.4, 131.6, 133.0, 134.8, 135.4, 139.2, 143.4, 151.7, 164.7, 167.0, 167.6, 169.9, 172.8; Anal. calcd for C24H18N4O5.0.5H2O: C, 63.85; H, 4.24; N, 12.41. Found: C, 63.85; H, 3.93; N, 12.31.
    • 5.110 5-BUTYLPYRIDINE-2-CARBOXYLIC ACID [2-(2,6-DIOXO PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00387
  • A mixture of fusaric acid (0.36 g, 2.0 mmol) and thionyl chloride (10 mL) was heated to reflux for 1 hour. Excess thionyl chloride was removed under vacuum. To the acid chloride, was then added 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol), THF (30 mL) and triethylamine (0.61 g, 6.0 mmol), and the resulting mixture was stirred at room temperature for 16 hours. The solvent was evaporated, and the crude residue was chromatographed using a methylene chloride-methanol gradient, eluting the product with 95:5 methylene chloride-methanol. This material was further purified by preparative HPLC, eluting with 1:1 acetonitrile-water, providing 0.58 g of the purified product in 64% yield: mp 137-139° C.; 1H NMR (DMSO-d6) δ 0.91 (t, J=7.3 Hz, 3H), 1.24-1.39 (m, 2H), 1.54-1.65 (m, 2H), 2.06-2.10 (m, 2H), 2.51-2.72 (m, 4H), 2.84-2.97 (m, 1H), 4.94 (d, J=6.4 Hz, 2H), 5.17 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 7.66-7.71 (m, 1H), 7.77-7.86 (m, 3H), 7.97 (d, J=8.0 Hz, 1H), 8.54 (d, J=1.7 Hz, 1H), 9.43 (t, J=6.4 Hz, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 13.7, 21.6, 22.0, 31.0, 31.7, 32.6, 38.5, 48.9, 121.8, 121.9, 127.2, 131.6, 133.0, 134.8, 137.3, 139.2, 141.2, 147.5, 148.5, 164.5, 167.0, 167.6, 169.9, 172.8; Anal. calcd for C24H24N4O5.0.3H2O: C, 63.51; H, 5.46; N, 12.34. Found: C, 63.52; H, 5.55; N, 12.05.
    • 5.111 6-BROMOPYRIDINE-2-CARBOXYLIC ACID [2-(2,6-DIOXO PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00388
  • A mixture of 6-bromopicolinic acid (0.40 g, 2.0 mmol) and CDI (0.39 g, 2.4 mmol) in DMF (25 mL) was stirred at ambient temperature under nitrogen for 2 hours. 4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) were added, and the mixture was allowed to stir for 16 hours. The solvent was evaporated under vacuum, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting the product with 97:3 methylene chloride-methanol. This material was further purified by preparative HPLC, eluting with 1:1 acetonitrile-water, providing 0.50 g of the purified product in 53% yield: mp 181-183° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.52-2.65 (m, 2H), 2.84-2.93 (m, 1H), 4.96 (d, J=6.3 Hz, 2H), 5.17 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 7.67-7.72 (m, 1H), 7.80-7.82 (m, 2H), 7.90 (dd, J=7.8 Hz, J=1.0 Hz, 1H), 7.97 (t, J=7.6 Hz, 1H), 8.07 (dd, J=7.3 Hz, J=1.1 Hz, 1H), 9.39 (t, J=6.3 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.5, 48.9, 121.7, 121.9, 127.1, 131.2, 131.6, 133.0, 134.8, 138.9, 140.3, 141.0, 151.0, 163.1, 167.0, 167.6, 169.8, 172.8; Anal. calcd for C20H15BrN4O5.0.5H2O: C, 50.01; H, 3.35; N, 11.66. Found: C, 49.97; H, 3.21; N, 11.56.
    • 5.112 6-METHYLPYRIDINE-2-CARBOXYLIC ACID [2-(2,6-DIOXO PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00389
  • A mixture of 6-methylpicolinic acid (0.27 g, 2.0 mmol) and CDI (0.39 g, 2.4 mmol) in DMF (25 mL) was stirred at ambient temperature under nitrogen for 1 hour. 4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) were added, and the mixture was allowed to stir for 16 hours. The solvent was evaporated under vacuum, and the residue was purified by preparative HPLC, eluting with 45:55 acetonitrile-water, providing 0.34 g of the product in 54% yield: mp 197-199° C.; 1H NMR (DMSO-d6) δ 2.06-2.11 (m, 1H), 2.53-2.65 (m, 2H), 2.58 (s, 3H), 2.84-2.94 (m, 1H), 4.96 (d, J=6.3 Hz, 2H), 5.18 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 7.49 (dd, J=6.8 Hz, J=1.9 Hz, 1H), 7.69 (dd, J=8.5 Hz, J=4.1 Hz, 1H), 7.79-7.93 (m, 4H), 9.36 (t, J=6.3 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 23.9, 30.9, 38.3, 48.9, 119.2, 121.9, 126.3, 127.2, 131.6, 133.0, 134.8, 137.9, 139.2, 149.0, 157.3, 164.5, 167.0, 167.6, 169.8, 172.8; Anal. calcd for C21H18N4O5.0.6H2O: C, 60.45; H, 4.63; N, 13.42. Found: C, 60.47; H, 4.53; N, 13.36.
    • 5.113 PYRAZINE-2-CARBOXYLIC ACID [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00390
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.63 g, 1.9 mmol), 2-pyrazinecarbonylchloride (0.25 g, 1.9 mmol) and triethylamine (0.61 g, 6.0 mmol) in THF (30 mL) was stirred at ambient temperature under nitrogen for 18 hours. The mixture was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting the product with 95:5 methylene chloride-methanol. This material dissolved in 4 mL acetonitrile, and this solution was poured into 50 mL of water, resulting in precipitation of the product, which was filtered, washed with additional water (20 mL), and dried, providing 0.46 g (61% yield): mp >260° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.54-2.65 (m, 2H), 2.84-2.91 (m, 1H), 4.97 (d, J=6.3 Hz, 2H), 5.18 (dd, J=12.0 Hz, d=5.4 Hz, 1H), 7.69-7.83 (m, 3H), 8.29 (t, J=1.9 Hz, 1H), 8.91 (d, J=2.5 Hz, 1H), 9.21 (d, J=1.4 Hz, 1H), 9.61 (t, J=6.3 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.3, 48.9, 121.9, 127.2, 131.2, 131.6, 133.0, 134.7, 143.5, 143.6, 144.5, 147.7, 163.4, 167.0, 167.6, 169.8, 172.8; Anal. calcd for C19H15N5O5.0.5H2O: C, 56.71; H, 4.01; N, 17.41. Found: C, 56.64; H, 3.75; N, 17.28.
    • 5.114 QUINOXALINE-2-CARBOXYLIC ACID [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00391
  • A mixture of 2-quinoxalinecarboxylic acid (0.35 g, 2.0 mmol) and CDI (0.39 g, 2.4 mmol) in DMF (25 mL) was stirred at ambient temperature under nitrogen for 90 minutes. 4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) were added, and the mixture was allowed to stir for 16 hours. The mixture was poured into water, resulting in precipitation of the product, which was filtered, washed with additional water (40 mL) and dried, providing 0.61 g, in 69% yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.07-2.12 (m, 1H), 2.56-2.65 (m, 2H), 2.85-2.98 (m, 1H), 5.05 (d, J=6.3 Hz, 2H), 5.19 (dd, J=12.6 Hz, d=5.4 Hz, 1H), 7.78-7.83 (m, 3H), 7.98-8.04 (m, 2H), 8.19-8.24 (m, 2H), 9.50 (s, 1H), 9.76 (t, J=6.3 Hz, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.4, 48.9, 121.9, 127.2, 129.1, 129.4, 131.3, 131.6, 132.0, 133.1, 134.8, 138.7, 139.8, 143.0, 143.8, 144.1, 163.7, 167.0, 167.6, 169.8, 172.8; Anal. calcd for C23H17N5O5.0.5H2O: C, 61.06; H, 4.01; N, 15.47. Found: C, 61.19; H, 3.95; N, 15.37.
    • 5.115 PYRIMIDINE-5-CARBOXYLIC ACID [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE
  • Figure US20070049618A1-20070301-C00392
  • A mixture of pyrimidine-5-carboxylic acid (0.25 g, 2.0 mmol) and CDI (0.39 g, 2.4 mmol) in DMF (25 mL) was stirred at ambient temperature under nitrogen for 2 hours. 4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) were added, and the mixture was allowed to stir for 16 hours. The solvent was evaporated under vacuum, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting with 95:5 methylene chloride-methanol, providing 0.39 g of the product in 50% yield: mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.10 (m, 1H), 2.53-2.65 (m, 2H), 2.83-2.91 (m, 1H), 4.98 (d, J=5.7 Hz, 2H), 5.18 (dd, J=12.4 Hz, d=5.4 Hz, 1H), 7.84 (s, 3H), 9.24 (s, 2H), 9.35 (s, 1H), 9.52 (t, J=5.7 Hz, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.3, 48.9, 122.1, 127.3, 127.5, 131.6, 133.4, 134.9, 138.4, 156.0, 160.1, 163.5, 167.0, 167.5, 169.8, 172.8; Anal. calcd for C19H15N5O5.0.3H2O: C, 57.23; H, 3.94; N, 17.56. Found: C, 57.27; H, 3.71; N, 17.27.
    • 5.116 2,5-DICHLORO-N-[2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]NICOTINAMIDE
  • Figure US20070049618A1-20070301-C00393
  • A mixture of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol), 2,5-dichloropyridine-3-carbonyl chloride (0.42 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) in THF (30 mL) was stirred at ambient temperature under nitrogen for 18 hours. The mixture was evaporated, and the residue was chromatographed using a methylene chloride-methanol gradient, eluting with 95:5 methylene chloride-methanol, providing 0.50 g of the product (54% yield): mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.53-2.58 (m, 2H), 2.83-2.97 (m, 1H), 4.93 (d, J=5.7 Hz, 2H), 5.17 (dd, J=12.5 Hz, d=5.3 Hz, 1H), 7.82-7.91 (m, 3H), 8.28 (d, J=2.5 Hz, 1H), 8.61 (d, J=2.5 Hz, 1H), 9.35 (t, J=5.7 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 30.9, 38.3, 48.9, 122.1, 127.3, 130.3, 131.6, 133.4, 134.9, 137.8, 138.0, 145.0, 148.8, 164.1, 166.9, 167.5, 169.8, 172.8; Anal. calcd for C20H14Cl2N4O5.0.2H2O: C, 51.68; H, 3.12; N, 12.05. Found: C, 51.64; H, 3.05; N, 11.98.
    • 5.117 6-(3-ETHOXY-4-METHOXYPHENYL)PYRIDINE-2-CARBOXYLIC ACID [2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]AMIDE 5.117.1 3-Ethoxy-4-Methoxyphenylboronic Acid
  • Figure US20070049618A1-20070301-C00394
  • A mixture of 4-Bromo-2-ethoxy-1-methoxybenzene (4.00 g, 17.3 mmol) in THF (75 mL) was cooled to −78° C.; during cooling, a precipitate formed. t-BuLi (22.4 mL, 1.7 M in pentane, 38.1 mmol) was added dropwise, while maintaining the temperature at −78° C. The mixture was stirred at −78° C. for 1 hour following completion of the addition. B(Oi-Pr)3 (9.76 g, 51.9 mmol) was added. The mixture was allowed to gradually warm to room temperature, and then stirred under nitrogen for 16 hours. 3N HCl (20 mL) was added, and the mixture stirred for 10 minutes. The mixture was poured into water (100 mL) and extracted with diethyl ether (3×75 mL), and the combined ethereal layers were washed with water (3×75 mL), dried (MgSO4) and evaporated, providing 3.15 g of the product in 93% yield: 1H NMR (DMSO-d6) δ 1.32 (t, J=7.0 Hz, 3H), 3.75 (s, 3H), 3.99 (q, J=7.0 Hz, 2H), 6.90 (d, J=8.3 Hz, 1H), 7.35-7.37 (m, 2H).
    • 5.117.2 3′-Ethoxy-4′-Methoxybiphenyl-3-Carboxylic Acid
  • Figure US20070049618A1-20070301-C00395
  • 6-Bromonicotinic acid (2.02 g, 10.0 mmol) was dissolved in DME (80 mL) under nitrogen. Pd(PPh3)4 (0.58 g, 0.5 mmol) was added, and the resulting mixture was stirred at ambient temperature for 15 minutes. 3-ethoxy-4-methoxyphenylboronic acid (2.4 g, 12.2 mmol) and 2N Na2CO3 (40 mL, 80 mmol) were added, and the resulting mixture was heated to reflux with stirring for 24 hours. The mixture was poured into 300 mL of water and extracted with ethyl acetate (3×200 mL), and the product precipitated upon standing, providing 2.05 g of the product in 76% yield: 1H NMR (CDCl3) δ 1.53 (t, J=7.0 Hz, 3H), 3.96 (s, 3H), 4.22 (q, J=7.0 Hz, 2H), 7.00 (d, J=8.6 Hz, 1H), 7.53-7.58 (m, 2H), 7.91-8.02 (m, 2H), 8.12 (dd, J=6.9 Hz, J=1.5 Hz, 1H).
    • 5.117.3 6-(3-Ethoxy-4-Methoxyphenyl)Pyridine-2-Carboxylic Acid [2-(2,6-Dioxopiperidin-3-yl)-1,3-Dioxo-2,3-Dihydro-1H-Isoindol-4-yl-Methyl]Amide
  • Figure US20070049618A1-20070301-C00396
  • A mixture of 3′-ethoxy-4′-methoxybiphenyl-3-carboxylic acid (0.55 g, 2.0 mmol) and CDI (0.39 g, 2.4 mmol) in DMF (30 mL) was stirred at ambient temperature under nitrogen for 90 minutes. 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride (0.65 g, 2.0 mmol) and triethylamine (0.61 g, 6.0 mmol) were added, and the mixture was allowed to stir for 3 hours. The mixture was poured into water (200 mL) and extracted with ethyl acetate (3×100 mL). The combined organic phases were washed with water (3×150 mL), dried (MgSO4), and evaporated, providing 0.75 g of the product as a pale yellow solid (69% yield): mp 196-198° C.; 1H NMR (DMSO-d6) δ 1.36 (t, J=6.9 Hz, 3H), 2.05-2.10 (m, 1H), 2.54-2.64 (m, 2H), 2.85-2.98 (m, 1H), 3.83 (s, 3H), 4.18 (q, J=6.3 Hz, 2H), 5.02 (d, J=6.3 Hz, 2H), 5.20 (dd, J=12.7 Hz, d=5.4 Hz, 1H), 7.06 (d, J=8.5 Hz, 1H), 7.74-7.83 (m, 4H), 7.87-7.94 (m, 2H), 8.03 (t, J=7.8 Hz, 1H), 8.16 (d, J=7.7 Hz, 1H), 9.56 (t, J=6.3 Hz, 1H), 11.18 (s, 1H); 13C NMR (DMSO-d6) δ 14.8, 22.0, 31.0, 38.6, 49.0, 55.5, 64.0, 111.8, 119.8, 120.0, 122.0, 122.4, 127.3, 130.1, 131.7, 133.3, 134.9, 138.6, 139.1, 148.2, 149.2, 150.5, 155.1, 164.5, 167.0, 167.8, 169.8, 172.7; Anal. calcd for C29H26N4O7.0.5H2O: C, 63.15; H, 4.93; N, 10.16. Found: C, 63.36; H, 4.80; N, 10.19.
    • 5.118 1H-INDOLE-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00397
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.8 g, 5.0 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) in DMF (30 mL). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.3 g, 2.4 mmol) and indole-2-carboxylic acid (0.4 g, 2.2 mmol) were added. The reaction was initiated by adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.0 mmol) and stirred at room temperature overnight. The mixture was poured into cold water (120 mL) and extracted with EtOAc (3×50 mL). The combined EtOAc solution was washed with water (3×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the solid residue was slurried with hot acetone (20 mL) to give 1H-indole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.6 g, 70%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.08-2.11 (m, 1H), 2.56-2.65 (m, 2H), 2.85-2.98 (m, 1H), 4.99 (d, J=5.5 Hz, 2H), 5.15-5.22 (dd, J=5.4 and 12.7 Hz, 1H), 7.05 (t, J=7.5 Hz, 1H), 7.16-7.22 (m, 3H), 7.42 (d, J=8.1 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.75-7.83 (m, 3H), 9.15 (t, J=5.4 Hz, 1H), 11.15 (s, 1H), 11.64 (s, 1H); 13C NMR (DMSO-d6) δ 22.00, 30.34, 37.92, 48.89, 102.95, 112.31, 119.78, 121.54, 121.92, 123.45, 127.04, 127.14, 131.18, 131.57, 133.06, 134.33, 136.54, 139.29, 161.52, 166.97, 167.55, 169.83, 172.75; Anal. calcd. for C23H18N4O5+0.24H2O: C, 63.54; H, 4.28; N, 12.89. Found: C, 63.39; H, 4.38; N, 12.80.
    • 5.119 1,5-DIMETHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00398
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 g, 6.6 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) in acetonitrile (40 mL). After stirring for 10 minutes, 1,5-dimethyl-1H-pyrazole-3-carbonyl chloride (0.4 g, 2.6 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (80 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (SiO2, CH2Cl2:CH3OH 97.5:2.5) to give 1,5-dimethyl-1H-pyrazole-3-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.3 g, 38%) as a white solid: mp 213-215° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.28 (s, 3H), 2.50-2.64 (m, 2H), 2.84-2.97 (m, 1H), 3.79 (s, 3H), 4.86 (d, J=5.9 Hz, 2H), 5.13-5.20 (dd, J=5.1 and 12.4 Hz, 1H), 6.44 (s, 1H), 7.65-7.79 (m, 3H), 8.69 (t. J=5.9 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 10.66, 21.97, 30.93, 36.39, 37.80, 48.86, 105.53, 121.71, 127.01, 131.51, 132.78, 134.70, 139.60, 140.35, 144.26, 161.91, 167.00, 167.56, 169.83, 172.75; Anal. calcd. for C20H19N5O5+0.4H2O: C, 57.66; H, 4.79; N, 16.81. Found: C, 57.85; H, 4.80; N, 16.64.
    • 5.120 5-METHYL-ISOXAZOLE-3-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00399
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 g, 6.6 mmol) was added to a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol) in acetonitrile (40 mL). After stirring for 10 minutes, 5-methylisoxazole-3-carbonyl chloride (0.4 g, 2.6 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (80 mL). The CH2Cl2 solution was washed with water (2×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (SiO2, CH2Cl2:CH3OH 97.5:2.5) to give 5-methyl-isoxazole-3-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.4 g, 44%) as a light brown solid: mp 207-209° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.48 (s, 3H), 2.50-2.64 (m, 2H), 2.84-2.98 (m, 1H), 4.91 (d, J=6.0 Hz, 2H), 5.13-5.20 (dd, J=5.4 and 12.6 Hz, 1H), 6.58 (s, 1H), 7.69-7.87 (m, 3H), 9.35 (t, J=6.0 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 11.82, 21.97, 30.92, 38.00, 48.88, 101.35, 121.99, 127.18, 131.55, 132.87, 134.84, 138.39, 158.61, 159.15, 166.93, 167.47, 169.81, 171.36, 172.84; Anal. calcd. for C19H16N4O6+0.2H2O: C, 57.03; H, 4.14; N, 14.00. Found: C, 57.34; H, 3.99; N, 13.70.
    • 5.121 1-METHYL-1H-PYRROLE-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00400
  • A mixture of 1-methyl-1H-pyrrole-2-carboxylic acid (0.3 g, 2.6 mmol) and carbonyl diimidazole (0.5 g, 3.0 mmol) in DMF (30 mL) was stirred for 2 hours. Triethylamine (0.8 g, 6.0 mmol) was added, followed by 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol). The mixture was stirred at 75° C. (oil bath) overnight. The mixture was cooled to room temperature and concentrated. The residue was stirred with EtOAc (80 mL) and water (30 mL). The EtOAc solution was washed with water (2×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (SiO2, CH2Cl2:CH3OH 97.5:2.5) to give 1-methyl-1H-pyrrole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.2 g, 25%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.06-2.10 (m, 1H), 2.50-2.65 (m, 2H), 2.84-2.97 (m, 1H), 3.83 (s, 3H), 4.86 (d, J=5.8 Hz, 2H), 5.13-5.20 (dd, J=5.5 and 12.7 Hz, 1H), 6.04 (t, J=3.4 Hz, 1H), 6.88-6.93 (m, 2H), 7.70-7.86 (m, 3H), 8.63 (t, J=5.8 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.98, 30.93, 36.19, 37.47, 48.86, 106.75, 112.63, 121.73, 124.98, 126.95, 128.07, 131.49, 132.96, 134.76, 140.06, 161.56, 166.98, 167.58, 169.82, 172.74; Anal. calcd. for C20H18N4O5+0.18H2O+0.1 ether: C, 60.49; H, 4.82; N, 13.83. Found: C, 60.54; H, 4.74; N, 13.50.
    • 5.122 3-METHYL-3H-IMIDAZOLE-4-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00401
  • A mixture of 1-methyl-1H-imidazole-5-carboxylic acid (0.3 g, 2.6 mmol) and carbonyl diimidazole (0.5 g, 3.0 mmol) in DMF (30 mL) was stirred at room temperature for 3 hours. Triethylamine (0.8 g, 6.0 mmol) was added, followed by 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.0 mmol). The mixture was stirred at 75° C. (oil bath) for 3 hours. The mixture was cooled to room temperature and concentrated. The residue was dissolved in EtOAc (100 mL) and washed with water (2×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (SiO2, CH2Cl2:CH3OH 97.5:2.5) to give 3-methyl-3H-imidazole-4-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.2 g. 28%) as a white solid: mp >260° C.; 1H NMR (DMSO-d6) δ 2.05-2.09 (m, 1H), 2.50-2.64 (m, 2H), 2.84-2.97 (m, 1H), 3.81 (s, 3H), 4.89 (d, J=5.6 Hz, 2H), 5.13-5.20 (dd, J=5.2 and 12.5 Hz, 1H), 7.68-7.84 (m, 5H), 8.94 (t, J=5.5 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.98, 30.93, 33.51, 37.44, 48.88, 121.88, 125.45, 127.05, 131.52, 132.29, 133.09, 134.83, 139.42, 142.08, 160.25, 166.94, 167.53, 169.82, 172.74; Anal. calcd. for C19H17N5O5+0.13H2O+0.1 Et2O: C, 57.52; H, 4.54; N, 17.29. Found: C, 57.23; H, 4.27; N, 16.95.
    • 5.123 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00402
  • A mixture of 4-Aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.97 g, 3.0 mmol), 4-(trifluoromethyl)-benzoyl chloride (0.63 g, 3.0 mmol) and triethylamine (0.61 g, 6.00 mmol) in acetonitrile (20 mL) was stirred at room temperature for 13 hours. The reaction mixture was concentrated and the residue was purified by ISCO silica gel flash chromatography using a methanol-CH2Cl2 gradient, eluting the product at 5:95 methanol-CH2Cl2. The resulting solid was stirred in ether for 5 hours, filtered and dried to give the 0.66 g of the product as a white solid, in 48% yield: mp 238-240° C.; HPLC, Waters Symmetry C-18, 3.9×150 mm, 5 μm, 1 mL/min, 240 nm, 50/50 CH3CN/0.1% H3PO4, 3.90 (99.09%); 1H NMR (DMSO-d6) δ 2.07-2.12 (m, 1H), 2.54-2.65 (m, 2H), 2.86-2.98 (m, 1H), 4.97 (d, J=5.7 Hz, 2H), 5.18 (dd, J=12.6 Hz, J=5.4 Hz, 1H), 7.74-7.91 (m, 5H), 8.13 (d, J=8.1 Hz, 2H), 9.39 (t, J=5.7 Hz, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 22.0, 31.0, 38.5, 48.9, 122.0, 123.9 (q, J=270.8 Hz), 125.5 (q, J=3.75 Hz), 127.2, 128.3, 131.4 (q, J=31.5 Hz), 131.6, 133.2, 134.9, 137.7, 138.9, 165.5, 167.0, 167.5, 169.9, 172.8; Anal. Calcd for C22H16N3O5F3: C, 57.52; H, 3.51; N, 9.15. Found: C, 57.35; H, 3.23; N, 8.97.
    • 5.124 5-PHENYL-[1,3,4]OXADIAZOLE-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYLAMIDE
  • Figure US20070049618A1-20070301-C00403
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.55 g, 4.8 mmol) in CH3CN (15 ml), was added triethyl amine (1.67 mL, 11.98 mmol) and 5-phenyl-1,3,4-oxadiazole-2-carbonyl-chloride (1.0 g, 4.8 mmol). The mixture was stirred at room temperature for 21 hours and a suspension was obtained. The reaction mixture was filtered, and the solid was rinsed with CH3CN (20 mL), water (2×20 mL), EtOAc (20 mL) and MeOH (20 mL) to afford 5-phenyl-[1,3,4]oxadiazole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethylamide as a white solid (1.34 g, 61%): mp, 279-281° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.90 min. (99%); 1H NMR (DMSO-d6): δ 2.08-2.10 (m, 1H), 2.53-2.64 (m, 2H), 2.86-2.98 (m, 1H), 4.98 (d, J=5 Hz, 1H), 5.18 (dd, J=5, 13 Hz, 1H), 7.62-7.72 (m, 3H), 7.85 (broad, 3H), 8.09-8.12 (m, 2H). 9.97 (t, J=5 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.90, 30.85, 38.24, 48.82, 122.07, 122.70, 126.98, 127.16, 129.46, 131.49, 132.58, 133.03, 134.77, 137.63, 153.51, 158.29, 164.94, 166.84, 167.42, 169.74, 172.67. Anal Calcd for C23H17N5O6: C, 60.13; H, 3.73; N, 15.24. Found: C, 56.69; H, 3.34; N, 15.41.
    • 5.125 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00404
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (80 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3-trifluoromethylbenzoyl chloride (0.42 mL, 2.8 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was filtered, and the solid was rinsed with CH2Cl2 (15 mL) and acetone (15 mL). The solid was then recrystallized with MeOH to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-trifluoromethyl-benzamide as a white solid (0.5 g, 54%): mp, 241-243° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.4 min. (99%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.53-2.65 (m, 2H), 2.85-2.93 (m, 1H), 4.96 (d, J=5.8 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.46-7.84 (m, 6H), 9.33 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.92, 38.49, 48.86, 106.93, 110.58, 110.69, 110.82, 110.93, 121.99, 127.21, 131.54, 133.20, 134.83, 137.42, 138.62, 160.51, 160.67, 163.78, 163.95, 164.10, 166.92, 167.48, 169.81, 172.73. Anal Calcd for C21H15FN3O5: C, 59.02; H, 3.54; N, 9.83; F, 8.89. Found: C, 58.90; H, 3.15; N, 9.73; F, 9.08.
    • 5.126 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3,4-DIFLUORO-BENZAMIDE
  • Figure US20070049618A1-20070301-C00405
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3,4-difluorobenzoyl chloride (0.5 g, 2.8 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was quenched with MeOH (1 mL) and was filtered. The solid was rinsed with CH2Cl2 (5 mL) and then dissolved in acetone (4 mL). Ether (10 mL) and hexane (10 mL) were added to the solution and the resulting suspension was filtered to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3,4-difluoro-benzamide as a white solid (0.7 g, 75%): mp, 218-220° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.1 min. (99%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.51-2.64 (m, 2H), 2.87-2.93 (m, 1H), 4.95 (d, J=5.8 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.55-8.01 (m, 6H), 9.26 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.92, 39.20, 48.86, 116.77, 116.65, 116.89, 117.51, 117.74, 121.95, 124.75, 124.80, 124.85, 124.89, 127.18, 131.28, 131.32, 131.39, 131.53, 133.15, 134.82, 138.86, 147.42, 147.59, 149.70, 149.87, 150.68, 150.85, 153.02, 153.19, 164.45, 166.93, 167.49, 169.81, 172.74. Anal Calcd for C21H15F2N3O5: C, 59.02; H, 3.54; N, 9.83; F, 8.89. Found: C, 59.12; H, 3.60; N, 9.68; F, 8.86.
    • 5.127 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-FLUORO-BENZAMIDE
  • Figure US20070049618A1-20070301-C00406
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3-fluorobenzoyl chloride (0.45 g, 2.8 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was quenched with MeOH (1 mL) and concentrated in vacuo. The resulting oil was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2 for 10 min, then 5% MeOH in CH2Cl2 for 10 min) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-fluoro-benzamide as a white solid (0.7 g, 77%): mp, 215-217° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.2 min. (99%); 1H NMR (DMSO-d6): δ 2.07-2.12 (m, 1H), 2.54-2.65 (m, 2H), 2.87-2.93 (m, 1H), 4.96 (d, J=5.8 Hz, 2H), 5.15-5.21 (dd, J=5, 12 Hz, 1H), 7.39-7.84 (m, 7H), 9.26 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.40, 48.86, 114.29, 118.49, 121.92, 123.50, 127.15, 130.62, 131.52, 133.09, 134.82, 136.31, 138.97, 163.69, 165.31, 166.94, 167.51, 169.83, 172.74. Anal Calcd for C21H16FN3O5: C, 61.61; H, 3.94; N, 10.26; F, 4.64. Found: C, 61.36; H, 3.84; N, 10.00; F, 4.74.
    • 5.128 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-METHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00407
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and p-toluoyl chloride (0.43 g, 2.8 mmol). The mixture was then stirred at room temperature overnight and a suspension was obtained. The reaction mixture was quenched with MeOH (1 mL) and washed with H2O (40 mL), 1N HCl (40 mL) and brine (40 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The resulting mixture was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-methyl-benzamide as a white solid (0.5 g, 61%): mp, 218-220° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.3 (97%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.36 (s, 3H), 2.54-2.64 (m, 2H), 2.85-2.93 (m, 1H), 4.94 (d, J=5.7 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.31 (d, J=8.0 Hz, 2H), 9.07 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 20.93, 31.97, 30.92, 38.26, 48.85, 121.81, 127.08, 127.30, 128.87, 131.11, 131.51, 132.98, 134.77, 139.47, 141.35, 166.47, 166.97, 167.54, 169.83, 172.74. Anal Calcd for C22H19N3O5: C, 65.18; H, 4.72; N, 10.36. Found: C, 64.78; H, 4.72; N, 10.07.
    • 5.129 3,5-DICHLORO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00408
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3,5-difluorobenzoyl chloride (0.59 g, 2.8 mmol). This mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was then quenched with MeOH (1 mL) and washed with H2O (40 mL), 1N HCl (40 mL) and brine (40 mL). The organic layer was dried over MgSO4 and concentrated in vacuo, and the resulting mixture was stirred with acetone (10 mL). The resulting suspension was filtered, and the solid was washed with acetone and dried in vacuum oven to afford 3,5-dichloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a white solid (0.8 g, 76%): mp, 250-252° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 50/50 (CH3CN/H2O): tR=4.3 min (96%); 1H NMR (DMSO-d6): δ 2.05-2.11 (m, 1H), 2.53-2.64 (m, 2H), 2.85-2.93 (m, 1H), 4.95 (d, J=5.7 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.76-7.94 (m, 6H), 9.37 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.54, 48.86, 121.99, 126.20, 127.21, 130.82, 131.52, 133.27, 134.32, 134.83, 137.11, 138.54, 163.94, 166.92, 167.47, 169.81, 172.74. Anal Calcd for C21H15Cl2N3O5: C, 54.80; H, 3.28; N, 9.13; Cl, 15.41. Found: C, 54.93; H, 2.96; N, 9.01; Cl, 15.62.
    • 5.130 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3,5-DIFLUORO-BENZAMIDE
  • Figure US20070049618A1-20070301-C00409
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml) was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3,5-difluorobenzoyl chloride (0.5 g, 2.8 mmol). The reaction mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was then quenched with MeOH (1 mL) and washed with H2O (40 mL), 1N HCl (40 mL) and brine (40 mL). The organic layer was dried over MgSO4 and concentrated in vacuo, and the resulting mixture was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2 for 10 min, then 5% MeOH in CH2Cl2 for 10 min) to afford N-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3,5-difluoro-benzamide as a white solid (0.5 g, 54%): mp, 218-220° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.4 min. (99%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.53-2.65 (m, 2H), 2.85-2.93 (m, 1H), 4.96 (d, J=5.8 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.46-7.84 (m, 6H), 9.33 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.92, 38.49, 48.86, 106.93, 110.58, 110.69, 110.82, 110.93, 121.99, 127.21, 131.54, 133.20, 134.83, 137.42, 138.62, 160.51, 160.67, 163.78, 163.95, 164.10, 166.92, 167.48, 169.81, 172.73. Anal Calcd for C21H15F2N3O5: C, 59.02; H, 3.54; N, 9.83. Found: C, 58.90; H, 3.15; N, 9.73.
    • 5.131 4-CHLORO-N-2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00410
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 4-chlorobenzoyl chloride (0.5 g, 2.8 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was quenched with MeOH (1 mL). The suspension was then filtered, and the solid was rinsed with CH2Cl2 (10 mL) to afford 4-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a white solid (0.5 g, 52%): mp, 233-235° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.7 min. (99%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.53-2.64 (m, 2H), 2.84-2.93 (m, 1H), 4.95(d, J=5.8 Hz, 2H), 5.15-5.20(dd, J=5, 12 Hz, 1H), 7.56-7.59 (dd, J=1.7, 6.8 Hz, 2H), 7.72-7.83 (m, 3H), 7.93-7.96 (dd, J=1.8, 6.8 Hz, 2H), 9.23 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.38, 48.86, 121.90, 127.15, 128.45, 129.25, 131.53, 132.65, 133.09, 134.80, 136.28, 139.08, 165.57, 166.94, 167.51, 169.81, 172.74. Anal Calcd for C21H16ClN3O5: C, 59.23; H, 3.79; N, 9.87; Cl, 8.33. Found: C, 59.27; H, 3.42; N, 9.75; Cl, 8.57.
    • 5.132 2-CHLORO-N-2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00411
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 2-chlorobenzoyl chloride (0.5 g, 2.8 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was quenched with MeOH (1 mL) and then washed with H2O (40 mL), 1N HCl (40 mL), brine (40 mL), and dried over MgSO4. The organic layer was concentrated in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2 for 10 min, then 5% MeOH in CH2Cl2 for 10 min):) to afford 2-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a white solid (0.55 g, 60%): mp, 209-211° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.0 min (99%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.53-2.64 (m, 2H), 2.87-2.93 (m, 1H), 4.92(d, J=5.9 Hz, 2H), 5.14-5.20(dd, J=5, 12 Hz, 1H), 7.39-7.57 (m, 4H), 7.82-7.89 (m, 3H), 9.12 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.91, 38.10, 48.86, 121.95, 127.15, 128.97, 129.62, 129.83, 130.94, 131.54, 133.10, 134.80, 136.49, 138.74, 166.77, 166.93, 167.48, 169.80, 172.74. Anal Calcd for C21H16ClN3O5: C, 59.23; H, 3.79; N, 9.87; Cl, 8.33. Found: C, 59.24; H, 3.45; N, 9.71; Cl, 8.32.
    • 5.133 3-CHLORO-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DI-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-METHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00412
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 3-chloro-4-methyl-benzoic acid (0.4 g, 2.4 mmol) were added. To the reaction mixture, was then added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol), and the mixture was stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo, and the residue was stirred in H2O (50 mL). A suspension formed and after filtration the solid was reslurried in acetone (20 mL). The suspension was filtered to afford 3-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-methyl-benzamide as a white solid (0.75 g, 79%): mp, 249-251° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=6.8 min. (97%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.39 (s, 3H), 2.53-2.64 (m, 2H), 2.85-2.96 (m, 1H), 4.94(d, J=5.8 Hz, 2H), 5.15-5.20 (dd, J=5, 12 Hz, 1H), 7.47-7.97 (m, 6H), 7.82-7.89 (m, 3H), 9.22 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 19.55, 21.97, 30.92, 38.36, 48.86, 121.89, 126.07, 127.15, 127.60, 131.22, 131.52, 133.11, 133.33, 134.80, 139.06, 139.10, 165.13, 166.94, 167.50, 169.81, 172.74. Anal Calcd for C22H18ClN3O5: C, 60.08; H, 4.12; N, 9.55; Cl, 8.06. Found: C, 59.69; H, 4.15; N, 9.60; Cl, 8.08.
    • 5.134 BENZOFURAN-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00413
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 2-benzofuran carboxylic acid (0.39 g, 2.4 mmol) were added. To the reaction, was then added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 30% EtOAc in CH2Cl2 for 10 min, then 40% EtOAc in CH2Cl2 for 10 min) to afford benzofuran-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a white solid (0.59 g, 63%): mp, 292-295° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.3 min. (98%); 1H NMR (DMSO-d6): δ 2.09-2.10 (m, 1H), 2.55-2.65 (m, 2H), 2.84-2.93 (m, 1H), 4.97 (d, J=6.0 Hz, 2H), 5.15-5.21 (dd, J=5, 12 Hz, 1H), 7.33-7.84 (m, 8H), 9.40 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 37.90, 48.87, 109.90, 111.79, 121.95, 122.81, 123.74, 126.96, 127.09, 127.15, 131.54, 133.02, 134.83, 138.71, 148.71, 154.27, 158.52, 166.94, 167.51, 169.82, 172.74. Anal Calcd for C23H17N3O6+0.2H2O: C, 63.51; H, 4.03; N, 9.66. Found: C, 63.45; H, 3.76; N, 9.52.
    • 5.135 2-(3,4-DICHLORO-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00414
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 3,4-dichlorophenylacetic acid (0.49 g, 2.4 mmol) were added. The mixture was then added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol) and stirred overnight at room temperature. The reaction mixture was concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo. The resulting oil solidified on standing and the mixture was stirred in acetone (10 mL) then in MeOH (10 mL). The resulting solid was filtered and dried in vacuum oven to afford 2-(3,4-dichloro-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide as an off-white solid (0.69 g, 67%): mp, 163-165° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=6.5 min. (98%); 1H NMR (DMSO-d6): δ 2.03-2.08 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.92 (m, 1H), 3.58 (s, 2H), 4.73 (d, J=6.0 Hz, 2H), 5.12-5.18 (dd, J=5, 12 Hz, 1H), 7.26-7.82 (m, 6H), 8.69 (t, J=6 Hz, 1H), 11.14 (s, 1H). 13C NMR (DMSO-d6) δ: 21.95, 30.90, 37.92, 40.80, 48.83, 121.95, 127.16, 129.13, 129.58, 130.29, 130.65, 131.15, 131.52, 133.31, 134.68, 137.19, 138.92, 166.88, 167.39, 169.77, 172.72. Anal Calcd for C22H17Cl2N3O5+0.2H2O: C, 55.29; H, 3.67; N, 8.79; Cl, 14.84. Found: C, 55.19; H, 3.33; N, 8.83; Cl, 14.71.
    • 5.136 2-(3-CHLORO-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00415
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 3-chloro-phenylacetic acid (0.41 g, 2.4 mmol) were added. The reaction was then added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol) and was stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 30% EtOAc in CH2Cl2 for 10 min, then increase to 60% EtOAc in CH2Cl2 over 20 min) to afford 2-(3-chloro-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide as a white solid (0.73 g, 76%): mp, 185-187° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.2 min. (99%); 1H NMR (DMSO-d6): δ 2.03-2.08 (m, 1H), 2.52-2.63 (m, 2H), 2.86-2.91 (m, 1H), 3.56 (s, 2H), 4.73 (d, J=6.0 Hz, 2H), 5.12-5.18 (dd, J=5, 13 Hz, 1H), 7.23-7.82 (m, 7H), 8.70 (t, J=6 Hz, 1H), 11.13 (s, 1H). 13C NMR (DMSO-d6) δ: 21.95, 30.90, 37.87, 41.53, 48.83, 121.93, 126.40, 127.15, 127.82, 128.94, 130.04, 131.52, 132.74, 133.25, 134.66, 138.54, 139.01, 166.88, 167.41, 169.77, 170.03, 172.73. Anal Calcd for C22H18ClN3O5: C, 60.08; H, 4.12; N, 9.55; Cl, 8.06. Found: C, 59.92; H, 3.85; N, 9.55; Cl, 8.37.
    • 5.137 BENZO[1,3]DIOXOLE-5-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00416
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and piperonyloyl chloride (0.5 g, 2.8 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was quenched by the addition of MeOH (1 mL). The suspension was filtered, and the solid was rinsed with CH2Cl2 (10 mL) to afford benzo[1,3]dioxole-5-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a white solid (0.8 g, 85%): mp, 231-233° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.7 (99%); 1H NMR (DMSO-d6): δ 2.06-2.10 (m, 1H), 2.53-2.64 (m, 2H), 2.86-2.97 (m, 1H), 4.92(d, J=5.6 Hz, 2H), 5.14-5.20 (dd, J=5, 12 Hz, 1H), 6.11 (s, 2H), 7.03 (d, J=8.1 Hz, 1H), 7.45-7.85 (m, 5H), 9.00 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.33, 48.85, 101.68, 107.34, 107.90, 121.81, 122.35, 127.08, 127.88, 131.50, 133.01, 134.77, 139.44, 147.36, 149.87, 165.70, 166.96, 167.52, 169.82, 172.74. Anal Calcd for C22H17N3O7+0.2H2O: C, 60.19; H, 4.00; N, 9.57. Found: C, 60.15; H, 3.71; N, 9.46.
    • 5.138 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL-METHYL]-3,4-DIMETHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00417
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 3,4-dimethyoxybenzoyl chloride (0.6 g, 2.8 mmol). The mixture was stirred at room temperature overnight followed by the addition of MeOH (1 mL). The reaction mixture was then washed with water (40 mL), 1N HCl (2×40 mL), and brine (40 mL), dried over MgSO4, and concentrated in vacuo. The resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-3,4-dimethoxy-benzamide as a white solid (0.8 g, 79%): mp, 198-200° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.2 min. (99%); 1H NMR (DMSO-d6): δ 2.06-2.10 (m, 1H), 2.51-2.59 (m, 2H), 2.64 (m, 1H), 3.81 (s, 6H), 4.94 (d, J=5.9 Hz, 2H), 5.14-5.20 (dd, J=5, 12 Hz, 1H), 7.06 (d, J=8.5 Hz, 1H), 7.51-7.58 (m, 2H), 7.83-7.70 (m, 3H), 9.02 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.22, 48.86, 55.53, 55.60, 110.67, 110.92, 120.56, 121.80, 126.10, 127.05, 131.50, 133.06, 134.77, 139.66, 148.28, 151.44, 166.09, 166.96, 167.57, 169.83, 172.74. Anal Calcd for C23H21N3O7+0.2H2O: C, 60.71; H, 4.74; N, 9.23. Found: C, 60.39; H, 4.51; N, 8.99.
    • 5.139 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-TRIFLUOROMETHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00418
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 4-trifluoromethoxybenzoyl chloride (0.6 g, 2.8 mmol). The mixture was then stirred at room temperature overnight. The reaction mixture was quenched with MeOH (1 mL), washed with water (40 mL), 1N HCl (2×40 mL), and brine (40 mL), dried over MgSO4, and concentrated in vacuo. The resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-trifluoromethoxy-benzamide as an off-white solid (0.8 g, 78%): mp, 163-165° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=7.3 min. (99%); 1H NMR (DMSO-d6): δ 2.07-2.10 (m, 1H), 2.51-2.64 (m, 2H), 2.91-2.92 (m, 1H), 4.96(d, J=5.7 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.52 (d, J=8.0 Hz, 2H), 7.74-7.84 (m, 3H), 8.04-8.07 (dd, J=6.8, 1.9 Hz, 2H), 9.28 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.44, 118.23, 120.68, 121.64, 121.90, 127.15, 129.30, 129.67, 131.53, 133.01, 133.07, 134.80, 139.03, 150.39, 150.42, 165.39, 166.94, 167.51, 169.81, 172.74. Anal Calcd for C22H16F3N3O6: C, 55.59; H, 3.39; N, 8.84; F, 11.99. Found: C, 55.43; H, 3.00; N, 8.76; F, 11.77.
    • 5.140 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-TRIFLUOROMETHOXY-BENZAMIDE
  • Figure US20070049618A1-20070301-C00419
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.80 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 2-benzofuran carboxylic acid (0.39 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo, and the residue was stirred with water and filtered. The resulting solid was dissolved in CH2Cl2 (50 mL) and purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-trifluoromethoxy-benzamide as an off-white solid (0.75 g, 73%): mp, 162-164° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=7.2 min (99%); 1H NMR (DMSO-d6): δ 2.06-2.10 (m, 1H), 2.50-2.64 (m, 2H), 2.86-2.93 (m, 1H), 4.97 (d, J=5.7 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.57-7.99 (m, 7H), 9.34 (t, J=5.7 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.91, 30.86, 38.37, 48.81, 118.26, 119.78, 121.67, 121.89, 123.95, 126.37, 127.12, 130.57, 131.48, 133.12, 134.78, 136.02, 138.83, 148.27, 148.30, 164.93, 166.83, 167.45, 169.76, 172.68. Anal Calcd for C22H16F3N3O6: C, 55.59; H, 3.39; N, 8.84; F, 11.99. Found: C, 55.53; H, 3.01; N, 8.70; F, 11.94.
    • 5.141 4-DIFLUOROMETHOXY-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00420
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 4-difluoromethoxy benzoic acid (0.45 g, 2.4 mmol) were added followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL) and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford 4-difluoromethoxy-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a yellow solid (0.63 g, 64%): mp, 155-157° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.2 min. (97%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.50-2.65 (m, 2H), 2.85-2.92 (m, 1H), 4.95(d, J=5.8 Hz, 2H), 5.16-5.21(dd, J=5, 12 Hz, 1H), 7.28-7.30 (m, 2H), 7.36 (t, J=73.5 Hz, 1H), 7.72-7.86 (m, 3H), 7.98-8.02 (m, 2H), 9.18 (t, J=5.8 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.34, 48.86, 112.61, 116.03, 117.97, 119.45, 121.87, 127.13, 129.45, 130.55, 131.52, 133.05, 134.79, 139.22, 153.30, 165.60, 166.95, 167.52, 169.81, 172.74. Anal Calcd for C22H17F2N3O6: C, 57.77; H, 3.75; N, 9.19; F, 8.31. Found: C, 57.67; H, 3.59; N, 9.01; F, 8.22.
    • 5.142 3-DIFLUOROMETHOXY-N-[2-(2,6-DIOXO-PIPERIDIN-3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00421
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 3-difluoromethoxy benzoic acid (0.45 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was then washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford 3-difluoromethoxy-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a white solid (0.64 g, 65%): mp, 164-166° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.6 min (99%); 1H NMR (DMSO-d6): δ 2.04-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.85-2.93 (m, 1H), 4.92(d, J=6.0 Hz, 2H), 5.14-5.20 (dd, J=5, 12 Hz, 1H), 6.97-7.86 (m, 8H), 8.97 (t, J=6.0 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.95, 30.91, 38.29, 48.86, 113.18, 116.60, 119.08, 120.02, 121.91, 125.34, 127.12, 128.74, 129.58, 131.48, 131.54, 113.18, 116.60, 119.08, 120.02, 121.91, 125.34, 127.12, 127.74, 128.58, 131.48, 131.54, 132.96, 134.64, 138.89, 147.66, 165.60, 166.94, 167.51, 169.81, 172.73. Anal Calcd for C22H17F2N3O6: C, 57.77; H, 3.75; N, 9.19; F, 8.31. Found: C, 57.62; H, 3.60; N, 8.99; F, 8.32.
    • 5.143 2-DIFLUOROMETHOXY-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-BENZAMIDE
  • Figure US20070049618A1-20070301-C00422
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 2-difluoromethoxy benzoic acid (0.45 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was then washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford 4-difluoromethoxy-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-benzamide as a solid (0.64 g, 65%): mp, 164-166° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.6 (99%); 1H NMR (DMSO-d6): δ 2.04-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.85-2.93 (m, 1H), 4.92 (d, J=6.0 Hz, 2H), 5.14-5.20 (dd, J=5, 12 Hz, 1H), 6.97-7.86 (m, 8H), 8.97 (t, J=5.8 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.95, 30.91, 38.29, 48.86, 113.18, 116.60, 119.08, 120.02, 121.91, 125.34, 127.12, 128.74, 129.58, 131.48, 131.54, 132.96, 134.64, 138.89, 147.66, 165.60, 166.94, 167.51, 169.80, 172.73. Anal Calcd for C22H17F2N3O6: C, 57.77; H, 3.75; N, 9.19; F, 8.31. Found: C, 57.62; H, 3.60; N, 8.99; F, 8.32.
    • 5.144 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-FLUORO-BENZAMIDE
  • Figure US20070049618A1-20070301-C00423
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.16 mmol) in CH2Cl2 (60 ml), was added diisopropylethylamine (0.94 mL, 5.4 mmol) and 4-fluorobenzoyl chloride (0.45 g, 2.8 mmol). The mixture was stirred at room temperature overnight followed by addition of MeOH (1 mL). After filtration, the resulting solid was washed with CH2Cl2 then recrystallized in CH3OH to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-fluoro-benzamide as a white solid (0.5 g, 59%): mp, 233-235° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.6 (96%); 1H NMR (DMSO-d6): δ 2.06-2.11 (m, 1H), 2.53-2.64 (m, 2H), 2.86-2.98 (m, 1H), 4.95(d, J=5.7 Hz, 2H), 5.15-5.21(dd, J=5, 12 Hz, 1H), 7.30-7.38 (m, 2H), 7.72-7.86 (m, 3H), 7.96-8.03 (m2H), 9.18 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.97, 30.92, 38.35, 48.86, 115.15, 115.44, 121.87, 127.12, 129.91, 130.03, 130.37, 131.52, 133.05, 134.80, 139.21, 162.35, 165.54, 165.64, 166.95, 167.52, 169.82, 172.74. Anal Calcd for C21H16FN3O5: C, 66.61; H, 3.94; N, 10.26; F, 4.64. Found: C, 61.53; H, 3.82; N, 10.20; F, 4.72.
    • 5.145 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(4-FLUORO-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00424
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 4-fluorophenylacetic acid (0.37 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight and was then concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. The organic solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 0% MeOH in CH2Cl2 to 5% MeOH in 10 min then stay at this ratio for 15 min) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(4-fluoro-phenyl)-acetamide as a white solid (0.64 g, 65%): mp, 214-216° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.0 min (99%); 1H NMR (DMSO-d6): δ 2.03-2.08 (m, 1H), 2.51-2.63 (m, 2H), 2.86-2.91 (m, 1H), 3.53 (s, 2H), 4.72 (d, J=6.0 Hz, 2H), 5.12-5.18 (dd, J=5, 12 Hz, 1H), 7.10-7.16 (m, 2H), 7.29-7.34 (m, 2H), 7.62-7.65 (m, 1H), 7.78-7.81 (m, 2H), 8.67 (t, J=5.9 Hz, 1H), 11.14 (s, 1H). 13C NMR (DMSO-d6) δ: 21.95, 30.90, 37.83, 41.17, 48.82, 114.77, 115.05, 121.89, 127.12, 130.81, 130.92, 131.51, 132.24, 132.28, 133.19, 134.67, 139.09, 159.42, 162.62, 166.90, 167.42, 169.78, 170.51, 172.73. Anal Calcd for C22H18FN3O5: C, 62.41; H, 4.29; N, 9.92; F, 4.49. Found: C, 62.05; H, 4.18; N, 9.85; F, 4.48.
    • 5.146 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(3-FLUORO-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00425
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.70 g, 2.2 mmol) in CH3CN (60 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.35 g, 2.6 mmol) and 3-fluorophenylacetic acid (0.37 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.62 g, 3.2 mmol). After stirring at room temperature overnight, the mixture was concentrated in vacuo, and the residue was dissolved in CH2Cl2 (50 mL). The CH2Cl2 solution was then washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 40% EtOAc in CH2Cl2 for 5 min then increase to 80% EtOAc in CH2Cl2 over 20 min.) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(3-fluoro-phenyl)-acetamide as a white solid (0.63 g, 69%): mp, 192-194° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.0 min (98%); 1H NMR (DMSO-d6): δ 2.03-2.08 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.57 (s, 2H), 4.73 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5, 12 Hz, 1H), 7.03-7.14 (m, 3H), 7.31-7.39 (m, 1H), 7.63-7.67 (m, 1H), 7.78-7.81 (m, 2H), 8.69 (t, J=6.0 Hz, 1H), 11.14 (s, 1H). 13C NMR (DMSO-d6) δ: 21.94, 30.90, 37.86, 41.67, 48.82, 113.08, 113.35, 115.69, 115.98, 121.91, 125.19, 125.22, 127.13, 129.98, 130.09, 131.51, 133.22, 134.67, 138.77, 138.87, 139.03, 160.38, 163.60, 166.88, 167.41, 169.78, 170.06, 172.73. Anal Calcd for C22H18FN3O5: C, 62.41; H, 4.29; N, 9.92; F, 4.49. Found: C, 62.55; H, 4.04; N, 9.80; F, 4.36.
    • 5.147 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(2-FLUORO-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00426
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.82 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2-fluorophenylacetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The reaction mixture was stirred at room temperature overnight and was then concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL), and the solution was washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (eluent: EtOAc:CH2Cl2=4:6) to afford N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(2-fluoro-phenyl)-acetamide (0.7 g, 79%) as a white solid: mp 172-174° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.87 min. (98%); 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.94 (m, 1H), 3.61 (s, 2H), 4.75 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.12-7.38 (m, 4H), 7.68-7.86 (m, 3H), 8.70 (t, J=6.0 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-D6) δ 21.95, 30.90, 35.20, 37.87, 48.83, 114.83 (115.12), 121.88, 122.95 (123.17), 124.14 (124.19), 127.10, 128.60 (128.71), 131.51, 131.85 (131.91), 133.11, 134.68, 139.15, 158.96 (162.20), 166.90, 167.44, 169.59, 169.78, 172.73; Anal. Calcd. for C22H18N3O5F: C, 62.41; H, 4.29; N, 9.92; F, 4.49. Found: C, 62.65; H, 4.25; N, 9.95; F, 4.62.
    • 5.148 2-(3,5-DIFLUORO-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00427
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3,5-difluorophenylacetic acid (0.4 g, 2.4 mmol) were added followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight. The resulting suspension was filtered, and the solid was reslurried in hot acetone (15 mL) to afford 2-(3,5-difluoro-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.5 g, 56%) as a white solid: mp, 238-240° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.63 min. (97%); 1H NMR (DMSO-d6) δ 2.02-2.07 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.60 (s, 2H), 4.73 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 6.89-7.14 (m, 3H), 7.65-7.84 (m, 3H), 8.70 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.91, 41.41, 48.83, 101.62 (101.95, 102.30), 112.18 (112.28, 112.41, 112.51), 121.95, 127.16, 131.52, 133.29, 134.68, 138.91, 140.24 (140.37, 140.50), 160.39 (160.57, 163.64, 163.82), 166.88, 167.41, 169.53, 169.77, 172.72; Anal. Calcd. for C22H17N3O5F2: C, 59.87; H, 3.88; N, 9.52; F, 8.61. Found: C, 59.66; H, 3.83; N, 9.77; F, 8.47.
    • 5.149 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(4-TRIFLUOROMETHOXY-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00428
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 4-trifluoromethoxyphenylacetic acid (0.5 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL), and the solution was washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2=4:6) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(4-trifluoromethoxy-phenyl)-acetamide (0.7 g, 64%) as a white solid: mp 134-136° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=6.41 min. (98%); 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.59 (s, 2H), 4.73 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.29-7.32 (d, J=8.6 Hz, 2H), 7.40-7.43 (d, J=8.7 Hz, 2H), 7.63-7.82 (m, 2H), 8.72 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.85, 41.23, 48.83, 120.81, 118.37 (121.76, 125.15), 121.91, 127.14, 130.91, 131.52, 133.22, 134.65, 135.64, 139.02, 147.02, 166.88, 167.41, 169.78, 170.21, 172.72; Anal. Calcd. for C23H18N3O6F3: C, 56.45; H, 3.71; N, 8.59; F, 11.65. Found: C, 56.20; H, 3.39; N, 8.44; F, 11.87.
    • 5.150 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00429
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3,5-di-(trifluoromethyl)-phenylacetic acid (0.7 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The reaction mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (eluent: EtOAc:CH2Cl2 3:7) to afford 2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.6 g, 54%) as a white solid: mp 202-204° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=13.69 min. (97%); 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.92 (m, 1H), 3.82 (s, 2H), 4.75 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.67-7.83 (m, 3H), 8.00 (s, 3H), 8.82 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.93, 30.89, 37.91, 40.88, 48.83, 117.94, 120.21 (120.26, 120.31), 121.98, 117.94 (121.55, 125.17, 128.75), 127.19, 130.14, 129.28 (129.71, 130.57), 131.54, 133.27, 134.60, 138.86, 139.45, 166.87, 167.39, 169.43, 169.76, 172.71; Anal. Calcd. for C24H17N3O5F6: C, 53.24; H, 3.16; N, 7.76; F, 21.05. Found: C, 53.16; H, 2.99; N, 7.73; F, 21.14.
    • 5.151 (N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(4-TRIFLUOROMETHYL-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00430
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 4-(trifluoromethyl)phenylacetic acid (0.6 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). After stirring at room temperature overnight, the reaction mixture was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) then washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 4:6) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(4-trifluoromethyl-phenyl)-acetamide (0.7 g, 71%) as a white solid: mp 144-146° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=5.58 min. (97%); 1H NMR (DMSO-d6) δ 2.03-2.08 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.66 (s, 2H), 4.74 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.50-7.82 (m, 7H), 8.75 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.89, 41.75, 48.83, 121.93, 124.95 (125.01, 125.05, 125.10), 122.56 (126.16), 126.96 (127.15, 127.38), 129.94, 131.52, 133.26, 134.69, 138.95, 140.95, 166.88, 167.41, 169.78, 169.87, 172.73; Anal. Calcd. for C23H18N3O5F3: C, 58.35; H, 3.83; N, 8.88; F, 12.04. Found: C, 58.19; H, 3.53; N, 8.73; F, 12.07.
    • 5.152 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(3-TRIFLUOROMETHYL-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00431
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-(trifluoromethyl)phenylacetic acid (0.6 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(3-trifluoromethyl-phenyl)-acetamide (0.7 g, 70%) as a white solid: mp 156-158° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=5.36 min. (98%); 1H NMR (DMSO-d6) δ 2.03-2.09 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.67 (s, 2H), 4.74 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.52-7.82 (m, 7H), 8.77 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.84, 41.53, 48.83, 121.94, 123.12 (123.17, 123.22), 125.50 (125.56, 125.60, 125.66), 127.15, 128.68, 129.09, 129.23, 131.53, 133.19, 133.31, 134.61, 137.51, 138.99, 166.88, 167.40, 179.77, 170.00, 172.72; Anal. Calcd. for C23H18N3O5F3: C, 58.35; H, 3.83; N, 8.88; F, 12.04. Found: C, 58.13; H, 3.53; N, 8.83; F, 11.69.
    • 5.153 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(3-TRIFLUOROMETHOXY-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00432
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-trifluoromethoxyphenylacetic acid (0.5 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(3-trifluoromethoxy-phenyl)-acetamide (0.8 g, 74%) as a white solid: mp 178-180° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=6.32 min. (97%); 1H NMR (DMSO-d6) δ 2.02-2.09 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.83 (s, 2H), 4.72 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.23-8.10 (m, 7H), 8.74 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.84, 48.83, 118.96, 121.43, 121.93, 127.15, 128.29, 130.07, 131.53, 133.15, 134.61, 138.80, 139.00, 148.24, 166.88, 167.41, 169.77, 169.96, 172.72; Anal. Calcd. for C23H18N3O6F3: C, 56.45; H, 3.71; N, 8.59; F, 11.65. Found: C, 56.44; H, 3.44; N, 8.46; F, 11.89.
    • 5.154 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(3-FLUORO-4-METHYL-PHENYL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00433
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-fluoro-4-methylphenylacetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(3-fluoro-4-methyl-phenyl)-acetamide (0.7 g, 70%) as a white solid: mp 148-150° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.06 min. (98%); 1H NMR (DMSO-d6) δ 2.04-2.07 (m, 1H), 2.20 (s, 3H), 2.52-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.52 (s, 2H), 4.70 (d, J=5.7 Hz, 2H), 5.12-5.18 (dd, J=5.1 and 12.7 Hz, 1H), 6.99-7.07 (dd, J=11.2 and 14.7 hz, 2H), 7.21 (t, J=8.0 Hz, 1H), 7.63-7.76 (dd, J=3.3 and 7.5 Hz, 1H), 7.77-7.83 (dd, J=7.6 and 11.9 Hz, 2H), 8.65 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 13.74(13.78), 21.95, 30.90, 37.84, 41.41, 48.83, 115.31, 115.60, 121.89, 124.84 (124.87), 127.12, 131.02 (131.28), 131.51, 133.20, 134.66, 135.87 (135.97), 139.09, 158.77 (161.98), 166.90, 167.42, 169.78, 170.26, 172.73; Anal. Calcd. for C23H20N3O5F: C, 63.15; H, 4.61; N, 9.61; F, 4.34. Found: C, 62.78; H, 4.45; N, 9.32; F, 4.47.
    • 5.155 2-(3,5-DIMETHOXY-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00434
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3,5-dimethoxyphenylacetic acid (0.5 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was then concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford 2-(3,5-dimethoxy-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.8 g, 79%) as a white solid: mp 294-296° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.88 min. (98%); 1H NMR (DMSO-d6) δ 2.03-2.07 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.94 (m, 1H), 3.45 (s, 2H), 3.71 (s, 6H), 4.70 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.8 Hz, 1H), 6.37 (t, J=2.2 Hz, 1H), 6.46 (d, J=2.2 Hz, 2H), 7.51-7.67 (m, 1H), 7.72-7.81 (m, 2H), 8.61 (t, J=5.9 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.94, 30.90, 37.83, 42.51, 48.82, 55.05, 98.34, 107.08, 121.88, 127.12, 131.51, 133.17, 134.61, 138.20, 139.18, 160.28, 166.90, 167.42, 169.77, 170.34, 172.73; Anal. Calcd. for C24H23N3O7: C, 61.93; H, 4.98; N, 9.03. Found: C, 61.62; H, 4.61; N, 8.91.
    • 5.156 2-(4-CHLORO-PHENYL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00435
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.4 mmol) and 4-chlorophenylacetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was filtered. The solid was slurried with hot acetone (15 mL) to afford 2-(4-chloro-phenyl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.8 g, 82%) as a white solid: mp 243-245° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.04 min. (86%); 1H NMR (DMSO-d6) δ 2.02-2.08 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.54 (s, 2H), 4.72 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.8 Hz, 1H), 7.29-7.38 (m, 4H), 7.61-7.67 (m, 1H), 7.71-7.83 (m, 2H), 8.68 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 37.86, 41.31, 48.83, 121.90, 127.13, 128.14, 130.94, 131.14, 131.52, 133.22, 134.69, 135.11, 139.95, 166.89, 167.42, 169.78, 170.24, 172.73; Anal. Calcd. for C22H18N3O5Cl: C, 60.08; H, 4.12; N, 9.55; Cl, 8.06. Found: C, 60.06; H, 3.85; N, 9.67; Cl, 8.07.
    • 5.157 2-BENZO[1,3]DIOXO-5-YL-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00436
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.1 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3,4-(methylenedioxy)-phenylacetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford 2-benzo[1,3]dioxo-5-yl-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-s,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.8 g, 77%) as a white solid: mp 196-198° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.59 min. (98%); 1H NMR (DMSO-d6) δ 2.03-2.07 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.44 (s, 2H), 4.71 (d, J=5.7 Hz, 2H), 5.12-5.18 (dd, J=5.2 and 12.7 Hz, 1H), 5.97 (m, 2H), 6.73-6.75 (m, 1H), 6.83-6.85 (m, 2H), 7.61-7.66 (m, 1H), 7.79-7.83 (m, 2H), 8.56 (t, J=5.9 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 37.84, 41.78, 48.83, 100.73, 108.01, 109.48, 121.87, 1222.04, 127.11, 129.70, 131.51, 133.18, 134.66, 139.18, 145.80, 147.07, 166.90, 167.42, 169.78, 170.73, 172.73; Anal. Calcd. for C23H19N3O7: C, 61.47; H, 4.26; N, 9.35. Found: C, 61.53; H, 3.94; N, 9.16.
    • 5.158 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-PYRIDINYL-2-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00437
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2-pyridylacetic acid hydrochloride (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH/CH2Cl2 3:97) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-pyridinyl-2-yl-acetamide (0.7 g, 74%) as a white solid: mp 146-148° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=0.91 min. (96%); 1H NMR (DMSO-d6) δ 2.02-2.09 (m, 1H), 2.53-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.74 (s, 2H), 4.75 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.2 and 12.7 Hz, 1H), 7.24-7.37 (m, 2H), 7.71-7.85 (m, 4H), 8.50-8.52 (d, J=0.8 and 4.9 Hz, 1H), 8.74 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.91, 37.94, 44.77, 48.83, 121.81, 123.84, 127.07, 131.48, 133.23, 134.66, 136.52, 139.14, 148.92, 156.09, 166.93, 167.46, 169.65, 169.80, 172.73; Anal. Calcd. for C21H18N4O5: C, 62.07; H, 4.46; N, 13.79. Found: C, 61.74; H, 4.18; N, 13.41.
    • 5.159 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-PYRIDINYL-3-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00438
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-pyridylacetic acid hydrochloride (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 3:97) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-pyridinyl-3-yl-acetamide (0.5 g, 57%) as a white solid: mp 292-294° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=0.87 min. (97%); 1H NMR (DMSO-d6) δ 2.04-2.07 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.59 (s, 2H), 4.74 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.2 and 12.7 Hz, 1H), 7.32-7.36 (m, 1H), 7.65-7.71 (m, 2H), 7.80-7.84 (m, 2H), 8.43-8.49 (m, 2H), 8.75 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 37.89, 39.03, 48.83, 121.93, 123.33, 127.15, 131.52, 131.79, 133.26, 134.70, 136.64, 138.97, 147.65, 150.01, 166.89, 167.41, 169.78, 170.03, 172.73; Anal. Calcd. for C21H18N4O5: C, 62.07; H, 4.46; N, 13.79. Found: C, 61.73; H, 4.46; N, 13.55.
    • 5.160 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-PYRIDIN-4-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00439
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (1.2 g, 7.8 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 4-pyridylacetic acid hydrochloride (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 3:97) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-pyridin-4-yl-acetamide (0.4 g, 50%) as white solid: mp 294-296° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=0.87 min. (98%); 1H NMR (DMSO-d6) δ 2.02-2.07 (m, 1H), 2.52-2.96 (m, 2H), 2.84-2.96 (m, 1H), 3.59 (s, 2H), 5.12-5.18 (dd, J=5.2 and 12.7 Hz, 1H), 7.31 (d, J=5.5 Hz, 2H), 7.64-7.70 (m, 1H), 7.79-7.84 (m, 2H), 8.50 (d, J=5.6 Hz, 2H), 8.77 (t, J=5.8 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 37.91, 41.27, 48.83, 121.96, 124.54, 127.17, 131.53, 133.30, 134.71, 138.88, 144.92, 149.37, 166.88, 167.41, 169.33, 169.78, 172.73; Anal. Calcd. for C21H18N4O5: C, 62.07; H, 4.46; N, 13.79. Found: C, 61.77; H, 4.39; N, 13.59.
    • 5.161 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-NAPHTHALEN-1-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00440
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 1-naphthylacetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL), washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-naphthalen-1-yl-acetamide (0.7 g, 74%) as a white solid: mp 187-189° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.70 min. (98%); 1H NMR (DMSO-d6) δ 1.98-2.06 (m, 1H), 2.54-2.63 (m, 2H), 2.83-2.96 (m, 1H), 4.03 (s, 2H), 4.74 (d, J=5.8 Hz, 2H), 5.11-5.17 (dd, J=5.2 and 12.8 Hz, 1H), 7.43-8.11 (m, 10H), 8.71 (t, J=4.6 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 37.89, 48.82, 121.86, 124.17, 125.52, 125.64, 125.95, 127.11, 127.15, 127.92, 128.37, 131.48, 131.90, 132.47, 133.23, 133.33, 134.56, 139.23, 166.89, 167.42, 169.77, 170.60, 172.72; Anal. Calcd. for C26H21N3O5: C, 68.56; H, 4.65; N, 9.23. Found: C, 68.24; H, 4.54; N, 9.19.
    • 5.162 2-(4,5-DIMETHYL-FURAN-2-YL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00441
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 4,5-dimethyl-2-furoic acid (0.3 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL), washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford 2-(4,5-dimethyl-furan-2-yl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-diox0-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.6 g, 72%) as a white solid: mp 221-223° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.85 min. (99%); 1H NMR (DMSO-d6) δ 1.95 (s, 3H), 2.05-2.11 (m, 1H), 2.26 (s, 3H), 2.52-2.64 (m, 2H), 2.85-2.97 (m, 1H), 4.86 (d, J=6.0 Hz, 2H), 5.13-5.19 (dd, J=5.3 and 12.6 Hz, 1H), 6.95 (s, 1H), 7.65-7.85 (m, 3H), 8.81 (t, J=6.0 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 9.41, 11.41, 21.96, 30.91, 37.55, 48.84, 116.30, 117.01, 121.80, 127.01, 131.48, 132.88, 134.76, 139.33, 144.63, 150.08, 158.18, 166.95, 167.52, 169.81, 172.74; Anal. Calcd. for C21H19N3O6: C, 61.61; H, 4.68; N, 10.36. Found: C, 61.63; H, 4.43; N, 10.03.
    • 5.163 2-(2,5-DIMETHYL-FURAN-3-YL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00442
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2,5-dimethyl-3-furoic acid (0.3 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford 2-(2,5-dimethyl-furan-3-yl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.65 g, 73%) as a white solid: mp 193-195° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.45 min. (99%); 1H NMR (DMSO-d6) δ 2.06-2.11 (m, 1H), 2.23 (s, 3H), 2.46 (s, 3H), 2.54-2.63 (m, 2H), 2.85-2.97 (m, 1H), 4.85 (d, J=5.9 Hz, 2H), 5.14-5.20 (dd, J=5.3 and 12.6 Hz, 1H), 6.49 (s, 1H), 7.67-7.86 (m, 3H), 8.54 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 12.98, 13.08, 21.96, 30.92, 37.53, 48.85, 104.86, 115.84, 121.77, 126.99, 131.48, 132.99, 134.76, 139.69, 149.11, 154.47, 163.32, 166.96, 167.54, 169.81, 172.74; Anal. Calcd. for C21H19N3O6: C, 61.61; H, 4.68; N, 10.26. Found: C, 61.66; H, 4.37; N, 9.99.
    • 5.164 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]2-(6-METHOXY-BENZOFURAN-3-YL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00443
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2-(6-methoxy-1-benzofuran-3-yl)-acetic acid were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). After stirring at room temperature overnight, the mixture was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (40 mL), 1NHCl (2×30 mL), water (40 mL), and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]2-(6-methoxy-benzofuran-3-yl)-acetamide (0.76 g, 73%) as a white solid: mp 143-145° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.41 min. (98%); 1H NMR (DMSO-d6) δ 2.03-2.07 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.60 (s, 2H), 3.79 (s, 3H), 4.74 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.8 Hz, 1H), 6.85-6.89 (dd, J=2.2 and 8.6 Hz, 1H), 7.15 (d, J=2.2 Hz, 1H), 7.46 (d, J=8.6 Hz, 1H), 7.64-7.81 (m, 4H), 8.69 (t, J=5.9 Hz, 1H), 11.14 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.51, 30.90, 37.91, 48.83, 55.53, 95.93, 111.42, 114.55, 120.21, 120.91, 121.90, 127.12, 131.49, 133.29, 134.63, 139.06, 142.19, 155.57, 157.68, 166.90, 167.43, 169.78, 172.63, 172.73; Anal. Calcd. for C25H21N3O7: C, 63.16; H, 4.45; N, 8.84. Found: C, 62.90; H, 4.44; N, 8.74.
    • 5.165 2-{2,5-DIMETHYL-1,3-THIAZOL-4-YL)-N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-ACETAMIDE
  • Figure US20070049618A1-20070301-C00444
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2-(2,5-dimethyl-1,3-thiazol-4-yl)acetic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 3:97) to afford 2-(2,5-dimethyl-1,3-thiazol-4-yl)-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide (0.7 g, 76%) as a white solid: mp 140-142° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=1.39 min. (99%); 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.31 (s, 3H), 2.56 (s, 3H), 2.51-2.63 (m, 2H), 2.84-2.91 (m, 1H), 3.56 (s, 2H), 4.73 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.76-7.85 (m, 3H), 8.58 (t, J=6.0 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 10.84, 18.56, 21.95, 30.91, 35.85, 37.94, 48.82, 121.81, 127.03, 127.91, 131.46, 133.21, 134.60, 139.26, 145.51, 160.87, 166.94, 167.48, 169.51, 169.79, 172.73; Anal. Calcd. for C21H20N4O5S: C, 57.27; H, 4.58; N, 12.72; S, 7.28. Found: C, 57.13; H, 4.71; N, 12.45; S, 7.18.
    • 5.166 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(3-METHYL-ISOXAZOL-5-YL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00445
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-methyl-5-isoxazoleacetic acid (0.3 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 5:95) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(3-methyl-isoxazol-5-yl)-acetamide (0.8 g, 84%) as a white solid: mp 179-181° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=1.71 min. (97%); 1H NMR (DMSO-d6) δ 2.04-2.09 (m, 1H), 2.20 (s, 3H), 2.53-2.63 (m, 2H), 2.84-2.92 (m,1H), 3.77 (s, 2H), 4.73 (d, J=5.8 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 6.21 (s, 1H), 7.69-7.87 (m, 3H), 8.80 (t, J=5.9 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 10.91, 21.95, 30.90, 33.46, 38.00, 48.85, 103.79, 121.99, 127.18, 131.54, 133.27, 134.75, 138.66, 159.51, 166.85, 166.90, 167.41, 169.77, 172.72; Anal. Calcd. for C20H18N4O6: C, 58.54; H, 4.42; N, 13.65. Found: C, 58.18; H, 4.19; N, 13.52.
    • 5.167 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-(1-METHYL-1H-INDOL-3-YL)-ACETAMIDE
  • Figure US20070049618A1-20070301-C00446
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 1-methyl-3-indoleacetic acid (0.5 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 5:95) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-(1-methyl-1H-indol-3-yl)-acetamide (0.8 g, 83%) as a yellow solid: mp 231-233° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.53 min. (98%); 1H NMR (DMSO-d6) δ 2.02-2.07 (m, 1H), 2.54-2.63 (m, 2H), 2.83-2.91 (m, 1H), 3.62 (s, 2H), 3.73 (s, 3H), 4.70 (d, J=5.9 Hz, 2H), 5.10-5.16 (dd, J=5.2 and 12.7 Hz, 1H), 6.99-7.04 (dd, J=7.1 and 7.9 Hz, 1H), 7.12-7.17 (dd, J=7.1 and 7.9 Hz, 1H), 7.21 (s, 1H), 7.40 (d, J=8.2 Hz, 1H), 7.54-7.79 (m, 4H), 8.47 (t, J=5.9 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 32.23, 32.34, 37.86, 48.83, 107.82, 109.50, 118.39, 118.78, 121.07, 121.79, 127.06, 127.47, 128.27, 131.46, 133.19, 134.54, 136.53, 139.38, 166.91, 167.45, 169.77, 171.15, 172.71; Anal. Calcd. for C25H22N4O5: C, 65.49; H, 4.84; N, 12.22. Found: C, 65.11; H, 4.54; N, 12.05.
    • 5.168 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-THIOPHEN-2-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00447
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 2-thiopheneacetic acid (0.3 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-thiophen-2-yl-acetamide (0.7 g, 78%) as a white solid: mp 171-173° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.24 min. (99%); 1H NMR (DMSO-d6) δ 2.02-2.09 (m, 1H), 2.51-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.77 (s, 2H), 4.72 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 6.95-6.97 (m, 2H), 7.35-7.38 (m, 1H), 7.65-7.69 (m, 1H), 7.78-7.84 (m, 2H), 8.70 (t, J=5.9 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 36.35, 37.87, 48.84, 121.91, 124.90, 126.22, 126.60, 127.13, 131.52, 133.21, 134.68, 137.33, 138.97, 166.89, 167.42, 169.61, 169.78, 172.73; Anal. Calcd. for C20H17N3O5S: C, 58.39; H, 4.16; N, 10.21; S, 7.79. Found: C, 58.41; H, 4.01; N, 10.07; S, 7.62.
    • 5.169 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-THIOPHEN-3-YL-ACETAMIDE
  • Figure US20070049618A1-20070301-C00448
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 3-thiopheneacetic acid (0.3 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL) and washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-thiophen-3-yl-acetamide (0.7 g, 80%) as a white solid: mp 163-165° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=2.39 min. (99%); 1H NMR (DMSO-d6) δ 2.02-2.09 (m, 1H), 2.52-2.63 (m, 2H), 2.84-2.96 (m, 1H), 3.55 (s, 2H), 4.71 (d, J=5.9 Hz, 2H), 5.12-5.18 (dd, J=5.3 and 12.7 Hz, 1H), 7.04-7.06 (m, 1H), 7.28-7.29 (m, 1H), 7.45-7.48 (m, 1H), 7.61-7.67 (m, 1H), 7.76-7.83 (m, 2H), 8.60 (t, J=5.9 Hz, 1H), 11.13 (s, 1H); 13C NMR (DMSO-d6) δ 21.95, 30.90, 36.88, 37.83, 48.83, 121.87, 122.35, 125.76, 127.11, 128.67, 131.51, 133.18, 134.67, 135.82. 139.17, 166.91, 167.44, 169.78, 170.23, 172.73; Anal. Calcd. for C20H17N3O5S: C, 58.39; H, 4.16; N, 10.21; S, 7.79. Found: C, 58.37; H, 3.98; N, 10.05; S, 7.83.
    • 5.170 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-3-FLUORO-4-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00449
  • To the stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) and 3-fluoro-4-trifluoromethylbenzoyl chloride (0.6 g, 2.8 mmol) in dry methylene chloride (60 mL), was added diisopropylethylamine (0.7 g, 5.4 mmol). After stirring at room temperature overnight, the reaction mixture was quenched with methanol (1 mL) and washed with water (2×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 3:97) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-3-fluoro-4-trifluoromethyl-benzamide (0.6 g, 53%) as a white solid: mp 165-167° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=8.20 min. (99%); 1H NMR (DMSO-d6) δ 2.06-2.12 (m, 1H), 2.53-2.65 (m, 2H), 2.87-2.93 (m, 1H), 4.98 (d, J=5.7 Hz, 2H), 5.15-5.21 (dd, J=5.3 and 12.5 Hz, 1H), 7.76-7.84 (m, 3H), 7.95-8.01 (m, 3H), 9.45 (t, J=5.7 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.97, 30.92, 38.54, 48.87, 115.88 (116.17), 118.56 (118.72, 119.00, 119.16), 122.30, 123.94 (123.98), 120.52 (124.13), 127.25, 127.74 (127.80), 131.55, 133.24, 134.83, 138.51, 140.42 (140.52), 157.04 (160.38), 164.19, 166.91, 167.48, 169.81, 172.74; Anal. Calcd. for C22H15N3O5F4: C, 55.35; H, 3.17; N, 8.80; F, 15.92. Found: C, 55.00; H, 2.95; N, 8.80; F, 15.92.
    • 5.171 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-FLUORO-4-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00450
  • To the stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) and 2-fluoro-4-trifluoromethylbenzoyl chloride (0.6 g, 2.8 mmol) in dry methylene chloride (60 mL), was added diisopropylethylamine (0.7 g, 5.4 mmol). The mixture was stirred at room temperature overnight, quenched with methanol (1 mL), washed with water (2×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: CH3OH:CH2Cl2 3:97) to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-methyl]-2-fluoro-4-trifluoromethyl-benzamide (0.9 g, 83%) as a white solid: mp 238-240° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=7.16 min. (99%); 1H NMR (DMSO-d6) δ 2.06-2.09 (m, 1H), 2.53-2.64 (m, 2H), 2.85-2.93 (m, 1H), 4.96 (d, J=5.8 Hz, 2H), 5.15-5.21 (dd, J=5.3 and 12.6 Hz, 1H), 7.69-7.92 (m, 6H), 9.22 (t, J=5.4 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.96, 30.91, 38.46, 48.87, 113.68 (113.72, 114.02, 114.07), 121.45 (121.49, 121.54), 122.04, 124.17 (124.81), 127.24, 127.65 (127.85), 131.39 (131.43), 131.60, 132.18 (132.50, 132.62), 133.00, 134.86, 138.40, 157.20 (160.53), 163.05, 166.91, 167.46, 169.80, 172.74; Anal. Calcd. for C22H15N3O5F4: C, 55.35; H, 3.17; N, 8.80; F, 15.92. Found: C, 55.12; H, 2.88; N, 7.74; F, 15.86.
    • 5.172 N-[2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-4-FLUORO-3-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00451
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) and 4-fluoro-3-trifluoromethyl-benzoyl chloride (0.6 g, 2.8 mmol) in dry methylene chloride (60 mL), was added diisopropylethylamine (0.7 g, 5.4 mmol). After stirring at room temperature overnight, the reaction mixture was quenched with methanol (1 mL). The resulting suspension was filtered, and the solid was washed with methylene chloride to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-4-fluoro-3-trifluoromethyl-benzamide (0.8 g, 79%) as a white solid: mp 171-173° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=7.5 min. (99%); 1H NMR (DMSO-d6) δ 2.06-2.12 (m, 1H), 2.54-2.65 (m, 2H), 2.85-2.98 (m, 1H), 4.97 (d, J=5.7 Hz, 2H), 5.15-5.21 (dd, J=5.4 and 12.5 Hz, 1H), 7.68 (t, J=8.9 Hz, 1H), 7.76-7.84 (m, 3H), 8.28-8.35 (m, 2H), 9.43 (t, J=5.7 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.91, 30.86, 38.43, 48.82, 116.20 (116.37, 116.64, 116.80), 117.35 (117.63), 120.50 (124.10), 121.92, 126.51 (126.56), 127.14, 130.65 (130.70), 131.48, 133.22, 134.58, 134.71 (134.77), 138.70, 158.78 (162.21), 164.19, 166.87, 167.44, 169.75, 172.68; Anal. Calcd. for C22H15N3O5F4+0.2H2O: C, 54.94; H, 3.23; N, 8.74; F, 15.80. Found: C, 54.68; H, 3.17; N, 8.63; F, 15.72.
    • 5.173 N-[2-(2,6-DIOXO-PIPERIDIN-3-Y]L)-[3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-2-FLUORO-3-TRIFLUOROMETHYL-BENZAMIDE
  • Figure US20070049618A1-20070301-C00452
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) and 2-fluoro-3-trifluoromethyl-benzoyl chloride (0.6 g, 2.8 mmol) in dry methylene chloride (60 mL), was added diisopropylethylamine (0.7 g, 5.4 mmol). The mixture was stirred at room temperature overnight then quenched with methanol (1 mL). The resulting suspension was filtered and the solid was washed with methylene chloride to afford N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-2-fluoro-3-trifluoromethyl-benzamide (0.8 g, 72%) as a white solid: mp 155-157° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=6.23 min. (99%); 1H NMR (DMSO-d6) δ 2.04-2.11 (s, 1H), 2.53-2.64 (m, 2H), 2.85-2.97 (m, 1H), 4.96 (d, J=5.8 Hz, 2H), 5.15-5.21 (dd, J=5.3 and 12.6 Hz, 1H), 7.52 (t, J=7.8 Hz, 1H), 7.79-8.01 (m, 5H), 9.26 (t, J=5.7 Hz, 1H), 11.15 (s, 1H); 13C NMR (DMSO-d6) δ 21.96, 30.91, 38.46, 48.87, 117.03 (117.29, 117.45), 120.65 (124.26), 122.03, 125.09 (125.15), 125.45 (125.64), 127.22, 129.24 (129.29), 131.58, 132.97, 134.89, 138.41, 154.37 (157.77), 162.90, 166.91, 167.45, 169.80, 172.73; Anal. Calcd. for C22H15N3O5F4: C, 55.35; H, 3.17; N, 8.80; F, 15.92. Found: C, 55.13; H, 2.95; N, 8.73; F, 15.69.
    • 5.174 BENZO[B]THIOPHENE-5-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00453
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.7 g, 2.2 mmol) in acetonitrile (60 mL), was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.8 g, 5.4 mmol). After stirring for 10 minutes, 1-hydroxybenzotriazole (0.4 g, 2.6 mmol) and 1-benzothiophene-5-carboxylic acid (0.4 g, 2.4 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6 g, 3.2 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (80 mL), washed with water (3×40 mL) and brine (40 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was purified by ISCO silica gel flash chromatography (Eluent: EtOAc:CH2Cl2 3:7) to afford benzo[b]thiophene-5-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (0.5 g, 53%) as a white solid: mp 261-263° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.22 min. (99%); 1H NMR (DMSO-d6) δ 2.07-2.11 (m, 1H), 2.55-2.65 (m, 2H), 2.86-2.98 (m, 1H), 4.99 (d, J=5.6 Hz, 2H), 5.16-5.22 (dd, J=5.0 and 12.4 Hz, 1H), 7.59 (d, J=5.4 Hz, 1H), 7.79-7.92 (m, 5H), 8.11 (d, J=8.4 Hz, 1H), 8.48 (s, 1H), 9.24 (t, J=5.5 Hz, 1H), 11.16 (s, 1H); 13C NMR (DMSO-d6) δ 21.99, 30.93, 38.44, 48.88, 121.85, 122.50, 122.91, 122.95, 124.39, 127.14, 128.84, 130.39, 131.54, 133.07, 134.79, 139.18, 139.38, 141.92, 166.79, 166.97, 167.55, 169.83, 172.74; Anal. Calcd. for C23H17N3O5S+0.2H2O: C, 61.24; H, 3.89; N, 9.32; S, 7.11. Found: C, 61.04; H, 3.57; N, 8.96; S, 7.19.
    • 5.175 4-METHYL-OXAZOLE-5-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00454
  • To a suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.90 g, 5.9 mmol) in CH3CN (25 ml), were added triethyl amine (2.05 mL, 14.7 mmol) and 4-methyl-oxazole-5-carbonyl-chloride (0.85 g, 5.9 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was filtered, and the solid was rinsed with CH3CN (20 mL), water (2×20 mL) and EtOAc (20 mL) to afford 4-methyl-oxazole-5-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a white solid (1.82 g, 78%): mp, 308-310° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, gradient from 10/90 (CH3CN/H2O) to 95/5 (CH3CN/H2O) in 10 minutes: tR=5.49 (98%); 1H NMR (DMSO-d6): δ 2.06-2.10 (m, 1H), 2.38 (s, 3H), 2.59-2.64 (m, 2H), 2.85-2.97 (m, 1H), 4.88 (d, J=5.9 Hz, 2H), 5.17 (dd, J=6, 12 Hz, 1H), 7.70-8.47 (m, 4H), 9.05 (t, J=5.9 Hz, 1H), 11.16 (s, 1H). 13C NMR (DMSO-d6) δ 12.52, 21.96, 30.92, 37.57, 48.86, 121.91, 127.09, 131.51, 133.01, 134.81, 138.86, 138.89, 140.67, 151.42, 157.96, 166.94, 167.51, 169.82, 172.74. Anal Calcd for C19H16N4O6: C, 57.58; H, 4.07; N, 14.14. Found: C, 57.48; H, 4.04; N, 14.33.
    • 5.176 4-METHYL-2-PHENYL-THIAZOLE-5-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYLAMIDE
  • Figure US20070049618A1-20070301-C00455
  • To a suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.45 g, 4.5 mmol) in CH3CN (25 ml), were added triethyl amine (1.56 mL, 11.22 mmol) and 4-methyl-2-phenyl-1,3-thiazole-5-carbonyl-chloride (1.07 g, 4.5 mmol). The mixture was stirred at room temperature overnight. The resulting suspension was filtered, and the solid was rinsed with CH3CN (20 mL), water (2×20 mL) and EtOAc (20 mL) to afford 4-methyl-2-phenyl-thiazole-5-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a white solid (1.45 g, 66%): mp, 277-279° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, gradient from 10/90 (CH3CN/H2O) to 95/5 (CH3CN/H2O) in 10 minutes: tR=6.96 min. (99%); 1H NMR (DMSO-d6): δ 2.08-2.10 (m, 1H), 2.55-2.59 (m, 2H), 2.66 (s, 3H), 2.86-2.98 (m, 1H), 4.91 (d, J=5.6 Hz, 2H), 5.18 (dd, J=6, 12 Hz, 1H), 7.53-7.98 (m, 8H), 8.91 (t, J=5.6 Hz, 1H), 11.16 (s, 1H). 13C NMR (DMSO-d6) δ: 17.20, 30.92, 38.56, 48.87, 121.98, 125.65, 126.65, 126.25, 127.18, 129.37, 130.95, 131.57, 132.36, 133.15, 134.85, 138.83, 155.65, 161.37, 166.14, 166.93, 167.51, 169.82, 172.75. Anal Calcd for C25H20N4O5S: C, 61.47; H, 4.13; N, 11.47; S: 6.56. Found: C, 61.44; H, 4.04; N, 11.63; S: 6.49.
    • 5.177 ISOXAZOLE-5-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00456
  • To a suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (2.7 g, 8.4 mmol) in CH3CN (25 ml), were added triethyl amine (2.9 mL, 8.4 mmol) and isoxazole-5-carbonyl-chloride (1.07 g, 4.5 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was filtered, and the solid was rinsed with CH3CN (20 mL), water (2×20 mL) and EtOAc (20 mL). The solid was dissolved in CH2Cl2 (5 mL) and purified by ISCO silica gel flash chromatography (eluent: 2% MeOH in CH2Cl2) to afford isoxazole-5-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a light yellow solid (0.87 g, 27%): mp, 257-259° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, gradient from 10/90 (CH3CN/H2O) to 95/5 (CH3CN/H2O) in 10 minutes: tR=5.62 (99%); 1H NMR (DMSO-d6): δ 2.04-2.11 (m, 1H), 2.53-2.64 (m, 2H), 2.85-2.97 (m, 1H), 4.93 (d, J=5.6 Hz, 2H), 5.17 (dd, J=6, 12 Hz, 1H), 7.14-8.78 (m, 5H), 9.60 (t, J=5.6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.92, 37.96, 48.87, 106.26, 122.11, 127.25, 131.56, 133.14, 134.89, 138.00, 151.75, 155.95, 162.35, 166.90, 167.44, 169.80, 172.73. Anal Calcd for C18H14N4O6: C, 56.55; H, 3.69; N, 14.65. Found: C, 56.20; H, 3.36; N, 14.47.
    • 5.178 THIAZOLE-2-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00457
  • To a suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (0.57 g, 1.75 mmol) in CH3CN (10 ml), were added triethyl amine (0.61 mL, 4.4 mmol) and 1,3-thiazole-2-carbonyl-chloride (1.07 g, 4.5 mmol). The mixture was stirred at room temperature overnight and a suspension was obtained. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The resulting oil was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2) to afford thiazole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a white solid (0.52 g, 74%): mp, 189-191° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, gradient from 10/90 (CH3CN/H2O) to 95/5 (CH3CN/H2O) in 10 minutes: tR=5.9 min (97%); 1H NMR (DMSO-d6): δ 2.05-2.12 (m, 1H), 2.53-2.65 (m, 2H), 2.86-2.98 (m, 1H), 4.94 (d, J=6.2 Hz, 2H), 5.18 (dd, J=5, 11 Hz, 1H), 7.68-8.10 (m, 5H), 9.50 (t, J=6 Hz, 1H), 11.15 (s, 1H). 13C NMR (DMSO-d6) δ: 21.96, 30.92, 38.32, 48.88, 121.98, 125.99, 127.17, 131.56, 132.92, 134.85, 138.43, 143.98, 159.59, 163.18, 166.93, 167.51, 169.81, 172.73. Anal Calcd for C18H14N4O5S: C, 54.27; H, 3.54; N, 14.06; S, 8.05. Found: C, 53.98; H, 3.49; N, 13.75; S, 8.22.
    • 5.179 BENZO[C]ISOXAZOLE-3-CARBOXYLIC ACID [2-(2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00458
  • To a stirred suspension of 4-aminomethyl-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione hydrochloride (1.8 g, 5.7 mmol) in DMF (20 ml), was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.9 g, 6.8 mmol). After stirring for 10 minutes, 1-hydroxybenzenetriazole (0.9 g, 6.8 mmol) and benzo[c]isoxazole-3-carboxylic acid (1.0 g, 6.3 mmol) were added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.6 g, 8.5 mmol). The mixture was stirred at room temperature overnight and was concentrated in vacuo. The residue was dissolved in CH2Cl2 (50 mL), washed with water (2×30 mL) and brine (30 mL), and dried over MgSO4. Solvent was removed in vacuo, and the resulting oil was purified by ISCO silica gel flash chromatography (eluent: 3% MeOH in CH2Cl2) to afford benzo[c]isoxazole-3-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide as a yellow solid (1.93 g, 78%): mp, 253-255° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, gradient from 10/90 (CH3CN/H2O) to 95/5 (CH3CN/H2O) in 10 minutes: tR=6.6 min (96%); 1H NMR (DMSO-d6): δ 2.08-2.13 (m, 1H), 2.53-2.65 (m, 2H), 2.86-2.94 (m, 1H), 5.02 (d, J=6.0 Hz, 2H), 5.19 (dd, J=6, 12 Hz, 1H), 7.27-7.97 (m, 5H), 9.90 (t, J=6 Hz, 1H), 11.16(s, 1H). 13C NMR (DMSO-d6) δ: 21.98, 30.93, 40.33, 48.89, 115.15, 118.27, 120.74, 122.07, 127.24, 131.54, 131.96, 133.20, 134.88, 138.13, 156.43, 156.52, 156.97, 160.91, 166.93, 167.49, 169.82, 172.75. Anal Calcd for C22H16N4O6+0.2H2O: C, 60.61; H, 3.79; N, 12.85. Found: C, 60.38; H, 3.50; N, 12.80.
    • 5.180 CYCLOPROPANECARBOXYLIC ACID [2-((3S)-2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YLMETHYL]-AMIDE
  • Figure US20070049618A1-20070301-C00459
  • Step 1: Triethylamine (1.2 g, 11.8 mmol) was added to a stirred suspension of (1,3-dioxo-1,3-dihydro-isobenzofuran-4-ylmethyl)carbamic acid t-butyl ester (2.1 g, 7.9 mmol) and L-glutamine t-butyl ester hydrochloride (2.1 g, 8.6 mmol) in toluene (90 mL). The mixture was refluxed under Dean-Stark water separator overnight. The mixture was cooled to room temperature and diluted with CH2Cl2 (60 mL). The solution was washed with H2O (2×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (silica gel) to give (2S)-2-[4-(t-butoxycarbonylamino-methyl)-1,3-dioxo-1,3-dihydro-isoindol-2-yl]-4-carbamoyl-butyric acid t-butylester (1.1 g, 29%): 1H NMR (CDCl3) δ 1.41 (s, 9H), 1.43 (s, 9H), 2.25-3.60 (m, 4H), 4.65 (d, J=6.5 Hz, 2H), 4.76-4.82 (dd, J=4.9 and 9.8 Hz, 1H), 5.47-5.61 (m, 3H), 7.67-7.79 (m, 3H); Chiral HPLC: Daicel ChiralPak AD, 46×250 mm, 20/80 IPA/hexane, 1 mL/min, 240 nm, 8.87 min (98% ee).
  • Step 2: 2N HCl/ether (14 mL) was added to a stirred solution of (2S)-2-[4-(t-butoxycarbonylamino-methyl)-1,3-dioxo-1,3-dihydro-isoindol-2-yl]-4-carbamoyl-butyric acid t-butyl ester (2.5 g, 5.4 mmol) in CH2Cl2 (25 mL). The mixture was stirred for 5 hours. Solid was collected by filtration to give (2S)-2-(4-aminomethyl-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-carbamoyl butyric acid t-butyl ester hydrochloride (2.1 g, 97%): 1H NMR (DMSO-d6) δ 1.37 (s, 9H), 2.08-2.37 (m, 4H), 4.47-4.51 (m, 2H), 4.73-4.79 (dd, J=4.6 and 10.0 Hz, 1H), 6.73 (s, 1H), 7.25 (s, 1H), 7.92-8.03 (m, 3H), 8.68 (s, 3H).
  • Step 3: Triethylamine (1.3 g, 12.6 mmol) was added to a stirred suspension of (2S)-2-(4-aminomethyl-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-carbamoyl butyric acid t-butyl ester hydrochloride (2.1 g, 5.2 mmol) in acetonitrile (45 mL). The mixture was stirred for 10 minutes, and cyclopropanecarbonyl chloride (0.7 g, 6.8 mmol) was added slowly at 20° C. The mixture was stirred at room temperature for 3 hours. The mixture was concentrated, and the residue was dissolved in CH2Cl2 (100 mL). The CH2Cl2 solution was washed with H2O (2×30 mL) and brine (30 mL), and dried (MgSO4). Solvent was removed, and the residue was purified by chromatography (silica gel) to (2S)-4-carbamoyl-2-{4-[(cyclopropanecarbonyl-amino)-methyl]-1,3-dioxo-1,3-dihydro-isoindol-2-yl}-butyric acid t-butyl ester (1.4 g, 64%): 1H NMR (CDCl3) δ 0.70-0.75 (m, 2H), 0.90-0.96 (m, 2H), 1.35-1.40 (m, 1H), 1.43 (s, 9H), 2.25-2.31 (m, 2H), 2.44-2.59 (m, 2H), 4.73 (d, J=6.5 Hz, 2H), 4.76-4.83 (dd, J=5.1 and 9.8 Hz, 1H), 5.45 (s, 1H), 5.60 (s, 1H), 6.92 (t, J=6.3 Hz, 1H), 7.63-7.78 (m, 3H).
  • Step 4: HCl (gas) was bubbled into a stirred solution of (2S)-4-carbamoyl-2-{4-[cyclopropanecarbonyl-amino)-methyl]-1,3-dioxo-1,3-dihydro-isoindol-2-yl}-butyric acid t-butyl ester (1.4 g, 3.3 mmol) in CH2Cl2 (25 mL) for 1 hour. The mixture was stirred for another 1 hour then filtered to give (2S)-4-carbamoyl-2-{4-[(cyclopropanecarbonyl-amino)-methyl]-1,3-dioxo-1,3-dihydro-isoindol-2-yl}-butyric acid (1.2 g, 96%) as a white solid: 1H NMR (DMSO-d6) δ 0.69-0.72 (m, 4H), 1.65-1.69 (m, 1H), 2.06-2.38 (m, 4H), 4.72-4.77 (m, 3H), 6.73 (s, 1H), 7.22 (s, 1H), 7.66-7.87 (m, 3H), 8.73 (t, J=5.8 Hz, 1H); 13C NMR (DMSO-d6) δ 6.42, 13.50, 23.97, 31.35, 37.70, 51.17, 121.76, 127.03, 131.51, 133.17, 134.65, 139.34, 167.16, 167.72, 170.37, 173.06, 173.12.
  • Step 5: A suspension of (2S)-4-carbamoyl-2-{4-[(cyclopropanecarbonyl-amino)-methyl]-1,3-dioxo-1,3-dihydro-isoindol-2-yl}-butyric acid (1.4 g, 3.8 mmol) in dry CH2Cl2 (87 mL) was cooled to −40° C. with IPA/dry ice bath. Thionyl chloride (0.5 g, 4.1 mmol) was added dropwise, followed by pyridine (0.3 g, 4.1 mmol). The mixture was stirred at −40° C. for 30 minutes. Triethylamine (0.4 g, 4.2 mmol) was added dropwise, and the mixture was stirred at −30 to −40° C. for 3 hours. The mixture was filtered into ice water (150 mL). The aqueous layer was extracted with CH2Cl2 (40 mL), and the combined CH2Cl2 solution was washed with H2O (2×40 mL) and brine (40 mL), and dried (MgSO4). Solvent was removed, and the solid was slurried with ethanol (20 mL) to give cyclopropanecarboxylic acid {2-((3S)-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide (1.0 g, 74%) as a white solid: mp 219-221° C.; Chiral HPLC: Daicel ChiralPak AD, 46×250 mm, 70/30 IPA/hexane, 0.6 mL/min, 19.76 min (98.5% ee); 1H NMR (DMSO-d6) δ 0.69-0.72 (m, 4H), 1.61-1.71 (m, 1H), 2.04-2.08 (m, 1H), 2.50-2.63 (m, 2H), 2.83-2.97 (m, 1H), 4.74 (d, J=5.7 Hz, 2H, CH2), 5.11-5.18 (dd, J=5.2 and 12.4 Hz, 1H, CH), 7.67-7.88 (m, 3H, Ar), 8.69 (t, J=5.6 Hz, 1H, NH), 11.13 (s, 1H, NH); 13C NMR (DMSO-d6) δ 6.41, 13.50, 21.96, 30.91, 37.74, 48.84, 121.84, 127.08, 131.51, 133.31, 134.76, 139.39, 166.92, 167.44, 169.78, 172.72, 173.09; Anal. calcd. for C18H17N3O5: C, 60.84; H, 4.82; N, 11.82. Found: C, 60.49; H, 4.76; N, 11.51.
    • 5.181 2-AMINO-N-[2-(3-METHYL-2,6-DIOXO-PIPERIDIN-3-YL)-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]-ACETAMIDE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00460
  • Step 1: Chloroacetyl chloride (0.9 g, 7.8 mmol) was added to a stirred suspension of 4-amino-2-(3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (1.5 g, 5.2 mmol) in THF (20 mL). The mixture was refluxed for 30 minutes. The mixture was cooled to room temperature and filtered to give 2-chloro-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide (1.6 g, 84%): 1H NMR (DSO-d6) δ 1.89 (s, 3H, CH3), 2.03-2.08 (m, 1H), 2.50-2.70 (m, 3H), 4.53 (s, 2H, CH2), 7.60 (d, J=7.3 Hz, 1H, Ar), 7.84 (t, J=7.7 Hz, 1H, Ar), 8.51 (d, J=8.4 Hz, 1H, Ar), 10.26 (s, 1H, NH), 11.05 (s, 1H, NH); 13C NMR (DMSO-d6) δ 20.98, 28.53, 29.04, 43.14, 58.89, 116.95, 118.54, 125.27, 131.30, 135.39, 136.16, 165.69, 167.31, 168.74, 171.98, 172.16.
  • Step 2: A mixture of sodium azide (0.4 g, 6.2 mmol), sodium iodide (20 mg) and 2-chloro-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide (1.5 g, 4.1 mmol) in acetone (50 mL) was heated to reflux overnight. The mixture was cooled to room temperature and concentrated. The residue was stirred with H2O (30 mL) for 30 minutes then filtered. The solid was slurried with ethanol (15 mL) to give 2-azido-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindo-4-yl]-acetamide (1.4 g, 91%): 1H NMR (DMSO-d6) δ 1.90 (s, 3H, CH3), 2.03-2.10 (m, 1H), 2.48-2.70 (m, 3H), 4.34 (s, 2H, CH2), 7.59 (d, J=7.2 Hz, 1H, Ar), 7.80-7.86 (dd, J=7.4 and 8.3 Hz, 1H, Ar), 8.50 (d, J=8.4 Hz, 1H, Ar), 10.06 (s, 1H, NH), 11.05 (s, 1H, NH).
  • Step 3: A mixture of 2-azido-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide (1.4 g, 3.8 mmol) and 10% Pd/C (0.2 g) in methanol (100 mL) and 4N HCl (20 mL) was hydrogenated in Parr Shaker for 5 hours. H2O (10 mL) was added, and the mixture was filtered through celite. The filtrate was concentrated, and the residue was evaporated with ethanol (3×20 mL). The solid was slurried with hot methanol (30 mL) to give 2-amino-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide hydrochloride (0.5 g, 35%) as a yellow solid: mp 111-113° C.; 1H NMR (DMSO-d6) δ 1.90 (s, 3H, CH3), 2.04-2.09 (m, 1H), 2.50-2.72 (m, 3H), 3.97 (s, 2H, CH2), 7.64 (d, J=7.2 Hz, 1H, Ar), 7.86 (t, J=7.7 Hz, 1H, Ar), 8.32 (d, J=8.2 Hz, 1H, Ar), 8.40 (s, 3H, NH3), 10.30 (s, 1H, NH), 11.05 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.05, 28.55, 29.10, 41.11, 58.83, 117.98, 118.92, 127.13, 131.76, 134.74, 135.99, 166.18, 167.22, 167.75, 172.04, 172.18; Anal. calcd. for C16H17N4O5Cl: C, 50.47; H, 4.50; N, 14.71; Cl, 9.31. Found: C, 50.35; H, 4.40; N, 14.54; Cl, 9.01.
    • 5.181-1 (3′S)-2-AMINO-N-[2′-(3′-METHYL-2′,6′-DIOXO-PIPERIDIN-3′-YL)-1″,3″-DIOXO-2″,3″-DIHYDRO-1″H-ISOINDOL-4″-YL]-ACETAMIDE HYDROCHLORIDE
  • Figure US20070049618A1-20070301-C00461
  • Step 1: Chloroacetyl chloride (0.9 g, 7.8 mmol) was added to a stirred suspension of (3′S)-4-amino-2-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-isoindole-1,3-dione (1.5 g, 5.2 mmol) in THF (40 mL). The resulting mixture was refluxed for 30 minutes then cooled to room temperature. The mixture was concentrated to half volume, and ether (30 mL) was added. The mixture was stirred for 30 minutes then filtered to give (3′S)-2-chloro-N-[2′-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-1″,3″-dioxo-2″,3″-dihydro-1″H-isoindol-4″-yl]-acetamide (1.9 g, 100%) as an off-white solid: 1H NMR (DMSO-d6) δ 1.89 (s, 3H, CH3), 2.03-2.10 (m, 1H), 2.49-2.68 (m, 3H), 4.53 (s, 2H, CH2), 7.60 (d, J=7.3 Hz, 1H, Ar), 7.84 (t, J=7.8 Hz, 1H, Ar), 8.51 9d, J=8.3 Hz, 1H, Ar), 10.26 (s, 1H, NH), 11.05 (s, 1H, NH).
  • Step 2: A mixture of (3′S)-2-chloro-N-[2′-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-1″,3″-dioxo-2″,3″-dihydro-1″H-isoindol-4″-yl]-acetamide (1.9 g, 4.1 mmol), sodium azide (0.5 g, 7.8 mmol), and sodium iodide (40 mg) in acetone (70 mL) was refluxed overnight. The mixture was cooled to room temperature and then concentrated. The residue was stirred with H2O (30 mL) for 30 minutes then filtered. The solid was slurried with ethanol (20 mL) to give (3′S)-2-azido-N-[2″-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-1″,3″-dioxo-2″,3″-dihydro-1″H-isoindol-4″-yl]-acetamide (1.8 g, 94%) as a yellow solid: 1H NMR (DMSO-d6) δ 1.90 (s, 3H, CH3), 2.03-2.10 (m, 1H), 2.49-2.71 (m, 3H), 4.34 (s, 2H, CH2), 7.59 (d, J=7.2 Hz, 1H, Ar), 7.83 (t, J=7.7 Hz, 1H, Ar), 8.50 (d, J=8.4 Hz, 1H, Ar), 10.05 (s, 1H, NH), 11.05 (s, 1H, NH).
  • Step 3: A mixture of (3′S)-2-azido-N-[2′-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-1″,3″-dioxo-2″,3″-dihydro-1″H-isoindol-4″-yl]-acetamide (1.8 g, 4.9 mmol), 110% Pd/C (150 mg), and 4N HCl (20 mL) in methanol (200 mL) was hydrogenated at 60 psi of H2 for 5 hours. H2O (20 mL) was added, and the mixture was filtered through celite. The filtrate was concentrated and the residue was evaporated with ethanol (3×20 mL). The residue was slurried with hot methanol (30 mL) to give 1.4 g of crude product. The crude product was recrystallized from methanol (150 mL) to give (3′S)-2-amino-N-[2′-(3′-methyl-2′,6′-dioxo-piperidin-3′-yl)-1″,3″-dioxo-2″,3″-dihydro-1″H-isoindol-4″-yl]-acetamide hydrochloride (0.9 g, 46%) as a yellow solid: mp >260° C.; 1H NMR (DMSO-d6) δ 1.90 (s, 3H, CH3), 2.04-2.09 (m, 1H), 2.51-2.72 (m, 3H), 3.97 (s, 2H, CH2), 7.64 (d, J=7.2 Hz, 1H, Ar), 7.86 (t, J=7.5 Hz, 1H), 8.32 (d, J=8.4 Hz, 1H, Ar), 8.40 (b, 3H, NH3), 10.30 (b, 1H, NH), 11.05 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.06, 28.57, 29.11, 41.11, 58.83, 117.99, 118.94, 127.14, 131.77, 134.74, 136.00, 166.19, 167.24, 167.76, 172.06, 172.20; Anal. calcd. for C16H17N4O5Cl+0.46H2O: C, 49.39; H, 4.64; N, 14.40; Cl, 9.11. Found: C, 49.07; H, 4.52; N, 14.11; Cl, 8.81.
    • 5.182 3-{4-[(BENZOFURAN-2-YLMETHYL)-AMINO]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL}-PIPERIDINE-2,6-DIONE
  • Figure US20070049618A1-20070301-C00462
  • A mixture of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-1,3-dione (0.7 g, 2.7 mmol) and 2-benzofurancarboxaldehyde (0.4 g, 3.0 mmol) in methanol (40 mL) was refluxed for 3 hours. Methanol was removed in vacuo, and the residue was dissolved in acetic acid (15 mL). The resulting mixture was treated with sodium triacetoxyborohydride (0.9 g, 4.1 mmol) and stirred overnight. The mixture was diluted with ethyl acetate (120 mL) and washed with water (2×45 mL), Sat. NaHCO3 (2×45 mL), water (45 mL), and brine (45 mL), and dried over MgSO4. Solvent was removed in vacuo, and the residue was slurried in hot acetone to give a crude product. The crude product was recrystallized from methanol to afford 3-{4-[(benzofuran-2-ylmethyl)-amino]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione (0.7 g, 64%) as a white solid: mp 253-255° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=5.42 min. (99%); 1H NMR (DMSO-d6) δ 2.03-2.07 (m, 1H), 2.25-2.39 (m, 1H), 2.59-2.65 (m, 1H), 2.87-2.99 (m, 1H), 4.22 (d, J=17.3 Hz, 1H), 4.28 (d, J=17.1 Hz, 1H), 4.58 (d, J=5.5 Hz, 2H), 5.09-5.15 (dd, J=5.1 and 13.2 Hz, 1H), 6.40 (t, J=5.8 Hz, 1H), 6.79 (s, 1H), 6.90 (d, J=8.0 Hz, 1H), 6.98 (d, J=7.4 Hz, 1H), 7.17-7.29 (m, 3H), 7.50-7.57 (m, 2H), 11.02 (s, 1H); 13C NMR (DMSO-d6) δ 22.76, 31.22, 45.74, 51.52, 103.67, 110.81, 110.87, 112.37, 120.76, 122.72, 123.76, 126.84, 128.08, 129.10, 132.17, 142.92, 154.15, 156.18, 168.67, 171.19, 172.86; Anal. Calcd. for C22H19N3O4: C, 67.86; H, 4.92; N, 10.79. Found: C, 67.82; H, 4.97; N, 10.76.
    • 5.183 3-{4-[(4,5-DIMETHYL-FURAN-2-YLMETHYL)-AMINO]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL}-PIPERIDINE-2,6-DIONE
  • Figure US20070049618A1-20070301-C00463
  • A mixture of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-1,3-dione (1.0 g, 3.9 mmol) and 4,5-dimethylfuraldehyde (0.5 g, 4.2 mmol) in methanol (40 mL) was refluxed for 2 hours. Methanol was removed in vacuo, and the residue was dissolved in acetic acid (15 mL). Sodium triacetoxyborohydride (1.2 g, 5.8 mmol) was added, and the resulting mixture was stirred at room temperature overnight. The mixture was then diluted with CH2Cl2 (40 mL) and filtered to afford 1 g of crude product. The crude product was recrystallized from methanol (250 mL) to afford 3-{4-[(4,5-dimethyl-furan-2-ylmethyl)-amino]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione (0.7 g, 48%) as a white solid: mp 237-239° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=4.82 min. (99%); 1H NMR (DMSO-d6) δ 1.84 (s, 3H), 2.01-2.05 (m, 1H), 2.12 (s, 3H), 2.24-2.35 (m, 1H), 2.59-2.64 (m, 1H), 2.86-2.98 (m, 1H), 4.10-4.28 (m, 4H), 5.07-5.14 (dd, J=5.1 and 13.2 Hz, 1H), 6.08 (s, 1H), 6.13 (t, J=6.6 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 6.96 (d, J=7.4 Hz, 1H), 7.27 (t, J=7.7 Hz, 1H), 11.01 (s, 1H); 13C NMR (DMSO-d6) δ 9.67, 11.22, 22.88, 31.34, 39.75, 45.86, 51.61, 110.38, 110.62, 112.42, 114.17, 126.83, 129.16, 132.19, 143.22, 145.81, 149.75, 168.86, 171.32, 172.99; Anal. Calcd. for C20H21N3O4: C, 65.38; H, 5.76; N, 11.44. Found: C, 65.30; H, 5.74; N, 11.36.
    • 5.184 3-{4-[(5-METHYL-FURAN-2-YLMETHYL)-AMINO]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL}-PIPERIDINE-2,6-DIONE
  • Figure US20070049618A1-20070301-C00464
  • A mixture of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (1.0 g, 3.9 mmol) and 5-methylfurfural (0.5 g, 4.2 mmol) in methanol (40 mL) was refluxed for 2 hours. Methanol was removed in vacuo, and the residue was dissolved in acetic acid (15 mL). Sodium triacetoxyborohydride (1.2 g, 5.8 mmol) was added, and the resulting mixture was stirred at room temperature for 2 hours. The mixture was diluted with CH2Cl2 (40 mL) and filtered. The resulting solid was recrystallized from methanol (400 mL) to afford 3-{4-[(5-methyl-furan-2-ylmethyl)-amino]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione (0.8 g, 57%) as a white solid: mp 242-244° C.; HPLC: Waters Symmetry C-18, 3.9×150 mm, 5 micro, 1 mL/min, 240 nm, 40/60 (CH3CN/H2O): tR=3.44 min. (99%); 1H NMR (DMSO-d6) δ 2.00-2.06 (m, 1H), 2.21 (s, 3H), 2.27-2.35 (m, 1H), 2.58-2.64 (m, 1H), 2.86-2.98 (m, 1H), 4.11-4.30 (m, 4H), 5.07-5.14 (dd, J=5.1 and 13.2 Hz, 1H), 5.97 (d, J=1.9 Hz, 1H), 6.17-6.19 (m, 2H), 6.86 (d, J=8.0 Hz, 1H), 6.96 (d, J=7.3 Hz, 1H), 7.26 (t, J=7.7 Hz, 1H), 11.01 (s, 1H); 13C NMR (DMSO-d6) δ 13.27, 22.75, 31.21, 39.65, 45.74, 51.48, 106.25, 107.93, 110.53, 112.32, 126.72, 129.02, 132.08, 143.09, 150.55, 150.87, 168.72, 171.19, 172.86; Anal. Calcd. for C19H19N3O4: C, 64.58; H, 5.42; N, 11.89. Found: C, 64.51; H, 5.70; N, 11.88.
    • 5.185 Assays 5.185.1 TNFα Inhibition Assay in PMBC
  • Peripheral blood mononuclear cells (PBMC) from normal donors are obtained by Ficoll Hypaque (Pharmacia, Piscataway, N.J., USA) density centrifugation. Cells are cultured in RPMI 1640 (Life Technologies, Grand Island, N.Y., USA) supplemented with 10% AB+human serum (Gemini Bio-products, Woodland, Calif., USA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies).
  • PBMC (2×105 cells) are plated in 96-well flat-bottom Costar tissue culture plates (Corning, N.Y., USA) in triplicate. Cells are stimulated with LPS (from Salmonella abortus equi, Sigma cat. no. L-1887, St. Louis, Mo., USA) at 1 ng/ml final in the absence or presence of compounds. Compounds of the invention are dissolved in DMSO (Sigma) and further dilutions are done in culture medium immediately before use. The final DMSO concentration in all assays can be about 0.25%. Compounds are added to cells 1 hour before LPS stimulation. Cells are then incubated for 18-20 hours at 37° C. in 5% CO2, and supernatants are then collected, diluted with culture medium and assayed for TNFα levels by ELISA (Endogen, Boston, Mass., USA). IC50s are calculated using non-linear regression, sigmoidal dose-response, constraining the top to 100% and bottom to 0%, allowing variable slope (GraphPad Prism v3.02).
    • 5.185.2 IL-2 and MIP-3α Production by T Cells
  • PBMC are depleted of adherent monocytes by placing 1×108 PBMC in 10 ml complete medium (RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin) per 10 cm tissue culture dish, in 37° C., 5% CO2 incubator for 30-60 minutes. The dish is rinsed with medium to remove all non-adherent PBMC. T cells are purified by negative selection using the following antibody (Pharmingen) and Dynabead (Dynal) mixture for every 1×108 non-adherent PBMC: 0.3 ml Sheep anti-mouse IgG beads, 15 μl anti-CD16, 15 μl anti-CD33, 15 μl anti-CD56, 0.23 ml anti-CD19 beads, 0.23 ml anti-HLA class II beads, and 56 μl anti-CD14 beads. The cells and bead/antibody mixture is rotated end-over-end for 30-60 minutes at 4° C. Purified T cells are removed from beads using a Dynal magnet. Typical yield is about 50% T cells, 87-95% CD3+ by flow cytometry.
  • Tissue culture 96-well flat-bottom plates are coated with anti-CD3 antibody OKT3 at 5 μg/ml in PBS, 100 μl per well, incubated at 37° C. for 3-6 hours, then washed four times with complete medium 100 μl/well just before T cells are added. Compounds are diluted to 20 times of final in a round bottom tissue culture 96-well plate. Final concentrations are about 10 μM to about 0.00064 μM. A 10 mM stock of compounds of the invention is diluted 1:50 in complete for the first 20× dilution of 200 μM in 2% DMSO and serially diluted 1:5 into 2% DMSO. Compound is added at 10 μl per 200 μl culture, to give a final DMSO concentration of 0.1%. Cultures are incubated at 37° C., 5% CO2 for 2-3 days, and supernatants analyzed for IL-2 and MIP-3 cc by ELISA (R&D Systems). IL-2 and MIP-3α levels are normalized to the amount produced in the presence of an amount of a compound of the invention, and EC50s calculated using non-linear regression, sigmoidal dose-response, constraining the top to 100% and bottom to 0%, allowing variable slope (GraphPad Prism v3.02).
    • 5.185.3 Cell Proliferation Assay
  • Cell lines Namalwa, MUTZ-5, and UT-7 are obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany). The cell line KG-1 is obtained from the American Type Culture Collection (Manassas, Va., USA). Cell proliferation as indicated by 3H-thymidine incorporation is measured in all cell lines as follows.
  • Cells are plated in 96-well plates at 6000 cells per well in media. The cells are pre-treated with compounds at about 100, 10, 1, 0.1, 0.01, 0.001, 0.0001 and 0.1M in a final concentration of about 0.25% DMSO in triplicate at 37° C. in a humidified incubator at 5% CO2 for 72 hours. One microcurie of 3H-thymidine (Amersham) is then added to each well, and cells are incubated again at 37° C. in a humidified incubator at 5% CO2 for 6 hours. The cells are harvested onto UniFilter GF/C filter plates (Perkin Elmer) using a cell harvester (Tomtec), and the plates are allowed to dry overnight. Microscint 20 (Packard) (25 μl/well) is added, and plates are analyzed in TopCount NXT (Packard). Each well is counted for one minute. Percent inhibition of cell proliferation is calculated by averaging all triplicates and normalizing to the DMSO control (0% inhibition). Each compound is tested in each cell line in three separate experiments. Final IC50s are calculated using non-linear regression, sigmoidal dose-response, constraining the top to 100% and bottom to 0%, allowing variable slope. (GraphPad Prism v3.02).
    • 5.185.4 Immunoprecipitation and Immunoblot
  • Namalwa cells are treated with DMSO or an amount of a compound of the invention for 1 hour, then stimulated with 10 U/ml of Epo (R&D Systems) for 30 minutes. Cell lysates are prepared and either immunoprecipitated with Epo receptor Ab or separated immediately by SDS-PAGE. Immunoblots are probed with Akt, phospo-Akt (Ser473 or Thr308), phospho-Gab1 (Y627), Gab1, IRS2, actin and IRF-1 Abs and analyzed on a Storm 860 Imager using ImageQuant software (Molecular Dynamics).
    • 5.185.5 Cell Cycle Analysis
  • Cells are treated with DMSO or an amount of a compound of the invention overnight. Propidium iodide staining for cell cycle is performed using CycleTEST PLUS (Becton Dickinson) according to manufacturer's protocol. Following staining, cells are analyzed by a FACSCalibur flow cytometer using ModFit LT software (Becton Dickinson).
    • 5.185.6 Apoptosis Analysis
  • Cells are treated with DMSO or an amount of a compound of the invention at various time points, then washed with annexin-V wash buffer (BD Biosciences). Cells are incubated with annexin-V binding protein and propidium iodide (BD Biosciences) for 10 minutes. Samples are analyzed using flow cytometry.
    • 5.185.7 Luciferase Assay
  • Namalwa cells are transfected with 4 μg of AP1-luciferase (Stratagene) per 1×106 cells and 3 μl Lipofectamine 2000 (Invitrogen) reagent according to manufacturer's instructions. Six hours post-transfection, cells are treated with DMSO or an amount of a compound of the invention. Luciferase activity is assayed using luciferase lysis buffer and substrate (Promega) and measured using a luminometer (Turner Designs).
  • The embodiments of the invention described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the invention and are encompassed by the appended claims.
  • All of the patents, patent applications and publications referred to herein are incorporated herein in their entireties. Citation or identification of any reference in this application is not an admission that such reference is available as prior art to this invention. The full scope of the invention is better understood with reference to the appended claims.

Claims (38)

1. A compound of formula (I):
Figure US20070049618A1-20070301-C00465
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
X is O or S;
R1 is H or methyl;
R2 is: (C2-C6)alkyl, excluding cycloalkyl; (C4-C6)cycloalkyl; (C1-C4)alkoxy;
(C1-C6)alkyl, substituted with (C1-C4)alkoxy;
(C1-C6)alkyl-phenyl, wherein the phenyl is optionally substituted with one or more of halogen, (C1-C4)alkoxy, (C1-C4)alkyl, or cyano;
(C0-C1)alkyl-(5 to 6 membered heteroaryl), wherein the heteroaryl is optionally substituted with one or more of (C1-C4)alkyl or halogen; or
(C0-C3)alkyl-NR3R4;
R3 and R4 are each independently:
H; (C1-C6)alkyl; (C3-C6)cycloalkyl;
(C0-C1)alkyl-(C6-C10)aryl, wherein the aryl is optionally substituted with one or more of (C1-C4)alkoxy, halogen, methyl, cyano, or —O—CH2—O—;
(C0-C1)alkyl-(5 to 10 membered heteroaryl), wherein the heteroaryl is substituted with one or more of (C1-C4)alkoxy, halogen, or methyl; or C(O)R5; and
R5 is (C1-C4)alkoxy or (C1-C2)alkyl-O—(C1-C2)alkyl;
with the proviso that if one of R3 and R4 is H, then the other is not ethyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is O.
3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is S.
4. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is phenyl, optionally substituted with one or more halogen.
5. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is NHR4.
6. The compound of claim 5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is (C6-C10)aryl or 5 to 10 membered heteroaryl, both optionally substituted with one or more of (C1-C4)alkoxy, halogen, or methyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the aryl or heteroaryl is phenyl, pyridyl, or naphthyl.
8. The compound of claim 1, which is:
1
Figure US20070049618A1-20070301-C00466
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo2,3-dihydro-1H- isoindol-4-ylmethyl]-2- phenyl-acetamide 2
Figure US20070049618A1-20070301-C00467
 1-Cyclohexyl-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 3
Figure US20070049618A1-20070301-C00468
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- benzamide 4
Figure US20070049618A1-20070301-C00469
 Furan-2-carboxylic acid[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 5
Figure US20070049618A1-20070301-C00470
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- butyramide 6
Figure US20070049618A1-20070301-C00471
 3-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-benzamide 7
Figure US20070049618A1-20070301-C00472
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- propyl-urea 8
Figure US20070049618A1-20070301-C00473
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- nicotinamide 9
Figure US20070049618A1-20070301-C00474
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- phenyl-urea 10
Figure US20070049618A1-20070301-C00475
 [2-(2,6-Dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- carbamic acid tert-butyl ester 11
Figure US20070049618A1-20070301-C00476
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- methoxy-benzamide 12
Figure US20070049618A1-20070301-C00477
 3-Cyano-N-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-benzamide 13
Figure US20070049618A1-20070301-C00478
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-4- methoxy-benzamide 14
Figure US20070049618A1-20070301-C00479
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-2- methoxy-benzamide 15
Figure US20070049618A1-20070301-C00480
 1-[2-(2,6-Dioxo-pipderidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (3-methoxy-phenyl)-urea 16
Figure US20070049618A1-20070301-C00481
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (4-methoxy-phenyl)-urea 17
Figure US20070049618A1-20070301-C00482
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- (2-methoxy-phenyl)-urea 18
Figure US20070049618A1-20070301-C00483
 1-(3-Cyano-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 19
Figure US20070049618A1-20070301-C00484
 1-(3-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 20
Figure US20070049618A1-20070301-C00485
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- isonicotinamide 21
Figure US20070049618A1-20070301-C00486
 Pyridine-2-carboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 22
Figure US20070049618A1-20070301-C00487
 1-Benzyl-3-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-urea 23
Figure US20070049618A1-20070301-C00488
 1-(3,4-Dichloro-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 24
Figure US20070049618A1-20070301-C00489
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- pyridin-3-yl-urea 25
Figure US20070049618A1-20070301-C00490
 3-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- 1,1-dimethyl-urea 26
Figure US20070049618A1-20070301-C00491
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-3- methyl-benzamide 27
Figure US20070049618A1-20070301-C00492
 (2-{[2-(2,6-Dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-carbamoyl}- ethyl)-carbamic acid t-butyl ester 28
Figure US20070049618A1-20070301-C00493
 3-Amino-N-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-propionamide Hydrochloride 29
Figure US20070049618A1-20070301-C00494
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]-2- methoxy-acetamide 30
Figure US20070049618A1-20070301-C00495
 2-Dimethylamino-N-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide Hydrochloride 31
Figure US20070049618A1-20070301-C00496
 (3-{[2-(2,6-Dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-carbamoyl}- propyl)-carbamic acid t- butyl ester 32
Figure US20070049618A1-20070301-C00497
 4-Amino-[2-(2,6-dioxo- piperidin-3-yl)-1-oxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-butyramide hydrochloride 33
Figure US20070049618A1-20070301-C00498
 1-(4-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 34
Figure US20070049618A1-20070301-C00499
 1-(3,4-Dimethyl-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 35
Figure US20070049618A1-20070301-C00500
 1-Cyclohexyl-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- thiourea 36
Figure US20070049618A1-20070301-C00501
 3,4-Dichloro-N-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide 37
Figure US20070049618A1-20070301-C00502
 1-(3-Chloro-4- methylphenyl)-3-[2-(2,6- dioxo-piperidin-3-yl)-1- oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]urea 38
Figure US20070049618A1-20070301-C00503
 1-[2-(2,6-Dioxopiperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-3- naphthalen-1-yl-urea 39
Figure US20070049618A1-20070301-C00504
 1-[2-(2,6-Dioxopiperidin-3- yl)-1-oxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-3- naphthalen-2-yl-urea.
9. A compound of formula (II):
Figure US20070049618A1-20070301-C00505
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is H or methyl; and
R2 is: (C6-C10)aryl, optionally substituted with one or more of: (C1-C8)alkyl, optionally substituted with NH2, NH(CH3), or N(CH3)2; (C1-C4)alkoxy, optionally substituted with NH2, NH(CH3), N(CH3)2, or 3 to 6 membered heterocycloalkyl; (C3-C6)cycloalkyl; (C5-C10)aryloxy; hydroxy; NH2;
NH(CH3); N(CH3)2; —CH2—CH2—CH2—; halogen; or —O—CH2—O—;
(C3-C6)alkyl, optionally substituted with one or more of (C1-C4)alkoxy;
(C1-C2)alkyl, optionally substituted with carboxyl;
(C1-C6)alkyl-(C3-C6)cycloalkyl; or
5 to 10 membered heterocycle;
with the proviso that if R2 is pentyl, then R1 is methyl.
10. The compound of claim 9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is phenyl, optionally substituted with one or more of (C1-C4)alkoxy or —O—CH2—O—.
11. The compound of claim 9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is (C3-C6)alkyl, optionally substituted with one or more of (C1-C4)alkoxy.
12. The compound of claim 9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is phenyl, substituted with one or more (C1-C4)alkyl, which is substituted with N(CH3)2.
13. The compound of claim 10, which is:
40
Figure US20070049618A1-20070301-C00506
 2-(2,6-Dioxopiperidin-3-yl)-4- phenylaminoisoindole-1,3- dione 41
Figure US20070049618A1-20070301-C00507
 2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- methylenedioxyphenylamino) isoindole-1,3-dione 42
Figure US20070049618A1-20070301-C00508
 2-(2,6-Dioxopiperidin-3-yl)-4- (3,4- dimethoxyphenylamino)isoin- dole-1,3-dione 43
Figure US20070049618A1-20070301-C00509
 2-(3-Methyl-2,6- dioxopiperidin-3-yl)-4- pentylaminoisoindole-1,3- dione 44
Figure US20070049618A1-20070301-C00510
 4-(Cyclopropylmethylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 45
Figure US20070049618A1-20070301-C00511
 [2-(2,6-Dioxopiperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-yl-amino]acetic acid 46
Figure US20070049618A1-20070301-C00512
 2-(2,6-Dioxopiperidin-3-yl)-4- (2-methoxy-1- methylethylamino)isoindole- 1,3-dione 47
Figure US20070049618A1-20070301-C00513
 4-(4-tert-Butylphenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 48
Figure US20070049618A1-20070301-C00514
 4-(4-Isopropylphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 49
Figure US20070049618A1-20070301-C00515
 2-(2,6-Dioxo-piperidin-3-yl)- 4-(indan-5-ylamino)-isoindole- 1,3-dione 50
Figure US20070049618A1-20070301-C00516
 4-(2,4- Dimethoxyphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 51
Figure US20070049618A1-20070301-C00517
 2-(2,6-Dioxopiperidin-3-yl)-4- (4-methoxyphenylamino) isoindole-1,3-dione 52
Figure US20070049618A1-20070301-C00518
 2-(2,6-Dioxopiperidin-3-yl)-4- (3-ethoxy-4- methoxyphenylamino)- isoindole-1,3-dione 53
Figure US20070049618A1-20070301-C00519
 2-(2,6-Dioxopiperidin-3-yl)-4- (3-hydroxy-4- methoxyphenylamino)- isoindole-1,3-dione 54
Figure US20070049618A1-20070301-C00520
 2-(2,6-Dioxopiperidin-3-yl)-4- (naphthalen-2-ylamino) isoindole-1,3-dione 55
Figure US20070049618A1-20070301-C00521
 4-(4-Cyclohexylphenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 56
Figure US20070049618A1-20070301-C00522
 4-(2-Methoxyphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 57
Figure US20070049618A1-20070301-C00523
 4-(2,5- Dimethoxyphenylamino)-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 58
Figure US20070049618A1-20070301-C00524
 4-(2-Phenoxyphenylamino)-2- (2,6-dioxopiperidin-3-yl) isoindole-1,3-dione 59
Figure US20070049618A1-20070301-C00525
 4-(4- Dimethylaminophenylamino)- 2-(2,6-dioxopiperidin-3- yl)isoindole-1,3-dione 60
Figure US20070049618A1-20070301-C00526
 4-[4-(2- Dimethylaminoethoxy)-2- methoxyphenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione 61
Figure US20070049618A1-20070301-C00527
 4-[4-(2- Dimethylaminoethoxy)-2- methoxyphenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione hydrochloride 62
Figure US20070049618A1-20070301-C00528
 4-{2-(2-Dimethylaminoethoxy)- 4-methoxyphenylamino]-2- (2,6-dioxopiperidin-3- yl)isoindole-1,3-dione hydrochloride 63
Figure US20070049618A1-20070301-C00529
 2-(2,6-Dioxopiperidin-3-yl)-4- [2-methoxy-4-(2-morpholin-4- ylethoxy)phenylamino]- isoindole-1,3-dione hydrochloride 64
Figure US20070049618A1-20070301-C00530
 4-(4-Dimethylaminomethyl-2- methoxyphenylamino)-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione 65
Figure US20070049618A1-20070301-C00531
 4-(4-Dimethylaminomethyl-2- methoxyphenylamino)-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione hydrochloride 66
Figure US20070049618A1-20070301-C00532
 4-[4-(3- Dimethylaminopropoxy)-2- methoxyphenylamino]-2-(2,6- dioxopiperidin-3-yl)isoindole- 1,3-dione hydrochloride 67
Figure US20070049618A1-20070301-C00533
 4-[4-(2-Dimethylamino- ethoxy)-phenylamino]-2-(2,6- dioxo-piperidin-3-yl)- isoindole-1,3-dione 68
Figure US20070049618A1-20070301-C00534
 4-[4-(2-Dimethylamino- ethoxy)-2-isopropoxy- phenylamino]-2-(2,6-dioxo- piperidin-3-yl)-isoindole-1,3- dione 69
Figure US20070049618A1-20070301-C00535
 2-(2,6-Dioxo-piperidin-3-yl)- 4-(4-methoxy-2-phenoxy- phenylamino)-isoindole-1,3- dione 70
Figure US20070049618A1-20070301-C00536
 4-[4-(2-Dimethylamino- ethoxy)-2-phenoxy- phenylamino]-2-(2,6-dioxo- piperidin-3-yl)-isoindole-1,3- dione 71
Figure US20070049618A1-20070301-C00537
 2-(2,6-Dioxo-piperidin-3-yl)- 4-[4-(2-morpholin-4-yl- ethoxy)-phenylamino]- isoindole-1,3-dione 72
Figure US20070049618A1-20070301-C00538
 2-(2,6-Dioxo-piperidin-3-yl)- 4-[3-(2-morpholin-4-yl- ethoxy)-phenylamino]- isoindole-1,3-dione 73
Figure US20070049618A1-20070301-C00539
 2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-methoxy-4-(2-piperidin- 1-yl-ethoxy)-phenylamino]- isoindole-1,3-dione 74
Figure US20070049618A1-20070301-C00540
 2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-methoxy-4-(2-pyrrolidin- 1-yl-ethoxy)-phenylamino]- isoindole-1,3-dione 75
Figure US20070049618A1-20070301-C00541
 2-(2,6-Dioxo-piperidin-3-yl)- 4-[2-fluoro-4-(2-morpholin-4- yl-ethoxy)-phenylamino]- isoindole-1,3-dione 76
Figure US20070049618A1-20070301-C00542
 4-(2,4-Dimethoxy- phenylamino)-2-[(3S)-3- methyl-2,6-dioxo-piperidin-3- yl]-isoindole-1,3-dione 77
Figure US20070049618A1-20070301-C00543
 4-(Indan-5-ylamino)-2-[(3S)- 3-methyl-2,6-dioxo-piperidin- 3-yl]-isoindole-1,3-dione 78
Figure US20070049618A1-20070301-C00544
 2-(2,6-Dioxo-piperidin-3-yl)- 4-(3-methoxy-phenylamino)- isoindole-1,3-dione.
14. A compound of formula (III):
Figure US20070049618A1-20070301-C00545
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is H or methyl; and
R2 is: amino, optionally substituted with one or more of (C1-C6)alkyl, (C3-C6)cycloalkyl, or phenyl; 3 to 6 membered heterocycloalkyl; or (C1-C4)alkoxy.
15. The compound of claim 14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is —NH(CH3) or —N(CH3)2.
16. The compound of claim 14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is (C3-C6)cycloalkyl.
17. The compound of claim 14, which is:
79
Figure US20070049618A1-20070301-C00546
 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide 80
Figure US20070049618A1-20070301-C00547
 [2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]acetic acid methyl ester 81
Figure US20070049618A1-20070301-C00548
 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-methylacetamide 82
Figure US20070049618A1-20070301-C00549
 N-Cyclopropyl-2-[2-(2,6- dioxopiperidin-3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylamino]acetamide 83
Figure US20070049618A1-20070301-C00550
 4-(2-(Azetidin-1-yl)-2- oxoethylamino)-2-(2,6-dioxo piperidin-3-yl)isoindoline-1,3- dione 84
Figure US20070049618A1-20070301-C00551
 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H-isoindol-4- ylamino]-N-phenyl-acetamide.
18. A compound of formula (IV):
Figure US20070049618A1-20070301-C00552
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is H or methyl; and R2 is 5 to 6 membered heteroaryl;
with the proviso that if R2 is furan or thiophene, then R1 is methyl; and
with the proviso that if R2 is pyridine, then the pyridine is not connected to the core at the 3 position.
19. The compound of claim 18, which is:
85
Figure US20070049618A1-20070301-C00553
 2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-2-yl- methyl)amino]isoindole-1,3-dione hydrochloride 86
Figure US20070049618A1-20070301-C00554
 2-(2,6-Dioxopiperidin-3-yl)-4- [(pyridin-4-yl- methyl)amino]isoindole-1,3-dione hydrochloride 87
Figure US20070049618A1-20070301-C00555
 4-[(Furan-2-ylmethyl)amino]-2- (3-methyl-2,6-dioxopiperidin-3- yl)isoindole-1,3-dione.
20. A compound of formula (V):
Figure US20070049618A1-20070301-C00556
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is H or methyl; and
R2 is: H; methyl; ethyl;
phenyl, substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, cyano, or —O—CH2—O—;
naphthyl, optionally substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, or cyano; or
5 to 10 membered heteroaryl, optionally substituted with one or more of (C1-C6)alkyl, halogen, (C1-C4)alkoxy, or cyano;
with the proviso that if R2 is ethyl, then R1 is methyl; and
with the proviso that if R2 is pyridine, then the pyridine is not connected to the core at the 3 position.
21. The compound of claim 20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is phenyl, optionally substituted with one or more of methyl, halogen, (C1-C4)alkoxy, cyano, or —O—CH2—O—.
22. The compound of claim 20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is naphthyl.
23. The compound of claim 20, which is:
88
Figure US20070049618A1-20070301-C00557
 1-Ethyl-3-[2-(3-methyl- 2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 89
Figure US20070049618A1-20070301-C00558
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(3-methoxy- phenyl)-urea 90
Figure US20070049618A1-20070301-C00559
 1-(3-Chloro-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 91
Figure US20070049618A1-20070301-C00560
 1-(3-Cyano-phenyl)-3-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-urea 92
Figure US20070049618A1-20070301-C00561
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(4-methoxy- phenyl)-urea 93
Figure US20070049618A1-20070301-C00562
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-(2-methoxy- phenyl)-urea 94
Figure US20070049618A1-20070301-C00563
 1-(3,4- Methylenedioxyphenyl)-3- [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4- ylmethyl]urea 95
Figure US20070049618A1-20070301-C00564
 1-(3-Chloro-4- methylphenyl)-3-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]urea 96
Figure US20070049618A1-20070301-C00565
 1-(3,4-dichlorophenyl)-3- [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4- ylmethyl]urea 97
Figure US20070049618A1-20070301-C00566
 1-[2-(2,6-Dioxopiperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-naphthalen-1- yl-urea 98
Figure US20070049618A1-20070301-C00567
 1-[2-(2,6-Dioxopiperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-naphthalen-2- yl-urea 99
Figure US20070049618A1-20070301-C00568
 1-(3,4-Dimethyl-phenyl)-3- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- urea 100
Figure US20070049618A1-20070301-C00569
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-m-tolyl-urea 101
Figure US20070049618A1-20070301-C00570
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-pyridin-2-yl- urea 102
Figure US20070049618A1-20070301-C00571
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-p-tolyl-urea 103
Figure US20070049618A1-20070301-C00572
 1-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-o-tolyl-urea 104
Figure US20070049618A1-20070301-C00573
 [2-(2,6-Dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- urea.
24. A compound of formula (VI):
Figure US20070049618A1-20070301-C00574
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is H or methyl; and
R2 is: N(CH3)2;
(C0-C1)alkyl-(C6-C10)aryl, substituted with one or more of: methyl, itself optionally substituted with one or more halogen; (C1-C4)alkoxy, itself optionally substituted with one or more halogen; or halogen;
(C0-C1)alkyl-(5 to 10 membered heteroaryl), optionally substituted with one or more of (C1-C4)alkyl, (C1-C4)alkoxy, or halogen; or
(5 to 6 membered heteroaryl)-phenyl, wherein the heteroaryl and phenyl are each independently optionally substituted with one or more of (C1-C4)alkyl or (C1-C4)alkoxy;
with the proviso that R2 is not unsubstituted pyridine, furan, or thiophene.
25. The compound of claim 24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is phenyl, substituted with one or more of methyl, (C1-C4)alkoxy, or halogen.
26. The compound of claim 24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is pyrazine, pyrimidine, quinoxaline, or isoquinoline, optionally substituted with one or more of (C1-C4)alkyl or halogen.
27. The compound of claim 24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is 5 membered heteroaryl, substituted with one of more (C1-C4)alkyl.
28. The compound of claim 24, which is:
105
Figure US20070049618A1-20070301-C00575
 3-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-1,1-dimethyl- urea 106
Figure US20070049618A1-20070301-C00576
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-methoxy- benzamide 107
Figure US20070049618A1-20070301-C00577
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-methyl- benzamide 108
Figure US20070049618A1-20070301-C00578
 3,4-Dichloro-N-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl- methyl]benzamide 109
Figure US20070049618A1-20070301-C00579
 Isoquinoline-3-carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 110
Figure US20070049618A1-20070301-C00580
 5-Butylpyridine-2- carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 111
Figure US20070049618A1-20070301-C00581
 6-Bromopyridine-2- carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 112
Figure US20070049618A1-20070301-C00582
 6-Methylpyridine-2- carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 113
Figure US20070049618A1-20070301-C00583
 Pyrazine-2-carboxylic acid [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-yl- methyl]amide 114
Figure US20070049618A1-20070301-C00584
 Quinoxaline-2-carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 115
Figure US20070049618A1-20070301-C00585
 Pyrimidine-5-carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 116
Figure US20070049618A1-20070301-C00586
 2,5-Dichloro-N-[2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl- methyl]nicotinamide 117
Figure US20070049618A1-20070301-C00587
 6-(3-Ethoxy-4- methoxyphenyl)pyridine-2- carboxylic acid [2-(2,6- dioxopiperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]amide 118
Figure US20070049618A1-20070301-C00588
 1H-Indole-2-carboxylic acid [2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-amide 119
Figure US20070049618A1-20070301-C00589
 1,5-Dimethyl-1H-pyrazole- 3-carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 120
Figure US20070049618A1-20070301-C00590
 5-Methyl-isoxazole-3- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 121
Figure US20070049618A1-20070301-C00591
 1-Methyl-1H-pyrrole-2- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 122
Figure US20070049618A1-20070301-C00592
 3-Methyl-3H-imidazole-4- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 123
Figure US20070049618A1-20070301-C00593
 N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4- trifluoromethyl-benzamide 124
Figure US20070049618A1-20070301-C00594
 5-Phenyl- [1,3,4]oxadiazole-2- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethylamide 125
Figure US20070049618A1-20070301-C00595
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3- trifluoromethyl-benzamide 126
Figure US20070049618A1-20070301-C00596
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3,4-difluoro- benzamide 127
Figure US20070049618A1-20070301-C00597
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-fluoro- benzamide 128
Figure US20070049618A1-20070301-C00598
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-methyl- benzamide 129
Figure US20070049618A1-20070301-C00599
 3,5-Dichloro-N-[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide 130
Figure US20070049618A1-20070301-C00600
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3,5-difluoro- benzamide 131
Figure US20070049618A1-20070301-C00601
 4-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-benzamide 132
Figure US20070049618A1-20070301-C00602
 2-Chloro-N-[2-(2,6-dioxo- piperidin-3-)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-benzamide 133
Figure US20070049618A1-20070301-C00603
 3-Chloro-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-4-methyl- benzamide 134
Figure US20070049618A1-20070301-C00604
 Benzofuran-2-carboxylic acid [2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-amide 135
Figure US20070049618A1-20070301-C00605
 2-(3,4-Dichloro-phenyl)-N- [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- acetamide 136
Figure US20070049618A1-20070301-C00606
 2-(3-Chloro-phenyl)-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide 137
Figure US20070049618A1-20070301-C00607
 Benzo[1,3]dioxole-5- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 138
Figure US20070049618A1-20070301-C00608
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4-yl- methyl]-3,4-dimethoxy- benzamide 139
Figure US20070049618A1-20070301-C00609
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4- trifluoromethoxy- benzamide 140
Figure US20070049618A1-20070301-C00610
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3- trifluoromethoxy- benzamide 141
Figure US20070049618A1-20070301-C00611
 4-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide 142
Figure US20070049618A1-20070301-C00612
 3-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide 143
Figure US20070049618A1-20070301-C00613
 2-Difluoromethoxy-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- benzamide 144
Figure US20070049618A1-20070301-C00614
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-fluoro- benzamide 145
Figure US20070049618A1-20070301-C00615
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(4-fluoro- phenyl)-acetamide 146
Figure US20070049618A1-20070301-C00616
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-fluoro- phenyl)-acetamide 147
Figure US20070049618A1-20070301-C00617
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(2-fluoro- phenyl)-acetamide 148
Figure US20070049618A1-20070301-C00618
 2-(3,5-Difluoro-phenyl)-N- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- acetamide 149
Figure US20070049618A1-20070301-C00619
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(4- trifluoromethoxy-phenyl)- acetamide 150
Figure US20070049618A1-20070301-C00620
 2-(3,5-Bis-trifluoromethyl- phenyl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide 151
Figure US20070049618A1-20070301-C00621
 (N-[2-(2,6-Dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-2-(4- trifluoromethyl-phenyl)- acetamide 152
Figure US20070049618A1-20070301-C00622
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3- trifluoromethyl-phenyl)- acetamide 153
Figure US20070049618A1-20070301-C00623
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3- trifluoromethoxy-phenyl)- acetamide 154
Figure US20070049618A1-20070301-C00624
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-fluoro-4- methyl-phenyl)-acetamide 155
Figure US20070049618A1-20070301-C00625
 2-(3,5-Dimethoxy-phenyl)- N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-acetamide 156
Figure US20070049618A1-20070301-C00626
 2-(4-Chloro-phenyl)-N-[2- (2,6-dioxo-piperidin-3-yl)- 1,3-dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide 157
Figure US20070049618A1-20070301-C00627
 2-Benzo[1,3]dioxo-5-yl-N- [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- acetamide 158
Figure US20070049618A1-20070301-C00628
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridinyl-2-yl- acetamide 159
Figure US20070049618A1-20070301-C00629
 N-[2-(2,6-dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridinyl-3-yl- acetamide 160
Figure US20070049618A1-20070301-C00630
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-pyridin-4-yl- acetamide 161
Figure US20070049618A1-20070301-C00631
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-naphthalen-1- yl-acetamide 162
Figure US20070049618A1-20070301-C00632
 2-(4,5-Dimethyl-furan-2- yl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide 163
Figure US20070049618A1-20070301-C00633
 2-(2,5-Dimethyl-furan-3- yl)-N-[2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-acetamide 164
Figure US20070049618A1-20070301-C00634
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]2-(6-methoxy- benzofuran-3-yl)- acetamide 165
Figure US20070049618A1-20070301-C00635
 2-{2,5-Dimethyl-1,3- thiazol-4-yl)-N-[2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]- acetamide 166
Figure US20070049618A1-20070301-C00636
 N-[2-(2,6-Dioxopiperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(3-methyl- isoxazol-5-yl)-acetamide 167
Figure US20070049618A1-20070301-C00637
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-(1-methyl-1H- indol-3-yl)-acetamide 168
Figure US20070049618A1-20070301-C00638
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-thiophen-2-yl- acetamide 169
Figure US20070049618A1-20070301-C00639
 N-[2-(2.6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-thiophen-2-yl- acetamide 170
Figure US20070049618A1-20070301-C00640
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-3-fluoro-4- trifluoromethyl-benzamide 171
Figure US20070049618A1-20070301-C00641
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-fluoro-4- trifluoromethyl-benzamide 172
Figure US20070049618A1-20070301-C00642
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-4-fluoro-3- trifluoromethyl-benzamide 173
Figure US20070049618A1-20070301-C00643
 N-[2-(2,6-Dioxo-piperidin- 3-yl)-1,3-dioxo-2,3- dihydro-1H-isoindol-4- ylmethyl]-2-fluoro-3- trifluoromethyl-benzamide 174
Figure US20070049618A1-20070301-C00644
 Bnezo[b]thiophene-5- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 175
Figure US20070049618A1-20070301-C00645
 4-Methyl-oxazole-5- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide 176
Figure US20070049618A1-20070301-C00646
 4-Methyl-2-phenyl- thiazole-5-carboxylic acid [2-(2,6-dioxopiperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4- ylmethylamide 177
Figure US20070049618A1-20070301-C00647
 Isoxazole-5-carboxylic acid [2-(2,6-dioxo- piperidin-3-yl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4- ylmethyl]-amide 178
Figure US20070049618A1-20070301-C00648
 Thiazole-2-carboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- amide 179
Figure US20070049618A1-20070301-C00649
 Benzo[c]isoxazole-3- carboxylic acid [2-(2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-ylmethyl]-amide.
29. A compound of formula, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
180
Figure US20070049618A1-20070301-C00650
 cyclopropanecarboxylic acid [2-(2,6-dioxo-piperidin-3- yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-4-ylmethyl]- amide 181
Figure US20070049618A1-20070301-C00651
 2-amino-N-[2-(3-methyl-2,6- dioxo-piperidin-3-yl)-1,3- dioxo-2,3-dihydro-1H- isoindol-4-yl)-acetamide 182
Figure US20070049618A1-20070301-C00652
 3-[4-[(Benzofuran-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione 183
Figure US20070049618A1-20070301-C00653
 3-{4-[(4,5-Dimethyl-furan-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione 184
Figure US20070049618A1-20070301-C00654
 3-{4-[(5-Methyl-furan-2- ylmethyl)-amino]-1-oxo-1,3- dihydro-isoindol-2-yl}- piperidine-2,6-dione.
30. The compound of formula 29, or a pharmaceutically acceptable salt or solvate thereof, which is a stereomerically pure (R) isomer, a stereomerically pure (S) isomer, or a racemic mixture thereof.
31. A pharmaceutical composition comprising a compound of claim 1, 9, 14, 18, 20, 24, or 29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
32. A method of treating, managing or preventing a disease or disorder which comprises administering to a patient in need of such treatment, management or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 9, 14, 18, 20, 24, or 29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFα related disorder.
33. The method of claim 32, which further comprises administration of one or more additional active agents.
34. The method of claim 32, wherein the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is administered orally or parenterally.
35. A single unit dosage form comprising a compound of claim 1, 9, 14, 18, 20, 24, or 29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
36. The single unit dosage form of claim 35, which is suitable for oral or parenteral administration.
37. The single unit dosage form of claim 36, which is suitable for oral administration.
38. The single unit dosage form of claim 37, which is a tablet or a capsule.
US11/513,563 2005-08-31 2006-08-30 Isoindole-imide compounds and compositions comprising and methods of using the same Abandoned US20070049618A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/513,563 US20070049618A1 (en) 2005-08-31 2006-08-30 Isoindole-imide compounds and compositions comprising and methods of using the same
US13/030,075 US8481568B2 (en) 2005-08-31 2011-02-17 Isoindole-imide compounds and compositions comprising and methods of using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71238705P 2005-08-31 2005-08-31
US11/513,563 US20070049618A1 (en) 2005-08-31 2006-08-30 Isoindole-imide compounds and compositions comprising and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/030,075 Continuation US8481568B2 (en) 2005-08-31 2011-02-17 Isoindole-imide compounds and compositions comprising and methods of using the same

Publications (1)

Publication Number Publication Date
US20070049618A1 true US20070049618A1 (en) 2007-03-01

Family

ID=37758733

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/513,563 Abandoned US20070049618A1 (en) 2005-08-31 2006-08-30 Isoindole-imide compounds and compositions comprising and methods of using the same
US13/030,075 Active US8481568B2 (en) 2005-08-31 2011-02-17 Isoindole-imide compounds and compositions comprising and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/030,075 Active US8481568B2 (en) 2005-08-31 2011-02-17 Isoindole-imide compounds and compositions comprising and methods of using the same

Country Status (24)

Country Link
US (2) US20070049618A1 (en)
EP (1) EP1919892B1 (en)
JP (1) JP5578785B2 (en)
KR (1) KR20080042158A (en)
CN (1) CN101291924A (en)
AR (1) AR055150A1 (en)
AU (1) AU2006285144A1 (en)
BR (1) BRPI0614995A2 (en)
CA (3) CA2620085C (en)
CR (1) CR9772A (en)
DO (1) DOP2006000193A (en)
EC (1) ECSP088332A (en)
ES (1) ES2434946T3 (en)
GT (1) GT200600398A (en)
IL (1) IL189795A0 (en)
MX (1) MX2008002765A (en)
NO (1) NO20081554L (en)
PA (1) PA8693101A1 (en)
PE (1) PE20070541A1 (en)
RU (1) RU2008112221A (en)
TW (1) TW200745078A (en)
UA (1) UA91560C2 (en)
WO (1) WO2007027527A2 (en)
ZA (1) ZA200802490B (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052609A1 (en) * 2004-09-03 2006-03-09 Muller George W Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US20090148853A1 (en) * 2007-12-07 2009-06-11 Schafer Peter H Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
US20090176237A1 (en) * 2007-12-20 2009-07-09 Ferguson Gregory D Use of micro-rna as a biomarker of immunomodulatory drug activity
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
WO2010111631A1 (en) 2009-03-25 2010-09-30 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
US20110144158A1 (en) * 2005-08-31 2011-06-16 Sepracor Inc. Isoindole-imide compounds and compositions comprising and methods of using the same
US7994327B2 (en) 2005-06-30 2011-08-09 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
WO2012145309A1 (en) 2011-04-18 2012-10-26 Celgene Corporation Biomarkers for the treatment of multiple myeloma
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
EP2851070A1 (en) 2010-01-05 2015-03-25 Celgene Corporation A combination of lenalidomide and artesunate/artemisone for treating cancer
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9365640B2 (en) 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2017002078A1 (en) 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9611465B2 (en) 2009-05-25 2017-04-04 Celgene Corporation Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2019145214A1 (en) 2018-01-26 2019-08-01 Recordati Industria Chimica E Farmaceutica S.P.A TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
SG10201503486XA (en) 2007-09-26 2015-06-29 Celgene Corp 6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same
BRPI0919942B1 (en) * 2008-10-29 2019-02-19 Celgene Corporation COMPOSITION, PHARMACEUTICAL COMPOSITION UNDERSTANDING IT AND USE OF
RS59275B1 (en) 2010-02-11 2019-10-31 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN103396397A (en) * 2013-08-14 2013-11-20 中国人民解放军军事医学科学院毒物药物研究所 Lenalidomide derivative and use thereof as medicine
UA117141C2 (en) 2013-10-08 2018-06-25 Селджин Корпорейшн Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2015341301B2 (en) * 2014-10-30 2019-05-16 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (en) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Compounds and methods for targeted androgen receptor degradation
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2017246453A1 (en) * 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN110506039A (en) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 Compounds and methods for for androgen receptor targeting degradation
IL304982A (en) 2016-11-01 2023-10-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
LT3689868T (en) 2016-12-01 2023-12-27 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
CN117510491A (en) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018140809A1 (en) 2017-01-26 2018-08-02 Arvinas, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
BR112020020307A2 (en) 2018-04-04 2021-01-12 Arvinas Operations, Inc. PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE
JP7458324B2 (en) 2018-04-23 2024-03-29 セルジーン コーポレイション Substituted 4-aminoisoindoline-1,3-dione compounds and their use for the treatment of lymphoma
AU2019294835A1 (en) * 2018-06-29 2020-12-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
AR116109A1 (en) * 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
JP7297053B2 (en) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド Alpha-Synuclein Protein-Targeted Proteolysis Targeting Chimeric (PROTAC) Compounds with E3 Ubiquitin Ligase Binding Activity to Treat Neurodegenerative Diseases
WO2020064002A1 (en) 2018-09-30 2020-04-02 中国科学院上海药物研究所 Isoindoline compound, preparation method, pharmaceutical composition and use thereof
CN113423701A (en) * 2018-11-13 2021-09-21 拜欧斯瑞克斯公司 Substituted isoindolinones
US20220041578A1 (en) 2018-12-06 2022-02-10 Shanghai Institute Of Meteria Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
CN111747924B (en) * 2019-03-29 2023-11-10 华东师范大学 Lenalidomide/pomalidomide analogues and application thereof
AR119057A1 (en) * 2019-05-31 2021-11-17 Celgene Corp SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS OF THESE AND METHODS OF TREATMENT WITH SAID COMPOUNDS
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CR20220353A (en) 2019-12-19 2022-10-20 Arvinas Operations Inc Compounds and methods for the targeted degradation of androgen receptor
CN114057592B (en) * 2020-08-05 2023-08-22 沈阳化工研究院有限公司 Method for preparing 4-aminomethylbenzoic acid
US20230310478A1 (en) * 2020-09-02 2023-10-05 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
CN114591192A (en) * 2020-12-04 2022-06-07 江西仰立新材料有限公司 Preparation method of N-cyclopropylmethylaniline compound
WO2022148459A1 (en) * 2021-01-11 2022-07-14 和径医药科技（上海）有限公司 Class of novel smad3 protein degraders and application thereof
JP2024504932A (en) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド isoindolinone compound
CN115504963A (en) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 C-Myc protein degradation agent
WO2023081224A1 (en) * 2021-11-03 2023-05-11 St. Jude Children's Research Hospital, Inc. Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096841A1 (en) * 2000-12-27 2003-05-22 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB508048A (en) 1937-12-24 1939-06-26 Marconi Wireless Telegraph Co Improvements in or relating to aerial systems
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
IT1274549B (en) 1995-05-23 1997-07-17 Indena Spa USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
ES2529190T3 (en) 1996-07-24 2015-02-17 Celgene Corporation 2- (2,6-Dioxopiperidin-3-yl) -amino-substituted phthalimides to reduce TNF-alpha levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
KR19980074060A (en) * 1997-03-21 1998-11-05 김윤배 Novel substituted 3,4-dialkoxyphenyl derivatives
NZ506432A (en) * 1998-03-16 2003-08-29 Celgene Corp 2-(2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
JP2001106673A (en) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd Biarylurea derivative
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
MX2008002765A (en) * 2005-08-31 2008-04-07 Celgene Corp Isoindole-imide compounds and compositions comprising and methods of using the same.
WO2010003001A1 (en) 2008-07-03 2010-01-07 Dow Global Technologies Inc. Improved method of operating a compression ignition internal combustion engine
KR20160100584A (en) 2015-02-16 2016-08-24 에스케이하이닉스 주식회사 Semiconductor memory device and method of testing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096841A1 (en) * 2000-12-27 2003-05-22 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052609A1 (en) * 2004-09-03 2006-03-09 Muller George W Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US7863451B2 (en) 2004-09-03 2011-01-04 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US9822093B2 (en) 2005-06-30 2017-11-21 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US10266514B2 (en) 2005-06-30 2019-04-23 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US8785644B2 (en) 2005-06-30 2014-07-22 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US7994327B2 (en) 2005-06-30 2011-08-09 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US20110224440A1 (en) * 2005-06-30 2011-09-15 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US9394274B2 (en) 2005-06-30 2016-07-19 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US8481568B2 (en) 2005-08-31 2013-07-09 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US20110144158A1 (en) * 2005-08-31 2011-06-16 Sepracor Inc. Isoindole-imide compounds and compositions comprising and methods of using the same
US20090148853A1 (en) * 2007-12-07 2009-06-11 Schafer Peter H Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
US8771944B2 (en) 2007-12-20 2014-07-08 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
US7964354B2 (en) 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
US20090176237A1 (en) * 2007-12-20 2009-07-09 Ferguson Gregory D Use of micro-rna as a biomarker of immunomodulatory drug activity
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
EP3489352A1 (en) 2009-03-25 2019-05-29 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
WO2010111631A1 (en) 2009-03-25 2010-09-30 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
US9611465B2 (en) 2009-05-25 2017-04-04 Celgene Corporation Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
US9226913B2 (en) 2010-01-05 2016-01-05 Celgene Corporation Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
EP2851070A1 (en) 2010-01-05 2015-03-25 Celgene Corporation A combination of lenalidomide and artesunate/artemisone for treating cancer
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
WO2012145309A1 (en) 2011-04-18 2012-10-26 Celgene Corporation Biomarkers for the treatment of multiple myeloma
US9365640B2 (en) 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US10047151B2 (en) 2011-04-29 2018-08-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
EP3489682A1 (en) 2012-06-29 2019-05-29 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
EP3904875A1 (en) 2012-06-29 2021-11-03 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US11040925B2 (en) 2013-01-14 2021-06-22 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US10202316B2 (en) 2013-01-14 2019-02-12 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US11820720B2 (en) 2013-01-14 2023-11-21 Salarius Pharmaceuticals, Inc. 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9913845B2 (en) 2013-03-14 2018-03-13 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US10555946B2 (en) 2013-03-14 2020-02-11 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US11491156B2 (en) 2013-03-14 2022-11-08 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
US10668057B2 (en) 2014-06-27 2020-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11419861B2 (en) 2014-06-27 2022-08-23 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2017002078A1 (en) 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11733233B2 (en) 2015-12-28 2023-08-22 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2019145214A1 (en) 2018-01-26 2019-08-01 Recordati Industria Chimica E Farmaceutica S.P.A TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof

Also Published As

Publication number Publication date
CA2620085A1 (en) 2007-03-08
DOP2006000193A (en) 2007-05-31
WO2007027527A3 (en) 2007-05-24
CA2822094C (en) 2015-10-27
KR20080042158A (en) 2008-05-14
PE20070541A1 (en) 2007-08-10
AR055150A1 (en) 2007-08-08
CN101291924A (en) 2008-10-22
UA91560C2 (en) 2010-08-10
EP1919892A2 (en) 2008-05-14
NO20081554L (en) 2008-06-02
AU2006285144A1 (en) 2007-03-08
IL189795A0 (en) 2008-08-07
TW200745078A (en) 2007-12-16
JP5578785B2 (en) 2014-08-27
US8481568B2 (en) 2013-07-09
ES2434946T3 (en) 2013-12-18
CA2620085C (en) 2016-07-12
CA2822094A1 (en) 2007-03-08
BRPI0614995A2 (en) 2010-01-12
PA8693101A1 (en) 2009-05-15
EP1919892B1 (en) 2013-08-14
RU2008112221A (en) 2009-10-10
MX2008002765A (en) 2008-04-07
US20110144158A1 (en) 2011-06-16
CR9772A (en) 2008-07-24
CA2899923A1 (en) 2007-03-08
JP2009506117A (en) 2009-02-12
WO2007027527A2 (en) 2007-03-08
ZA200802490B (en) 2009-10-28
GT200600398A (en) 2007-05-15
ECSP088332A (en) 2008-04-28

Similar Documents

Publication Publication Date Title
US8481568B2 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
US9801868B2 (en) 5-substituted isoindoline compounds
US10385037B2 (en) 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
EP2057143B1 (en) 5-substituted isoindoline compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELGENE CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MULLER, GEORGE W.;CHEN, ROGER S.;MAN, HON W.;AND OTHERS;REEL/FRAME:018438/0805

Effective date: 20061004

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION